0001493152-22-006231.txt : 20220308 0001493152-22-006231.hdr.sgml : 20220308 20220308060742 ACCESSION NUMBER: 0001493152-22-006231 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220308 DATE AS OF CHANGE: 20220308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Matinas BioPharma Holdings, Inc. CENTRAL INDEX KEY: 0001582554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463011414 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38022 FILM NUMBER: 22720243 BUSINESS ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 908-484-8805 MAIL ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 10-K 1 form10k.htm
0001582554 false FY P3Y P10Y3M P3Y 0001582554 2021-01-01 2021-12-31 0001582554 2021-06-30 0001582554 2022-03-04 0001582554 2021-12-31 0001582554 2020-12-31 0001582554 2020-01-01 2020-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2019-12-31 0001582554 us-gaap:CommonStockMember 2019-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001582554 us-gaap:RetainedEarningsMember 2019-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001582554 2019-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2020-12-31 0001582554 us-gaap:CommonStockMember 2020-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001582554 us-gaap:RetainedEarningsMember 2020-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001582554 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001582554 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001582554 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2021-12-31 0001582554 us-gaap:CommonStockMember 2021-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001582554 us-gaap:RetainedEarningsMember 2021-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001582554 MTNB:AtTheMarketSalesAgreementMember 2021-01-01 2021-01-31 0001582554 us-gaap:CommonStockMember MTNB:UnderwrittenPublicOfferingMember 2020-01-12 2020-01-14 0001582554 MTNB:UnderwrittenPublicOfferingMember 2020-01-12 2020-01-14 0001582554 srt:MinimumMember 2021-01-01 2021-12-31 0001582554 srt:MaximumMember 2021-01-01 2021-12-31 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:FirstAnniversaryMember 2018-06-18 2018-06-19 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:SecondAnniversaryMember 2018-06-18 2018-06-19 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:ThirdAnniversaryMember 2018-06-18 2018-06-19 0001582554 MTNB:CFFResearchGrantRevenueMember 2020-01-01 2020-12-31 0001582554 MTNB:ThreeMoleculesMember MTNB:FeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-11 2019-12-12 0001582554 MTNB:PerMoleculesMember MTNB:FeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-11 2019-12-12 0001582554 MTNB:GenentechMember MTNB:PerMoleculesMember 2021-01-01 2021-12-31 0001582554 MTNB:GenentechMember MTNB:PerMoleculesMember 2020-01-01 2020-12-31 0001582554 MTNB:CFFAgreementMember 2021-01-01 2021-12-31 0001582554 MTNB:CFFAgreementMember 2020-01-01 2020-12-31 0001582554 MTNB:StockOptionsMember 2021-01-01 2021-12-31 0001582554 MTNB:StockOptionsMember 2020-01-01 2020-12-31 0001582554 MTNB:PreferredStockAndAccruedDividendUponConversionMember 2021-01-01 2021-12-31 0001582554 MTNB:PreferredStockAndAccruedDividendUponConversionMember 2020-01-01 2020-12-31 0001582554 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001582554 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001582554 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member MTNB:StateAndMunicipalBondsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001582554 us-gaap:EquipmentMember 2021-12-31 0001582554 us-gaap:EquipmentMember 2020-12-31 0001582554 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001582554 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001582554 MTNB:CFFAgreementMember 2021-12-31 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember 2021-12-31 0001582554 MTNB:CFFAgreementMember 2020-12-31 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember 2020-12-31 0001582554 2013-11-01 0001582554 2013-11-01 2013-11-01 0001582554 2020-09-23 0001582554 2020-09-22 2020-09-23 0001582554 2016-12-15 0001582554 2016-12-14 2016-12-15 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-11-19 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-11-18 2020-11-19 0001582554 MTNB:CysticFibrosisFoundationMember MTNB:AwardAgreementMember 2021-11-18 2021-11-19 0001582554 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-12-31 0001582554 MTNB:CysticFibrosisFoundationMember 2021-01-01 2021-12-31 0001582554 MTNB:AccruedExpenseAndOtherCurrentLiabilitiesMember MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-12-31 0001582554 MTNB:UponAchievementOfSalesMilestonesMember MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-11-19 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2021-01-01 2021-12-31 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-01-01 2020-12-31 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-01 2019-12-12 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-13 0001582554 MTNB:GenentechMember 2020-01-01 2020-12-31 0001582554 MTNB:GenentechMember 2021-01-01 2021-12-31 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2016-02-16 2016-02-19 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2019-04-15 2019-04-16 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2019-04-16 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2019-04-02 0001582554 MTNB:LicenseAgreementMember 2021-01-01 2021-12-31 0001582554 srt:MaximumMember us-gaap:SeriesAPreferredStockMember 2016-09-12 0001582554 us-gaap:SeriesAPreferredStockMember 2016-09-01 2016-09-12 0001582554 srt:MaximumMember MTNB:FourPointFivePercentOfNetSalesMember us-gaap:SeriesAPreferredStockMember 2016-09-12 0001582554 srt:MaximumMember MTNB:SevenPointFivePercentOfNetSalesMember us-gaap:SeriesAPreferredStockMember 2016-09-12 0001582554 MTNB:FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsMember 2021-12-31 0001582554 MTNB:UnderwrittenPublicOfferingMember MTNB:SalesAgreementMember 2020-06-29 2020-07-02 0001582554 MTNB:SalesAgreementMember MTNB:UnderwrittenPublicOfferingMember 2021-01-02 2021-01-31 0001582554 MTNB:AquariusMergerAgreementMember MTNB:HoldersOfAquariusBiotechnologiesIncMember MTNB:UnregisteredSharesMember 2021-09-01 2021-09-03 0001582554 MTNB:AquariusMergerAgreementMember MTNB:HoldersOfAquariusBiotechnologiesIncMember MTNB:UnregisteredSharesMember 2021-09-03 0001582554 us-gaap:CommonStockMember 2020-01-12 2020-01-14 0001582554 us-gaap:CommonStockMember 2020-01-14 0001582554 2020-01-12 2020-01-14 0001582554 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582554 us-gaap:SeriesAPreferredStockMember MTNB:DesignatedMember 2021-12-31 0001582554 us-gaap:SeriesBPreferredStockMember 2018-06-19 0001582554 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:SeriesBPreferredStockMember 2021-06-16 2021-06-18 0001582554 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:CommonStockMember 2021-06-16 2021-06-18 0001582554 us-gaap:SeriesBPreferredStockMember 2021-06-19 2021-06-19 0001582554 us-gaap:CommonStockMember 2021-07-19 2021-07-19 0001582554 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001582554 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001582554 MTNB:AquariusMergerAgreementMember MTNB:HoldersOfAquariusBiotechnologiesIncMember MTNB:UnregisteredSharesMember 2021-06-19 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:HoldersMember 2021-06-17 2021-06-19 0001582554 us-gaap:SeriesBPreferredStockMember 2021-06-19 0001582554 us-gaap:SeriesBPreferredStockMember 2020-06-19 0001582554 srt:MaximumMember 2021-12-31 0001582554 srt:MinimumMember 2021-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2021-01-01 2021-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember srt:MinimumMember 2021-01-01 2021-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember srt:MaximumMember 2021-01-01 2021-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2021-12-31 0001582554 2014-05-07 2014-05-08 0001582554 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001582554 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001582554 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001582554 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001582554 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2020-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2020-01-01 2020-12-31 0001582554 2021-01-02 0001582554 2019-01-01 2019-12-31 0001582554 MTNB:ExercisePriceOneMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceOneMember 2021-12-31 0001582554 MTNB:ExercisePriceTwoMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceTwoMember 2021-12-31 0001582554 MTNB:ExercisePriceThreeMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceThreeMember 2021-12-31 0001582554 MTNB:ExercisePriceFourMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceFourMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft MTNB:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934

 

For the fiscal year ended December 31, 2021

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from           to            

 

Commission File Number: 001-38022

 

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   No. 46-3011414

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

1545 Route 206 South, Suite 302

Bedminster, New Jersey 07921

(Address of principal executive offices) (Zip Code)

 

908-484-8805

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001   MTNB   NYSE American

 

Securities registered pursuant to Section 12(g) of the Act: None.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold on June 30, 2021 was approximately $160.0 million.

 

As of March 4, 2022, there were 216,864,526 shares of the registrant’s common stock, $0.0001 par value, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 
 

 

MATINAS BIOPHARMA HOLDINGS, INC.

 

Annual Report on Form 10-K

 

Fiscal Year Ended December 31, 2021

 

Table of Contents

 

    Page
PART I   1
Item 1. Business 2
Item 1A. Risk Factors 33
Item 2. Properties 62
Item 3. Legal Proceedings 62
Item 4. Mine Safety Disclosures 62
PART II   62
Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities 62
Item 6. Selected Financial Data 62
Item 7. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations 63
Item 7A. Quantitative And Qualitative Disclosures About Market Risk 69
Item 8. Financial Statements And Supplementary Data 69
Item 9. Changes In And Disagreements With Accountants On Accounting And Financial Disclosure 69
Item 9A. Controls And Procedures 69
Item 9B. Other Information 70
PART III   70
Item 10. Directors, Executive Officers And Corporate Governance 70
Item 11. Executive Compensation 76
Item 12. Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters 82
Item 13. Certain Relationships, Related Transactions, And Director Independence 84
Item 14. Principal Accounting Fees And Services 85
PART IV   86
Item 15. Exhibits And Financial Statement Schedules 86
Item 16. Form 10-K Summary 87
Financial Statements F-1

 

i

 

 

PART I

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

 

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

 

● our ability to raise additional capital to fund our operations and to develop our product candidates;
   
● our anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials and product approvals;
   
● our history of operating losses in each year since inception and the expectation that we will continue to incur operating losses for the foreseeable future;
   
● our dependence on product candidates which are still in an early development stage;
   
● our reliance on our proprietary lipid nanocrystal (LNC) platform delivery technology, which is licensed to us by Rutgers University;
   
● our ability to manufacture GMP batches of our product candidates which are required for preclinical and clinical trials and, subsequently, if regulatory approval is obtained for any of our products, our ability to manufacture commercial quantities;
   
● our ability to complete required clinical trials for our lead product candidate and other product candidates and obtain approval from the FDA or other regulatory agents in different jurisdictions;
   
● our dependence on third parties, including third parties to manufacture our intermediates and final product formulations and third-party contract research organizations to conduct our clinical trials;
   
● our ability to maintain or protect the validity of our patents and other intellectual property;
   
● our ability to retain and recruit key personnel;

 

● our ability to internally develop new inventions and intellectual property;
   
● interpretations of current laws and the passages of future laws;
   
● our lack of a sales and marketing organization and our ability to commercialize products, if we obtain regulatory approval, whether alone or through potential future collaborators;
   
● our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates;
   
● the accuracy of our estimates regarding expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;
   
● developments and projections relating to our competitors or our industry; and
   
● our operations, business and financial results could be adversely impacted by the current public health pandemic related to COVID-19.

 

 1 

 

 

These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report on Form 10-K and are subject to risks and uncertainties. We discuss many of these risks in greater detail under “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

 

You should read this Annual Report on Form 10-K and the documents that we reference and have filed as exhibits to the Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Annual Report on Form 10-K by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Item 1. Business

 

Company Overview

 

We are a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules through our lipid nanocrystal (LNC) delivery platform technology. Our current pipeline consists of two potent anti-infective small molecules, MAT2203 (oral amphotericin B) and MAT2501 (oral amikacin). We are also expanding the application of our LNC platform through collaborations with well-respected pharmaceutical companies whose molecules and compounds benefit from the unique capabilities of our delivery technology, which can provide oral bioavailability and facilitate non-toxic and efficient intracellular delivery. We are intent on further expansion of our LNC platform, both internally and through external partnerships, into the field of nucleic acids where delivery into cells remains a critical element of therapeutic effect.

 

Matinas BioPharma is dedicated to maximizing the value associated with our unique LNC platform delivery technology. This proprietary platform technology, licensed from Rutgers University on an exclusive worldwide basis, nano-encapsulates chemical and biological payloads in a way that facilitates safe, efficient, and targeted intracellular delivery for a wide variety of molecules, including nucleic acids (mRNA, DNA, siRNA, antisense oligonucleotides (ASOs)), proteins and small molecules. Our LNCs are primarily comprised of phospholipids, like phosphatidylserine (PS), and calcium (which is required to keep LNCs intact), and are well differentiated from other viral and lipid nano-particle delivery technologies. LNCs have a novel targeting profile utilizing PS fusion and PS-receptor mediated endocytosis. LNCs have a neutral immunogenic profile enabling repeated administration, which is a significant drawback associated with both viral vector (AAV) and lipid nanoparticle (LNP) delivery. The structure of an LNC is highly stable, protecting the payload throughout formulation and following administration into the human body. This stability allows for the avoidance of extreme cold chain storage temperatures required for maintaining the integrity of LNPs and facilitates the oral administration of LNCs, which is not possible with either AAV or LNP delivery as they protect the vulnerable payload from the gastric environment and potential extracellular degradation. LNCs can also be administered via IV injection and intranasally. Because of their unique composition, LNCs can be delivered into a cell through both endocytosis and membrane fusion. Once LNCs gain access to the inside of a cell, they naturally unwind due to the necessarily low calcium concentrations inside a cell. Thereafter, depending on the target, payloads either have their desired impact inside a cell, or utilize the cell as a vehicle to target tissues, in the case of infection or inflammation.

 

 2 

 

 

Clinical and preclinical studies have demonstrated success in delivering LNCs to professional phagocytes, including macrophages, sites of infection and inflammation, and tumors. Each of these target cells either have exposed PS, enabling cellular fusion, or specific and dedicated PS receptors which facilitate receptor mediated cellular uptake. This tissue targeting, coupled with the potential to deliver a broad range of therapeutic agents, including small molecules, vaccines, peptides and proteins, as well as nucleic acid polymers (e.g., mRNA, DNA , ASOs, and siRNA,) provide a broad array of potential targets and modalities from which to create a broad pipeline of internal product candidates and partnerships.

 

Our lead drug candidate based on the LNC platform delivery technology is MAT2203, an oral formulation of amphotericin B, a well-known and highly effective antifungal drug. Amphotericin B is currently only available in IV formulations which are associated with significant renal toxicity and labeled restrictions on its use for up to 2 weeks in the United States and only 1 week in most parts of the world due to its toxicities, the most prevalent of which is severe nephrotoxicity. Despite these limitations, amphotericin B is currently used and approved to treat a variety of invasive, and potentially deadly, fungal infections due to its potency. MAT2203, which is formulated using our LNC delivery technology, has the potential to preserve the efficacy of amphotericin B while eliminating the risk of nephrotoxicity and providing more convenient and cost-effective oral administration. MAT2203’s product profile could potentially allow physicians and patients to use MAT2203 for longer periods of time and more broadly than amphotericin B could ever have been used previously.

 

The initial planned indication for MAT2203 is as step-down therapy from IV amphotericin B during induction treatment in patients with cryptococcal meningitis (CM), a deadly fungal infection located in the brain, and which primarily affects immunocompromised patients. The induction treatment period is typically 14 days and step-down therapy with MAT2203 would begin following an initial, short 1–2-day treatment course with IV amphotericin followed by 12-13 days of MAT2203. This initial step-down indication is a gateway indication, as we plan to expand the utilization of MAT2203 into consolidation therapy in CM patients (weeks 3-6) and then into the treatment of other invasive fungal infections and even for prophylaxis against invasive fungal infections in immunocompromised patients, such as transplant patients.

 

MAT2203 has been developed to date with the assistance and financial support of the National Institutes of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). MAT2203 has been designated as a Qualified Infectious Disease Product (QIDP) with Fast Track Status for the treatment of invasive candidiasis, the treatment of aspergillosis, the prevention of invasive fungal infections in patients who are on immunosuppressive therapy, and, most recently, the treatment of cryptococcosis. MAT2203 has also received an Orphan drug designation from FDA. Upon approval, MAT2203 could be eligible for up to 12 years of regulatory exclusivity in the United States.

 

In partnership with the NIH, we have conducted numerous preclinical studies of MAT2203 in cryptococcal meningitis and demonstrated that MAT2203 was able to (a) cross the blood-brain barrier, (b) effectively treat this infection and (c) eliminate the toxicity normally associated with delivery of amphotericin B intravenously. The NIH has funded a grant submission from the University of Minnesota for a clinical study of MAT2203 in patients with cryptococcal meningitis in Uganda, where this disease is highly prevalent among the human immunodeficiency virus (HIV)-positive community. This study, the Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT), initiated in 2019 and currently enrolling patients in Cohort 4 of the trial. In this trial we are exploring the use of MAT2203 for both induction (step-down and all oral) and consolidation therapy, and we believe that, if positive, this trial could form the foundation for the filing of a New Drug Application for MAT2203. The first three cohorts of EnACT have been completed, with the data from each of the cohorts reviewed by an independent Data Safety Monitoring Board (DSMB) prior to progression from one cohort to the next. EnACT is currently enrolling patients in Cohort 4, which is designed to test an all-oral regimen of MAT2203 during the induction period. Results from Cohort 4 are expected in the third quarter of 2022.

 

Based upon the data from the first two cohorts of EnACT, we held a meeting with the FDA in December of 2021 to discuss potential registration pathways for MAT2203. Following feedback from FDA, we plan to expand the EnACT trial to include a new, Cohort 5, which will replicate the design from Cohort 2, and include more patients where MAT2203 will be evaluated as step-down treatment to IV amphotericin. We anticipate meeting again with FDA in the first half of 2022 to finalize the protocol for Cohort 5 and agree on the requirements for NDA filing for this initial indication.

 

 3 

 

 

Data to date from EnACT validates the use of MAT2203 in difficult-to-treat fungal infections, and we believe positions MAT2203 to become a best-in-class antifungal drug for the treatment of additional invasive fungal infections. Furthermore, the demonstration that MAT2203 effectively crosses the blood-brain barrier in humans positions our LNC platform delivery technology to potentially be used more broadly with many other types of molecules, potentially including nucleic acids.

 

Our second clinical-stage program is the development of MAT2501, our oral amikacin development program, which also utilizes our LNC platform technology. MAT2501 is currently being studied in a Phase 1, single ascending dose (SAD) pharmacokinetic study in healthy volunteers, with results expected late in the first half of 2022. This program is funded in large part by the Cystic Fibrosis Foundation (CFF) and together we are developing MAT2501 initially for the treatment of non-tuberculous mycobacterial (NTM) infection, a serious lung infection which can be especially problematic in patients with cystic fibrosis (CF). To date, we have received commitments totaling approximately $4.6 million from the CFF based, in part, upon the positive preclinical proof-of-concept data generated by Colorado State University testing MAT2501 efficacy against both amikacin-sensitive and resistant strains of infecting organisms in a CF mouse model for NTM infections.

 

We plan to establish a broad internal and external pipeline of drug candidates utilizing our LNC platform. Internally, we have increased our efforts to demonstrate, validate and optimize the formulation and intracellular delivery of nucleic acids. We also are in active discussions with third parties concerning the formulation of proprietary nucleic acids utilizing our LNC platform and are concentrating on those parties with demonstrated scientific expertise and competitive advantages in the nucleic acid space. We have ongoing collaborations with third parties which have successfully broadened the application of our LNC platform and remain ongoing.

 

● In December 2019, we announced a feasibility collaboration with Genentech relating to the development of oral formulations of up to three Genentech proprietary compounds applying the LNC platform delivery technology. This collaboration has resulted in the successful formulation of two Genentech compounds and the agreement was recently extended to allow for the formulation and testing of a third proprietary Genentech compound.
   
● In December 2020, we announced a collaboration with the National Institute of Allergy and Infectious Diseases to evaluate oral formulations of Gilead’s antiviral remdesivir utilizing our LNC platform delivery technology. To date, successful in vitro and in vivo studies of LNC formulations of remdesivir have been conducted and another in vivo study is expected to commence in the first quarter of 2022.

 

We continue to evaluate additional potential strategic collaborations with other interested biotechnology and pharmaceutical partners. These collaborations could enable us to grow our external pipeline and generate upfront, license, milestone and royalty payments as we maximize the value of the overall LNC platform delivery technology.

 

Strategy

 

We are focused on redefining the intracellular delivery of nucleic acids and small molecules through our LNC drug delivery platform and its application to overcome current challenges in safely and effectively delivering small molecules, nucleic acids, gene therapies, proteins/peptides, and vaccines.

 

Key elements of our strategy include:

 

● Advancing our clinical stage assets based on our LNC platform delivery technology and continuing to expand utilization of this promising technology into areas of innovative medicine beyond small molecules, including nucleic acids (e.g. mRNA, DNA, ASOs) and proteins, both internally and through additional external collaborations and partnerships.
   
● Advancing MAT2203 toward NDA filing through the ongoing EnACT study for the treatment of cryptococcal meningitis, which highlights the safety and efficacy of this promising drug candidate, while also demonstrating the ability of our LNC platform technology to deliver potent medicines across the blood-brain barrier with oral administration.
   
● Progressing the development of MAT2501 through extensive preclinical toxicology and efficacy studies in NTM infections and completing a single ascending dose (SAD) pharmacokinetic study in healthy volunteers later in 2022, all with the financial support of the CFF.

 

 4 

 

 

Our Lipid Nanocrystal (LNC) Platform Delivery Technology

 

Efficient and safe delivery of medicines remains one of the biggest challenges in the pharmaceutical and biotech industry today. The importance of cell-mediated immunity and current challenges associated with effective intracellular drug delivery has created a significant area of need. Current technology options, including liposomes, lipid nanoparticles (LNPs) and viral vectors, have been widely adopted but each have significant limitations including inefficient delivery, undesirable and dangerous toxicity and immunogenicity, and unstable formulations forcing challenging storage conditions (Figure 1). The method in which these technologies gain access to a cell varies and often is responsible for significant adverse effects for patients. Despite these known challenges, adoption has been widespread due to the lack of viable alternatives. Today, LNPs and viral vectors are being used to deliver both small molecules and gene therapy.

 

Figure 1: Current Delivery Technologies

 

 

Our Solution: LNCs

 

Our proprietary LNCs are primarily composed of two naturally occurring materials: a phospholipid, like phosphatidylserine (PS), and calcium. They are stable and have a unique multilayered structure consisting of a large, continuous, solid, lipid bilayer sheet rolled up in a spiral or as stacked sheets, with no internal aqueous space. This unique structure provides protection from degradation for molecules trapped in or between lipid bilayers. Components within the interior of the LNCs remain intact, even though the outer layers of the LNCs may be exposed to harsh environmental conditions or enzymes (Figure 2).

 

 5 

 

 

Figure 2 LNC Formulation

 

 

 

Our LNCs protect active pharmaceutical ingredients in lipid bilayers and can intercalate into the phospholipid interior or otherwise remain trapped within the bilayers (Figure 3). The presence of minimal amounts of calcium keeps the LNCs intact.

 

Figure 3 LNCs Protect API in Bilayers

 

 

LNCs can be delivered in a variety of ways, including orally, intramuscularly, intravenously and intranasally. This flexibility represents a significant advantage over other delivery modalities and presents significant opportunities to efficiently encapsulate many different molecules, both water soluble and water insoluble, including small molecules, nucleic acids such as antisense oligonucleotides (ASOs), messenger RNA (mRNA) and small interfering RNA (siRNA), and nucleotides as large as eleven kilobases including DNA plasmids and potentially CRISPR/Cas9, a gene editing technology.

 

Intracellular delivery of molecules is usually accomplished by either endocytosis (through a variety of pathways including phagocytosis, clathrin-mediated endocytosis (CME), caveolin-mediated endocystosis, and macro- and micropinocytosis), or through membrane fusion. LNPs are limited in that they can typically only access a cell via CME, followed by disruption of the endosomal membrane within the cell to gain access to the cytoplasm. LNPs typically are very inefficient, and patients also experience injection site adverse events (AEs) and other toxicities associated with LNPs, thereby limiting chronic use. LNPs also cannot be delivered orally. Viral vectors, including adeno-associated virus, attempt to utilize nature’s intracellular delivery mechanisms to facilitate fusion with the cell membrane and delivery of molecules into a cell. Unfortunately, viral vectors have historically been associated with severe negative immune responses and, like LNPs, cannot be delivered orally. We believe LNCs can effectively delivery molecules through both endocytosis and membrane fusion, in addition to having great flexibility with the desired route of administration.

 

 6 

 

 

We believe that LNC’s unique ability to enter a cell through endocytosis (including phagocytosis and macropinocytosis), membrane fusion, or a combination thereof, relates directly to the presence of a phospholipid, like phosphatidylserine. Phosphatidylserine (PS) is present in virtually all cells and is an integral part of the cell membrane. PS is normally localized to the inner part of the membrane bilayer by active cellular processes. However, with cell “activation”, which occurs when there is infection, inflammation, injury, stimulation, cell death or some other issue impacting a particular cell, PS moves from the inner layer to the outer layer and facilitates fusion with our LNCs (Figure 4). Certain cells also contain PS receptors, which actively take up LNCs due to the presence of PS (Figure 5).

 

Figure 4: Asymmetry of the Phospholipid Membrane

 

 

Figure 5: Role of PS and PS Receptors in the Uptake of LNCs into Cells

 

 

 7 

 

 

Through phagocytosis, macrophage and other cells containing PS receptors readily engulf LNCs and their drug cargo into vesicles, or endosomes, facilitating intracellular delivery. LNCs can also fuse with cell membranes and deliver drug cargo directly to the cytoplasm. LNCs have been designed to mimic enveloped viruses and can efficiently deliver drugs and/or molecules to cells without adverse immune responses.

 

For some molecules, the goal is simply to achieve safe and effective intracellular delivery. This is especially relevant when delivering sensitive genetic material and other molecules desiring cellular impact (i.e., antivirals). For other molecules, or drugs, utilizing activated cells as a mechanism to deliver drug to infected tissues or other areas of the body becomes critical.

 

LNCs in pre-clinical studies have been shown to improve existing drugs by providing 1) cell-targeted delivery; 2) reduced blood levels thereby reducing toxicity; and 3) oral delivery of drugs now only available intravenously. For example, LNCs delivered orally work by encapsulating molecules of drugs in a solid, anhydrous, crystalline structure, protecting them as they pass through the GI tract where they cross the mucous membrane. Once the LNCs have crossed the mucosal barrier of the GI tract into the lymphatic system, they are picked up by activated cells including cells of the mononuclear phagocytic system, such as macrophages and dendritic cells. Professional phagocytes, with drug-loaded LNCs inside, are believed to follow natural signal molecule paths and migrate to the site of infection or to the target organ and deliver their payload.

 

Therapeutic applications of our proprietary delivery technology have been initially focused on the delivery of several potent and highly efficacious anti-fungal and anti-bacterial agents, which are currently still associated with serious side effects, including irreversible toxic effects on kidney and hearing function. We believe our technology has the potential for targeted delivery of these agents, which positions us to be at the forefront of dealing with these very serious problems. We have now also expanded our research and development efforts for our LNC platform delivery technology to focus on the delivery of a wide range of therapeutic treatments, in particular those in the oligonucleotide class of agents (antisense oligonucleotides, mRNA, and CRISPR-Cas9).We continue to advance our business development efforts to further expand our collaborations across pharma and biotech companies who have innovative therapies with delivery challenges, which may be addressed with our LNC platform delivery technology.

 

Safety: A key innovation of our LNC platform delivery technology is our ability to package medication inside lipid-crystal particles without leaking. Because of their crystalline nature, these particles are truly solid and hold on tightly to their medication payload. This is where the LNC platform delivery technology differs markedly from other lipid-based delivery technology, such as liposomal delivery. Liposomes are liquid delivery systems which typically leak some of their drug content into the circulatory system, thus still exposing vulnerable organs and tissues to potential toxic effects. Keeping potentially organ-toxic medications inside the lipid-crystal particles significantly differentiates our LNC platform delivery technology from other drug-delivery approaches.

 

Targeted Delivery: The size of our individual LNCs is typically in the range of 50-500 nanometers. This is very small and by comparison close to the size of a large virus or a small bacterium. Our body produces many activated cell-types that are predisposed to interact with our LNCs. These activated cell types, including bone marrow-derived hematopoietic cells such as macrophages, infected cells, injured cells, tumor cells and epithelial cells are all prone to engulf or fuse with our phosphatidylserine-based LNCs. Because of the size of our LNCs and their PS surface structure (the cell membranes of bacteria are also made up from PS), activated cells tend to take up these LNCs very efficiently and without any adverse immune response.

 

Oral Formulation: Many drugs that are currently on the market are only effective in treating diseases when administered intravenously. For example, many anti-infective drugs must be administered intravenously in order to be effective. IV administration presents several challenges to care, such as risk of infection, patient discomfort from injections, and higher cost of care than anti-infective drugs that can be taken orally (IV delivery must be performed by a doctor or nurse, often within a very expensive hospital setting). Although several technologies have been used to attempt to convert IV drugs to orally delivered medications, success has been limited due to the difficulty in achieving adequate bioavailability (i.e., the amount of drug that is absorbed into the body) with an oral formulation. We believe that the unique LNC structure in our platform technology protects the drug from degradation when it passes through the GI tract and that its lipid surface features facilitate the particle being absorbed into the blood stream. The potential application of our LNC platform delivery technology for the delivery of injectable medications offers significant clinical and commercial value with successfully demonstrated safety and efficacy in human clinical trials.

 

 8 

 

 

Our LNC platform technology changes the delivery of medicines in a unique manner and alters the bio-distribution of these medications by targeting tissues and organs that are affected by infection and inflammation. In addition to IV-only anti-infectives such as amphotericin B and amikacin, in animal studies we have orally delivered vaccines, siRNAs, NSAIDs, other anti-infectives such as atovaquone, and many other compounds across multiple therapeutic areas, demonstrating the potential broad application of our technology. We have observed rapid local accumulation in infected tissues, which appear to be the result of transport of our drug-loaded LNCs by and to activated cells.

 

Our LNC Clinical Stage Assets

 

We have leveraged our platform LNC delivery technology to develop two clinical-stage products that we believe have the potential to become best-in-class drugs in their respective therapeutic classes. Our lead product candidate, MAT2203, is an orally-administered LNC formulation of a broad spectrum anti-fungal drug called amphotericin B. Based on the data generated in Cohort 2 of the EnACT Trial and following an End of Phase 2 Meeting with FDA, we believe we have a pathway to NDA submission for MAT2203 following confirmatory data to be generated in an additional cohort (Cohort 5) in the ongoing EnACT Trial. We additionally believe there are opportunities for approval of MAT2203 for the treatment of additional invasive fungal infections in areas of high unmet medical need, which we will be evaluating in a number of preclinical animal models in Candida auris and mucormycosis in 2022.

 

Based upon the preclinical data generated by the NIH, the NIH has financially supported a grant application from the University of Minnesota to conduct the EnACT study in Uganda. This study was initiated in October 2019 and is exploring the use of MAT2203 for both induction and maintenance therapy in the treatment of CM, which is one of the most frequent and opportunistic infections in HIV patients. Given the high morbidity and mortality associated with CM in HIV patients, the clinical unmet need is very high with the global burden estimated at 1 million cases annually. We plan to leverage a 505(b)(2) regulatory pathway for MAT2203, in part relying upon FDA’s findings of safety based upon the available preclinical tox data for IV amphotericin B. This strategy was discussed with the FDA in June 2019, where we outlined our development plans for MAT2203 in CM and received FDA approval to proceed with the EnACT study which is currently enrolling subjects in Cohort 4 of the trial. We have received four qualified infectious disease (QIDP) designations as well as an orphan designation for the treatment of cryptococcosis, which, if approved, would result in twelve years of market exclusivity for MAT2203. We met with the FDA in an End of Phase 2 Meeting in December 2021 to review the Cohort 2 data from the EnACT Trial and discuss a potential path to NDA filing. Following our meeting with FDA, we now have a pathway to NDA submission following confirmatory data to be generated in an additional cohort (Cohort 5) in the ongoing EnACT Trial. We will be meeting with FDA early in the second quarter of 2022 to gain agreement on the design of this confirmatory cohort.

 

Our second clinical stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram negative and intracellular bacterial infections. In May 2017, we completed and announced topline results from a Phase 1 single escalating dose clinical trial of MAT2501 in healthy volunteers in which no serious AEs were reported and where oral administration of MAT2501 at all tested doses yielded blood levels that were well below the safety levels recommended for injected amikacin, supporting further development of MAT2501 for the treatment of NTM infections. Following reformulation work, in 2019 we received a grant from the CFF to complete preclinical studies with Colorado State University which further demonstrated the potential for MAT2501 in treating CF-associated NTM lung infections. In November 2020, we received an additional grant from the CFF in the amount of $3.75 million to support the continued development of MAT2501 through a comprehensive preclinical toxicology program and a SAD study in healthy volunteers with our new and improved formulation of MAT2501. The grant was later increased by $0.3 million in November 2021 to bring the CFF’s total commitment towards the development of MAT2501 to $4.6 million. This most recent grant was based upon the positive preclinical proof of concept data generated by Dr. Diane Ordway at Colorado State University in a rigorous mouse model of NTM infection in mice with underlying CF disease. We are currently conducting key acute and long-term toxicology studies to support Phase 2 clinical trials as well as an ongoing Single Ascending Dose (SAD) Trial.

 

 9 

 

 

MAT2203

 

Our lead anti-fungal product candidate, MAT2203, is an application of our LNC platform delivery technology to a broad spectrum and potent anti-fungal drug called amphotericin B. Traditionally, amphotericin B is an IV-administered drug used as a last resort for treatment of systemic fungal infections resistant to triazoles and echinocandins, including resistant candidiasis, cryptococcal meningoencephalitis, and aspergillosis. To date, there have been little to no reported clinically observed drug-resistance to amphotericin B, further bolstering the use of this compound as the most likely last resort treatment for fungal infections in the foreseeable future. However, the use of amphotericin B is relatively limited because it is currently only available as an IV-administered product and has documented history of severe toxicity (most notably nephrotoxicity). By utilizing our LNC platform delivery technology to nano-encapsulate amphotericin B, there is now an opportunity for the drug to be administered orally with targeted delivery to infected cells, which we believe may have fewer side effects than the currently available IV-formulations of amphotericin B. Our LNC delivery of amphotericin B changes the bio-distribution, resulting in a higher level of amphotericin B at the site of infection and a lower level of free circulating drug. By reducing the amount of circulating drug, our LNC platform delivery technology may reduce overall toxicity. Importantly, drug concentrations will be high only in target tissues due to the migratory nature of drug-carrying phagocytes to inflammatory regions. Based upon data generated to date, we believe MAT2203 has the potential to offer improved safety and reduced toxicity and, as a result, we believe MAT2203 will be able to offer a categorically different and improved formulation that delivers orally administered amphotericin B, directly to the target cell at the site of infection. In collaboration with the NIH, in multiple studies, we have demonstrated in CM mouse models that our LNC-delivered amphotericin B, following oral administration, can successfully cross the blood brain barrier to the site of infection in mice. This demonstration provides important data indicating that our LNC platform delivery technology could become an important delivery solution for a variety of CNS-based disorders and diseases. These preclinical data have now been born-out in clinical data from Cohort 2 of the EnACT Trial.

 

We believe that MAT2203 has the potential to become a best-in-class induction and consolidation therapy for the treatment of CM in HIV patients by offering the following key potential benefits:

 

● Potential to treat resistant pathogens. We believe that MAT2203 has the potential to prevent and treat fungal infections caused by drug-resistant fungi, including those resistant to existing azoles and echinocandins, due to amphotericin B’s fungicidal (i.e., killing the fungi) nature and potency against resistant strains and the potential for our LNC platform delivery technology to provide higher drug exposure directly at the site of infection early in the course of therapy.
   
● Enabling an all-oral therapy. CM has become the most common cause of adult meningitis in many parts of Africa, where cryptococcosis now rivals tuberculosis in all-cause mortality. While long-term survival has improved with widespread use of antiretroviral therapy in high-income countries, early mortality remains high. Early mortality rates are often ~ 70% in routine practice where access to diagnostics or medications is limited or unavailable, intracranial pressure is uncontrolled, or in settings where other barriers to the management of CM exist. IV administration of amphotericin B is not often possible in resource-limited settings, even when it is available.
   
● Shorter and less costly hospital stays and lower outpatient costs. By providing physicians and patients with access to an orally available, broad spectrum fungicidal agent in MAT2203, there is the potential to reduce hospital costs, which account for over 70% of the overall treatment cost of invasive fungal infections.

 

The FDA has granted MAT2203 designations for Qualified Infectious Disease Product, or QIDP, and Fast Track for the treatment of invasive candidiasis and aspergillosis, for the prevention of invasive fungal infections in patients on immunosuppressive therapy, and the treatment of cryptococcosis. We recently also received Orphan Drug Designation for MAT2203 for the treatment of cryptococcosis and associated CM. The FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. The orphan drug designation provides eligibility for orphan drug exclusivity in the United States upon FDA approval if a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation. For a product that obtains orphan drug designation based on a plausible hypothesis that it is clinically superior to the same drug that is already approved for the same indication, in order to obtain orphan drug exclusivity upon approval, clinical superiority of such product to this same drug that is already approved for the same orphan indication must be demonstrated. Orphan drug exclusivity means that the FDA may not approve any other applications, including a new drug application (NDA), to market the same drug for the same indication for seven years, except in limited circumstances such as if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Similarly, the FDA can subsequently approve a drug with the same active moiety for the same condition during the exclusivity period if the FDA concludes that the later drug is clinically superior, meaning the later drug is safer, more effective or makes a major contribution to patient care. Orphan drug designation also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, a waiver from payment of user fees, an exemption from performing clinical studies in pediatric patients unless the FDA requires otherwise by regulation, and tax credits for the cost of the clinical research. The QIDP designation, provided under the Generating Antibiotic Incentives Now Act, or the GAIN Act, offers certain incentives for the development of new antibacterial or antifungal drugs, including eligibility for Fast Track designation, priority review and, if approved by the FDA, eligibility for an additional five years of marketing exclusivity. Fast Track designation enables more frequent interactions with FDA to expedite drug development and review. Fast Track designation does not change the standards for approval, and we can provide no assurances that we can maintain Fast Track designation for MAT2203 or that such designation will result in faster regulatory review. The seven-year period of marketing exclusivity provided through orphan designation, if granted, combined with an additional five years of marketing exclusivity provided by the QIDP designation positions MAT2203 with a potential for a total of 12 years of marketing exclusivity to be granted at the time of FDA approval.

 

 10 

 

 

MAT2203 - Product Profile

 

MAT2203 is an orally-administered, LNC formulation of amphotericin B (a broad-spectrum fungicidal agent). Little to no clinical resistance has been reported to date with amphotericin B as compared to the rapidly emerging drug resistance seen with other antifungal therapies. Currently, IV administered amphotericin B is the only broad spectrum fungicidal drug; however, it also has significant treatment-limiting side effects, most notably nephrotoxicity. We believe that the ability to provide amphotericin B orally using our proprietary LNC platform delivery technology, may offer a new and promising alternative for patients and doctors.

 

The data from animal toxicity studies for MAT2203 indicate a substantial advantage over other amphotericin B formulations in observed toxicities and side effects, which we believe is driven by two primary factors:

 

● The LNC is a solid particle that does not significantly “leak” its drug content while circulating. The particle releases its medication pay-load only when inside the target cells, and thus appears that the use of MAT2203 does not result in off-organ toxicities normally seen in the kidneys when using current formulations of amphotericin B.
   
● Because of this targeted delivery, we have been able to increase the therapeutic window on a mg/kg basis as compared to IV amphotericin B formulations. We have observed equivalent efficacy at lower doses as well as been able to use oral doses of up to 10x the highest tolerable IV dose in animal model studies.

 

Development History of MAT2203 and Initial Target Indication

 

Preclinical Data:

 

Oral MAT2203 has demonstrated antifungal activity when administered orally in several animal models for Cryptococcus, Candida, and Aspergillus infection [Zarif et al, 2000; Perlin, 2004; Lu et al, 2019]. The efficacy in these animal models have shown to demonstrate comparable or superior antifungal activity compared to IV amphotericin B but with reduced toxicity.

 

The in vivo efficacy of MAT2203 has been shown in multiple mouse models infected with Cryptococcus neoformans; these studies were conducted by Dr Peter Williamson at NIH [Lu et al, 2019]. Multiple studies demonstrated the potential for MAT2203 administered in combination with 5FC to provide an effective oral formulation for treatment of cryptococcal meningitis. Using a 3-day delayed model of murine cryptococcal meningoencephalitis and a large inoculum of a highly virulent strain of serotype A C. neoformans, MAT2203, administered in combination with 5FC, was found to have efficacy equivalent to administered amphotericin B deoxycholate with 5FC and superior to oral fluconazole without any observed toxicity. Transport of fluorescent MAT2203 particles to the brain as well as significant brain levels of amphotericin drug was demonstrated in treated mice, and immunological profiles were similar to those of mice treated with conventional amphotericin B. These studies offer the potential for an efficacious oral formulation of a known fungicidal drug against intrathecal cryptococcal disease. MAT2203 therefore provides a promising therapeutic option for CM.

 

 11 

 

 

Additional preclinical studies of MAT2203 are planned to investigate the treatment of invasive fungal infections, such as Candida auris and mucormycosis (black fungus), to position MAT2203 for label expansion. Data is expected in late 2022.

 

Clinical Data:

 

Clinical studies conducted and previously completed with MAT2203 include 2 Phase 1 studies in healthy subjects (Study CAM-102 and Study MB-70011), and 2 Phase 2 studies: 1 completed study in patients with moderate to severe vulvovaginal candidiasis (VVC) (Study MB-70005) and 1 study in patients with mucocutaneous candidiasis who are refractory or intolerant to standard non-IV therapies (MB-70004).

 

As of the end of January 2022, MAT2203 has been administered to a total of 247 subjects in 5 clinical trials as follows: 52 healthy subjects (Studies CAM-102 and MB-70011), 36 patients with HIV and 65 patients with cryptococcal meningitis (in EnACT Trial MB-70007), 91 patients with VVC (MB-70005), and 4 patients with mucocutaneous (esophageal and oropharyngeal) candidiasis (MB-70004). In these studies, single doses of MAT2203 up to 2.0 g and repeated doses of MAT2203 up to 2.0 g/day and as long as 60 months have been safe and well-tolerated. Results of these studies support efficacy of oral MAT2203 against Cryptococcus and overall safety of longer-term MAT2203 treatment.

 

The EnACT Trial (MB-70007) consists of 2 parts. Part 1 of the EnACT Trial was conducted in HIV-positive patients with a history of cryptococcosis evaluated ascending oral doses of MAT2203, and identified a safe maximum tolerated dose for Part 2 of the trial.

 

Part 2 of the EnACT Trial is a prospective, randomized, open-label clinical trial to investigate the safety, tolerability, and efficacy of oral MAT2203 compared to Standard of Care (SoC) for the treatment of CM in patients with HIV and was originally divided into four distinct patient cohorts. Cohort 2 of the EnACT Study was designed to assess the potential to treat CM infections with oral MAT2203 as a step-down treatment during the induction phase of treatment immediately following only 2 days of IV amphotericin treatment, with continued treatment with MAT2203 for up to 6 weeks during early maintenance treatment. We believe that the clinical benefit of step-down treatment from IV amphotericin to oral MAT2203 will provide compelling clinical evidence of efficacy in treating this deadly infection with our oral agent. This cohort of patients also provided key data to support the further advancement of the EnACT Study to ultimately test the potential to treat CM infections with an all-oral amphotericin dosing regimen in subsequent cohorts (Cohorts 3 and 4). The primary efficacy endpoint for Part 2 of EnACT is early fungicidal activity (EFA) defined as rate of clearance of Cryptococcus from the cerebrospinal fluid (CSF) (log10 colony forming units [CFU]/mL/day) as measured by serial quantitative fungal cultures over the first 2 weeks of treatment.

 

In Part 2, cohorts 1, 2, and 3 have been completed and Cohort 4 is ongoing. Enrollment in Cohort 3 has completed with 14 subjects enrolled, 8 of whom are still active in the trial; 10 of the 14 patients received at least 1 dose of MAT2203. Eight patients have been enrolled in Cohort 4 as of 26 January 2022; 5 of these 7 patients received at least 1 dose of MAT2203.

 

In Part 2, Cohort 2 of the EnACT Trial (MB-70007), 40 patients with active CM were treated with MAT2203. The mean EFA for these 40 patients who received MAT2203 during induction was 0.422 log10 CFU/mL/day (95% CI: 0.294, 0.550). The primary efficacy endpoint for the trial was met because the lower bound of the 95% CI for the mean EFA excluded 0.20 log10 CFU/mL/day. In addition, among patients treated with MAT2203, CSF sterilization rates were greater than 90% and all patients who completed the induction phase achieved sterile CSF cultures at end of induction or during consolidation treatment. Survival rates in Cohort 2 were high and there were no relapses in patients receiving MAT2203 during consolidation. Additional analysis of final data from Cohort 2 demonstrated survival at Day 30 of 98% in patients receiving MAT2203 vs. 88% in patients receiving IV amphotericin B and culture conversion (sterility) assessed at any time during the trial of 97% in patients receiving MAT2203 and 76% in patients receiving IV amphotericin B.

 

 12 

 

 

MAT2203 was demonstrated to be safe and well-tolerated over 6 weeks of treatment in Part 2, Cohort 2 of EnACT. The majority of SAEs and AEs reported were considered to be expected in this HIV patient population and there was no evidence of MAT2203-associated renal toxicity or electrolyte abnormalities in patients who received MAT2203. Additionally, GI AEs reported were generally transient, moderate in severity, and did not have an impact on the ability of patients to tolerate the planned treatment course.

 

Health Authority Interactions:

 

In December 2021, the Company had a meeting with FDA to discuss a potential registration pathway for MAT2203. The outcome of the meeting reinforced the FDA’s ongoing commitment to anti-infective drug development generally and to MAT2203 specifically. During the meeting, the FDA expressed no concerns with any data generated to date related to the efficacy, safety, or tolerability of MAT2203. Additional confirmatory evidence was requested for an indication for step-down therapy during induction treatment, but there was no requirement for a separate stand-alone study or enrollment of U.S. patients. The FDA expressed openness to an expansion of EnACT to include a new Cohort 5 to run alongside Cohort 4 in Uganda, increasing the number of clinical sites from two to five to streamline the development program in support of an accelerated NDA submission. The Company is planning to meet with FDA in April 2022 to finalize cohort design, including sample size required for non-inferiority and to discuss a potential primary endpoint of 30-day survival. NIH financial support of EnACT expansion to Cohort 5 is anticipated and the Company continues to evaluate the timing for submission of an application for Breakthrough Designation. A key chemistry, manufacturing, and controls (CMC) meeting with FDA is scheduled late in the first quarter of 2022 to discuss and evaluate our MAT2203 formulation in support of a potential NDA submission in late 2023. The Company also plans to submit a formal Request for Scientific Advice to the European Medicines Agency (EMA) in 2022 to align and plan for expanding the regulatory footprint for MAT2203 globally.

 

Antifungal Market Opportunity

 

The overall global antifungal market accounted for approximately $11.9 billion in 2018 and is expected to reach approximately $13.9 billion by 2026. In 2018, the global invasive fungal infection market was valued at more than $6 billion. This includes therapies used as active treatment or prophylaxis (preventative) in the inpatient and outpatient setting, therapies used for the treatment of hospitalized patients and therapies used for the treatment of patients who are being discharged from the hospital. We estimate that, each year, there are over 1.5 million cases of invasive fungal infections caused by various species of Candida, Aspergillus and Cryptococcus, the three most common invasive fungal pathogens, globally. The estimated incidence in the U.S. for these conditions is approximately 46,000 for invasive candidiasis, 15,000 for invasive aspergillosis, and 3,700 for CM. For example, aspergillosis-associated hospitalizations in the U.S. alone came at an estimated treatment cost of more than $1 billion. The rapid progression of disease and high mortality rates (20% - 50%) associated with documented invasive fungal infections often result in antifungal therapy being administered in suspected (unconfirmed) cases or as a preventative measure in patients at high risk. Also, the increasingly widespread use of immune suppressive drugs as cancer chemotherapy or for organ transplantation or treatment of autoimmune disease has resulted in an increasing population of patients at risk for invasive fungal infections. Furthermore, the limited number of systemic antifungal drug classes, consisting of azoles, echinocandins and polyenes, and their extensive use, has led to increased numbers of infections with drug-resistant strains. The Centers for Disease Control and Prevention (CDC) has listed fluconazole-resistant Candida as a serious threat requiring prompt and sustained action and has also identified a rise in echinocandin resistance, especially among Candida glabrata. In June 2016, the CDC issued an extraordinary alert for healthcare facilities and providers to be on the lookout for patients with Candida auris, a multidrug resistant strain with high mortality (approximately 60%). Almost half of Candida auris isolates are multidrug resistant to two or more antifungal classes (large majority resistant to fluconazole, 40% resistant to echinocandins). We believe this underscores the urgent need for new agents with demonstrated activity against resistant strains and that can be administered with significantly less toxicity and the potential to discharge patients earlier to reduce hospital stays and associated costs.

 

 13 

 

 

Physicians’ options for the treatment of fungal infections are limited by a lack of innovative therapies. Several factors have contributed to the low rate of antifungal drug development, including a previously challenging regulatory environment that necessitated large and costly clinical trials. As a result of this regulatory environment and other factors, the number of antifungals in development has decreased, while anti-microbial resistance has increased.

 

MAT2501

 

MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic agent amikacin, which utilizes our proprietary LNC platform to achieve oral bioavailability, limit toxicity, and enable targeted delivery to sites of infection. Currently, amikacin can only be delivered parenterally or through inhalation and is used to treat a variety of chronic and acute bacterial infections, including both NTM infections and various multi-drug resistant gram-negative bacterial infections. IV and inhaled amikacin, however, are associated with major side-effects including nephrotoxicity and ototoxicity (permanent loss of hearing) with long-term use. We believe that MAT2501’s ability to orally deliver high levels of amikacin directly to the lung and without use-limiting toxicity, distinguishes it from all available therapies and could provide an important solution for patients and physicians. We are currently developing MAT2501 for the treatment of NTM lung disease, including infections in patients with CF. MAT2501 has been designated as a Qualified Infectious Disease Product (QIDP) and as an Orphan Drug for the treatment of NTM by the FDA.

 

NTM lung disease is a chronic, debilitating condition arising from an NTM infection in the lungs and is associated with significant patient morbidity and mortality. The signs and symptoms of NTM lung disease often overlap with the underlying lung conditions that increase the risk for NTM, like CF, bronchiectasis, COPD, and asthma. The most common pathogens for NTM infections in the United States are Mycobacterium avium complex (MAC), which accounts for more than 80% of all NTM infections in the US. Patients with NTM lung infections frequently require lengthy hospital stays and prolonged courses of antibiotics to manage their disease. The prevalence of human disease attributable to NTM has increased over the past two decades and is now growing at more than 8% per year and is even more prevalent than tuberculosis in the US. In 2018, it was estimated that between 75,000 and 100,000 patients were diagnosed with NTM lung disease in the US alone.

 

NTM infections are extremely difficult to treat, especially so in patients with CF (Eikani, et. al., 2018). The infecting organisms are frequently resistant to most antibiotics, and current treatment regimens require combination therapies with highly toxic drugs for long periods of time, further complicated by challenges in delivering therapeutic levels of these toxic drugs across plasma membranes of infected cells.

 

These challenges are amplified in CF patients, with the thick buildup of pulmonary secretions that further impair treatment of infecting organisms. Pulmonary infections represent the most frequent type of infection in CF patients, and are responsible for more than 90% of deaths in the CF population (Rowe SM, et.al. 2005). MAC and Mycobacterium abscessus complex (MABSC) are NTM species that have emerged in recent years as important opportunistic pathogens frequently responsible for pulmonary infections in CF patients (Brode SK, et. al. 2014). Infections due to MAC and MABSC are difficult to treat and to eradicate since these organisms are naturally resistant to most antibiotics. The recommended treatment for MAC and MABSC pulmonary infections includes a combination of a macrolide (clarithromycin or azithromycin), an aminoglycoside (amikacin), and an antimycobacterial antibiotic for MAC (rifampin and ethambutol), while MABSC many times requires intravenous β-lactam (cefoxitin or imipenem) at least for 12 months (Floto RA, et. al., 2016). The cure rate is only 25-40% in the case of macrolide resistance, which is present in 40 to 60% of the isolates (Roux AL et. al., 2015). Moreover, unsuccessful eradication of MAC and MABSC is considered as a contraindication for lung transplantation by several CF centers, and significantly restrict therapeutic options in severely ill patients. Therefore, more specific and active and less toxic antimicrobials are urgently needed.

 

MAT2501 Previous and Ongoing Studies

 

The most recently completed pre-clinical animal model studies testing the preclinical efficacy of MAT2501 were funded by a grant from the CFF. An additional grant from the CFF was awarded in February of 2020 to support the screening of new optimized formulations of MAT2501 in collaboration with Diane Ordway, Ph.D. of Colorado State University (CSU). Most recently, a CFF grant of $3.75 million was awarded to us in November 2020, and later increased by approximately $0.3 million in November 2021, to support the early development of MAT2501 through the end of Phase 1. The recent grant from the CF Foundation was based upon the data generated by CSU and summarized below.

 

 14 

 

 

Preclinical and Clinical Studies

 

The Investigational New Drug (IND) application for MAT2501, was opened in January 2016 to investigate MAT2501 in the proposed indication for treatment of NTM infections. The early development plan for MAT2501 builds upon the preclinical proof of concept in vitro studies which have demonstrated antibiotic activity against both sensitive and multidrug resistant strains M. abscessus and M avium. The ongoing toxicology program is evaluating the optimized formulation of MAT2501 in a rigorous battery of studies to assess and characterize the safety profile of MAT2501. The studies will support the safety package required to progress the development of MAT2501 into Phase 2 clinical trials. These studies are designed to carefully monitor the safety signals known to be associated with IV amikacin treatment (hearing loss and kidney/renal safety). These studies include:

 

  ● 28-day rat toxicity study to assess any potential effects of MAT2501 on hearing and associated side effects; and
     
  ● 3- and 9-month long-term safety study in dog to support longer-term dosing in clinical trials.

 

We are also currently conducting a Single Ascending Dose (SAD) trial with the optimized formulation of MAT2501 which is currently in the enrollment phase of the study in which we are assessing the PK, safety, and tolerability of escalating doses of MAT2501. Topline data from the trial are expected in the later part of the second quarter of 2022. Additional Phase 1B and Phase 2 trials for the treatment of NTM are expected to commence in 2023, pending additional financial support from the CFF.

 

NTM Treatment Guidelines and Limitations of Current Treatments

 

The American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMIID), and Infectious Diseases Society of America (IDSA) jointly sponsored the recent development of updated NTM Treatment Guidelines in adults (Daley C, et.al, 2020). The guidelines recommend a standard NTM lung disease treatment with a combination of 3-4 medications. These include amikacin (or streptomycin), clarithromycin (or azithromycin), rifampin (or rifabutin), and ethambutol. Amikacin is an important drug used for treatment of Mycobacterium abscessus pulmonary disease. Certain combinations of antibiotics work better together because of their unique mechanisms of action that work in concert to eliminate the infection. It is for this reason that sputum samples are qualified for precise identification of the species and sensitivity testing of the microorganism. When treatment failures arise, another combination of antibiotics will be recommended depending on the NTM strain.

 

Multiple drug therapy in NTM lung disease can cause adverse effects, which leads to treatment discontinuation or patient nonadherence. Current guidelines recommend monitoring for drug toxicity at repeat intervals. Gastrointestinal side effects with oral agents are common. Due to severe gastrointestinal disturbance, the use of macrolides may require dose adjustment. Drug-induced hepatotoxicity due to rifampin and other agents must be monitored by liver function tests and monitoring complete blood count when using rifampin or tigecycline is recommended. Renal function testing is required with IV amikacin use due to its known renal toxicity liability, an issue that we believe could be addressed with our novel targeted LNC oral formulation of amikacin, MAT2501. Due to the established risk of otoxicity such as hearing loss, tinnitus, or vestibular toxicity, patients who receive IV amikacin or streptomycin need to be educated regarding the signs and symptoms of toxicity with audiometry testing at the start of therapy and again on subsequent visits with discontinuation, or a decrease in dose or frequency if signs suggestive of toxicity occur. There remains a significant unmet clinical need for safer, yet potent, agents for the improved management of NTM lung disease. MAT2501 has the potential of providing a safer and more targeted approach to the treatment of NTM disease.

 

LYPDISO

 

The Company continues to evaluate potential options for its legacy asset, LYPDISO™. LYPDISO is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, intended for the treatment of cardiovascular and metabolic conditions. This next-generation omega-3 therapy has been shown in two head-to-head studies to provide effective triglyceride-lowering and significantly higher EPA blood levels than Vascepa®. A global process to identity and potentially secure a partner to continue development of LYPDISO remains ongoing.

 

 15 

 

 

Strategic Collaborations Using LNC Platform Delivery Technology

 

We believe our LNC platform delivery technology can be used to reformulate a wide variety of molecules and drugs which, (i) require delivery technology to effectively protect molecules and drugs in the body and could benefit from efficient delivery and cellular uptake by target cells, and (ii) are currently only available in IV formulations or, (iii) otherwise experience significant toxicity-related AEs. We have tested a range of pharmaceutical compounds reformulated by our LNC platform delivery technology in proof-of-concept animal studies, including oligonucleotides (mRNA, siRNA, DNA plasmids), vaccines, anti-inflammatory agents, NSAIDs and atovaquone. We intend to pursue opportunities to develop products, either alone or in partnership with other pharmaceutical or biotech companies, and this remains a key part of our strategy to maximize the value of this unique and disruptive LNC delivery technology.

 

In December 2019, we announced a feasibility collaboration with Genentech, a Roche company, to evaluate formulations of a number of Genentech compounds utilizing our LNC platform delivery technology. Genentech recently extended this collaboration for another year, through 2022. The original agreement provided for cooperation on up to three proprietary Genentech compounds for initial in vitro testing. Two of the programs have been completed. Each demonstrated the successful intracellular delivery of LNC-formulated small molecules and oligonucleotides, without accompanying toxicity. Genentech is evaluating the third proprietary compound to provide the Company for testing, and the Company anticipates additional data from this program during 2022.

 

In December 2020, we announced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to develop oral formulations of Gilead’s remdesivir, which is currently only available as an intravenous therapy in the fight against COVID-19. We believe the attributes of our LNC platform technology will allow for oral bioavailability and efficient intracellular delivery. In the fourth quarter of 2021, the NIAID, together with the Department of Epidemiology at the University of North Carolina at Chapel Hill (UNC), conducted an in vivo test of our LNC formulation of Gilead Science’s remdesivir (LNC-RDV) in a standard genetically modified mouse model of SARS-CoV-2 infection. In this animal model, orally administered LNC-RDV reduced viral titers and improved clinical parameters of body weight and congestion scores five days following infection, with effects similar to those seen with subcutaneous administered remdesivir. Following discussion with both NIAID and Gilead, these highly encouraging results position LNC-RDV for further in vivo work to be conducted at UNC and supported by NIAID. This preclinical study is anticipated to commence late in the first quarter of 2022, with data expected in the second half of 2022.

 

We continue to evaluate additional potential strategic collaborations with other interested biotechnology and pharmaceutical partners. These early stage, proof-of-concept evaluations could provide an efficient, less expensive pathway to create numerous strategic verticals in areas of innovative medicine while capitalizing on the development expertise and financial resources of well-established partners. Data from these evaluations could position us as a licensor of our LNC platform delivery technology to numerous strategic partners better positioned to absorb the risks and costs of drug development while allowing our company to become a royalty aggregator with the potential to generate upfront license, milestone and royalty payments as we maximize the value of the overall LNC platform delivery technology.

 

Exclusive License Agreement with Rutgers University

 

Through our acquisition of Aquarius Biotechnologies Inc., we acquired a license from Rutgers University for the LNC platform delivery technology. We changed the name of Aquarius Biotechnologies Inc. to Matinas BioPharma Nanotechnologies, Inc. and in February of 2022, the parties agreed to a Second Amended and Restated Exclusive License Agreement. The agreement provides for (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $100,000 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of $50,000 over the term of the license agreement. There was also a reduction in the consideration paid to Rutgers in the event of a sublicense to a third party of the exclusive patent rights granted pursuant to the Agreement. In consideration of the concessions made by Rutgers in the license agreement, the Company issued Rutgers 400,000 shares of common stock in February 2022. We also agreed to continue to assume the responsibility to pay required patent prosecution and maintenance fees covering the technology.

 

 16 

 

 

Unless otherwise terminated by either party, the term of the license, on a country-by-country basis, shall be the longer of 8-1/2 years from the date of first commercial sale of a product in a country using the licensed technology or until the expiration of the last-to-expire patent rights licensed under the agreement, whichever is longer. Rutgers has the right to terminate the license agreement if we have not commenced commercial sales of at least one product using the licensed technology within eight years of the effective date of the Second Amended and Restated License Agreement.

 

Intellectual Property

 

The proprietary nature of, and protection for, our product candidates and our discovery programs, processes and know-how are important to our business. We will seek to protect our products and associated technologies for their manufacturing and development through a combination of patents, trade secrets, proprietary know-how, FDA exclusivity and contractual restrictions on disclosure. Our policy is to pursue, maintain and defend patent rights and to protect the technology, inventions and improvements that are commercially important to the development of our business. Our success will significantly depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology and inventions and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely heavily on know-how and continuing technological innovation to develop and maintain our proprietary position.

 

Exclusively Licensed and Matinas-Owned Intellectual Property Relating to Our Proprietary LNC Platform Delivery Technology and MAT2203

 

The patents and patent applications that we exclusively license from Rutgers University provide patent protection for the proprietary chemistry technology used in our process to make our lipid nanocrystal and geodate cochleates and formulate the active pharmaceutical ingredients delivered inside this delivery technology, as in MAT2203, our lead product comprising the LNC platform delivery technology. Pursuant to our license agreement, we acquired rights to a portfolio that currently includes 2 pending applications and 30 issued U.S. and foreign patents, including 20 patents issued within the last 5 years, which extends patent protection until at least 2033. In addition, over the past 6 years, we have over 30 Matinas-owned pending patent applications filed both in the United States and in foreign jurisdictions. We have chosen to file these patent applications in selected foreign markets that we consider important for our product candidates. These international markets generally include Europe, China, India, Brazil, Russia, Canada, Japan, Korea, Australia and Mexico. These pending patent applications can extend patent protection through 2040. This patent portfolio covers our LNC platform delivery technology which covers a broad spectrum of technology, including amphotericin B LNCs, geodate LNCs, methods of delivering nutrients or biologically relevant molecules to a host using LNCs, LNC vaccine compositions and protein-lipid vesicles, small interfering RNA LNCs, methods of enhancing the LNC encapsulation of hydrophilic molecules, LNCs made with low purity soy phosphatidylserine, use of site-regulating agents to control LNC size, methods of treating Mycobacterial infections, methods of treating cryptococcus infections, and LNC-mediated delivery of nucleic acids.

 

Matinas-Owned Intellectual Property Relating to LYPDISO

 

We have sought patent protection in the United States and internationally for our LYPDISO discovery program, and any other inventions to which we have rights, where available and when appropriate. Our policy is to pursue, maintain and defend patent rights, whether developed internally or licensed from third parties, and to protect the technology, inventions and improvements that are commercially important to the development of our business.

 

Our current patent portfolio relating to LYPDISO is comprised of two issued U.S. patents and one issued foreign patent in Australia. The issued patents cover the Company’s proprietary methods relating to triglyceride levels, total cholesterol, VLDL-cholesterol or apolipoprotein C-III by administering a pharmaceutical composition comprising omega-3 fatty acids including eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). These patents provide important protection to LYPDISO through 2033. In addition, we have eight additional patent applications across four patent families covering the oil composition for LYPDISO, other omega-3 fatty acid compositions, as well as formulations of LYPDISO and similar formulations. All of these filed patent applications also comprise methods of use of such oil compositions and formulations. Any patents that may issue from these filed United States patent applications and their counterpart international application covering the LYPDISO drug substance, formulation, and methods for use in treatment would extend protection until at least 2033.

 

 17 

 

 

We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may own or license in the future, nor can we be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our technology. For this and more comprehensive risks related to our intellectual property, please see “Risk Factors—Risks Relating to Our Intellectual Property and Regulatory Exclusivity.”

 

In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, significant aspects of our proprietary LNC platform delivery technology are based on unpatented trade secrets and know-how. Trade secrets and know-how can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

 

We also plan to seek trademark protection in the United States and outside of the United States where available and when appropriate. We intend to use these registered marks in connection with our pharmaceutical research and development as well as our product candidates.

 

Competition

 

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. Many of these companies have far greater human and financial resources and may have product candidates in more advanced stages of development and many will reach the market before our product candidates. Competitors may also develop products that are more effective, safer or less expensive or that have better tolerability or convenience.

 

Although we believe that our proprietary LNC platform delivery technology, experience, and knowledge in our areas of focus provide us with competitive advantages, potential competitors could reduce our commercial opportunities. For many of our product candidates, we anticipate facing competition from other products that are available on a generic basis and offered at low prices. Many of these generic products have been marketed by third parties for many years and are well accepted by physicians, patients, and payers.

 

We believe that MAT2203 and MAT2501 and any other development candidate we may pursue in the future using our proprietary LNC platform delivery technology, paralleled with our scientific and development expertise in the field of drug delivery, provide us with competitive advantages over our peers. However, we face potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as from generic drug manufacturers, academic institutions, governmental agencies, and public and private research institutions.

 

 18 

 

 

MAT2203 will primarily compete with antifungal classes approved for the treatment of fungal and mold infections, which include polyenes, azoles and echinocandins. The approved branded therapies for these indications include Cancidas (caspofungin, marketed by Merck & Co.), Eraxis (anidulafungin, marketed by Pfizer, Inc.), Mycamine (micafungin, marketed by Astellas Pharma US, Inc.), Diflucan (fluconazole, marketed by Pfizer, Inc.), Noxafil (posaconazole, marketed by Merck & Co.), Vfend (voriconazole, marketed by Pfizer, Inc.), Sporanox (itraconazole, marketed by Jansen Pharmaceuticals, Inc.), Cresemba (isavuconazole, marketed by Astellas Pharma US, Inc.), Ambisome (liposomal amphotericin B, marketed by Astellas Pharma US, Inc.) Abelcet (lipid complex amphotericin B, marketed by Sigma Tau Pharmaceuticals Inc.) and amphotericin B deoxycholate (marketed by X-Gen Pharmaceuticals, Inc.). There currently are and may be more generic versions of these products available at the time of MAT2203 market approval, which will create added competition. In addition to approved therapies, we expect that MAT2203 may compete with product candidates that we are aware of in clinical development by third parties, such as rezafungin acetate (being developed by Cidara Therapeutics, Inc.) and certain products being developed by Viamet Pharmaceuticals Holdings, LLC, Vical Incorporated and F2G, Ltd.

 

MAT2501 will primarily compete with aminoglycosides indicated for the treatment of NTM lung infections and will include Arikayce®, an inhaled formulation of amikacin (marketed by Insmed) and IV amikacin (Amikin; marketed by Bristol Myers Squibb) as well as a number of generic manufacturers of IV amikacin.

 

Manufacturing

 

We currently lease and operate in-house manufacturing capabilities for our lead LNC platform delivery technology product candidates, MAT2203 and MAT2501, and for our LNC platform discovery programs in the gene therapy and vaccine spaces. While sufficient to produce the clinical supplies of product necessary to conduct our ongoing clinical trials and potentially early commercialization of MAT2203 and MAT2501, we are exploring relationships with well-respected third-party contract manufacturers for the formulation and manufacture of MAT2203 necessary to support the filing of an NDA and to support commercial manufacture for this product. We may also need to expand our internal manufacturing capabilities in the future. If we are not able to retain our current manufacturing facilities and if we do not develop additional in-house manufacturing capability for our MAT2203, MAT2501 and product candidates sufficient to produce product for commercialization of these products, we will need to develop relationships with third-party manufacturers for the manufacture of our product candidates which could be time consuming and expensive.

 

There are several potential third-party suppliers for amphotericin B, the generic active pharmaceutical ingredient in our lead clinical stage product candidate – MAT2203 and for amikacin, the generic active pharmaceutical ingredient in our preclinical LNC product candidate – MAT2501. Although to date we have not entered into formal supply agreements to secure sufficient supply of amphotericin B or amikacin to support our clinical programs for MAT2203 or MAT2501, we believe we will be able to secure supply of amphotericin B and amikacin to support our clinical programs for MAT2203 and MAT2501 and from one or more third-party suppliers. As we move through development for our product candidates, we expect to enter into long term supply arrangements for key active pharmaceutical ingredients.

 

Sales and Marketing

 

We currently do not have any sales and marketing infrastructure. We plan to retain U.S. marketing and sales rights or co-promotion rights for our product candidates for which we receive marketing approvals, particularly in situations where it is possible to access the market through a focused, specialized sales force. For situations in which a large sales force is required to access the market, and with respect to markets outside the United States, we generally plan to commercialize our product candidates through collaborative arrangements with leading pharmaceutical and biotechnology companies.

 

Review and Approval of Drugs in the United States

 

In the United States, FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA and the Department of Justice(DOJ) or other governmental entities.

 

 19 

 

 

Our product candidates must be approved by FDA through the NDA or biologics license application (BLA), in the case of biologic product candidates, process before they may be legally marketed in the United States. An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:

 

● completion of nonclinical laboratory tests, animal studies and formulation studies in compliance with FDA’s good laboratory practice (cGLP), regulations;
   
● submission to FDA of an investigational new drug applications (IND), which must take effect before human clinical trials may begin;
   
● approval by an independent institutional review board (IRB) representing each clinical site before each clinical trial may be initiated;
   
● performance of adequate and well-controlled human clinical trials in accordance with current good clinical practices (GCP), to establish the safety and efficacy of the proposed drug product for each indication;
   
● preparation and submission to FDA of an NDA or BLA;
   
● review of the product by an FDA advisory committee, where appropriate or if applicable;
   
● satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices (cGMP), requirements and to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;
   
● payment of user fees and securing FDA approval of the NDA or BLA; and
   
● compliance with any post-approval requirements, including a risk evaluation and mitigation strategy (REMS), and post-approval studies required by FDA.

 

Nonclinical Studies

 

Nonclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of nonclinical studies is subject to federal regulations and requirements, including cGLP regulations. The results of the nonclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to FDA as part of an IND.

 

Companies usually must complete some long-term nonclinical testing, such as animal tests of reproductive AEs and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.

 

 20 

 

 

Human Clinical Trials in Support of a Regulatory Approval

 

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by FDA, unless before that time FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and FDA must resolve any outstanding concerns before the clinical trial can begin. Accordingly, submission of an IND may or may not result in FDA allowing clinical trials to commence.

 

In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.

 

A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to FDA in support of an NDA or IND so long as the clinical trial is conducted in accordance with GCP and if FDA is able to validate the data from the clinical trial through an on-site inspection if FDA deems it necessary.

 

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

 

Phase 1: The drug is initially introduced into a small number of healthy human subjects or patients with the target disease (e.g. cancer) or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.

 

Phase 2: The drug is administered to a larger number of trial participants, up to several hundred, who usually have the disease or condition that the experimental drug is intended to treat, to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

 

Phase 3: These clinical trials are commonly referred to as “pivotal” studies, which typically denotes a study which presents the data that FDA or another relevant regulatory agency will use to determine whether or not to approve a drug. In Phase 3 clinical trials, the drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

 

Progress reports detailing the results of the clinical trials must be submitted at least annually to FDA and more frequently if serious AEs occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.

 

 21 

 

 

Submission of an NDA to FDA

 

Regulatory approval for most new drug or biologic products is based on two adequate and well-controlled Phase 3 clinical trials that provide evidence of the safety and efficacy of the proposed new product. Assuming successful completion of required clinical testing and other requirements, the results of the nonclinical and clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee and the sponsor of an approved NDA is also subject to annual prescription drug program fees and establishment user fees. These fees are typically increased annually.

 

FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after FDA’s receipt of the submission whether the application is sufficiently complete to permit substantive review. FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before FDA accepts it for filing. Once the submission is accepted for filing, FDA begins an in-depth substantive review. FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for “priority review” products are meant to be reviewed within six months of filing. The review process may be extended by FDA for various reasons, and for various time periods, including for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by FDA following the original submission.

 

Before approving an NDA, FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections cover all facilities associated with an NDA submission, including drug component manufacturing (such as Active Pharmaceutical Ingredients), finished drug product manufacturing and control testing laboratories. FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, FDA will typically inspect one or more clinical sites to assure compliance with GCP.

 

FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

 

Fast Track, Breakthrough Therapy and Priority Review Designations

 

FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are fast track designation, breakthrough therapy designation and priority review designation.

 

Specifically, FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with FDA and FDA may initiate review of sections of a fast-track product’s NDA before the application is complete. This rolling review may be available if FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, FDA’s time goal for reviewing a Fast Track application does not begin until the last section of the NDA is submitted. In addition, the Fast Track designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

 

Second, in 2012, Congress enacted the Food and Drug Administration Safety and Improvement Act, or FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as “breakthrough therapies.” A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.

 

 22 

 

 

Third, FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. FDA determines, on a case-by-case basis, whether the proposed drug represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten FDA’s goal for taking action on a marketing application from ten months to six months.

 

Under Section 524 of the FDCA, FDA is authorized to award a priority review voucher to sponsors of certain tropical disease product applications that meet the criteria specified in the Act. A priority review voucher may be used by the sponsor who obtains it, or it may be transferred to another sponsor who may use it to obtain priority review for a different application. Priority review vouchers can result in the acceleration of review and approval of a product candidate by up to four months. In order to be eligible for a tropical disease priority review voucher, the application must be: for a listed tropical disease; submitted under Section 505(b)(1) of the FDCA or Section 351 of the Public Health Service Act; for a product that contains no active ingredient that has been approved in any other application under those statutory provisions; and must qualify for priority review. FDA has identified in guidance those product applications for the prevention or treatment of tropical diseases that may qualify for a priority review voucher.

 

Accelerated Approval Pathway

 

FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

 

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.

 

The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by FDA.

 

 23 

 

 

FDA’s Decision on an NDA

 

Based on FDA’s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for FDA to reconsider the application. When those deficiencies have been addressed to FDA’s satisfaction in a resubmission of the NDA, FDA will issue an approval letter. FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

 

If FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions which can materially affect the potential market and profitability of the product. In addition, as a condition of approval, FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals and elements to assure safe use, which may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.

 

FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

 

Post-Approval Requirements

 

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.

 

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with FDA and state agencies and are subject to periodic unannounced inspections by FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.

 

 24 

 

 

Once an approval is granted, FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

 

● restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
   
● fines, warning or untitled letters or holds on post-approval clinical trials;
   
● refusal of FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;
   
● product seizure or detention, or refusal to permit the import or export of products; or
   
● injunctions or the imposition of civil or criminal penalties.

 

FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

 

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.

 

Abbreviated New Drug Applications (ANDA) for Generic Drugs

 

In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized FDA to approve generic drugs that are the same as drugs previously approved by FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (ANDA), to the agency. In support of such applications, a generic manufacturer may rely on the nonclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (RLD).

 

Specifically, for an ANDA to be approved, FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form and the strength of the drug. At the same time, FDA must also determine that the generic drug is “bioequivalent” to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.

 

Upon approval of an ANDA, FDA indicates whether the generic product is therapeutically equivalent to the RLD in its publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” also referred to as the “Orange Book.” Physicians and pharmacists consider a therapeutically equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, FDA’s designation of therapeutic equivalence often results in automatic substitution of the generic drug by the pharmacist without the knowledge or consent of either the prescribing physician or patient.

 

Under the Hatch-Waxman Amendments, FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be submitted to FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication.

 

 25 

 

 

Hatch-Waxman Patent Certification and the 30 Month Stay

 

Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with FDA each patent with claims that cover the applicant’s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant submits its application to FDA, the applicant is required to certify to FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:

 

● the required patent information has not been filed;
   
● the listed patent has expired;
   
● the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or
   
● the listed patent is invalid, unenforceable or will not be infringed by the new product.

 

A certification that the new product will not infringe the already approved product’s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.

 

If the ANDA applicant has provided a Paragraph IV certification to FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant.

 

Pediatric Studies and Exclusivity

 

Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, FDA and FDA’s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. FDA or the applicant may request an amendment to the plan at any time.

 

FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA.

 

Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to FDA’s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which FDA cannot approve another application.

 

 26 

 

 

Orphan Designation and Exclusivity

 

Under the Orphan Drug Act, FDA may designate a drug product as an “orphan drug” if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting a NDA. If the request is granted, FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

 

If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product will be entitled to orphan product exclusivity. Orphan product exclusivity means that FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.

 

21st Century Cures Act

 

On December 13, 2016, Congress passed the 21st Century Cures Act, or the Cures Act. The Cures Act is designed to modernize and personalize healthcare, spur innovation and research, and streamline the discovery and development of new therapies through increased federal funding of particular programs. It authorizes increased funding for FDA to spend on innovation projects. The new law also amends the Public Health Service Act to reauthorize and expand funding for the National Institutes of Health. The Act establishes the NIH Innovation Fund to pay for the cost of development and implementation of a strategic plan, early-stage investigators and research. It also charges NIH with leading and coordinating expanded pediatric research. In addition, the Cures Act includes provisions requiring FDA to assess and publish guidance on the use of novel clinical trial designs, the use of real-world evidence in applications, the availability of summary level review for supplemental applications for certain indications, and the qualification of drug development tools. Because the Cures Act has only recently been enacted, its potential effect on our business remains unclear with the exception of a provision requiring that we post our policies on the availability of expanded access programs for individuals. Because these provisions allow FDA to spend several years developing these policies, the effect on us could be delayed.

 

With amendments to the FDCA and the Public Health Service Act, or PHSA, Title III of the Cures Act seeks to accelerate the discovery, development, and delivery of new medicines and medical technologies. To that end, and among other provisions, the Cures Act reauthorizes the existing priority review voucher program for certain drugs intended to treat rare pediatric diseases until 2026; creates a new priority review voucher program for drug applications determined to be material national security threat medical countermeasure applications; and revises the FDCA to streamline review of combination product applications.

 

Section 3042 of the Cures Act authorizes a new “Limited Population Pathway” to expedite approval of antimicrobial products intended to treat serious or life-threatening infections for which there are unmet medical needs. Drugs approved under this provision would be required to adhere to special labeling requirements, including a prominent “Limited Population” statement. Additionally, in recognition of increasing concerns about drug-resistant infections, the Act requires the U.S. Government Accountability Office (GAO) to compile a report on antimicrobial resistance by 2021, which would include a review of any effect of the new Limited Population Pathway on antibacterial or antifungal resistance. We will monitor these developments but cannot currently assess how this initiative may impact our business.

 

 27 

 

 

Other Health Care Regulations

 

Health Privacy Laws

 

We are subject to data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the FTC Act), govern the collection, use, disclosure, and protection of health-related and other personal information. Failure to comply with data protection laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation and/or adverse publicity that could negatively affect our operating results and business. In addition, we may obtain health information from third parties (e.g., principal investigators involved in our clinical trials) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, or HIPPA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH. HIPAA generally requires that covered entities (healthcare providers, health plans and healthcare clearinghouses) obtain written authorizations from patients prior to disclosing protected health information of the patient (unless an exception to the authorization requirement applies). If authorization is required and the patient fails to execute an authorization or the authorization fails to contain all required provisions, then we may not be allowed access to and use of the patient’s information and our research efforts could be impaired or delayed. Furthermore, use of protected health information that is provided to us pursuant to a valid patient authorization is subject to the limits set forth in the authorization (e.g., for use in research and in submissions to regulatory authorities for product approvals). Among other things, HITECH makes HIPAA’s privacy and security standards, as well as the various penalties or failure to comply, directly applicable to “business associates”—independent contractors or agents of covered entities performing certain functions involving the creation or use of protected health information on behalf of a covered entity or providing services to a covered entity. While we do not believe we are a “business associate” under HIPAA, regulatory agencies may disagree.

 

The General Data Protection Regulation, or GDPR, adopted in 2016, establishes a regulatory framework designed to protect the security of personal data collected about residents of the EU and the movement of such personal data across the national borders of the EU Member States, including, but not limited to, requirements to obtaining consent of the individuals to whom the personal data relates, the nature and scope of notifications provided to the individuals, the security and confidentiality of the personal data, data breach notification and using third party processors in connection with the processing of the personal data. Failure to comply with the EU Directive and the GDPR could subject us to regulatory sanctions, delays in clinical trials, criminal prosecution and/or civil fines or penalties. Additionally, GDPR creates a direct cause of action by individual data subjects.

 

Fraud and Abuse Laws

 

In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Violations of the anti-kickback statute are punishable by imprisonment, criminal prosecution, civil monetary penalties and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor.

 

Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the federal anti-kickback statute and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

 

 28 

 

 

Affordable Care Act

 

In late March 2010, the Federal government enacted the comprehensive health care reform package, the Affordable Care Act (ACA). Among other provisions, the ACA imposes individual and employer health insurance requirements, provides certain insurance subsidies (e.g., premiums and cost sharing), mandates extensive insurance market reforms, creates new health insurance access points (e.g., State and federal-based health insurance exchanges), expands the Medicaid program, promotes research on comparative clinical effectiveness of different technologies and procedures, and makes a number of changes to how products and services will be reimbursed by the Medicare program. Amendments to the Federal False Claims Act under the ACA have made it easier for private parties to bring “qui tam” (whistleblower) lawsuits against companies, under which the whistleblower may be entitled to receive a percentage of any money paid to the government.

 

Since its enactment, there have been judicial and Congressional challenges and amendments to certain aspects of the ACA. There is continued uncertainty about the implementation of the ACA, including the potential for further amendments to the ACA and legal challenges to or efforts to repeal the ACA. If the ACA is repealed or further modified, or if implementation of certain aspects of the ACA are delayed, such repeal, modification or delay may materially adversely impact our business, strategies, prospects, operating results or financial condition. We are unable to predict the full impact of any repeal, modification or delay in the implementation of the ACA on us at this time. Due to the substantial regulatory changes that will need to be implemented by CMS and others, and the numerous processes required to implement these reforms, we cannot predict which healthcare initiatives will be implemented at the federal or state level, the timing of any such reforms, or the effect such reforms or any other future legislation or regulation will have on our business.

 

Designation of and Exclusivity for Qualified Infectious Disease Products

 

In 2012, Congress passed legislation known as the Generating Antibiotic Incentives Now Act, or GAIN Act. This legislation is designed to encourage the development of antibacterial and antifungal drug products that treat pathogens that cause serious and life-threatening infections. To that end, the law grants an additional five years of marketing exclusivity upon the approval of an NDA for a drug product designated by FDA as a Qualified Infectious Disease Product, or QIDP. Thus, for a QIDP, the periods of five-year new chemical entity exclusivity, three-year new clinical investigation exclusivity and seven-year orphan drug exclusivity, would become 10 years, eight years, and 12 years, respectively.

 

A QIDP is defined in the GAIN Act to mean “an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by—(1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens;” or (2) certain “qualifying pathogens.” A “qualifying pathogen” is a pathogen that has the potential to pose a serious threat to public health (e.g., resistant gram-positive pathogens, multi-drug resistant gram-negative bacteria, multi-drug resistant tuberculosis and Clostridium difficile) and that is included in a list established and maintained by FDA. A drug sponsor may request FDA to designate its product as a QIDP any time before the submission of an NDA. FDA must make a QIDP determination within 60 days of the designation request. A product designated as a QIDP will be granted priority review by FDA and can qualify for “fast track” status.

 

The additional five years of market exclusivity under the GAIN Act for drug products designated by FDA as QIDPs applies only to a drug that is first approved on or after July 9, 2012. Additionally, the five-year exclusivity extension does not apply to: a supplement to an application under Section 505(b) of the FDCA for any QIDP for which an extension is in effect or has expired; a subsequent application submitted with respect to a product approved by FDA for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength; or a product that does not meet the definition of a QIDP under Section 505(g) based upon its approved uses.

 

 29 

 

 

Patent Term Restoration and Extension

 

A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product’s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with FDA.

 

Review and Approval of Drug Products in the European Union

 

To market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.

 

Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents.

 

To obtain marketing approval of a drug under European Union regulatory systems, an applicant must submit a marketing authorization application, or MAA, either under a centralized or decentralized procedure.

 

The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional.

 

Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days.

 

 30 

 

 

The decentralized procedure is available to applicants who wish to market a product in various European Union member states where such product has not received marketing approval in any European Union member states before. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one-member state designated by the applicant, known as the reference member state. Under this procedure, an applicant applies based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment report and drafts of the related materials within 210 days after receipt of a valid application. Within 90 days of receiving the reference member state’s assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related materials.

 

If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states.

 

Pharmaceutical Coverage, Pricing and Reimbursement

 

Significant uncertainty exists as to the coverage and reimbursement status of products approved by FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.

 

In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Third party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.

 

In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.

 

 31 

 

 

Healthcare Law and Regulation

 

Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with third party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such restrictions under applicable federal and state healthcare laws and regulations, include the following:

 

● the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
   
● the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
   
● the HIPPA imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
   
● HIPAA, as amended by the HITECH and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
   
● the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;
   
● the federal transparency requirements under the ACA requires manufacturers of drugs to report to the Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests and the reported information will be made publicly available on a searchable website; and
   
● analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.

 

Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

 

Human Capital Resources

 

As of February 25, 2022, we had 31 full-time employees. There are no collective bargaining agreements covering any of our employees.

 

We believe that our success depends on our ability to attract, develop and retain key personnel. We believe that the skills, experience and industry knowledge of our key employees significantly benefit our operations and performance.

 

Employee health and safety in the workplace is one of our core values. The COVID-19 pandemic has underscored for us the importance of keeping our employees safe and healthy. In response to the pandemic, we have taken actions aligned with the World Health Organization and the Centers for Disease Control and Prevention in an effort to protect our workforce so they can more safely and effectively perform their work.

 

Employee levels are managed to align with the pace of business and management believes it has sufficient human capital to operate its business successfully.

 

 32 

 

 

Research and Development

 

For the years ended December 31, 2021 and 2020, we incurred approximately $14.6 and approximately $14.4 million, respectively, on research and development activities. These expenses include cash and non-cash expenses relating to the development of our clinical and pre-clinical programs, including our anti-infective product candidates, MAT2203 and MAT2501 as well as support and enhancement of our drug delivery technology. Our research and development expenses reflect the reimbursement of certain MAT2501 program expenses of approximately $2.2 million and approximately $0.1 million during the years ended December 31, 2021 and 2020, respectively, related to the CFF grant agreement.

 

Corporate and Available Information

 

We were incorporated in Delaware under the name Matinas BioPharma Holdings, Inc. in May 2013. We have two operating subsidiaries: Matinas BioPharma, Inc., a Delaware corporation originally formed on August 12, 2011 as Nereus BioPharma LLC, and Matinas BioPharma Nanotechnologies, Inc., a Delaware corporation originally formed on January 29, 2015 as Aquarius Biotechnologies, Inc.

 

Our principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921, and our telephone number is (908) 484-8805. Our website address is www.matinasbiopharma.com. Our website and the information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference into this Annual Report on Form 10-K or any other report we file with or furnish to the SEC.

 

We make available on our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. Our SEC reports can be accessed through the Investors section of our internet website. Further, a copy of this Annual Report on Form 10-K is located at the SEC’s Public Reference Rooms at 100 F Street, N.E., Washington, D. C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information statements and other information regarding our filings at http://www.sec.gov.

 

Item 1A. Risk Factors

 

An investment in our common stock is speculative and involves a high degree of risk, including a risk of loss of your entire investment. You should carefully consider the risks described below and the other information in this Annual Report before purchasing shares of our common stock. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties may also adversely impair our business operations. If any of the events described in the risk factors below actually occur, our business, financial condition or results of operations could suffer significantly. In such event, the value of our common stock could decline, and you could lose all or a substantial portion of the money that you pay for our common stock.

 

Summary of Risk Factors

 

● We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
● We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
● Raising additional capital may cause dilution to stockholders, restrict operations or require us to relinquish rights to our technologies or product candidates.
● Our stockholders may be subject to substantial dilution by exercises of outstanding options and warrants.
● Our operating history to date may make it difficult to evaluate the success of our business and assess our future viability.
● We are early in our development efforts, which may not be successful.

 

 33 

 

 

● We cannot be certain that our product candidates will receive regulatory approval, without which we cannot market any of our product candidates. Any delay in the approval process will harm our business.
● Clinical drug development involves a lengthy and expensive process and uncertain as to outcome.
● Delays in any aspect of our clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates.
● We may not have or be able to obtain sufficient quantities of our products to meet our supply and clinical studies obligations and our business, financial condition and results of operation may be adversely affected.
● If we are unable to successfully commercialize our products our ability to generate revenue will be limited.
● If our preclinical and clinical studies do not produce positive results, if our clinical trials are delayed or if serious side effects are identified during such studies or trials, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates.
● If we cannot enroll enough patients to complete our clinical trials, our business, financial condition and results of operations may be adversely affected.
● We may not be able to obtain or maintain orphan drug designation, Fast Track designation, qualified infection disease designation or breakthrough therapy designation for any of our product candidates, and even if granted, such designations may not actually lead to a faster development or regulatory review, and would not assure FDA approval of any of our product candidates.
● If we are unsuccessful in identifying and developing additional product candidates, our potential for growth may be impaired.
● If we are unable to establish satisfactory sales and marketing capabilities, we may not successfully commercialize any of our product candidates, even if regulatory approval is obtained.
● If we are unable to file for approval of MAT2203 or MAT2501 under Section 505(b)(2) of the FDCA or if we are required to generate additional data related to safety and efficacy in order to obtain approval under Section 505(b)(2), we may be unable to meet our anticipated development and commercialization timelines.
● We face competition from other biotechnology and pharmaceutical companies.
● Even if we obtain marketing approval for any product candidate, we will be subject to ongoing obligations and continued regulatory review and requirements, which may result in significant additional expense.
● We are in the process of evaluating potential next steps in the development of LYPIDISO.
● Future legislation, and/or regulations and policies adopted by the FDA may increase the time and cost required for us to conduct and complete clinical trials.
● Changes in health care law and implementing regulations may have a material adverse effect on us.
● Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
● If we market our product candidates in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.
● We expect that we will rely on third parties to conduct clinical trials for our product candidates.
● We are, and will be, completely dependent on third parties to manufacture our product candidates, who may not perform as expected.
● Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives could harm our business.
● Outbreaks of communicable diseases may materially and adversely affect our business, financial condition and results of operations.
● We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from discovering, developing and commercializing our product candidates.
● If we discontinue development of the LNC platform delivery technology, we would be required to return such technology to the former stockholders of Aquarius and/or Rutgers and we would lose the rights to our lead product candidates.
● It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.
● If we fail to obtain or maintain patent or trade secret protection for our technologies, third parties could use our proprietary information.
● Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.
● We will need to increase the size of our organization to grow our business, and we may experience difficulties in managing this growth.

 

 34 

 

 

● If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
● If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
● Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
● We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.
● The rights of the holders of common stock may be impaired by the potential issuance of preferred stock.
● We do not intend to pay dividends on our common stock in the foreseeable future.
● An active public trading market for our common stock may not be sustained.
● Our share price has been and could remain volatile.
● If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.
● Upon dissolution of our Company, you may not recoup all or any portion of your investment.
● Anti-takeover provisions of our certificate of incorporation, bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult.
● Our certificate of incorporation allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock
● Stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees could be limited.
● Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

 

Risks Related to Our Financial Position and Need for Additional Capital

 

We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.

 

We have incurred significant operating losses in every year since inception and expect to incur net operating losses for the foreseeable future. Our net loss was $23.3 million and $22.4 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $131.6 million. We do not know whether or when we will become profitable. To date, we have not generated any revenues from product sales and have financed our operations through private placements and public offerings of our equity securities and, to a lesser extent, through funding from the Cystic Fibrosis Foundation, or CFF, and the National Institutes of Health, or the NIH. We have devoted substantially all of our financial resources and efforts to the research and development of potential product candidates. All of our product candidates are in the development stage, and we have not completed development of any product candidate. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ deficit and working capital. We anticipate that our expenses will increase substantially if and as we:

 

● conduct further clinical and preclinical studies of MAT2203 AND MAT2501, our lead LNC product candidates;
   
● support the conduct of further clinical studies of MAT2203, even if such studies are primarily financed with non-dilutive funding from the NIH;
   
● seek to discover and develop additional product candidates;
   
● seek regulatory approvals for any product candidates that successfully complete clinical trials;
   
● require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;
   
● maintain, expand and protect our intellectual property portfolio;
   
● hire additional clinical, quality control and scientific personnel; and
   
● add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts and personnel and infrastructure necessary to help us comply with our obligations as a public company.

 

 35 

 

 

Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue until we are able to obtain marketing approval for, and successfully commercialize, one or more of our product candidates. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates, manufacturing, marketing and selling any products for which we may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. We are only in the preliminary stages of most of these activities and have not yet commenced other of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.

 

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration, or the FDA, or comparable non-U.S. regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase.

 

Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

 

We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

 

We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct additional clinical studies of our product candidates, including the ongoing EnACT clinical trial of MAT2203 in CM, our preclinical toxicology program for MAT2501, and conduct additional preclinical and clinical trials to further validate and expand our LNC platform delivery technology, continue research and development, initiate clinical trials and, if development succeeds, seek regulatory approval of our product candidates. Our expenses could further increase if we initiate new research and preclinical development efforts for other product candidates. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

 

We believe that our existing cash, cash equivalents and marketable securities, including restricted cash, of approximately $49.9 million as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements through 2023. We have based this estimate on assumptions that may prove to be wrong in the future, and we could use our capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. Our future capital requirements, both short-term and long-term, will depend on many factors, including:

 

● the progress, timing, costs and results of our ongoing and planned clinical trials of our product candidates;
   
● the scope, progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, other product candidates, including MAT2203, any future product candidates based upon our LNC platform delivery technology, including MAT2501, and any preclinical or clinical work done to further validate our LNC platform delivery technology, generally;

 

 36 

 

 

● our ability to enter into and the terms and timing of any collaborations, licensing or other arrangements that we may establish;
   
● the number and development requirements of other product candidates that we pursue;
   
● the costs, timing and outcome of regulatory review of our product candidates by the FDA and comparable non-U.S. regulatory authorities;
   
● the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
   
● the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
   
● our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
   
● the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
   
● the extent to which we acquire or in-license other products and technologies;
   
● the costs of operating as a public company; and
   
● the effect of competing technological and market developments.

 

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.

 

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

 

Until such time, if ever, as we can generate product revenues sufficient to achieve profitability, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements. We do not have any committed external source of funds other than limited grant funding from the NIH and the CFF. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, your ownership interest may be materially diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. Securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management’s ability to oversee the development of our product candidates.

 

If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

 

 37 

 

 

Our stockholders may be subject to substantial dilution by exercises of outstanding options and warrants.

 

As of December 31, 2021, we had outstanding options to purchase an aggregate of 28,184,291 shares of our common stock at a weighted average exercise price of $1.21 per share and warrants to purchase an aggregate of 988,000 shares of our common stock at a weighted average exercise price of $0.56 per share. The exercise of such outstanding options and the warrants will result in dilution of the value of our shares.

 

Our operating history to date may make it difficult to evaluate the success of our business to date and to assess our future viability.

 

We commenced active operations in 2013 and our product candidates are in early stages of clinical development. We have not yet demonstrated our ability to successfully obtain regulatory approvals for any of our product candidates, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

 

In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. Even if we obtain regulatory approval, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.

 

We expect our financial condition and operating results to continue to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.

 

Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization

 

We are early in our development efforts, which may not be successful.

 

Because we are still in the clinical stage of our development efforts, and are in the process of determining the overall clinical development path for our current and future product candidates, the timing and costs of the regulatory paths we will follow. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of MAT2203, MAT2501 and any other product candidates we may develop will depend on many factors, including the following:

 

● successful completion of preclinical studies;
   
● successful enrollment in, and completion of, clinical trials:
   
● demonstrating safety and efficacy;
   
● receipt of marketing approvals from applicable regulatory authorities;
   
● establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;
   
● obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and technologies;

 

 38 

 

 

● launching commercial sales of the product candidates, if and when approved, whether alone or selectively in collaboration with others;
   
● acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payers;
   
● effectively competing with other therapies;
   
● a continued acceptable safety profile of the products following approval; and
   
● enforcing and defending intellectual property rights and claims.

 

If we do not accomplish one or more of these goals in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business.

 

We cannot be certain that any of our product candidates will receive regulatory approval, without which we will not be able to market any of our product candidates. Any delay in the approval process will harm our business.

 

We expect to invest most of our capital in the development of our LNC platform delivery technology. Our ability to generate revenue related to product sales, which we do not expect will occur for at least the next several years, if ever, will depend on the successful development and regulatory approval of one or more of our product candidates. All of our product candidates require regulatory review and approval prior to commercialization. Any delays in the regulatory review or approval of our product candidates would delay market launch, increase our cash requirements and result in additional operating losses. This failure to obtain regulatory approvals would prevent our product candidate from being marketed and would have a material and adverse effect on our business.

 

The process of obtaining FDA and other required regulatory approvals, including foreign approvals, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Furthermore, this approval process is extremely complex, expensive and uncertain. We may be unable to submit any NDA in the United States or any marketing approval application in foreign jurisdictions for any of our products. If we submit an NDA including any amended NDA or supplemental NDA, to the FDA seeking marketing approval for any of our product candidates, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any of these submissions will be accepted for filing and reviewed by the FDA, or that the marketing approval application submissions to any other regulatory authorities will be accepted for filing and review by those authorities. We cannot be certain that we will be able to respond to any regulatory requests during the review period in a timely manner, or at all, without delaying potential regulatory action. We also cannot be certain that any of our product candidates will receive favorable recommendations from any FDA advisory committee or foreign regulatory bodies or be approved for marketing by the FDA or foreign regulatory authorities. In addition, delays in approvals or rejections of marketing applications may be based upon many factors, including regulatory requests for additional analyses, reports, data and studies, regulatory questions regarding data and results, changes in regulatory policy during the period of product development and the emergence of new information regarding such product candidates.

 

Data obtained from preclinical studies and clinical trials are subject to different interpretations, which could delay, limit or prevent regulatory review or approval of any of our product candidates. Furthermore, regulatory attitudes towards the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, policy changes and agency funding, staffing and leadership. We do not know whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects.

 

 39 

 

 

In addition, the environment in which our regulatory submissions may be reviewed changes over time. For example, average review times at the FDA for NDAs have fluctuated in recent years, and we cannot predict the review time for any of our submissions with any regulatory authorities. Review times can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes. Moreover, in light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of the U.S. Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of REMS measures that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials. Data from clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion or require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or may result in approval for a more limited indication than originally sought.

 

We depend in part on technology owned or licensed to us by third parties, the loss of which would terminate or delay the further development of our product candidates, injure our reputation or force us to pay higher royalties.

 

We rely heavily on the LNC platform delivery technology that we have licensed from Rutgers. The loss of access to this technology could materially impair our business and future viability, and could result in delays in developing, introducing or maintaining our product candidates and formulations until equivalent technology, if available, is identified, licensed and integrated. In addition, any defects in the technology we license could prevent the implementation or impair the functionality of our product candidates or formulation, delay new product or formulation introductions or injure our reputation. If we are required to enter into license agreements with third parties for replacement technology, we could be subject to higher royalty payments.

 

We may not have or be able to obtain sufficient quantities of our products to meet our supply and clinical studies obligations and our business, financial condition and results of operation may be adversely affected.

 

To date, we have only developed limited in-house manufacturing capabilities for the LNC platform delivery technology needed for the clinical development our MAT2203 and MAT2501 product candidates. If we do not develop a long-term in-house manufacturing capability for our LNC platform product candidates sufficient to produce product for continued development and, if regulatory approval is obtained, then commercialization of these products, we will be dependent on a small number of third-party manufacturers for the manufacture of our product candidates. We may not have long-term agreements with any of these third parties, and if they are unable or unwilling to perform for any reason, we may not be able to locate alternative acceptable manufacturers or formulators or enter into favorable agreements with them. Any inability to acquire sufficient quantities of our products in a timely manner from these third parties could delay clinical trials and prevent us from developing our products in a cost-effective manner or on a timely basis. In addition, manufacturers of our product candidates are subject to cGMP and similar foreign standards and we would not have control over compliance with these regulations by our manufacturers. If one of our contract manufacturers fails to maintain compliance, the production of our products could be interrupted, resulting in delays and additional costs. In addition, if the facilities of such manufacturers do not pass a pre-approval or post-approval plant inspection, the FDA will not grant approval and may institute restrictions on the marketing or sale of our products.

 

We may be reliant on third party manufactures and suppliers to meet the demands of our clinical supplies. Delays in receipt of materials, scheduling, release, custom’s control, and regulatory compliance issues may adversely impact our ability to initiate, maintain, or complete clinical trials that we are sponsoring. Commercial manufacturing and supply agreements have not been established. Issues arising from scale-up, environmental controls, public health crises, such as pandemics and epidemics, equipment requirements, or other factors, may have an adverse impact on our ability to manufacture our product candidates.

 

 40 

 

 

If we are unable to successfully commercialize our products our ability to generate revenue and will be limited.

 

Even if we obtain regulatory approval for our product candidates, our long-term viability and growth depend on the successful commercialization of products which lead to revenue and profits. Pharmaceutical product development is an expensive, high risk, lengthy, complicated, resource intensive process. In order to succeed, among other things, we must be able to:

 

● identify potential drug product candidates;
   
● design and conduct appropriate laboratory, preclinical and other research;
   
● submit for and receive regulatory approval to perform clinical studies;
   
● design and conduct appropriate preclinical and clinical studies according to good laboratory and good clinical practices;
   
● select and recruit clinical investigators;
   
● select and recruit subjects for our studies;
   
● collect, analyze and correctly interpret the data from our studies;
   
● submit for and receive regulatory approvals for marketing; and
   
● manufacture the drug product candidates according to cGMP.

 

The development program with respect to any given product will take many years and thus delay our ability to generate profits. In addition, potential products that appear promising at early stages of development may fail for a number of reasons, including the possibility that the products may require significant additional testing or turn out to be unsafe, ineffective, too difficult or expensive to develop or manufacture, too difficult to administer, or unstable. Failure to successfully commercialize our products will adversely affect our business, financial condition and results of operations.

 

If our preclinical and clinical studies do not produce positive results, if our clinical trials are delayed or if serious side effects are identified during such studies or trials, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates.

 

Before obtaining regulatory approval for the sale of our product candidates, we must conduct, generally at our own expense, extensive preclinical tests to demonstrate the safety of our product candidates in animals, and clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Preclinical and clinical testing is expensive, difficult to design and implement and can take many years to complete. A failure of one or more of our preclinical studies or clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, preclinical testing and the clinical trial process that could delay or prevent our ability to obtain regulatory approval or commercialize our product candidates, including:

 

● our preclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical testing or clinical trials or we may abandon projects that we expect to be promising;
   
● regulators or institutional review boards may not authorize us to commence a clinical trial or conduct a clinical trial at a prospective trial site;
   
● conditions imposed on us by the FDA or any non-U.S. regulatory authority regarding the scope or design of our clinical trials may require us to resubmit our clinical trial protocols to institutional review boards for re-inspection due to changes in the regulatory environment;
   
● the number of patients required for our clinical trials may be larger than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;
   
● our third-party contractors or clinical investigators may fail to comply with regulatory requirements or fail to meet their contractual obligations to us in a timely manner;

 

 41 

 

 

● we might have to suspend or terminate one or more of our clinical trials if we, the regulators or the institutional review boards determine that the participants are being exposed to unacceptable health risks;
   
● regulators or institutional review boards may require that we hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;
   
● the cost of our clinical trials may be greater than we anticipate;
   
● the supply or quality of our product candidates or other materials necessary to conduct our clinical trials may be insufficient or inadequate or we may not be able to reach agreements on acceptable terms with prospective clinical research organizations; and
   
● the effects of our product candidates may not be the desired effects or may include undesirable side effects or the product candidates may have other unexpected characteristics.

 

In addition, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete our clinical trials or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:

 

● be delayed in obtaining, or may not be able to obtain, marketing approval for one or more of our product candidates;
   
● obtain approval for indications that are not as broad as intended or entirely different than those indications for which we sought approval; or
   
● have the product removed from the market after obtaining marketing approval.

 

Our product development costs will also increase if we experience delays in testing or approvals. We do not know whether any preclinical tests or clinical trials will be initiated as planned, will need to be restructured or will be completed on schedule, if at all. Significant preclinical or clinical trial delays also could shorten the patent protection period during which we may have the exclusive right to commercialize our product candidates. Such delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or product candidates.

 

If we cannot enroll enough patients to complete our clinical trials, our business, financial condition and results of operations may be adversely affected.

 

The completion rate of clinical studies of our products is dependent on, among other factors, the patient enrollment rate. Patient enrollment is a function of many factors, including:

 

● investigator identification and recruitment;
   
● regulatory approvals to initiate study sites;
   
● patient population size;
   
● the nature of the protocol to be used in the trial;
   
● patient proximity to clinical sites;
   
● eligibility criteria for the study;
   
● competition from other companies’ clinical studies for the same patient population; and
   
● ability to obtain comparator drug/device.

 

 42 

 

 

We believe our procedures for enrolling patients have been appropriate; however, delays in patient enrollment would increase costs and delay ultimate commercialization and sales, if any, of our products. Such delays could materially adversely affect our business, financial condition and results of operations.

 

We may not be able to maintain orphan drug designation or exclusivity for our anti-infective product candidates.

 

We have received orphan drug designation for MAT2203 and MAT2501 in the United States and may seek additional orphan drug designation for other product candidates. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same indication for that drug during that time period. For a product that obtains orphan drug designation on the basis of a plausible hypothesis that it is clinically superior to the same drug that is already approved for the same indication, in order to obtain orphan drug exclusivity upon approval, clinical superiority of such product to this same drug that is already approved for the same orphan indication must be demonstrated. The exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

 

We cannot assure you that the application for orphan drug designation of MAT2203, MAT2501, or any future application with respect to any other product candidate, will be maintained or granted. If we are unable to maintain orphan drug designation in the United States, we will not be eligible to obtain the period of market exclusivity that could result from orphan drug designation or be afforded the financial incentives associated with orphan drug designation. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.

 

Any Fast Track designation or grant of priority review status by the FDA may not actually lead to a faster development or regulatory review or approval process, nor will it assure FDA approval of our product candidates. Additionally, our product candidates may treat indications that do not qualify for priority review vouchers.

 

We have received Fast Track designation for MAT2203 for the treatment of invasive candidiasis, the treatment of aspergillosis, the prevention of invasive fungal infections due to immunosuppressive therapy and the treatment of cryptococcosis and may seek Fast Track designation for some of our other product candidates or priority review of applications for approval of our product candidates for certain indications. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation. If a product candidate offers major advances in treatment, the FDA may designate it eligible for priority review. The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for these designations, we cannot assure you that the FDA would decide to grant them. Even if we do receive Fast Track designation or priority review, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.

 

 43 

 

 

Any breakthrough therapy designation granted by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

 

We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval if the relevant criteria are met.

 

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

 

Designation of our product candidates as qualified infectious disease products is not assured and, in any event, even if granted, may not actually lead to a faster development or regulatory review, and would not assure FDA approval of our product candidates.

 

We have received a qualified infectious disease product, or QIDP, designation for MAT2203 and MAT2501 for certain indications and we may be eligible for designation of future product candidates as QIDPs. A QIDP is “an antibacterial or antifungal drug intended to treat serious or life-threatening infections, including those caused by an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens or certain “qualifying pathogens.” A product designated as a QIDP will be granted priority review by the FDA and may qualify for “fast track” status. Upon the approval of an NDA for a drug product designated by the FDA as a QIDP, the product is granted a period of five years of regulatory exclusivity in addition to any other period of regulatory exclusivity for which the product is eligible. The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for such designation or status, the FDA could decide not to grant it. Moreover, even if we do receive such a designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures and there is no assurance that our product candidate, even if determined to be a QIDP, will be approved by the FDA.

 

If we are unsuccessful in identifying and developing additional product candidates, our potential for growth may be impaired.

 

Even if we receive regulatory approval for MAT2203, MAT2501 or any other product candidates we may develop, we still may not be able to successfully commercialize such products and the revenue that we generate from its sales, if any, may be limited.

 

If approved for marketing, the commercial success of MAT2203, MAT2501 or any other product candidates we may develop will depend upon its acceptance by the medical community, including physicians, patients and health care payors. The degree of market acceptance of MAT2203, MAT2501 or such other product candidate will depend on a number of factors, including:

 

● demonstration of clinical safety and efficacy of such product candidate;
   
● relative convenience and ease of administration;
   
● the prevalence and severity of any adverse effects;

 

 44 

 

 

● the willingness of physicians to prescribe such product candidates and of the target patient population to try new therapies;
   
● pricing and cost-effectiveness;
   
● the inclusion or omission of such product candidate in applicable treatment guidelines;
   
● the effectiveness of our or any future collaborators’ sales and marketing strategies;
   
● limitations or warnings contained in FDA approved labeling;
   
● our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payors; and
   
● the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement.

 

If MAT2203, MAT2501 or any other product candidates we may develop is approved but does not achieve an adequate level of acceptance by physicians, health care payors and patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of such product candidate may require significant resources and may never be successful.

 

In addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize such product candidate successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render such product candidate not commercially viable. For example, regulatory authorities may approve such product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for such product candidate, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve such product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that indication. Further, the FDA may place conditions on approvals including potential requirements or risk management plans and the requirement for a Risk Evaluation and Mitigation Strategy (REMS) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of such product candidate. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of such product candidate.

 

We currently have no sales and marketing organization. If we are unable to establish satisfactory sales and marketing capabilities, we may not successfully commercialize any of our product candidates, even if regulatory approval is obtained.

 

At present, we have no sales or marketing personnel. In order to commercialize products that are approved for commercial sales, we must either develop a sales and marketing infrastructure or collaborate with third parties that have such commercial infrastructure. If we elect to develop our own sales and marketing organization, we do not intend to begin to hire sales and marketing personnel until the time of NDA submission to the FDA at the earliest, and we do not intend to establish our own sales organization in the United States until shortly prior to FDA approval of MAT2203, MAT2501 or any of our other product candidates.

 

 45 

 

 

We may not be able to establish a direct sales force in a cost-effective manner or realize a positive return on this investment. In addition, we will have to compete with established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to commercialize MAT2203, MAT2501 or any of our other product candidates in the United States without strategic partners or licensees include:

 

● our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
   
● the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe our future products;
   
● the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
   
● unforeseen costs and expenses associated with creating an independent sales and marketing organization.

 

If we are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, or if we do not successfully enter into appropriate collaboration arrangements, we will have difficulty successfully commercializing MAT2203, MAT2501 or any other product candidates we may develop, which would adversely affect our business, operating results and financial condition. Outside the United States, we may commercialize our product candidates by entering into collaboration agreements with pharmaceutical partners. We may not be able to enter into such agreements on terms acceptable to us or at all. In addition, even if we enter into such relationships, we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties

 

If we are unable to file for approval of MAT2203 or MAT2501 under Section 505(b)(2) of the FDCA or if we are required to generate additional data related to safety and efficacy in order to obtain approval under Section 505(b)(2), we may be unable to meet our anticipated development and commercialization timelines.

 

Our current plans for filing the NDAs for MAT2203 and MAT2501 include efforts to minimize the data we will be required to generate in order to obtain marketing approval for this product candidate and therefore reduce the development time. We intend to rely on the history of efficacy of amphotericin B, and although we met with the FDA in 2019 and again in 2021 to discuss our development plans for MAT2203, there is no assurance we will satisfy FDA’s requirements for approval of MAT2203 under a 505(b)(2) pathway. We have not yet met with FDA to discuss the regulatory pathway for MAT2501. The timelines for filing and review of our NDAs for MAT2203 and MAT2501 are based on our plan to submit these NDAs under Section 505(b)(2) of the FDCA, which would enable us to rely in part on data in the public domain or elsewhere. We have not yet filed an NDA under Section 505(b)(2) for any product candidate. Depending on the data that may be required by the FDA for approval, some of the data may be related to products already approved by the FDA. If the data relied upon is related to products already approved by the FDA and covered by third-party patents, we would be required to certify that we do not infringe the listed patents or that such patents are invalid or unenforceable. As a result of the certification, the third-party would have 45 days from notification of our certification to initiate an action against us.

 

In the event that an action is brought in response to such a certification, the approval of our NDA could be subject to a stay of up to 30 months or more while we defend against such a suit. Approval of our product candidates under Section 505(b)(2) may therefore be delayed until patent exclusivity expires or until we successfully challenge the applicability of those patents to our product candidates. Alternatively, we may elect to generate sufficient additional clinical data so that we no longer rely on data which triggers a potential stay of the approval of our product candidates. Even if no exclusivity periods apply to our applications under Section 505(b)(2), the FDA has broad discretion to require us to generate additional data on the safety and efficacy of our product candidates to supplement third-party data on which we may be permitted to rely. In either event, we could be required, before obtaining marketing approval for any of our product candidates, to conduct substantial new research and development activities beyond those we currently plan to engage in order to obtain approval of our product candidates. Such additional new research and development activities would be costly and time consuming.

 

We may not be able to realize a shortened development timeline for any of our product candidates, and the FDA may not approve our NDA based on their review of the submitted data. If our desired reference-listed drug containing products are withdrawn from the market by the FDA for any safety reason, we may not be able to reference such products to support a 505(b)(2) NDA for our product candidates, and we may need to fulfill the more extensive requirements of Section 505(b)(1). If we are required to generate additional data to support approval, we may be unable to meet our anticipated development and commercialization timelines, may be unable to generate the additional data at a reasonable cost, or at all, and may be unable to obtain marketing approval of our lead product candidates.

 

 46 

 

 

We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.

 

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have competitors in a number of jurisdictions, many of which have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than we have. We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. Established competitors may invest heavily to quickly discover and develop novel compounds that could make MAT2203, MAT2501 or any other product candidates we may develop obsolete or uneconomical. Any new product that competes with an approved product may need to demonstrate compelling advantages in efficacy, cost, convenience, tolerability and safety to be commercially successful. Other competitive factors, including generic competition, which could force us to lower prices or result in reduced sales, particularly those products that have been marketed by third parties for many years and are well accepted by physicians, patients and payers. In addition, new products developed by others could emerge as competitors to MAT2203, MAT2501 or any of our other product candidates. If we are not able to compete effectively against our current and future competitors, our business will not grow, and our financial condition and operations will suffer.

 

Further, although we believe that our proprietary LNC platform delivery technology, experience and knowledge in our areas of focus provide us with competitive advantages, potential competitors for MAT2203 could reduce our commercial opportunities.

 

Even if we obtain marketing approval for any product candidate, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates could be subject to labeling and other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our future products.

 

Even if we obtain United States regulatory approval of MAT2203, MAT2501 or any other product candidates that we may develop, FDA may still impose significant restrictions on its indicated uses or marketing or the conditions of approval or impose ongoing requirements for potentially costly and time-consuming post-approval studies, and post-market surveillance to monitor safety and efficacy. Our future products will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of AEs and other post-market information. These requirements include registration with FDA, as well as continued compliance with current Good Clinical Practices regulations, or cGCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continuous review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, cGMP, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.

 

FDA has the authority to require a REMS, as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment in a registry.

 

With respect to sales and marketing activities by us or any future partner, advertising and promotional materials must comply with FDA rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in other countries. In the United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change. We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.

 

 47 

 

 

In addition, our product labeling, advertising and promotion would be subject to regulatory requirements and continuing regulatory review. FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by FDA as reflected in the product’s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless legally prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions, including revocation of its marketing approval. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.

 

If we or a regulatory agency discovers previously unknown problems with a product, such as AEs of unanticipated severity or frequency, problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements, we may be subject to the following administrative or judicial sanctions:

 

● restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;
   
● issuance of warning letters or untitled letters;
   
● clinical holds;
   
● injunctions or the imposition of civil or criminal penalties or monetary fines;
   
● suspension or withdrawal of regulatory approval;
   
● suspension of any ongoing clinical trials;
   
● refusal to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;
   
● suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or
   
● product seizure or detention or refusal to permit the import or export of product.

 

The occurrence of any event or penalty described above may inhibit our ability to commercializeMAT2203, MAT2501 or any of our other product candidates and generate revenue. Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.

 

We are in the process of evaluating potential next steps in the development of LYPDISO.

 

We have initiated a global process to identify a partner to advance development of LYPDISO and have allocated resources away from a Phase 3 program for LYPDISO. However, there is no guarantee that we will identify a suitable partner for LYPDISO or that we will be able to enter into a partnering agreement on favorable terms. In the event that we do not identify a suitable partner, enter into a partnering agreement on favorable terms, or if a potential partner fails to satisfy its obligations to develop and commercialize LIPDOSO, we may never realize the full or any value from LYPDISO.

 

 48 

 

 

Future legislation, and/or regulations and policies adopted by the FDA may increase the time and cost required for us to conduct and complete clinical trials.

 

FDA has established regulations to govern the drug development and approval process, as have foreign regulatory authorities. The policies of FDA and other regulatory authorities may change, and additional laws or government regulations may be promulgated that could prevent, limit, delay but also accelerate regulatory review of our product candidates. For example, in December 2016, the Cures Act was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation. We cannot predict what if any effect the Cures Act or any existing or future guidance from FDA will have on development of our product candidates.

 

Changes in health care law and implementing regulations may have a material adverse effect on us.

 

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.

 

Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in the United States, the Patient Protection and Affordable Care Act of 2010 (“ACA”) substantially changed the way health care is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. Many provisions of the ACA impact the biopharmaceutical industry, including that in order for a biopharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the drug pricing program under the Public Health Services Act, or PHS. Since its enactment, there have been judicial and Congressional challenges and amendments to certain aspects of ACA. There is continued uncertainty about the implementation of the ACA, including the potential for further amendments to the ACA and legal challenges to or efforts to repeal the ACA.

 

Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the now-departed Trump administration proposed numerous prescription drug cost control measures. Similarly, the new Biden administration has made lowering prescription drug prices one of its priorities. The Biden administration has not yet proposed any specific plans, but we expect that these will be forthcoming in the near term. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Other examples of proposed changes include, but are not limited to, expanding post-approval requirements, changing the Orphan Drug Act, and restricting sales and promotional activities for pharmaceutical products.

 

We cannot be sure whether additional legislative changes will be enacted, or whether government regulations, guidance or interpretations will be changed, or what the impact of such changes would be on the marketing approvals, sales, pricing, or reimbursement of our drug candidates or products, if any, may be. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

 

 49 

 

 

In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for our product candidates. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could, among other things, require:

 

● additional clinical trials to be conducted prior to obtaining approval;
   
● changes to manufacturing methods;
   
● recalls, replacements, or discontinuance of one or more of our products; and
   
● additional recordkeeping.

 

Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of our product candidates. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial condition, and results of operations.

 

Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower-cost products that are already reimbursed, may be incorporated into existing payments for other products or services, and may reflect budgetary constraints and/or imperfections in Medicare or Medicaid data used to calculate these rates. Net prices for products may be reduced by mandatory discounts or rebates required by government health care programs. Such legislation, or similar regulatory changes or relaxation of laws that restrict imports of products from other countries, could reduce the net price we receive for any future marketed products. As a result, our future products might not ultimately be considered cost-effective. We cannot be certain that reimbursement will be available for any of our product candidates. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, any future products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize any product candidates that we develop.

 

Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

 

Our future profitability will depend, in part, on our ability to commercialize our product candidates in foreign markets for which we intend to rely on collaborations with third parties. If we commercialize MAT2203, MAT2501 or any other product candidates that we may develop in foreign markets, we would be subject to additional risks and uncertainties, including:

 

● our customers’ ability to obtain reimbursement for our product candidates in foreign markets;
   
● our inability to directly control commercial activities because we are relying on third parties;
   
● the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;
   
● different medical practices and customs in foreign countries affecting acceptance in the marketplace;
   
● import or export licensing requirements;
   
● longer accounts receivable collection times;
   
● longer lead times for shipping;

 

 50 

 

 

● language barriers for technical training;
   
● reduced protection of intellectual property rights in some foreign countries;
   
● foreign currency exchange rate fluctuations; and
   
● the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

 

Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs, any of which may adversely affect our results of operations.

 

If we market our product candidates in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.

 

FDA enforces laws and regulations which require that the promotion of pharmaceutical products be consistent with the approved prescribing information. While physicians may prescribe an approved product for a so-called “off label” use, it is unlawful for a pharmaceutical company to promote its products in a manner that is inconsistent with its approved label and any company which engages in such conduct can subject that company to significant liability. Similarly, industry codes in the EU and other foreign jurisdictions prohibit companies from engaging in off-label promotion and regulatory agencies in various countries enforce violations of the code with civil penalties. While we intend to ensure that our promotional materials are consistent with our label, regulatory agencies may disagree with our assessment and may issue untitled letters, warning letters or may institute other civil or criminal enforcement proceedings. In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include the U.S. Anti-Kickback Statute, U.S. False Claims Act and similar state laws. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be

 

The U.S. Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted broadly to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the U.S. Anti-Kickback Statute and criminal health care fraud statutes; a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid.

 

Over the past few years, several pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicare or Medicaid for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Most states also have statutes or regulations similar to the U.S. Anti-Kickback Statute and the U.S. False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include substantial civil monetary penalties, exclusion of a manufacturer’s products from reimbursement under government programs, substantial criminal fines and imprisonment.

 

 51 

 

 

We have been and expect to be significantly dependent on our collaborative agreements for the development of MAT2203 and MAT2501, which exposes us to the risk of reliance on the performance of third parties.

 

In conducting our research and development activities for MAT2203 and MAT2501, we currently rely, and expect to continue to rely, on collaborative agreements with universities, governmental agencies and not-for-profit organizations for both strategic and financial resources. Key among these agreements is our collaboration agreements with the NIH for the development of MAT2203 and our award agreement with the CFF for the development of MAT2501. The loss of, or failure to perform by us or our partners under any applicable agreements or arrangements, or our failure to secure additional agreements for our product candidates, would substantially disrupt or delay our research and development activities, including our in-process and anticipated clinical trials. Any such loss would likely increase our expenses and materially harm our business, financial condition and results of operation.

 

We expect that we will rely on third parties to conduct clinical trials for our product candidates, which exposes us to the risk of reliance on the performance of third parties.

 

We expect to enter into agreements with third-party CROs, or governmental entities like the NIH, to conduct and manage our clinical programs. We rely heavily on these parties for execution of clinical studies for MAT2203, MAT2501 and our other product candidates and can control only certain and very limited aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the NIH or CROs would not relieve us of our regulatory responsibilities. We, the NIH and our CROs would be required to comply with cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces these cGCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the NIH or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, our clinical trials must be conducted with products produced under cGMP regulations and will require a large number of test subjects. Our failure or the failure of the NIH or our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties.

 

As a result, many important aspects of our drug development programs would be outside of our direct control. In addition, the NIH or the CROs may not perform all of their obligations under their arrangements with us or in compliance with regulatory requirements. If NIH or the CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development and commercialization of MAT2203, MAT2501 or any other product candidates that we may develop may be delayed or our development program may be materially and irreversibly harmed. We cannot control the amount and timing of resources these CROs would devote to our program or our product candidates. If we are unable to rely on the clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of our clinical trials, which could significantly delay commercialization and require significantly greater expenditures. If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. As a result of the foregoing, our financial results and the commercial prospects for MAT2203, MAT2501 and our other product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.

 

 52 

 

 

We are, and will be, completely dependent on third parties to manufacture our product candidates, and our commercialization of efforts could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of any product candidate or fail to do so at acceptable quality levels or prices.

 

We do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture the active pharmaceutical ingredient, or API, in MAT2203, MAT2501, or any of our product candidates, for use in our clinical trials or for commercial product, if any. As a result, we will rely on contract manufacturers throughout the development process and then if and when MAT2203, MAT2501, or any of our product candidates are approved for commercialization. We have not entered into any agreement with any contract manufacturers for commercial supply and may not be able to engage a contract manufacturer for commercial supply of MAT2203, MAT2501, or any of our product candidates, on favorable terms to us, or at all.

 

The facilities used by our contract manufacturers to manufacture any of our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs for manufacture of both active drug substances and finished drug products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating to our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of a product candidate or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market such product candidate , if approved.

 

Our contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. We do not have control over our contract manufacturers’ compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our product candidates , delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers to comply with or maintain any of these standards could adversely affect our ability to develop, obtain regulatory approval for or market any of our product candidates .

 

If, for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them, and we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing processes for our API or finished product or should cease doing business with us, we could experience significant interruptions in product supply or may not be able to create a supply of any product candidate at all. Were we to encounter manufacturing issues, our ability to produce a sufficient product supply might be negatively affected. Our inability to coordinate the efforts of our third-party manufacturing partners, or the lack of capacity available at our third party manufacturing partners, could impair our ability to supply any product candidate at required levels. Because of the significant regulatory requirements that we would need to satisfy in order to qualify a new bulk or finished product manufacturer, if we face these or other difficulties with our current manufacturing partners, we could experience significant interruptions in product supply if we decided to transfer manufacturing to one or more alternative manufacturers in an effort to deal with the difficulties.

 

Any manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to a future contract manufacturer caused by problems at suppliers could delay shipment of our product candidates, increase our cost of goods sold and result in lost sales.

 

We cannot guarantee that our manufacturing and supply partners will be able to reduce the costs of commercial scale manufacturing of any product candidate over time. If the commercial-scale manufacturing costs of LYPDISO are higher than expected, these costs may significantly impact our operating results. In order to reduce costs, we may need to develop and implement process improvements. However, in order to do so, we will need, from time to time, to notify or make submissions with regulatory authorities, and the improvements may be subject to approval by such regulatory authorities. We cannot be sure that we will receive these necessary approvals or that these approvals will be granted in a timely fashion. We also cannot guarantee that we will be able to enhance and optimize output in our commercial manufacturing process. If we cannot enhance and optimize output, we may not be able to reduce our costs over time.

 

 53 

 

 

Outbreaks of communicable diseases may materially and adversely affect our business, financial condition and results of operations.

 

We face risks related to health epidemics or outbreaks of communicable diseases. The outbreak of communicable diseases, such as COVID-19, have resulted in a widespread health crisis that has adversely affected general commercial activity and the economies and financial markets of many countries. Since some of our business partners are outside of the U.S., in China and other Asian countries, including manufacturing operations for our active pharmaceutical ingredient, an outbreak of communicable diseases in Asia or elsewhere, or the perception that such an outbreak could occur, and the measures taken by the governments of countries affected could adversely affect our business, financial condition or results of operations. For example, an outbreak could significantly disrupt our business by limiting our ability to travel or ship materials within or outside China and forcing temporary closure of facilities that we rely upon.

 

Adverse global conditions, including economic uncertainty, may negatively impact our financial results.

 

Global conditions, dislocations in the financial markets, or inflation could adversely impact our business. In addition, the global macroeconomic environment has been and may continue to be negatively affected by, among other things, instability in global economic markets, increased U.S. trade tariffs and trade disputes with other countries, instability in the global credit markets, supply chain weaknesses, instability in the geopolitical environment as a result of the Russian invasion of the Ukraine, the withdrawal of the United Kingdom from the European Union, and other political tensions, and foreign governmental debt concerns. Such challenges have caused, and may continue to cause, uncertainty and instability in local economies and in global financial markets, which may adversely affect our business.

 

Risks Relating to Our Intellectual Property Rights and Regulatory Exclusivity

 

We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from discovering, developing and commercializing our product candidates.

 

We rely exclusively upon our LNC platform delivery technology which is licensed to us by Rutgers. We do not own some of the patents that underly this in-license technology. Our rights to use the technology we license are subject to the negotiation of, continuation of and compliance with the terms of our license agreement with Rutgers. Pursuant to the terms of our license agreement with Rutgers, we control the prosecution, maintenance, or filing of the patents to which we hold licenses, as well as the enforcement of these patents against third parties. However, some of our patents and patent applications were either acquired from another company who acquired those patents and patent applications from yet another company or are licensed from a third party. Thus, these patents and patent applications were not written by us or our attorneys, and we did not have control over the drafting and prosecution of certain of these patents. The former patent owners and our licensors might not have given the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owners of the patents and applications and had control over the drafting and prosecution. We cannot be certain that drafting and/or prosecution of the licensed patents and patent applications by the licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.

 

Our rights to use the technology we license are subject to the validity of the owner’s intellectual property rights. Enforcement of our licensed patents or defense or any claims asserting the invalidity of these patents is often subject to the control or cooperation of our licensors. Legal action could be initiated against the owners of the intellectual property that we license and an adverse outcome in such legal action could harm our business because it might prevent such companies or institutions from continuing to license intellectual property that we may need to operate our business. In addition, such licensors may resolve such litigation in a way that benefits them but adversely affects our ability to use the licensed technology for our products.

 

Certain of our licenses contained in our agreement with Rutgers contain provisions that allow the licensor to terminate the license if (i) we breach any payment obligation or other material provision under the agreement and fail to cure the breach within a fixed time following written notice of termination, (ii) we or any of our affiliates, licensees or sub licensees directly or indirectly challenge the validity, enforceability, or extension of any of the licensed patents or (iii) we declare bankruptcy or dissolve. Our rights under the licenses are subject to our continued compliance with the terms of the license, including the payment of royalties due under the license. Termination of these licenses may prevent us from discovering, developing and commercializing product candidates based on the LNC platform delivery technology, including our lead anti-infective product candidates, MAT2203 and MAT2501. Determining the scope of the license and related royalty obligations can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from discovering, developing and commercializing product candidates based on the LNC platform delivery technology, including our lead anti-infective product candidates.

 

 54 

 

 

If we discontinue development of the LNC platform delivery technology, we would be required to return such technology to the former stockholders of Aquarius and/or Rutgers and we would lose the rights to our lead product candidates.

 

Under certain circumstances, we will be required to transfer Aquarius’ LNC platform delivery technology back to the former shareholders of Aquarius. This transfer would be required under the Aquarius Merger Agreement pursuant to which we acquired the rights to the LNC platform delivery technology in the event the following conditions are met: (i) we shall have discontinued efforts to develop or commercialize the LNC platform delivery technology (as conclusively demonstrated by our omission of the LNC platform delivery technology in at least two consecutive royalty, progress and payment reports delivered to Rutgers pursuant to the license agreement entered into between Aquarius and Rutgers) and (ii) as of the Transfer Date, no unresolved indemnification claims for us and our indemnified parties are pending. If the foregoing conditions are met, we would transfer the LNC platform delivery technology to the stockholder representative or to a newly formed entity as directed by the stockholder representative (in either case for the benefit of the former Aquarius stockholders) following receipt of any necessary third-party consents required for the transfer, which we shall use its commercially reasonable efforts to obtain. If we are required to transfer the LNC platform delivery technology back to the former shareholders of Aquarius, we would lose our rights to our lead product candidates, which would have a material and adverse effect on our business.

 

It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.

 

Our commercial success will depend, in part, on obtaining and maintaining patent protection for our technologies, products and processes, successfully defending these patents against third-party challenges and successfully enforcing these patents against third party competitors. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowable or enforceable in our patents (including patents owned and licensed by us). We currently own or have rights to 30 issued patents relating to our LNC platform delivery technology, as well as pending patent applications for our LNC platform delivery technology that may never be approved by the United States or foreign patent offices. Furthermore, any patents which may eventually be issued from existing patent applications for any of our technologies, may be challenged, invalidated or circumvented by third parties and might not protect us against competitors with similar products or technologies.

 

The degree of future protection for our proprietary rights is uncertain, because legal means afford only limited protection and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive advantage at all. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed by us, or that we will not be involved in interference, opposition or invalidity proceedings before the United States or foreign patent offices.

 

We also rely on trade secrets to protect technology, especially in cases where we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. While we require employees, academic collaborators, consultants and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our proprietary technology and other confidential information, our ability to receive patent protection and our ability to protect valuable information owned by us may be imperiled. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.

 

 55 

 

 

If we fail to obtain or maintain patent or trade secret protection for our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability.

 

We may also develop trademarks to distinguish our products from the products of our competitors. We cannot guarantee that any trademark applications filed by us or our business partners will be approved. Third parties may also oppose such trademark applications, or otherwise challenge our use of the trademarks. In the event that the trademarks we use are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. Further, we cannot provide assurance that competitors will not infringe the trademarks we use, or that we will have adequate resources to enforce these trademarks.

 

Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.

 

Our success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Identification of third-party patent rights that may be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally, because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of MAT2203, MAT2501 or any future product candidate. There may be certain issued patents and patent applications claiming subject matter that we may be required to license in order to research, develop or commercialize MAT220, MAT2501 or any future product candidate and we do not know if such patents and patent applications would be available to license on commercially reasonable terms, or at all. Any claims of patent infringement asserted by third parties against us would be time-consuming and may:

 

● result in costly litigation;
   
● divert the time and attention of our technical personnel and management;
   
● prevent us from commercializing a product until the asserted patent expires or is held finally invalid or not infringed in a court of law;
   
● require us to cease or modify our use of the technology and/or develop non-infringing technology; or
   
● require us to enter into royalty or licensing agreements.

 

Although no third party has asserted a claim of infringement against us, others may hold proprietary rights that could prevent MAT2203 or MAT2501 from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to LYPDISO, MAT2203, MAT2501 or our processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our current product candidates or any future product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign, MAT2203, MAT2501or any future product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing MAT2203, MAT2501 or a future product candidate, which could harm our business, financial condition and operating results.

 

We anticipate that competitors may from time to time oppose our efforts to obtain patent protection for new technologies or to submit patented technologies for regulatory approval. Competitors may seek to oppose our patent applications to delay the approval process or to challenge our granted patents, for example, by requesting a reexamination of our patent at the United States Patent and Trademark Office, or the USPTO, or by filing an opposition in a foreign patent office, even if the opposition or challenge has little or no merit. Such proceedings are generally highly technical, expensive and time consuming, and there can be no assurance that such a challenge would not result in the narrowing or complete revocation of any patent of ours that was so challenged.

 

 56 

 

 

General Company-Related Risks

 

We will need to increase the size of our organization to grow our business, and we may experience difficulties in managing this growth.

 

We have 31 employees as of February 25, 2022. As our development and commercialization plans and strategies develop, we will need to expand the size of our employee base for managerial, development, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our future financial performance and our ability to commercialize our product candidates and our ability to compete effectively will depend, in part, on our ability to effectively manage any future growth.

 

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. In addition, the loss of the services of certain key employees would adversely impact our business prospects.

 

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. In addition, the loss of the services of certain key employees, including Jerome D. Jabbour, our Chief Executive Officer and President, Theresa Matkovits, our Chief Development Officer, and Dr. Hui Liu, our Chief Technology Officer, would adversely impact our business prospects.

 

Our ability to compete in the highly competitive pharmaceutical industry depends in large part upon our ability to attract highly qualified managerial, scientific and medical personnel. In order to induce valuable employees to remain with us, we intend to provide employees with stock options that vest over time. The value to employees of stock options that vest over time will be significantly affected by movements in our stock price that we will not be able to control and may at any time be insufficient to counteract more lucrative offers from other companies.

 

Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize product candidates would be limited.

 

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

 

We face a potential risk of product liability as a result of the clinical testing of MAT2203, MAT2501 or any future product candidates and will face an even greater risk if we commercializeMAT2203, MAT2501 or any other future product. For example, we may be sued if any product we develop or any material that we use in our products allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of MAT2203 or MAT2501. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

 

● decreased demand for MAT2203, MAT2501 or any future products that we may develop;
   
● injury to our reputation;

 

 57 

 

 

   
● withdrawal of clinical trial participants;
   
● costs to defend the related litigation;
   
● a diversion of management’s time and our resources;
   
● substantial monetary awards to trial participants or patients;
   
● product recalls, withdrawals or labeling, marketing or promotional restrictions;
   
● loss of revenue;
   
● the inability to commercialize our product candidates; and
   
● a decline in our stock price.

 

Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We have obtained product liability insurance covering our clinical trials in the amount of greater than or equal to $5 million in the aggregate. Although we will maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

 

Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

 

Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage or disruption from computer viruses, software bugs, unauthorized access, natural disasters, terrorism, war, and telecommunication, equipment and electrical failures. While we have not, to our knowledge, experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, our information security systems and those of our CROs are also subject to laws and regulations requiring that we take measures to protect the privacy and security of certain information gathered and used in our business. For example, HIPAA and its implementing regulations impose, among other requirements, certain regulatory and contractual requirements regarding the privacy and security of personal health information. In the European Union the General Data Protection Regulation, or GDPR, is even more restrictive with respect to all personal information, including information masked by a coding system. In addition to HIPAA and GDPR, numerous other federal and state laws, including, without limitation, state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and storage of personal information. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liability, the further development of our product candidates could be delayed, our competitive position could be compromised, or our business reputation could be harmed.

 

We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.

 

We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.

 

 58 

 

 

Risks related to our Securities

 

Pursuant to the terms of our Series A Preferred Stock, we may be obligated to pay significant royalties.

 

Pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations (the “Certificate of Designations”) for our Series A Preferred Stock, we are required to pay royalties of up to $35 million per year. If and when we obtain FDA or EMA approval of MAT2203 and/or MAT2501, which we do not expect to occur before 2024, if ever, and/or if we generate sales of such products, or we receive any proceeds from the licensing or other disposition of MAT2203 or MAT2501, we are required to pay to the holders of our Series A Preferred Stock, subject to certain vesting requirements, in aggregate, a royalty equal to (i) 4.5% of Net Sales (as defined in the Certificate of Designations), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Certificate of Designations), subject in all cases to a cap of $10 million per calendar year. The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033.

 

The rights of the holders of common stock may be impaired by the potential issuance of preferred stock.

 

Our articles of incorporation give our board of directors the ability to designate and issue preferred stock in one or more series. As a result, the board of directors may, without stockholder approval, issue new series of preferred stock with voting, dividend, conversion, liquidation or other rights which could adversely affect the relative voting power and equity interest of the holders of common stock. Additional issuances of preferred stock, which could be issued with the right to more than one vote per share, could have the effect of discouraging, delaying or preventing a change of control of us. The possible impact on takeover attempts could adversely affect the price of our common stock. Although we have no present intention to designate any new series, or issue any shares, of preferred stock, we may do so in the future.

 

We do not intend to pay dividends on our common stock in the foreseeable future.

 

The Board of Directors will determine, in its sole discretion, our dividend policy after considering our financial condition, results of operations and capital requirements, as well as other factors. We do not anticipate paying cash dividends on our common stock in the foreseeable future and you should not invest in us with the anticipation of receiving dividend income.

 

An active public trading market for our common stock may not be sustained.

 

Although our common stock was listed on the NYSE American, the market for our shares has demonstrated varying levels of trading activity, and we cannot assure you that an active trading market will be sustained. A lack of an active market may impair your ability to sell shares of our common stock at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the price of shares of our common stock. An inactive market may also impair our ability to raise capital by selling shares of capital stock and may impair our ability to acquire other companies or technologies by using our common stock as consideration.

 

Our share price has been and could remain volatile.

 

The market price of our common stock has historically experienced and may continue to experience significant volatility. Our progress in developing our product candidates, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in substantial costs and diversion of management’s attention and resources and could harm our stock price, business, prospects, results of operations and financial condition.

 

 59 

 

 

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

 

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. Our research coverage by industry and financial analysts is currently limited. Even if our analyst coverage increases, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

Upon dissolution of our company, you may not recoup all or any portion of your investment.

 

In the event of a liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the proceeds and/or assets of our company remaining after giving effect to such transaction, and the payment of all of our debts and liabilities will be distributed first to the holders of our preferred stock and thereafter to the stockholders of common stock (including the holders of our preferred stock on an “as converted” basis) on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of common stock, or any amounts, upon such a liquidation, dissolution or winding-up of our Company. In this event, you could lose some or all of your investment.

 

Our certificate of incorporation allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.

 

Our board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to issue up to 10,000,000 additional shares of our preferred stock without further stockholder approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.

 

 60 

 

 

Anti-takeover provisions of our certificate of incorporation, bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.

 

Certain provisions of our amended and restated certificate of incorporation and bylaws could discourage, delay or prevent a merger, acquisition or other change of control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your Shares. Furthermore, these provisions could prevent or frustrate attempts by our stockholders to replace or remove members of our board of directors. These provisions also could limit the price that investors might be willing to pay in the future for our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. These provisions, among other things:

 

● they provide that special meetings of stockholders may be called only by the board of directors, President or our Chairman of the Board of Directors, or at the request in writing by stockholders of record owning at least fifty (50%) percent of the issued and outstanding voting shares of common stock;
   
● they do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority stockholder holding a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative voting may have the effect of limiting the ability of minority stockholders to effect changes in our board of directors; and
   
● they allow us to issue, without stockholder approval, up to 10,000,000 shares of preferred stock (all of which remain available for issuance) that could adversely affect the rights and powers of the holders of our common stock.

 

In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed period of time.

 

Stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees may be limited.

 

Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. Our certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery and federal district courts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Some companies that adopted a similar federal district court forum selection provision are currently subject to a suit in the Chancery Court of Delaware by stockholders who assert that the provision is not enforceable. If a court were to find either choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. For example, the Court of Chancery of the State of Delaware recently determined that the exclusive forum provision of federal district courts of the United States of America for resolving any complaint asserting a cause of action arising under the Securities Act is not enforceable. As a result of this decision, we do not currently intend to enforce the federal forum selection provision in our certificate of incorporation, unless the decision is reversed on appeal. However, if the decision is reviewed on appeal and ultimately overturned by the Delaware Supreme Court, we would enforce the federal district court exclusive forum provision.

 

 61 

 

 

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

 

As a result of our merger with Aquarius Biotechnologies, Inc., our ability to utilize our U.S. federal net operating loss, carryforwards and U.S. federal tax credits may be limited under Sections 382 of the Internal Revenue Code of 1986, as amended. The limitations apply if an “ownership change,” as defined by Section 382 and Section 383, occurs. Generally, an ownership change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect “five percent shareholders” increases by more than 50 percentage points over their lowest ownership percentage at any time during the applicable testing period (typically three years). In addition, future changes in our stock ownership, which may be outside of our control, may trigger an “ownership change” and, consequently, Section 382 and Section 383 limitations. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, the Tax Act, among other things, imposes significant additional limitations on the deductibility of interest and limits net operating loss (NOL) deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017.

 

Item 2. Properties

 

Facilities

 

Our administrative offices consist of approximately 8,900 square feet of office space in Bedminster, NJ that we occupy under a lease that expires in August 2028. We also lease laboratory space approximating 14,000 square feet in Bridgewater, NJ, that expires in July 2027.

 

Item 3. Legal Proceedings

 

We are not currently a party to any legal proceedings, and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.

 

Item 4. Mine Safety Disclosures

 

Not applicable

 

PART II

 

Item 5. Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities

 

Our common stock is quoted on the NYSE American under the symbol “MTNB”.

 

On February 25, 2022, the closing sale price of our common stock, as reported by the NYSE MKT, was $0.60 per share and we had approximately 107 record holders of our common stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. VStock Transfer, LLC is the transfer agent and registrar for our common stock.

 

Dividends

 

We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

 

Recent Sales of Unregistered Securities

 

On February 8, 2022, 400,000 shares of our common stock were issued to Rutgers, The State University of New Jersey (“Rutgers”), as partial consideration of the Second Amended and Restated Exclusive License Agreement, dated February 8, 2022, between us and Rutgers. Such shares were issued to Rutgers pursuant to an exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act because we believe: (i) the securities were offered and sold only to an accredited investor; and (ii) Rutgers had knowledge and experience in financial and business matters which allowed it to evaluate the merits and risk of the receipt of these securities, and that it was knowledgeable about our operations and financial condition. Further, there was no general solicitation or general advertising related to this issuance of such shares.

 

On September 3, 2021, 1,500,000 shares of our common stock were issued to the holders of Aquarius Biotechnologies Inc. (“Aquarius”) as partial consideration of the Amendment, dated September 3, 2021, to the Agreement and Plan of Merger by and among the Company, Saffron Merger Sub, Inc., Aquarius and J Carl Craft, as holder representative, dated January 19, 2015 (the “Aquarius Merger Agreement”). Such shares were issued in place of certain milestone payments previously included under the Aquarius Merger Agreement upon the achievement of specified development milestones. Such shares were issued to the holders of Aquarius, as defined in the Aquarius Merger Agreement, pursuant to an exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act because we believe: (i) the securities were offered and sold only to accredited investors; and (ii) the holders had knowledge and experience in financial and business matters which allowed each of them to evaluate the merits and risk of the receipt of these securities, and that each holder was knowledgeable about our operations and financial condition. Further, there was no general solicitation or general advertising related to this issuance of such shares.

 

Repurchases of Equity Securities by the Issuer and Affiliated Purchasers

 

We did not purchase any of our registered securities during the period covered by this Annual Report.

 

Item 6. [Reserved]

 

62

 

 

Item 7. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and financing needs, includes forward-looking statements that involve risks and uncertainties and should be read together with the “Risk Factors” section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report and in other reports we file with the Securities and Exchange Commission, particularly those under “Risk Factors.” Dollars in tabular format are presented in thousands, except per share data, or otherwise indicated.

 

Overview

 

We are focused on redefining the intracellular delivery of nucleic acids and small molecules through our lipid nanocrystal (LNC) drug delivery platform and its application to overcome current challenges in safely and effectively delivering small molecules, nucleic acids, gene therapies, proteins/peptides, and vaccines.

 

Key elements of our strategy include:

 

● Advancing our clinical stage assets based on our LNC platform delivery technology and continuing to expand utilization of this promising technology into areas of innovative medicine beyond small molecules, including nucleic acids (e.g. mRNA, DNA, antisense oligonucleotides (ASOs)) and proteins, both internally and through additional external collaborations and partnerships.
   
● Advancing MAT2203 toward NDA filing through the ongoing EnACT study for the treatment of cryptococcal meningitis, which highlights the safety and efficacy of this promising drug candidate, while also demonstrating the ability of our LNC platform technology to deliver potent medicines across the blood-brain barrier with oral administration.
   
● Progressing the development of MAT2501 through extensive preclinical toxicology and efficacy studies in NTM infections and completing a single ascending dose (SAD) pharmacokinetic study in healthy volunteers later in 2022, all with the financial support of the CFF.

 

We have incurred losses for each period from inception. Our net loss was approximately $23.3 million and $22.4 million for the fiscal years ended December 31, 2021 and 2020, respectively. We expect to incur significant expenses and operating losses over the next several years. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would impact our going concern and would have a negative impact on our financial condition and our ability to pursue our business strategy and continue as a going concern. We will need to generate significant revenues to achieve profitability, and we may never do so.

 

Financial Operations Overview

 

Revenue

 

During the years ended December 31, 2021 and 2020, we generated approximately $33 thousand and $158 thousand, respectively, in contract research revenues, resulting from a grant with the CFF in 2020 and a feasibility study agreement entered into with Genentech in 2019. Our ability to generate product revenue, which we do not expect to occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our early-stage product candidates.

 

63

 

 

Research and Development Expenses

 

Research and development expenses consist of costs incurred for the development of product candidates MAT2203, and MAT2501and advancement of our LNC platform delivery technology, which include:

 

● the cost of conducting pre-clinical work;
   
● the cost of acquiring, developing and manufacturing pre-clinical and human clinical trial materials;
   
● costs for consultants and contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regulatory operations;
   
● expenses incurred under agreements with contract research organizations, or CROs, including the NIH, that conduct our pre-clinical or clinical trials;
   
●

employee-related expenses, including salaries and stock-based compensation expense for those employees involved in the research and development process; and

 

● the reimbursement of certain expenses related to the CFF award agreement.

 

The table below summarizes our direct research and development expenses for our product candidates and development platform for the years ended December 31, 2021 and 2020. Our direct research and development expenses consist principally of external costs, such as fees paid to contractors, consultants, analytical laboratories and CROs and/or the NIH, in connection with our development work. We typically use our employee and infrastructure resources for manufacturing clinical trial materials, conducting product analysis, study protocol development and overseeing outside vendors. Included in “Internal Staffing, Overhead and Other” below is the cost of laboratory space, supplies, research and development (R&D) employee costs (including stock option expenses), travel and medical education.

 

   Years Ended December 31, 
   (in thousands) 
   2021   2020 
Direct research and development expenses:          
Manufacturing process development  $2,724   $1,421 
Preclinical trials   401    744 
Clinical development   2,261    5,149 
Regulatory   339    95 
Internal staffing, overhead and other   8,858    6,950 
Total research & development  $14,583   $14,359 

 

Research and development activities are central to our business model. We expect our research and development expenses to increase because product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage human trials. Our research and development expenses reflect the reimbursement of certain MAT2501 program expenses related to the CFF award agreement. In addition, we will look to strategically expand the use of our drug platform technology through additional development work. During 2022, we will be focused on advancing our lead product candidate, MAT2203, to efficacy data in the treatment of CM, accelerating the development of MAT2501 and also expanding application of our LNC platform delivery technology through both internal efforts and collaborations with third parties. We have also initiated a global process to identify a suitable partner to continue the development of LYPDISO.

 

64

 

 

General and Administrative Expenses

 

General and administrative expenses consist principally of salaries and related costs for personnel in executive and finance functions. Other general and administrative expenses include facility costs, insurance, investor relations expenses, professional fees for legal, patent review, consulting and accounting/audit services. We anticipate that our general and administrative expenses during 2022 will remain relatively consistent with expenses incurred during 2021.

 

Sale of Net Operating Losses (NOLs)

 

Income obtained from selling unused net operating losses (NOLs) and unused research tax credits under the New Jersey Technology Business Tax Certificate Program was approximately $1.3 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively.

 

Other Income, net

 

Other income, net is largely comprised of interest income (expense) and franchise taxes.

 

Application of Critical Accounting Policies and Accounting Estimates

 

A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

 

For a description of our significant accounting policies, refer to “Note 3 – Summary of Significant Accounting Policies.” Of these policies, the following are considered critical to an understanding of our Consolidated Financial Statements as they require the application of the most difficult, subjective and complex judgments; (i) Stock-based compensation, (ii) Fair value measurements, (iii) Research and development costs, (iv) Goodwill and other intangible assets, and (v) Basic and diluted net loss per common share.

 

Current Operating Trends

 

Our current R&D efforts are focused on advancing our lead LNC product candidates, MAT2203, through clinical development toward an initial indication for the treatment of CM, accelerating development of MAT2501 with the assistance of the CFF, and expanding application of our LNC platform delivery technology through both internal efforts and collaborations with third parties. Our R&D expenses consist of manufacturing work and the cost of active pharmaceutical ingredients and excipients used in such work, fees paid to consultants for work related to clinical trial design and regulatory activities, fees paid to providers for conducting various clinical studies as well as for the analysis of the results of such studies, and for other medical research addressing the potential efficacy and safety of our drugs. We believe that significant investment in product development is a competitive necessity, and we plan to continue these investments in order to be in a position to realize the potential of our product candidates and proprietary technologies.

 

We expect that most of our R&D expenses in the near-term future will be incurred in support of our current and future preclinical and clinical development programs. These expenditures are subject to numerous uncertainties relating to timing and cost to completion. We test compounds in numerous preclinical studies for safety, toxicology and efficacy. At the appropriate time, subject to the approval of regulatory authorities, we expect to conduct early-stage clinical trials for each drug candidate. We anticipate funding these trials ourselves, and possibly with the assistance of federal grants, contracts or other agreements. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials may take several years, and the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.

 

The commencement and completion of clinical trials for our products may be delayed by many factors, including lack of efficacy during clinical trials, unforeseen safety issues, slower than expected participant recruitment, lack of funding or government delays. In addition, we may encounter regulatory delays or rejections as a result of many factors, including results that do not support the intended safety or efficacy of our product candidates, perceived defects in the design of clinical trials and changes in regulatory policy during the period of product development. As a result of these risks and uncertainties, we are unable to accurately estimate the specific timing and costs of our clinical development programs or the timing of material cash inflows, if any, from our product candidates. Our business, financial condition and results of operations may be materially adversely affected by any delays in, or termination of, our clinical trials or a determination by the FDA that the results of our trials are inadequate to justify regulatory approval, insofar as cash in-flows from the relevant drug or program would be delayed or would not occur.

 

65

 

 

Results of Operations

 

Years Ended December 31, 2021 and 2020

 

The following table summarizes our operating expenses for the years ended December 31, 2021 and 2020 (in thousands):

 

   Years Ended December 31, 
   2021   2020 
Revenues  $33   $158 
           
Expenses:          
Research and development  $14,583   $14,359 
General and administrative   10,185    10,006 
Operating Expenses  $24,768   $24,365 
           
Sale of net operating losses (NOLs)  $1,328   $1,073 

 

Revenues. We generated approximately $33 thousand and approximately $158 thousand for the years ended December 31, 2021 and 2020, respectively. The amount earned in 2021 consists of contract research revenue resulting from the feasibility study agreement with Genentech, Inc. Amounts earned in 2020 consists of contract research revenue resulting from a grant with the CFF and the feasibility study agreement with Genentech Inc.

 

Research and Development expenses. R&D expense for the years ended December 31, 2021 and 2020 was approximately $14.6 million and $14.4 million, respectively. The increase of approximately $0.2 was due to a $1.2 million expense related to the Aquarius Merger Agreement, an increase of $1.1 million in product development expenses, and an increase of approximately $0.9 million of compensation expense, primarily related to headcount increases and the exercise of stock options, offset by a $3.0 million decrease in clinical trial expenses, primarily related to the reimbursement of certain MAT2501 program expenses of approximately $2.2 million and approximately $0.8 million decrease in other clinical trials expenses due to the completion of the MAT9001 clinical trials in 2020.

 

General and Administrative expenses. General and administrative expense for the year ended December 31, 2021 was approximately $10.2 million, an increase of approximately $0.2 million over prior year. The increase in general and administrative expense was primarily due to higher compensation expense related to the exercise of stock options and increased insurance expense offset by lower professional fees & consulting expense.

 

Sale of net operating losses (NOLs). The Company recognized approximately $1.3 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively, in connection with the sale of state net operating losses and state research and development credits to a third party under the New Jersey Technology Business Tax Certificate Program.

 

Liquidity and capital resources

 

Sources of Liquidity

 

We have funded our operations since inception primarily through private placements of our preferred stock and our common stock and common stock warrants. As of December 31, 2021, we have raised a total of approximately $156.7 million in gross proceeds and $144.0 million, net, from sales of our equity securities.

 

As of December 31, 2021, we had cash, cash equivalents and marketable securities, excluding restricted cash, totaling $49.6 million.

 

66

 

 

2020 At-The-Market Sales Agreement

 

On July 2, 2020, we entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which we may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of our common stock having an aggregate offering price of up to $50,000,000, subject to certain limitations on the amount of common stock that may be offered and sold by us set forth in the Sales Agreement. BTIG will be paid a 3% commission on the gross proceeds from each sale. We may terminate the Sales Agreement at any time; BTIG may terminate the Sales Agreement in certain limited circumstances. As of December 31, 2020, we did not sell any shares of our common stock under the ATM Sales Agreement. During January 2021, BTIG sold 3,023,147 shares of the Company’s common stock generating gross proceeds of approximately $5.8 million and net proceeds of approximately $5.6 million, after deducting BTIG’s commission on gross proceeds.

 

2020 Common Stock Offering

 

On January 14, 2020, the Company closed an underwritten public offering of its common stock. The offering resulted in the sale of approximately 32.3 million shares to the public at a price of $1.55 per share. The Company generated net proceeds of approximately $46.7 million. The Company granted the underwriters a 30-day option (the “option”) to purchase up to approximately 4.8 million additional shares of common stock subject to the same terms and conditions. No additional shares of the Company’s common stock were sold pursuant to this option.

 

Cash Flows

 

The following table sets forth the primary sources and uses of cash for each of the period set forth below (in thousands):

 

   Years Ended December 31 
   2021   2020 
Cash used in operating activities  $(15,223)  $(17,368)
Cash used in investing activities   16,770    (40,667)
Cash provided by financing activities   6,964    48,047 
Net (decrease)/increase in cash and cash equivalents and restricted cash  $8,511   $(9,988)

 

Operating Activities

 

Net cash used in operating activities for the year ended December 31, 2021 was approximately $15.2 million, compared to approximately $17.4 million in the prior year. The decrease of approximately $2.2 million for the period was primarily due to a decrease of approximately $2.0 million of working capital adjustments due to the timing of receipts and payments in the ordinary course of business and approximately $0.9 million of net non-cash items offset by approximately $0.8 million of an increase in net loss in the current period. We expect that there will be an increase in cash used in operations during 2022 due to higher research and development expenses as we continue to move our product candidates and LNC platform delivery technology forward in their development cycles.

 

Investing Activities

 

Approximately $16.8 million of cash was provided by and approximately $40.7 million of cash was used in investing activities for the years ended December 31, 2021 and 2020, respectively. The increase of $57.5 million was primarily due to the approximately $8.8 million increase in proceeds received from maturities of our marketable securities and the decrease of approximately $48.9 million in purchases of marketable securities as compared to the prior year partially offset by $0.2 million in purchases of equipment and leasehold improvements for the year ended December 31, 2021.

 

Financing Activities

 

Net cash provided by financing activities was approximately $7.0 million and approximately $48.0 million for the years ended December 31, 2021 and 2020, respectively. The decrease of $41.0 million in cash provided by financing activities is primarily due to the Company raising approximately $5.6 million of net proceeds from the January 2021 ATM sales of our common stock compared to the approximately $46.7 million of net proceeds that was raised from the January 2020 public offering of common stock. Other financing activities included a decrease of approximately $0.8 million from the exercising of warrants offset by an increase of approximately $0.8 million from the exercising of stock options.

 

67

 

 

Funding Requirements and Other Liquidity Matters

 

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

 

● conduct further preclinical and clinical studies of MAT2203, our lead product candidate, even is such studies are primarily financed with non-dilutive funding from NIH;
   
● support the conduct of further preclinical and clinical studies of MAT2501, even if such studies are primarily financed with non-dilutive funding from the CFF;
   
● seek to discover and develop additional product candidates;
   
● seek regulatory approvals for any product candidates that successfully complete clinical trials;
   
● require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;
   
● maintain, expand and protect our intellectual property portfolio;
   
● hire additional clinical, quality control and scientific personnel; and
   
● add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts and personnel and infrastructure necessary to help us comply with our obligations as a public company.

 

We expect that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditures requirements through 2023.

 

Until such time, if ever, that we can generate product revenues sufficient to achieve profitability, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements. We do not have any committed external source of funds other than limited grant funding from the CFF and NIH. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interest of our stockholders may be materially diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights of our common stockholders. Debt financing and preferred equity financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. Securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management’s ability to oversee the development of our product candidates.

 

If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

 

68

 

 

Contractual Obligations and Commitments

 

Refer to Note 10 – “Commitments” in the accompanying notes to the consolidated financial statements for a discussion of the Company’s contractual obligations and commitments.

 

Off-Balance Sheet Arrangements

 

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

Refer to Note 3 - “Significant Accounting Policies,” in the accompanying notes to the consolidated financial statements for a discussion of recent accounting pronouncements.

 

Item 7A. Quantitative And Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 8. Financial Statements And Supplementary Data

 

Our financial statements, together with the independent registered public accounting firm report thereon, are incorporated by reference from the applicable information set forth in Part IV Item 15, “Exhibits, Financial Statement Schedules” of this Annual Report on Form 10-K which includes the report of EisnerAmper LLP (PCAOB ID: 247).

 

Item 9. Changes In And Disagreements With Accountants On Accounting And Financial Disclosure

 

Not applicable.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure Controls and Procedures:

 

As of December 31, 2021, under the supervision and with the participation of our principal executive officer and principal financial officer we have evaluated, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2021.

 

Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports that we filed or submitted under the Exchange Act is recorded, processed, summarized and reported within time periods specified by the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

69

 

 

Management’s Report on Internal Control over Financial Reporting:

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.

 

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, any projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate.

 

Management assessed the effectiveness of our internal control over financial reporting based on criteria established in “Internal Control—Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management has concluded as of December 31, 2021, our internal control over financial reporting was effective, as management did not identify any deficiencies in internal control over financial reporting that was determined to be a material weakness.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

 

Changes in Internal Control Over Financial Reporting:

 

There was no change in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that occurred during the period ended December 31, 2021 covered by this report that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

None

 

PART III

 

Item 10. Directors, Executive Officers And Corporate Governance

 

All directors hold office for one-year terms until the election and qualification of their successors. Officers are appointed by our board of directors and serve at the discretion of the board, subject to applicable employment agreements. The following table sets forth information regarding our executive officers and the members of our board of directors.

 

Name   Age   Position(s)
Herbert Conrad   89   Chairman of the Board, Director
Jerome D. Jabbour   47   Chief Executive Officer and President, Director
James J. Ferguson   68   Chief Medical Officer
Thomas J. Hoover   52   Chief Business Officer
Keith A. Kucinski   52   Chief Financial Officer
Hui Liu   54   Chief Technology Officer
Raphael J. Mannino   74   Chief Scientific Officer
Theresa Matkovits   54   Chief Development Officer
Kathryn Corzo   61   Director
Eric Ende   53   Director
Natasha Giordano   60   Director
James S. Scibetta   57   Director
Matthew Wikler   72   Director

 

70

 

 

Management

 

Jerome D. Jabbour, JD was appointed Chief Executive Officer in March 2018. He has served as our President since March 2016. Prior to that he served as our Executive Vice President, Chief Business Officer, General Counsel and Secretary since October 2013 and as one of our directors from April 2012 until November 2013. Mr. Jabbour is also a Co-founder of Matinas BioPharma. Prior to joining our management team, he was the Executive Vice President and General Counsel of MediMedia USA, or MediMedia, from 2012 to October 2013, a privately held diversified health care services company. Prior to MediMedia, he was the Senior Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012), a global pharmaceutical and biotechnology company, and Senior Counsel and Assistant Secretary at Reliant (2004-2008). Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. (2003-2004) and as a Corporate Associate at Lowenstein Sandler LLP (1999-2003). Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore.

 

James J. Ferguson, MD was appointed Chief Medical Officer in February 2019. Prior to joining the Company he served as the Cardiovascular and Bone Therapeutic Area Head for U.S. Medical Affairs, at Amgen (NASDAQ: AMGN), multinational biopharmaceutical company, from 2016 to 2019. Prior to Amgen Dr. Ferguson held a number of senior positions at AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, including Vice President of US Cardiovascular Medical and Scientific External Relations, Therapeutic Area Vice President of Cardiovascular Global Medical Affairs, U.S. Development Brand Leader for BRILINTA®, and Senior Director, Clinical Research. Before joining AstraZeneca he was Vice President of Surgical and Critical Care for The Medicines Company. In addition, Dr. Ferguson had more than 20 years of academic experience as the Associate Director of Clinical Cardiology Research at the Texas Heart Institute, Co-Director of the Cardiology Fellowship Training Program at St. Luke’s Episcopal Hospital in Houston, where he was an Associate Professor of Medicine at Baylor College of Medicine, and a Clinical Assistant Professor at the University of Texas Health Science Center at Houston. Dr. Ferguson has served on the Editorial Board of numerous peer-reviewed journals and has over 400 publications and book chapters. Dr. Ferguson received his B.A. (cum laude) in Biology from Harvard University, his M.D. from the University of Pennsylvania School of Medicine and completed his post-graduate training at the University of Michigan Medical Center, Ann Arbor, Michigan and Beth Israel Hospital, Boston, Massachusetts.

 

Thomas J. Hoover, MBA has served as Chief Business Officer since December 2021. Prior to joining the Company, Mr. Hoover was the Chief Business Officer at Millendo Therapeutics, (now Tempest Therapeutics, Inc.) a clinical stage biotech, from 2016 to 2021. Prior to joining Millendo, Mr. Hoover was Vice President of New Product Planning and Corporate Development and Licensing at Sunovion Pharmaceuticals Inc., a global biopharmaceutical company. Mr. Hoover started his pharmaceutical career at GSK in 2001 working in the Global Commercial Strategy group. Earlier in his career, Mr. Hoover worked for The Boston Consulting Group. Mr. Hoover holds a M.B.A. from the University of North Carolina and a B.A. from Harvard College.

 

Keith A. Kucinski, MBA, CPA was appointed Chief Financial Officer in January 2019. He most recently served as Chief Financial Officer at RemedyOne, a privately held healthcare consulting organization, during 2018. Prior to that, he served as Vice President & Treasurer at Par Pharmaceutical Companies, Inc., an operating company of Endo International plc, a leading generics and specialty-branded pharmaceutical company, from 2009 to 2015. In addition, Mr. Kucinski held various roles at Barr Pharmaceuticals, Inc., including Senior Director, Finance & Corporate Development and Assistant Treasurer & Senior Director, Finance. Mr. Kucinski is a Certified Public Accountant. He received his Bachelor of Business Administration in Accounting from the University of Notre Dame and an M.B.A. in Finance & Management from the Leonard N. Stern School of Business at New York University.

 

71

 

 

Hui Liu, PhD, MBA has serves as Chief Technology Officer since December 2020. Prior to joining the Company, Dr. Liu was Director of Formulation and Delivery at Seqirus USA Inc., a privately held global leader in influenza and pandemic response, from 2017 to 2020. Prior to joining Seqirus, Dr. Liu was Director of CMC at Cellics Therapeutics, Inc., a privately held development stage biopharmaceutical company, in 2017, and Senior Technical Lead at Alcon Inc. (SIX/NYSE: ALC), a global leader in eye care, from 2015 to 2017. Earlier in his career, Dr. Liu held positions at Cellics Therapeutics, Inc., a privately held biotech company, and Allergan. Dr. Liu holds a Ph.D. in polymer chemistry from the University of Michigan, an M.B.A. from the University of Massachusetts, Amherst, and a B.S. from The University of Science and Technology of China.

 

Raphael J. Mannino has served as our Chief Scientific Officer since September 2015. From 1990 until August 2015, Dr. Mannino was an Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School. Dr. Mannino founded BioDelivery Sciences, Inc., and served as its President, Chief Executive Officer and Chief Scientific Officer and a member of its Board of Directors from 1995 to 2000, when it was acquired by BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Dr. Mannino served as BDSI’s Executive Vice President and Chief Scientific Officer from 2001 to 2009 and a member of its Board of Directors from 2000 to 2007. Dr. Mannino’s previous experience includes positions as Assistant, then Associate Professor, Albany Medical College (1980 to 1990), and Instructor then Assistant Professor, Rutgers Medical School (1977 to 1980). His postdoctoral training was from 1973 to 1976 at the Biocenter in Basel, Switzerland. Dr. Mannino received his Ph.D. in Biological Chemistry in 1973 from the Johns Hopkins University, School of Medicine.

 

Theresa Matkovits, PhD has served as Chief Development officer since October 2018. She joined the Company after having most recently served as the Chief Operating Officer of ContraVir Pharmaceuticals (NASDAQ: CTRV) (now Hepion Pharmaceuticals), a clinical stage biopharmaceutical company, from 2015 to 2018. From 2013 to 2015, Dr. Matkovits served as Global Program Leader at NPS Pharmaceuticals, a specialty pharmaceutical company that was purchased by Shire in 2015. Prior to her time at NPS, Dr. Matkovits was Vice President, Innovation Leader at The Medicines Company. Earlier in her career, Dr. Matkovits held a number of global leadership positions at Novartis across Global Development and the U.S. Commercial Organization, including as Head, Strategic Planning and Operations, U.S. Medical and Drug Regulatory Affairs. Dr. Matkovits began her career at the Roche Institute of Molecular Biology and Organon where she held positions in clinical development in women’s health and research in the area of infertility. Dr. Matkovits serves on the Board of Directors of Appili Therapeutics (TSX: APLI; OTCQX: APLIF) and GoodCap Pharmaceuticals, a privately held pharmaceutical company. Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ.

 

Directors

 

Herbert Conrad has served as our Chairman of the Board since July 2013 and as Chairman of the Board of Matinas BioPharma, Inc. since October 2012. He also serves on the board of directors of Celldex Therapeutics, Inc. (NASDAQ: CLDX), biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics, and as an Advisor to the Seaver Autism Center at Mount Sinai Hospital. Mr. Conrad was the President of the U.S. Pharmaceuticals Division of Hoffmann-La Roche, Inc. from 1982 until his retirement in 1993. Prior to that, he held many positions of increasing responsibility at Roche Pharmaceuticals in the United States. Mr. Conrad previously served on the board of directors of Arbutus Biopharma Corporation (NASDAQ: ABUS), Pharmasset, Inc. (chairman), Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), Dura Pharmaceuticals, Inc., UroCor, Inc., GenVec, Inc. (NASDAQ: GNVC) (chairman), Sicor, Inc., Bone Care International, Inc. (chairman), Sapphire Therapeutics, Inc. (chairman), the medical advisory board of Henry Schein Inc. (NASDAQ: HSIC), and he was a Director and Co-Founder of Reliant Pharmaceuticals. Pharmasset was acquired by Gilead Sciences, Inc. for $11 billion in 2011 and Reliant was acquired by GlaxoSmithKline for $1.65 billion in 2007. He received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University. We believe Mr. Conrad is qualified to serve on our board of directors due to his extensive expertise and experience in the life sciences industry and his extensive board experience.

 

72

 

 

Jerome D. Jabbour. See description under “Management.”

 

Kathryn Corzo, RPh, MBA has served on our board of directors since November 2021. Ms. Corzo is currently the Chief Operating Officer of bit.bio Ltd, a privately funded company coding human cells to precision engineer the next generation of medicines, a position she has held since 2021. Prior to bit.bio, Ms. Corzo was partner at Takeda Ventures, Inc., the corporate investment arm of Takeda Pharmaceutical Company Limited, and also served as Head, Oncology Cell Therapy Development at Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK), a global biopharmaceutical company, a position she held since 2020. Before Takeda, Ms. Corzo was Vice President, R&D Myeloma Program Leader at Sanofi Genzyme, a specialty care global business unit of Sanofi, from 2010 to 2019. From 1989-2010, Ms. Corzo worked at Hoffman – La Roche, Roche Molecular Systems, Eli Lilly and Syndax, during which time she held roles of increasing seniority in operations, global clinical development, medical affairs, business development, market access and brand management across multiple therapeutic products and indications. Ms. Corzo holds an MBA from Massachusetts Institute of Technology Sloan School of Management and a Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy. We believe Ms. Corzo is qualified to serve on our Board of Directors due to her broad experience in the life sciences industry.

 

Eric Ende has served on our board of directors since April 2017. Dr. Ende is president of Ende BioMedical Consulting Group, a privately-held consulting company which is focused on helping life sciences companies raise capital, identify licensing partners, and optimize corporate structure as well as analyzing both private and public investment opportunities for clients within the life sciences industry, a position he has held since 2009. In addition, Dr. Ende consulted with Icahn Enterprises in their efforts to appoint board members at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende served on the board of directors and as a member of the Audit and Risk Management Committee of Genzyme Corp. (NASDAQ: GENZ) from 2010 until it was acquired by Sanofi (NSYE: SNY) in 2011. Through another activist campaign, Dr. Ende served on the board of directors of Progenics Pharmaceuticals, Inc., an oncology company, from 2019 until it was acquired by Lantheus Holdings, Inc. in 2020, as Chair of the Compensation Committee and a member of the Audit and Science Committees. Dr. Ende also serves on the board of directors of Avadel Pharmaceuticals plc, a biopharmaceutical company, as Chair of the Nomination & Corporate Governance Committee and a member of the Audit and Compensation Committees and since January 2022 also serves on the board of NeuBase Therapeutics. Dr. Ende is currently serving on the Technology Transfer Committee of Mount Sinai Innovation Partners and served as the Chairman of the Unsecured Creditor’s Committee overseeing the bankruptcy of Egenix, Inc. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 through 2002, Dr. Ende was the senior biotechnology analyst at Banc of America Securities and, from 1997 to 2000, he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990. We believe Dr. Ende is qualified to serve on our board of directors due to his industry experience, including as president of Ende BioMedical Consulting Group and as a biotechnology analyst, and his prior public company board experience.

 

Natasha Giordano. Ms. Giordano has served as a member of our board of directors since September 2020. Ms. Giordano has been President, Chief Executive Officer and director of PLx Pharma Inc. (NASDAQ: PLXP), a late-stage specialty pharmaceutical company, since January 2016. Previously, Ms. Giordano served as Chief Executive Officer of ClearPoint Learning, Inc., a privately held learning and training platform company, from May 2015 through November 2015. She also served on the ClearPoint board of directors from December 2009 through November 2015. Previously, Ms. Giordano served as the Chief Executive Officer of Healthcare Corporation of America (NYSE: HCA), a leading healthcare provider, from January 2014 through August 2014. From June 2009 to August 2012, Ms. Giordano served as Chief Operating Officer and then as Chief Executive Officer, President and a member of the board of directors of Xanodyne Pharmaceuticals, Inc., a privately-held branded specialty pharmaceutical company with development and commercial capabilities focused on pain management and women’s health. Prior to that, she served as President, Americas, for Cegedim Dendrite (formerly Dendrite International Inc.), a global technology services company, from 2007 to 2008 and as Senior Vice President of the Global Customer Business Unit of Cegedim Dendrite from 2004 to 2007. Ms. Giordano holds a Bachelor of Science degree in nursing from Wagner College. We believe Ms. Giordano is qualified to serve as a director due to her extensive experience in commercialization, general management and knowledge of the pharmaceutical and health care industries.

 

73

 

 

James S. Scibetta has served as a member of our board of directors since November 2013. Mr. Scibetta is currently the Chief Executive Officer of ImmuneID, a privately held precision immunology company. Prior to ImmuneID, Mr. Scibetta was Chief Executive Officer of Maverick Therapeutics, a development stage immune-oncology company, from 2017 until 2021 when it was acquired by Takeda Pharmaceutical Company Limited. Prior to Maverick, he was President and Chief Financial Officer of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), a specialty pharmaceutical company, a position he held since October 2015. Prior to that, Mr. Scibetta was the Chief Financial Officer of Pacira Biosciences, Inc. (NASDAQ: PCRX), a non-opioid pain management and regenerative health solutions company, since 2008. Prior to joining Pacira in August 2008, he served as a consultant to Genzyme Corporation following the sale of Bioenvision Inc. (NASDAQ: BIVN) to Genzyme in 2007. From 2006 to 2007 Mr. Scibetta was CFO of Bioenvision. From 2001 to 2006, he was Executive Vice President and Chief Financial Officer of Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Mr. Scibetta has previously served on the board of directors at the following life sciences companies: Nephros Inc. (NASDAQ: NEPH), Merrimack Pharmaceuticals and Labopharm Inc. Prior to his executive management experience, Mr. Scibetta spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan. We believe Mr. Scibetta is qualified to serve on our board of directors because of his extensive management experience in the pharmaceutical industry, his investment banking experience and his experience as a chief financial officer and audit committee member of several publicly traded companies.

 

Matthew A. Wikler has served as a member of our board of directors since January 2018. Dr. Wikler currently serves as the Principal of Infectious Disease Technology Development Consulting (IDTD Consulting), a privately-held consulting firm, where he provides clinical, medical and regulatory strategic insight to companies developing new technologies for the treatment and prevention of infectious diseases, a position he has held since 2015. Prior to that from 2012 to 2015, Dr. Wikler served at The Medicines Company (NASDAQ: MDCO), a biopharmaceutical company, as VP, New Business Ventures and VP and Medical Director, Infectious Disease Care. Over the course of his career Dr. Wikler held senior leaderships positions for a number of pharmaceutical companies, including as Chief Development Officer of Rib-X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing new antibiotics to provide expanded coverage, safety and convenience for the treatment of serious and life-threatening infections, President and Chief Executive Officer of IASO Pharma Inc., a privately-held clinical stage biotechnology company focused on the development of antibacterial and antifungal therapeutics, the Institute for One World Health, a 501(c)(3) nonprofit drug development organization, Mpex Pharmaceuticals, Inc., a privately-held company focused on developing and manufacturing therapies for antibiotic resistance with focus on gram-negative organisms, Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections (acquired by Johnson & Johnson (NYSE: JNJ)), ViroPharma Incorporated (NASDAQ: VPHM), Bristol-Myers Squibb Company (NYSE:BMY), and Ortho-McNeil Pharmaceutical (a division of Johnson & Johnson). Dr. Wikler began his career at Smith Kline & French/Smith Kline Beecham where he held positions of increasing responsibilities over ten years. Dr. Wikler held a variety of positions at the FDA, including the Deputy Director of the Division of Anti-Infective Drug Products. Dr. Wikler earned a B.A. in Chemistry from Franklin and Marshall College, an M.D. degree from Temple University School of Medicine, and his M.B.A. from the University of Pennsylvania Wharton School of Business. He completed his Infectious Diseases Fellowship at the Hospital of the University of Pennsylvania and is a Fellow of the Infectious Diseases Society of America. We believe Dr. Wikler is qualified to serve on our board of directors because of his extensive management experience in the pharmaceutical industry and his clinical, drug development and regulatory experience.

 

There are no family relationships among any of our directors or executive officers.

 

Scientific Advisory Board

 

We believe in seeking and attracting scientific and clinical leaders in the field of cardiovascular medicine as well as infectious diseases to provide counsel and support our growth. We have established two separate Scientific Advisory Boards for MAT2203 and MAT2501, respectively, which consist of individuals who are experts in their chosen fields and recipients of many academic honors and awards.

 

Board Committees

 

Our board of directors has four standing committees — an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Scientific Advisory Committee.

 

74

 

 

Audit Committee. The Audit Committee oversees and monitors our financial reporting process and internal control system, reviews and evaluates the audit performed by our registered independent public accountants and reports to the Board any substantive issues found during the audit. The Audit Committee is directly responsible for the appointment, compensation and oversight of the work of our registered independent public accountants. The Audit Committee reviews and approves all transactions with affiliated parties. James Scibetta, Herbert Conrad, Eric Ende and Natasha Giordano currently serve as members of the Audit Committee, with James Scibetta, serving as its chairman. All members of the Audit Committee have been determined to be financially literate and are considered independent directors as defined under the NYSE MKT’s listing standards and applicable SEC rules and regulations. Mr. Scibetta qualifies as an audit committee “financial expert” as that term is defined by SEC regulations. The Audit Committee met four times during 2021. Our Board has adopted an Audit Committee Charter, which is available for viewing at www.matinasbiopharma.com.

 

Compensation Committee. The Compensation Committee provides advice and makes recommendations to the Board in the areas of employee salaries, benefit programs and director compensation. The Compensation Committee also reviews the compensation of our executive officers, including our chief executive officer, and makes recommendations in that regard to the Board as a whole. Eric Ende, Kathryn Corzo, James Scibetta and Matthew Wikler currently serve as members of the Compensation Committee, with Eric Ende serving as its chairman. All members of the Compensation Committee are considered independent directors as defined under the NYSE MKT’s listing standards. The Compensation Committee met four times during 2021. Our Board has adopted a Compensation Committee Charter, which is available for viewing at www.matinasbiopharma.com.

 

Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee nominates individuals to be elected to the full Board by our stockholders. The Nominating and Corporate Governance Committee considers recommendations from stockholders if submitted in a timely manner in accordance with the procedures set forth in our Bylaws and applies the same criteria to all persons being considered. Herbert Conrad, Eric Ende, and James Scibetta currently serve as members of the Nominating and Corporate Governance Committee, with Herbert Conrad serving as its chairman. All members of the Nominating and Corporate Governance Committee are considered independent directors as defined under the NYSE MKT’s listing standards. The Nominating and Corporate Governance Committee met four times during 2021. Our Board has adopted a Nominating and Corporate Governance Charter, which is available for viewing at www.matinasbiopharma.com.

 

Scientific Advisory Committee. The Board of Directors has established a Scientific Advisory Committee consisting of Dr. Matthew Wikler, Chair, and Jerome D. Jabbour. The primary function of the Scientific Advisory Committee is to assist the Board in undertaking periodic reviews of our research and development efforts, and clinical trials, and reporting to the Board about developments and strategy, at such times as the Committee determines to be appropriate.

 

Code of Business Conduct and Ethics

 

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial and accounting officer, or persons performing similar functions. A copy of the code is posted on the corporate governance section of our website, which is located at www.matinasbiopharma.com. If we make any substantive amendments to, or grant waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website.

 

75

 

 

Item 11. Executive Compensation

 

Summary Compensation Table – 2021

 

The following table presents information regarding the total compensation awarded to, earned by, or paid to our chief executive officer and the two most highly-compensated executive officers who were serving as executive officers as of December 31, 2021 for services rendered in all capacities to us for the years ended December 31, 2021 and December 31, 2020. These individuals are our named executive officers for 2021.

 

Name and Principal Position  Year  

Salary

($)

  

Bonus

($)

  

Option Awards

($) (1)

   All Other Compensation ($)   Total ($) 
Jerome D. Jabbour  2021    545,000    250,000    2,898,314    -    3,693,314 
Chief Executive Officer  2020    500,000    250,000    2,180,085    -    2,930,085 
                              
James J. Ferguson  2021    422,300    164,000    1,035,637         1,621,937 
Chief Medical Officer  2020    410,000    150,000    1,090,043    -    1,650,043 
                              
Theresa Matkovits  2021    378,525    147,000    812,636    -    1,338,161 
Chief Development Officer  2020    367,500    122,500    763,030    -    1,253,030 

 

(1)Amounts reflect the grant date fair value of option awards granted in 2021 and 2020 in accordance with Accounting Standards Codification Topic 718. These amounts do not correspond to the actual value that will be recognized by the named executive officers.

 

Narrative Disclosure to Summary Compensation Table

 

Employment Agreements with Our Named Executive Officers

 

Jabbour

 

On March 22, 2018, we entered into an employment agreement with Mr. Jabbour. Under the terms of Mr. Jabbour’s employment agreement, Mr. Jabbour received a signing bonus of $84,000 and a base salary of $350,000 per year. In addition, Mr. Jabbour is eligible to receive an annual bonus, which is targeted at 50% of his base salary but which may be adjusted by our Compensation Committee based on his individual performance and our performance as a whole. Mr. Jabbour is also eligible to receive option grants at the discretion of our Compensation Committee. Mr. Jabbour received an option grant to purchase 1,000,000 shares on March 22, 2018 and is also eligible to receive additional option grants and equity grants at the discretion of our Compensation Committee. If we terminate Mr. Jabbour’s employment without cause or Mr. Jabbour resigns with good reason (absent a change of control), we are required to pay him severance of up to twelve months of his base salary plus COBRA benefits for twelve months. In addition, the vesting of 50% of his outstanding options will be accelerated in full upon such termination and Mr. Jabbour will be provided with an extension through two years after the separation date of the exercise period for his vested stock options. If we terminate Mr. Jabbour’s employment without cause during the 24-month period immediately following a change of control or Mr. Jabbour resigns with good reason during the 24-month period immediately following a change of control, we are required to pay him severance of up to 24 months of his base salary and his target annual bonus plus 18 months of COBRA benefits. In addition, his outstanding options will be vested in full and Mr. Jabbour will be provided with an extension through two years after the separation date of the exercise period for his vested stock options. Mr. Jabbour is also subject to a customary non-disclosure agreement, pursuant to which Mr. Jabbour has agreed to be subject to a non-compete during the term of his employment and for a period of eighteen months following termination of his employment.

 

Ferguson

 

On February 22, 2019, we entered into an employment agreement with Mr. Ferguson which was effective as of February 25, 2019. Under the terms of Mr. Ferguson’s employment agreement, Mr. Ferguson receives a base salary of $375,000 per year. In addition, Mr. Ferguson is eligible to receive an annual bonus, which is targeted at 35% of his base salary but which may be adjusted by our Compensation Committee based on his individual performance and our performance as a whole. Mr. Ferguson is also eligible to receive option grants at the discretion of our Compensation Committee. If we terminate Mr. Ferguson’s employment without cause or Mr. Ferguson resigns with good reason, we are required to pay him severance of up to twelve months of his base salary plus benefits. In addition, the vesting of 50% of his outstanding options will be accelerated in full upon such termination. Mr. Ferguson is also subject to a customary non-disclosure agreement, pursuant to which Mr. Ferguson has agreed to be subject to a non-compete during the term of his employment and for a period of eighteen months following termination of his employment.

 

76

 

 

Matkovits

 

On September 25, 2018, we entered into an employment agreement with Ms. Matkovits which was effective as of October 15, 2018. Under the terms of Ms. Matkovits’ employment agreement, Ms. Matkovits receives a base salary of $350,000 per year. In addition, Ms. Matkovits is eligible to receive an annual bonus, which is targeted at 35% of her base salary but which may be adjusted by our Compensation Committee based on her individual performance and our performance as a whole. Ms. Matkovits is also eligible to receive option grants at the discretion of our Compensation Committee. If we terminate Ms. Matkovits’ employment without cause or Ms. Matkovits resigns with good reason, we are required to pay her severance of up to twelve months of his base salary plus benefits. In addition, the vesting of 50% of her outstanding options will be accelerated in full upon such termination. Ms. Matkovits is also subject to a customary non-disclosure agreement, pursuant to which Ms. Matkovits has agreed to be subject to a non-compete during the term of her employment and for a period of eighteen months following termination of his employment.

 

Outstanding Equity Awards at Fiscal Year-End Table – 2021

 

The following table summarizes, for each of the named executive officers, the number of shares of common stock underlying outstanding stock options held as of December 31, 2021.

 

   Option Awards
Name 

Number of

securities

underlying

unexercised

options (#)

exercisable

  

Number of

securities

underlying

unexercised

options (#)

unexercisable

  

Option

exercise

price ($)

  

Option

expiration

date

Jerome D. Jabbour   -    1,658,100   $0.92   Dec 13, 2031
    -    1,600,000   $1.36   Dec 31, 2030
    479,167    520,833   $2.27   Dec 31, 2029
    531,250    218,750   $1.08   Feb 10, 2029
    937,500    62,500   $0.98   Mar 21, 2028
    400,000    -   $3.32   Feb 20, 2027
    350,000    -   $0.43   Feb 4, 2026
    175,000    -   $0.41   Jan 27, 2025
    350,000    -   $1.28   July 20, 2024
    350,000    -   $0.94   Oct 3, 2023
                   
James J. Ferguson   -    587,600   $0.92   Dec 13, 2031
    -    575,000   $1.36   Dec 31, 2030
    239,584    260,416   $2.27   Dec 31, 2029
    247,917    102,083   $1.09   Feb 24, 2029
                   
Theresa Matkovits   -    500,000   $0.92   Dec 13, 2031
    -    425,000   $1.36   Dec 31, 2030
    167,709    182,291   $2.27   Dec 31, 2029
    247,917    102,083   $1.08   Feb 10, 2029
    277,084    72,916   $0.79   Oct 14, 2028

 

77

 

 

2013 Equity Compensation Plan

 

General

 

On August 2, 2013, our Board of Directors adopted the 2013 Equity Compensation Plan pursuant to the terms described herein. The 2013 Equity Compensation Plan was approved by the stockholders on August 7, 2013. Effective May 8, 2014, upon the approval of our Board of Directors and our stockholders, we amended and restated our 2013 Equity Compensation Plan, primarily to include “evergreen” provisions, which provides that the number of shares of common stock available for issuance under the Plan is subject to an automatic annual increase on January 1 of each year beginning in 2015 equal to 4% of the number of shares of common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares of common stock determined by the Board of Directors; to amend the definition of “fair market value”; and to increase the limits on awards under the Plan. The 2013 Equity Compensation Plan, as amended and restated, is referred to herein as the “2013 Plan.”

 

The general purpose of the 2013 Plan is to provide an incentive to our employees, directors, consultants and advisors by enabling them to share in the future growth of our business. Our Board of Directors believes that the granting of stock options, restricted stock awards, unrestricted stock awards and similar kinds of equity-based compensation promotes continuity of management and increases incentive and personal interest in the welfare of our Company by those who are primarily responsible for shaping and carrying out our long range plans and securing our growth and financial success.

 

Our Board of Directors believes that the 2013 Plan will advance our interests by enhancing our ability to (a) attract and retain employees, consultants, directors and advisors who are in a position to make significant contributions to our success; (b) reward our employees, consultants, directors and advisors for these contributions; and (c) encourage employees, consultants, directors and advisors to take into account our long-term interests through ownership of our shares.

 

Description of the 2013 Equity Compensation Plan

 

The following description of the principal terms of the 2013 Plan is a summary and is qualified in its entirety by the full text of the 2013 Plan, which is attached as Exhibit 10.1 hereto.

 

Administration. The 2013 Plan will be administered by the Compensation Committee of our Board of Directors, provided that the entire Board of Directors may act in lieu of the Compensation Committee on any matter, subject to certain requirements set forth in the 2013 Plan. The Compensation Committee may grant options to purchase shares of our common stock, stock appreciation rights, stock units, restricted shares of our common stock, performance shares, performance units, incentive bonus awards, other cash-based awards and other stock-based awards. The Compensation Committee also has broad authority to determine the terms and conditions of each option or other kind of award, and adopt, amend and rescind rules and regulations for the administration of the 2013 Plan. Subject to applicable law, the Compensation Committee may authorize one or more reporting persons (as defined in the 2013 Plan) or other officers to make awards (other than awards to reporting persons, or other officers whom the Compensation Committee has specifically authorized to make awards). No awards may be granted under the 2013 Plan on or after the ten year anniversary of the adoption of the 2013 Plan by our Board of Directors, but awards granted prior to such tenth anniversary may extend beyond that date.

 

Eligibility. Awards may be granted under the 2013 Plan to any person who is an employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary, or any person who is determined by the Compensation Committee to be a prospective employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary.

 

Shares Subject to the 2013 Plan. As of February 25, 2022 the aggregate number of shares of common stock available for issuance in connection with awards granted under the 2013 Plan is 45,603,238 shares, subject to customary adjustments for stock splits, stock dividends or similar transactions (the “Initial Limit”). Incentive Stock Options may be granted under the 2013 Plan with respect to all of those shares. The number of shares of common stock available for issuance under the 2013 Plan will automatically increase on January 1st of each year for a period of ten years, commencing on January 1, 2015, in an amount equal to four percent (4%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year (the “Annual Increase”). Notwithstanding the foregoing, the Board of Directors may act prior to the first day of any calendar year, to provide that there shall be no increase in the share reserve for such calendar year or that the Annual Increase in the share reserve for such calendar year shall be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. The number of shares of common stock which may be issued in respect of Incentive Stock Options is equal to the Current Limit, and will be increased on each January 1, by the Annual Increase for such calendar year.

 

78

 

 

To the extent that any award under the 2013 Plan payable in shares of common stock is forfeited, cancelled, returned to the Company for failure to satisfy vesting requirements or upon the occurrence of other forfeiture events, or otherwise terminates without payment being made thereunder, the shares of common stock covered thereby will be available for future grants under the 2013 Plan. Shares of common stock that otherwise would have been issued upon the exercise of a stock option or in payment with respect to any other form of award, that are surrendered in payment or partial payment of taxes required to be withheld with respect to the exercise of such stock option or the making of such payment, will also be available for future grants under the 2013 Plan.

 

Terms and Conditions of Options. Options granted under the 2013 Plan may be either “incentive stock options” that are intended to meet the requirements of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) or “nonqualified stock options” that do not meet the requirements of Section 422 of the Code. The Compensation Committee will determine the exercise price of options granted under the 2013 Plan. The exercise price of stock options may not be less than the fair market value, on the date of grant, per share of our common stock issuable upon exercise of the option (or 110% of fair market value in the case of incentive options granted to a ten-percent stockholder).

 

If on the date of grant the common stock is listed on a stock exchange or national market system, the fair market value shall generally be the closing sale price as of such date, or if there were no trades recorded on such date, then the most recent date preceding such date on which trades were recorded. If on the date of grant the common stock is traded in an over-the-counter market, the fair market will generally be the average of the closing bid and asked prices for the shares of common stock as of such date, or, if there are no closing bid and asked prices for the shares of common stock on such date, then the average of the bid and asked prices for the shares of common stock on the most recent date preceding such date on which such closing bid and asked prices are available. If the common stock is not listed on a national securities exchange or national market system or traded in an over-the-counter market, the fair market value shall be determined by the Compensation Committee in a manner consistent with Section 409A of the Internal Revenue Code of 1986, as amended. Notwithstanding the foregoing, if on the date of grant the common stock is listed on a stock exchange or is quoted on a national market system, or is traded in an over-the-counter market, then solely for purposes of determining the exercise price of any grant of a stock option or the base price of any grant of a stock appreciation right, the Compensation Committee may, in its discretion, base fair market value on the last sale before or the first sale after the grant, the closing price on the trading day before or the trading day of the grant, the arithmetic mean of the high and low prices on the trading day before or the trading day of the grant, or any other reasonable method using actual transactions of the common stock as reported by the exchange or market on which the common stock is traded. In addition, the determination of fair market value also may be made using any other method permitted under Treasury Regulation section 1.409A-1(b)(5)(iv).

 

No option may be exercisable for more than ten years from the date of grant (five years in the case of an incentive stock option granted to a ten-percent stockholder). Options granted under the 2013 Plan will be exercisable at such time or times as the Compensation Committee prescribes at the time of grant. No employee may receive incentive stock options that first become exercisable in any calendar year in an amount exceeding $100,000. The Compensation Committee may, in its discretion, permit a holder of a nonqualified stock option to exercise the option before it has otherwise become exercisable, in which case the shares of our common stock issued to the recipient will continue to be subject to the vesting requirements that applied to the option before exercise.

 

Generally, the option price may be paid in cash or by bank check, or such other means as the Compensation Committee may accept. As set forth in an award agreement or otherwise determined by the Compensation Committee, in its sole discretion, at or after grant, payment in full or part of the exercise price of an option may be made (a) in the form of shares of common stock that have been held by the participant for such period as the Compensation Committee may deem appropriate for accounting purposes or otherwise, valued at the fair market value of such shares on the date of exercise; (ii) by surrendering to the Company shares of common stock otherwise receivable on exercise of the option; (iii) by a cashless exercise program implemented by the Compensation Committee in connection with the 2013 Plan; and/or (iv) by such other method as may be approved by the Compensation Committee and set forth in an award agreement.

 

79

 

 

No option may be transferred other than by will or by the laws of descent and distribution, and during a recipient’s lifetime an option may be exercised only by the recipient or the recipient’s guardian or legal representative. However, the Compensation Committee may permit the transfer of a nonqualified stock option, share-settled stock appreciation right, restricted stock award, performance share or share-settled other stock-based award either (a) by instrument to the participant’s immediate family (as defined in the 2013 Plan), (b) by instrument to an inter vivos or testamentary trust (or other entity) in which the award is to be passed to the participant’s designated beneficiaries, or (c) by gift to charitable institutions. The Compensation Committee will determine the extent to which a holder of a stock option may exercise the option following termination of service.

 

Stock Appreciation Rights. The Compensation Committee may grant stock appreciation rights independent of or in connection with an option. The Compensation Committee will determine the terms applicable to stock appreciation rights. The base price of a stock appreciation right will be determined by the Compensation Committee, but will not be less than 100% of the fair market value of a share of our common stock with respect to the date of grant of such stock appreciation right. The maximum term of any SAR granted under the 2013 Plan is ten years from the date of grant. Generally, each SAR stock appreciation right will entitle a participant upon exercise to an amount equal to:

 

● the excess of the fair market value of a share of common stock on the date of exercise of the stock appreciation right over the base price of such stock appreciation right, multiplied by
   
● the number of shares as to which such stock appreciation right is exercised.

 

Payment may be made in shares of our common stock, in cash, or partly in common stock and partly in cash, all as determined by the Compensation Committee.

 

Restricted Stock and Stock Units. The Compensation Committee may award restricted common stock and/or stock units under the 2013 Plan. Restricted stock awards consist of shares of stock that are transferred to a participant subject to restrictions that may result in forfeiture if specified conditions are not satisfied. Stock units confer the right to receive shares of our common stock, cash, or a combination of shares and cash, at a future date upon or following the attainment of certain conditions specified by the Compensation Committee. The Compensation Committee will determine the restrictions and conditions applicable to each award of restricted stock or stock units, which may include performance-based conditions. Dividends with respect to restricted stock may be paid to the holder of the shares as and when dividends are paid to stockholders or at the times of vesting or other payment of the restricted stock award. Stock unit awards may be granted with dividend equivalent rights, which may be accumulated and may be deemed reinvested in additional stock units, as determined by the Compensation Committee in its discretion. If any dividend equivalents are paid while a stock unit award is subject to restrictions, the dividend equivalents shall be subject to the same restrictions on transferability as the underlying stock units, unless otherwise set forth in an award agreement. Unless the Compensation Committee determines otherwise, holders of restricted stock will have the right to vote the shares.

 

Performance Shares and Performance Units. The Compensation Committee may award performance shares and/or performance units under the 2013 Plan. Performance shares and performance units are awards which are earned during a specified performance period subject to the attainment of performance criteria, as established by the Compensation Committee. The Compensation Committee will determine the restrictions and conditions applicable to each award of performance shares and performance units.

 

Incentive Bonus Awards. The Compensation Committee may award Incentive Bonus Awards under the 2013 Plan. Incentive Bonus Awards may be based upon the attainment of specified levels of Company or subsidiary performance as measured by pre-established, objective performance criteria determined at the discretion of the Compensation Committee. Incentive Bonus Awards will be paid in cash or common stock, as set forth in an award agreement

 

Other Stock-Based and Cash-Based Awards. The Compensation Committee may award other types of equity-based or cash-based awards under the 2013 Plan, including the grant or offer for sale of unrestricted shares of our common stock and payment in cash or otherwise of amounts based on the value of shares of common stock.

 

80

 

 

Effect of Certain Corporate Transactions. The Compensation Committee may, at the time of the grant of an award, provide for the effect of a change in control (as defined in the 2013 Plan) on any award, including (i) accelerating or extending the time periods for exercising, vesting in, or realizing gain from any award, (ii) eliminating or modifying the performance or other conditions of an award, (iii) providing for the cash settlement of an award for an equivalent cash value, as determined by the Compensation Committee, or (iv) such other modification or adjustment to an award as the Compensation Committee deems appropriate to maintain and protect the rights and interests of participants upon or following a change in control. The Compensation Committee may, in its discretion and without the need for the consent of any recipient of an award, also take one or more of the following actions contingent upon the occurrence of a change in control: (a) cause any or all outstanding options and stock appreciation rights to become immediately exercisable, in whole or in part; (b) cause any other awards to become non-forfeitable, in whole or in part; (c) cancel any option or stock appreciation right in exchange for a substitute option; (d) cancel any award of restricted stock, stock units, performance shares or performance units in exchange for a similar award of the capital stock of any successor corporation; (e) redeem any restricted stock, stock unit, performance share or performance unit for cash and/or other substitute consideration with a value equal to the fair market value of an unrestricted share of our common stock on the date of the change in control; (f) cancel any option or stock appreciation right in exchange for cash and/or other substitute consideration based on the value of our common stock on the date of the change in control , and cancel any option or stock appreciation right without any payment if its exercise price exceeds the value of our common stock on the date of the change in control; (g) cancel any stock unit or performance unit held by a participant affected by the change in control in exchange for cash and/or other substitute consideration with a value equal to the fair market value per share of common stock on the date of the change in control, or (h) make such other modifications, adjustments or amendments to outstanding awards as the Compensation Committee deems necessary or appropriate.

 

Amendment, Termination. The Compensation Committee may amend the terms of awards in any manner not inconsistent with the 2013 Plan, provided that no amendment shall adversely affect the rights of a participant with respect to an outstanding award without the participant’s consent. In addition, our board of directors may at any time amend, suspend, or terminate the 2013 Plan, provided that (i) no such amendment, suspension or termination shall materially and adversely affect the rights of any participant under any outstanding award without the consent of such participant and (ii) to the extent necessary and desirable to comply with any applicable law, regulation, or stock exchange rule, the 2013 Plan requires us to obtain stockholder consent. Stockholder approval is required for any plan amendment that increases the number of shares of common stock available for issuance under the 2013 Plan or changes the persons or classes of persons eligible to receive awards.

 

Tax Withholding

 

The Company has the power and right to deduct or withhold, or require a participant to remit to the Company, the minimum statutory amount to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulations to be withheld.

 

Director Compensation

 

We maintain a policy pursuant to which our non-employee directors receive annualized compensation. The policy provides for the following compensation amounts payable in cash, or upon election by such non-employee director, in shares of unrestricted common stock: (i) each non-employee director is entitled to receive an annual fee of $50,000; (ii) the chairman of the board is entitled to receive an additional annual fee of $25,000; (iii) the vice chair, if one is appointed, is entitled to receive an additional annual fee of $20,000; (iv) the chair of our audit committee is entitled to receive an annual fee of $15,000 and other members of our audit committee are entitled to receive $7,500; (v) the chair of our compensation committee is entitled to receive an annual fee of $10,000 and other members of our compensation committee are entitled to receive $6,000; (vi) the chair of our nominating and corporate governance committee is entitled to receive an annual fee of $7,500, increasing to $8,000 on January 1, 2022, and other members are entitled to receive $4,000; and (vii) the chair of our scientific advisory committee is entitled to receive an annual fee of $7,500, increasing to $8,000 on January 1, 2022.

 

As of the date of each annual meeting of the shareholders, each non-employee director will receive an option grant to purchase shares of our common stock valued at $80,000 as determined by the Black Scholes method on the date of grant under our existing equity incentive plan, or any other equity incentive plan we may adopt in the future, which shall vest in twelve equal monthly installments.

 

All fees under the director compensation policy are paid on a quarterly basis in arrears and no per meeting fees are paid. All fees may be paid in unrestricted shares of common stock at the election of the director. We also reimburse non-employee directors for reasonable expenses incurred in connection with attending board of director and committee meetings.

 

81

 

 

Director Compensation Table – 2021

 

The following table summarizes the annual compensation for our non-employee directors during 2021.

 

Name  Cash Compensation
($)		  

Stock

Awards ($)

(1)

  

Option

Awards
($) (1)

   Total
($)		 
Herbert Conrad   90,000    -    80,000    170,000 
Kathryn Corzo   9,283    -    160,000    169,283 
Eric Ende   71,500    -    80,000    151,500 
Natasha Giordano   57,500    -    80,000    137,500 
Patrick G. LePore   66,739    -    -    66,739 
James S. Scibetta   75,000    -    80,000    155,000 
Matthew Wikler   31,750    31,750    80,000    143,500 

 

(1) Amounts reflect the grant date fair value of stock awards and option awards granted in 2021 in accordance with Accounting Standards Codification Topic 718. These amounts do not correspond to the actual value that will be recognized by the directors.

 

Compensation Committee Interlocks and Insider Participation

 

The Compensation Committee of the Board of Directors is currently composed of the following four non-employee directors: Eric Ende, Chair, Kathryn Corzo, James Scibetta and Matthew Wikler, with Ms. Corzo replacing Mr. LePore on the committee following the Company’s last Annual Shareholder meeting. No member of the Compensation Committee is or was formerly an officer or an employee of the Company during the last fiscal year. In addition, no executive officer of the Company serves on the compensation committee or board of directors of a company for which any of the Company’s directors serve as an executive officer. Please see Item 13.

 

Item 12. Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters.

 

The following table sets forth the number of shares of common stock beneficially owned as of February 25, 2022 by:

 

● each of our stockholders who is known by us to beneficially own 5% or more of our common stock;
   
● each of our executive officers;
   
● each of our directors; and
   
● all of our directors and current executive officers as a group.

 

Beneficial ownership is determined based on the rules and regulations of the SEC. A person has beneficial ownership of shares if such individual has the power to vote and/or dispose of shares. This power may be sole or shared and direct or indirect. Applicable percentage ownership in the following table is based on 216,864,526 shares outstanding as of February 25, 2022. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock that are subject to options or warrants held by that person and exercisable as of, or within 60 days of, February 25, 2022 are counted as outstanding. These shares, however, are not counted as outstanding for the purposes of computing the percentage ownership of any other person(s). Except as may be indicated in the footnotes to this table and pursuant to applicable community property laws, each person named in the table has sole voting and dispositive power with respect to the shares of common stock set forth opposite that person’s name. Unless indicated below, the address of each individual listed below is c/o Matinas BioPharma Holdings, Inc., 1545 Route 206 South, Suite 302, Bedminster, NJ 07921.

 

82

 

 

Name of Beneficial Owner  Number of Shares
Beneficially Owned		   Percentage of Shares
Beneficially Owned		 
         
Directors and Executive Officers          
Jerome D. Jabbour (1)   4,129,074    1.9%
Herbert Conrad (2)   5,889,819    2.7%
Kathryn Corzo (3)   25,245    *%
Eric Ende (4)   1,076,012    *%
Natasha Giordano (5)   197,398    *%
James Scibetta (6)   1,644,378    *%
Matthew Wikler (7)   1,070,309    *%
James J. Ferguson (8)   738,022    *%
Thomas J. Hoover (9)   -    *%
Keith A. Kucinski (10)   868,459    *%
Hui Liu (11)   194,792    *%
Raphael Mannino (12)   2,839,091    1.3%
Theresa Matkovits (13)   913,022    *%
Directors and Executive Officers as a group (13 persons) (14)   19,585,621    8.6%

 

* Less than 1%

 

(1) Includes 3,668,750 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 3,351,850 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(2) Includes 1,195,253 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 45,441 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(3) Includes 25,245 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 156,518 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(4) Includes 931,920 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 45,441 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(5) Includes 197,398 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 181,401 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(6) Includes 994,420 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 45,441 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(7) Includes 779,837 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 47,524 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(8) Includes 738,022 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 1,274,578 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(9) Does not include 850,000 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

83

 

 

(10) Includes 773,959 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 1,101,041 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(11) Includes 194,792 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 680,208 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(12) Includes 919,376 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 490,624 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(13) Includes 913,022 shares of common stock issuable upon exercise of options that are exercisable within sixty days of February 25, 2022. Does not include 1,061,978 shares of common stock underlying options that are not exercisable within sixty days of February 25, 2022.

 

(14) See notes (1) through (13).

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table summarizes information about our equity compensation plans as of December 31, 2021.

 

Plan Category  Number of Shares
of Common Stock to be Issued upon
Exercise of Outstanding Options
(a)		   Weighted-Average
Exercise Price of
Outstanding Options
(b)		   Number of Options
Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a))
(c)(2)		 
Equity compensation plans approved by stockholders(1)   28,184,291   $1.21    4,282,530 
Equity compensation plans not approved by stockholders   —    —    — 
Total   28,184,291   $1.21    4,282,530 

 

(1) The amounts shown in this row include securities under the Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Incentive Plan (the “2013 Plan”).
   
(2) In accordance with the “evergreen” provision in our 2013 Plan, an additional 8,650,778 shares were automatically made available for issuance on the first trading day of 2022, which represents 4% of the number of shares outstanding on December 31, 2021; these shares are excluded from this calculation.

 

Item 13. Certain Relationships, Related Transactions, And Director Independence

 

Certain Relationships and Related Party Transactions

 

Other than compensation arrangements for our named executive officers and directors, there has been no transaction or series of similar transactions, since January 1, 2021, to which we were a party or will be a party, in which:

 

● the amounts involved exceeded or will exceed the lesser of (i) $120,000 and (ii) one percent of the average of our total assets at year-end for the last two completed fiscal years; and
   
● any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.

 

84

 

 

Indemnification Agreements

 

We entered into indemnification agreements with our directors and executive officers. The indemnification agreements provide for indemnification against expenses, judgments, fines and penalties actually and reasonably incurred by an indemnitee in connection with threatened, pending or completed actions, suits or other proceedings, subject to certain limitations. The indemnification agreements also provide for the advancement of expenses in connection with a proceeding prior to a final, non-appealable judgment or other adjudication, provided that the indemnitee provides an undertaking to repay to us any amounts advanced if the indemnitee is ultimately found not to be entitled to indemnification by us. The indemnification agreement set forth procedures for making and responding to a request for indemnification or advancement of expenses, as well as dispute resolution procedures that apply to any dispute between us and an indemnitee arising under the Indemnification Agreements.

 

Policies and Procedures for Related Party Transactions

 

We have adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock, any members of the immediate family of any of the foregoing persons and any firms, corporations or other entities in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has a 5% or greater beneficial ownership interest, which we refer to collectively as related parties, are not permitted to enter into a transaction with us without the prior consent of our board of directors acting through the audit committee or, in certain circumstances, the chairman of the audit committee. Any request for us to enter into a transaction with a related party, in which the amount involved exceeds $100,000 and such related party would have a direct or indirect interest must first be presented to our audit committee, or in certain circumstances the chairman of our audit committee, for review, consideration and approval. In approving or rejecting any such proposal, our audit committee, or the chairman of our audit committee, is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the benefits to us, the availability of other sources of comparable products or services and the extent of the related party’s interest in the transaction.

 

Director Independence

 

Based on information requested from and provided by each of our directors, our board of directors has determined that Messrs. Herbert Conrad, Eric Ende, James Scibetta, Matthew Wikler and Mses. Kathryn Corzo and Natasha Giordano are “independent directors” as such term is defined in the rules of the NYSE MKT’s corporate governance requirements and Rule 10A-3 promulgated under the Securities Exchange Act of 1934, as amended.

 

Item 14. Principal Accounting Fees And Services

 

The following table represents aggregate fees billed to the Company for the fiscal years ended December 31, 2021 and 2020, by EisnerAmper LLP, the Company’s independent registered public accounting firm.

 

   Years Ended December 31, 
   2021   2020 
   (in thousands) 
Audit Fees  $249   $297 
Audit-Related Fees   -    - 
Tax Fees   -    - 
Total Fees  $249   $297 

 

85

 

 

Audit Fees consist of fees billed for professional services rendered for the audit of our annual financial statements, audit of internal controls over financial reporting, review of our interim consolidated financial statements and comfort letters.

 

Audit-Related Fees consist of fees billed for professional services rendered for assurance related services that are reasonably related to the performance of the audit or review of our financial services.

 

Tax Fees are for tax-related services related primarily to tax consulting and tax planning.

 

The Audit Committee pre-approves all auditing services and any non-audit services that the independent registered public accounting firm is permitted to render under Section 10A (h) of the Exchange Act. The Audit Committee may delegate the pre-approval to one of its members, provided that if such delegation is made, the full Audit Committee must be presented at its next regularly scheduled meeting with any pre-approval decision made by that member.

 

Part IV

 

Item 15. Exhibits And Financial Statement Schedules

 

Exhibit No.   Description
     
2.1   Merger Agreement, dated July 11, 2013, by and among the Company, Matinas Merger Sub, Inc., and Matinas BioPharma, Inc. (incorporated by reference to Exhibit 2.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014).
2.2   Agreement and Plan of Merger (the “Merger Agreement”) with Aquarius Biotechnologies, Inc., a Delaware corporation (“Aquarius”), Saffron Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”) and J. Carl Craft, as the stockholder representative (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2015).
3.1   Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014).
3.2   Bylaws (incorporated by reference to Exhibit 3.2 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014).
3.3   Certificate of Amendment, dated October 29, 2015 to Certificate of Incorporation. (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2015).
3.4   Certificate of Designation of Series A Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed August 1, 2016 with the Securities and Exchange Commission).
3.5   Certificate of Designation of Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed June 19, 2018 with the Securities and Exchange Commission).
4.1   Common Stock Specimen (incorporated by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed March 31, 2017 with the Securities and Exchange Commission).
4.2   Form of Warrant (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014).
4.3   Form of 2015 Investor Warrant. (incorporated by reference to Exhibit 4.4 to the post-effective amendment No. 1 to Form S-1 filed with the SEC on April 17, 2015).
4.4   Form of 2015 Placement Agent Warrant. (incorporated by reference to Exhibit 4.5 to the post-effective amendment No. 1 to Form S-1 filed with the SEC on April 17, 2015).
4.5   Form of 2016 Placement Agent Warrant (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form S-1 filed with the SEC on November 2, 2016).
4.6   Description of Securities*
10.1   Matinas BioPharma Holdings, Inc. Amended and Restated 2013 Equity Compensation Plan (incorporated herein by reference to Exhibit 10.6 to the Company’s Annual Report on Form 10-K filed on March 31, 2015.) †
10.2   Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014). †

 

86

 

 

10.3   Form of Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014). †
10.4   Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014). †
10.5   Lease, effective as of November 4, 2013, by and between the company and A-K Bedminster Associates, L.P. (incorporated by reference to Exhibit 10.17 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014).
10.6   Amended and Restated Exclusive License Agreement dated as of January 29, 2015, by and between Rutgers, the State University of New Jersey and Aquarius Biotechnologies, Inc. (incorporated herein by reference to Exhibit 10.18 to the Company’s Annual Report on Form 10-K filed on March 31, 2015). +
10.7   Employment Agreement, dated September 1, 2015, between Matinas Biopharma Holdings, Inc. and Raphael J. Mannino. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 1, 2015). †
10.8   Lease Agreement, dated as of December 15, 2016, by and between CIP II/AR Bridgewater Holdings LLC, and Matinas BioPharma Holdings, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 28, 2017).
10.9   Employment Agreement, dated March 22, 2018, between the Company and Jerome D. Jabbour (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 27, 2018). †
10.10   Employment Agreement, dated October 15, 2018, between Matinas Biopharma Holdings, Inc. and Theresa Matkovits (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2018). †
10.11   Employment Agreement, dated January 3, 2019, between Matinas Biopharma Holdings, Inc. and Keith Kucinski (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 3, 2019). †
10.12   Employment Agreement, dated February 25, 2019, between Matinas Biopharma Holdings, Inc. and James J. Ferguson III (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2019). †
10.13   At-The-Market Sales Agreement, dated July 2, 2020, between Matinas BioPharma Holdings, Inc. and BTIG, LLC (incorporated herein by reference to Exhibit 1.01 to the Company’s Current Report on Form 8-K filed with the SEC on July 2, 2020).
10.14   Therapeutic Development Award Agreement, dated November 19, 2020, between Matinas BioPharma Holdings, Inc. and the Cystic Fibrosis Foundation (incorporated by reference to Exhibit 10.1 to the Company’s Annual Report on Form 10-K filed on March 29, 2021).
10.15   Employment Agreement, dated December 1, 2020, between Matinas Biopharma Holdings, Inc. and Hui Liu. †*
10.16   Employment Agreement, dated December 6, 2021, between Matinas Biopharma Holdings, Inc. and Thomas Hoover. †*
21.1   Subsidiaries Index*
23.1   Consent of EisnerAmper LLP*
31.1   Certification of President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification of Acting Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1   Section 1350 Certifications**
101   The following financial information from the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, formatted in XBRL (eXtensible Business Reporting Language), is filed electronically herewith: (i) Consolidated Balance Sheets as of December 31, 2021 and 2020; (ii) Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020; (iii) Consolidated Statement of Changes in Stockholders’ Equity (Deficit) for the Years Ended December 31, 2021 and 2020; (iv) Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020; and (v) Notes to Consolidated Financial Statements.*
104   The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL.

 

+ Confidential treatment has been requested for certain provisions of this Exhibit pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.
† Indicates a management contract or compensation plan, contract or arrangement.
* Filed herewith.
** Furnished herewith.

 

Item 16. Form 10-K Summary.

 

None.

 

87

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Bedminster, State of New Jersey on March 8, 2022.

 

  MATINAS BIOPHARMA HOLDINGS, INC.
     
  By: /s/ Jerome D. Jabbour
  Name:  Jerome D. Jabbour
  Title: Chief Executive Officer
     
  By: /s/ Keith A. Kucinski
  Name:  Keith A. Kucinski
  Title: Chief Financial Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Person   Capacity   Date
         
/s/ Jerome D. Jabbour   Chief Executive Officer and Director   March 8, 2022
Jerome D. Jabbour   (Principal Executive Officer)    
         
/s/ Keith A. Kucinski   Chief Financial Officer   March 8, 2022
Keith A. Kucinski   (Principal Financial and Accounting Officer)    
         
/s/ Herbert Conrad   Chairman of the Board   March 8, 2022
Herbert Conrad        
         
/s/ Kathryn Corzo   Director   March 8, 2022
Kathryn Corzo        
         
/s/ Eric Ende   Director   March 8, 2022
Eric Ende        
         
/s/ Natasha Giordano   Director   March 8, 2022
Natasha Giordano        
         
/s/ James S. Scibetta   Director   March 8, 2022
James S. Scibetta        
         
/s/ Matthew A. Wikler   Director   March 8, 2022
Matthew A. Wikler        

 

88

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

Matinas BioPharma Holdings, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Matinas BioPharma Holdings, Inc. and Subsidiaries as of December 31, 2021 and 2020 and the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of their operations and their cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Accruals for research and development expenses

 

As disclosed in the consolidated statements of operations, for the year ended December 31, 2021, the Company incurred significant research and development (“R&D”) expenses, which amounted to approximately $14.6 million. At December 31, 2021, the Company had accrued $1.3 million for R&D expenses on the consolidated balance sheet. A large amount of the Company’s R&D expenses are service fees paid to contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”). The R&D activities with these CROs and CMOs are documented in contractual agreements and are typically performed over an extended period, and there may be several milestones of the services in one agreement. Therefore, the allocation of the service expenses based on the progress of the R&D projects and the milestones completed for the appropriate financial reporting period involved judgement and estimation.

 

We identified management’s estimate of accruals for R&D expenses as a critical audit matter due to the significance of these expenses to the financial statements and the subjectivity involved in estimating the progress of the R&D projects and service fees accrued for the completion of milestones by the CROs and CMOs. As a result, auditor judgement and additional testing were required to perform procedures and evaluate audit evidence related to the accruals for R&D expenses.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. Our audit procedures related to the accruals for R&D expenses included the following, among others, (i) we obtained an understanding of management’s process and evaluated the design of controls related to the accrual process for R&D expenses; (ii) we read selected research agreements to evaluate whether the progress and the completion of milestones reported by the representatives of the CROs and CMOs and the corresponding service fees are based on the respective contractual terms, (iii) we sent confirmations to CROs and CMOs, on a sample basis, to confirm the amount of the total R&D service fees incurred for the year and the amounts of outstanding payables under the terms of the contracts, and (iv) we selected projects from the open contract list at year end and made inquiries of the Company research personnel regarding the project status, and we also inspected invoices received subsequent to year-end and additional documents and correspondence with the CROs and CMOs, supporting management’s estimate of R&D expenditures.

 

/s/ EisnerAmper LLP

 

We have served as the Company’s auditor since 2011.

 

EISNERAMPER LLP

Iselin, New Jersey

March 8, 2022

 

 F-1 

 

 

Matinas BioPharma Holdings, Inc.

Consolidated Balance Sheets

 

   2021   2020 
   December 31, 
   2021   2020 
ASSETS:        
         
Current assets:          
Cash and cash equivalents  $21,029,806   $12,432,481 
Marketable securities   28,592,049    46,246,573 
Restricted cash   50,000    136,000 
Prepaid expenses and other current assets   1,321,466    2,739,791 
Total current assets   50,993,321    61,554,845 
           
Non-current assets:          
Leasehold improvements and equipment - net   1,537,728    1,523,950 
Operating lease right-of-use assets - net   4,218,890    3,276,639 
Finance lease right-of-use assets - net   22,270    58,007 
In-process research and development   3,017,377    3,017,377 
Goodwill   1,336,488    1,336,488 
Restricted cash - security deposits   200,000    200,000 
Total non-current assets   10,332,753    9,412,461 
Total assets  $61,326,074   $70,967,306 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY:          
           
Current liabilities:          
Accounts payable  $938,270   $349,941 
Accrued expenses and other liabilities   2,850,888    2,795,329 
Operating lease liabilities - current   538,546    391,498 
Financing lease liabilities - current   21,039    30,853 
Total current liabilities   4,348,743    3,567,621 
           
Non-current liabilities:          
Deferred tax liability   341,265    341,265 
Operating lease liabilities - net of current portion   4,140,387    3,304,063 
Financing lease liabilities - net of current portion   2,621    23,660 
Total non-current liabilities   4,484,273    3,668,988 
Total liabilities   8,833,016    7,236,609 
           
Stockholders’ equity:          
Series B Convertible preferred stock, stated value $1,000 per share, 8,000 shares authorized as of December 31, 2021 and 2020, respectively; 0 and 4,361 shares issued and outstanding as of December 31, 2021 and 2020, respectively   -    3,797,705 
Common stock par value $0.0001 per share, 500,000,000 shares authorized at December 31, 2021 and 2020, respectively; 216,269,450 and 200,113,431 issued and outstanding as of December 31, 2021 and 2020, respectively   21,627    20,010 
Additional paid-in capital   184,251,138    167,192,003 
Accumulated deficit   (131,634,208)   (107,507,193)
Accumulated other comprehensive (loss)/income   (145,499)   228,172 
Total stockholders’ equity   52,493,058    63,730,697 
Total liabilities and stockholders’ equity  $61,326,074   $70,967,306 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-2 

 

 

Matinas BioPharma Holdings, Inc.

Consolidated Statements of Operations and Comprehensive Loss

 

   2021   2020 
   For the Year Ended December 31, 
   2021   2020 
Revenue:        
Contract research revenue  $33,333   $158,333 
Costs and Expenses:          
Research and development   14,583,283    14,358,918 
General and administrative   10,184,805    10,005,967 
           
Total costs and expenses   24,768,088    24,364,885 
           
Loss from operations   (24,734,755)   (24,206,552)
Sale of New Jersey net operating loss   1,328,470    1,073,289 
Other income, net   122,870    686,425 
           
Net loss  $(23,283,415)  $(22,446,838)
           
Preferred stock series B accumulated dividends   (395,799)   (793,442)
Net loss attributable to common shareholders  $(23,679,214)  $(23,240,280)
Net loss attributable to common shareholders per share – basic and diluted  $(0.11)  $(0.12)
Weighted average common shares outstanding:          
Basic and diluted   210,178,332    196,894,628 
Other comprehensive (loss)/income, net of tax          
Net unrealized (loss)/gain on securities available-for-sale   (373,671)   237,537 
Reclassification of realized gain on securities available-for-sale to net loss   -    (8,485)
Other comprehensive (loss)/income, net of tax   (373,671)   229,052 
Comprehensive loss attributable to shareholders  $(23,657,086)  $(22,217,786)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-3 

 

 

Matinas BioPharma Holdings, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

 

   Shares   Amount   Shares   Amount   Capital   Deficit   (Loss)/Income   Equity 
   Redeemable
Convertible
Preferred Stock B		   Common Stock   Additional Paid - in   Accumulated   Accumulated Other Comprehensive   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   (Loss)/Income   Equity 
Balance, December 31, 2019   4,577   $3,985,805    163,156,984   $16,315   $113,427,897   $(84,377,555)  $(880)  $33,051,582 
Stock-based compensation   -    -    -    -    4,184,141    -    -    4,184,141 
Issuance of common stock as compensation for services   -    -    379,385    38    390,604    -    -    390,642 
Issuance of common stock in exchange for preferred shares B   (216)   (188,100)   432,000    43    188,057    -    -    - 
Issuance of common stock in public offering, net of stock issuance costs ($3,308,790)   -    -    32,260,000    3,226    46,700,984    -    -    46,704,210 
Issuance of common stock in exchange for Options   -    -    782,073    79    820,248    -    -    820,327 
Issuance of common stock in exchange for Warrants   -    -    1,737,389    172    797,409    -    -    797,581 
Stock dividends   -    -    1,365,600    137    682,663    (682,800)   -    - 
Other comprehensive income    -    -    -    -    -         229,052    229,052 
Net loss   -    -    -    -    -    (22,446,838)   -    (22,446,838)
Balance, December 31, 2020   4,361   $3,797,705    200,113,431   $20,010   $167,192,003   $(107,507,193)  $228,172   $63,730,697 
                                         
Stock-based compensation   -    -    -    -    4,192,082    -    -    4,192,082 
Issuance of common stock as compensation for services   -    -    31,769    4    31,748    -    -    31,752 
Issuance of common stock in exchange for preferred shares B   (4,361)   (3,797,705)   8,722,000    873    3,796,832    -    -    - 
Issuance of common stock in public offering, net of stock issuance costs ($172,592)   -    -    3,023,147    302    5,580,169    -    -    5,580,471 
Issuance of common stock in exchange for Options   -    -    1,076,946    107    1,415,035    -    -    1,415,142 
Issuance of common stock in exchange for Warrants   -    -    114,957    12    (12)   -    -    - 
Issuance of common stock pursuant to the Aquarius Merger   -    -    1,500,000    150    1,199,850    -    -    1,200,000 
Stock dividends   -    -    1,687,200    169    843,431    (843,600)   -    - 

Other comprehensive (loss)

   -    -    -    -    -    -    (373,671)   (373,671)
Net loss   -    -    -    -    -    (23,283,415)   -    (23,283,415)
Balance, December 31, 2021   -   $-    216,269,450   $21,627   $184,251,138   $(131,634,208)  $(145,499)  $52,493,058 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-4 

 

 

Matinas BioPharma Holdings, Inc.

Consolidated Statements of Cash Flows

 

   2021   2020 
   For the Year Ended December 31, 
   2021   2020 
Cash flows from operating activities:          
Net loss  $(23,283,415)  $(22,446,838)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   244,395    231,058 
Loss on disposal of equipment   2,207    - 
Stock-based compensation expense   4,292,355    4,564,787 
Amortization of operating lease right-of-use assets   501,359    484,568 
Amortization of finance lease right-of-use assets   35,737    58,961 
Amortization of bond discount   250,453    239,831 
Realized gain on sale of marketable securities   -    8,485 
Stock issued pursuant to the Aquarius Merger Agreement charged to Research and Development   1,200,000    - 
Changes in operating assets and liabilities:          
Operating lease liabilities   (460,239)   (423,741)
Prepaid expenses and other current assets   1,349,804    (611,397)
Accounts payable   588,329    (329,369)
Accrued expenses and other liabilities   55,560    855,819 
Net cash used in operating activities   (15,223,455)   (17,367,836)
           
Cash flows from investing activities:          
Purchases of marketable securities   (23,194,600)   (72,106,359)
Proceeds from sales of marketable securities   40,225,000    31,445,156 
Purchases of leasehold improvements and equipment   (260,380)   (5,749)
Net cash provided by/(used in) investing activities   16,770,020    (40,666,952)
           
Cash flows from financing activities:          
Net proceeds from public offering of common stock   5,580,471    46,704,210 
Proceeds from exercise of warrants   -    797,581 
Proceeds from exercise of options   1,415,142    599,713 
Payments of capital lease liability – principal   (30,853)   (54,673)
Net cash provided by financing activities   6,964,760    48,046,831 
           
Net increase/(decrease) in cash, cash equivalents and restricted cash   8,511,325    (9,987,957)
Cash, cash equivalents and restricted cash at beginning of period   12,768,481    22,756,438 
           
Cash, cash equivalents and restricted cash at end of period  $21,279,806   $12,768,481 
           
Supplemental non-cash financing and investing activities:          
Unrealized (loss)/gain on marketable securities  $(373,671)  $229,052 
Cashless exercise of warrants  $12   $- 
Stock dividends issued  $843,600   $682,800 
Non-cash prepaid from exercise of options  $-   $220,614 
Preferred stock conversion into common stock - series B  $3,797,705   $188,100 
Unearned restricted stock grants  $-   $68,521 
Right-of-use asset in exchange from liabilities from operating lease  $1,443,610   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 F-5 

 

 

Note 1 – Description of Business

 

Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma” or “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

 

Note 2 – Liquidity and Plan of Operations

 

The Company has experienced net losses and negative cash flows from operations each period since its inception. Through December 31, 2021, the Company had an accumulated deficit of approximately $131.6 million. The Company’s net loss for the years ended December 31, 2021 and 2020 were approximately $23.3 million and $22.4 million, respectively.

 

The Company has been engaged in developing LYPDISO (formerly MAT9001) as well as its lipid nanocrystal (“LNC”) platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501, since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales, and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability.

 

Assuming the Company obtains Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.

 

To continue to fund operations, during January 2021, the Company sold 3,023,147 shares of common stock under its At-The-Market Sales Agreement with BTIG, LLC, generating gross proceeds of approximately $5.8 million and net proceeds of approximately $5.6 million. In addition, on January 14, 2020, the Company completed an underwritten public offering of 32,600,000 shares of common stock, generating gross cash proceeds of approximately $50.0 million and net proceeds of approximately $46.7 million. (See Note 12 – Stockholders’ Equity).

 

As of December 31, 2021, the Company had cash and cash equivalents of approximately $21.0 million, marketable securities of approximately $28.6 million and restricted cash of approximately $0.3 million. The Company believes the cash and cash equivalents and marketable securities on hand are sufficient to fund planned operations through 2023.

 

Note 3 – Summary of Significant Accounting Policies

 

Basis of presentation and principles of consolidation

 

The accompanying audited consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.

 

 F-6 

 

 

COVID-19

 

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn.

 

The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the year ended December 31, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant items subject to such estimates and assumptions include, but are not limited to, the Company’s research and development expenses, the assessment of the impairment of goodwill and intangible assets, level 3 fair value measurement of financial instruments, income tax valuations, the determination of stock-based compensation and contingent consideration.

 

Segment and geographic information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

 

Cash, cash equivalents and restricted cash

 

The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. For a complete disclosure of the Company’s cash, cash equivalents and restricted cash, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.

 

Marketable Securities

 

Marketable securities, all of which are available-for-sale, consist of U.S. treasury bonds, U.S. government notes, corporate debt securities and state and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive (loss)/income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in other income, net. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in other income, net. For a complete disclosure of the Company’s marketable securities, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.

 

 F-7 

 

 

Concentration of credit risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company’s investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. Balances are maintained at U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. The Company has not experienced any credit losses associated with its balances in such accounts.

 

Leasehold improvements and equipment

 

Equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation on equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Capitalized costs associated with leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining term of the lease.

 

Goodwill and other intangible assets

 

Goodwill is recorded when consideration paid for an acquired entity exceeds the fair value of the net assets acquired. Goodwill is not amortized but rather is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances indicate the goodwill may be impaired. U.S. GAAP provides that the Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If the Company determine this is the case, the Company can perform further analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any.

 

A reporting unit is an operating segment, or one level below an operating segment. Historically, the Company has conducted its business in a single operating segment and reporting unit. For the years ended December 31, 2021 and 2020, the Company assessed goodwill impairment by performing a qualitative test for its reporting unit. As part of the qualitative review, the Company considered its cash position and its ability to obtain additional financing in the near term to meet its operational and strategic goals and substantiate the value of its business. Based on the results of the Company’s assessment, it was determined that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amount. There were no impairments of goodwill during the years ended December 31, 2021 and 2020. If a nonrecurring fair value measurement for a goodwill impairment was required, sufficient information will be provided to permit reconciliation of the fair value of the asset categorized within the fair value hierarchy as level 3 to the amounts presented in the statement of financial position.

 

Indefinite lived intangible assets are composed of in-process research and development (“IPR&D”) and represent projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition. These IPR&D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020.

 

Leases

 

The Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, “Leases”, establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required.

 

 F-8 

 

 

Preferred stock dividends

 

Subject to provisions detailed more fully in Note 12, Stockholders’ Equity, shares of Series B Preferred Stock earned dividends at rates of 10%, 15% and 20% once per year on the first, second and third anniversary, respectively, of June 19, 2018. The dividends were paid when earned to the holders of the Series B Preferred Stock in the form of shares of the Company’s common stock.

 

Income taxes

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

The Company adopted the provisions of Accounting Standard Codification 740-10 and has analyzed its filing positions in 2021 and 2020 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2021.

 

Since the Company incurred net operating losses in every tax year since inception, the 2014 through 2020 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.

 

Fair Value Measurements

 

As defined in ASC 820 “Fair Value Measurement”, fair value measurements should be disclosed separately by three levels of the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs (quoted prices in active markets) and minimized the use of unobservable inputs (the Company’s assumptions) when developing fair value measurements, in accordance with the established fair value hierarchy. For a complete disclosure of the Company’s fair value measurements, see Note 5 – Fair Value Measurements.

 

Stock-based compensation

 

Stock-based compensation to employees consist of stock option grants and restricted shares that are recognized in the consolidated statement of operations based on their fair values at the date of grant.

 

The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, Equity-Based Payments to Non-Employees based upon the fair-value of the underlying instrument. The equity instruments, consisting of stock options granted to consultants, are valued using the Black-Scholes valuation model. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.

 

The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.

 

 F-9 

 

 

Basic and diluted net loss per common share

 

Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a “participating security”). The Company considered its Preferred Stock to be participating securities because they included rights to participate in dividends with the common stock.

 

Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.

 

During the years ended December 31, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The reconciliation of the diluted shares as of December 31, 2021 and 2020 are as follows (in thousands):

 

   As of December 31, 
   2021   2020 
Stock options   28,184    22,551 
Preferred Stock and accrued dividend upon conversion   -    8,722 
Warrants   988    1,328 
Total   29,172    32,601 

 

Revenue recognition

 

Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied.

 

At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

 

For the years ended December 31, 2020, the Company’s revenues primarily consist of a research grant to provide research and development services to the Cystic Fibrosis Foundation (“CFF”). The grant contract has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this grant. The Company had approximately $125 thousand of CFF research grant revenue for the year ended December 31, 2020.

 

On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech paid the Company a total of $100 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. The Agreement has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this Agreement. As certain Agreement performance obligations in this agreement were completed, disaggregation of revenue is not required. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $33 thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.

 

 F-10 

 

 

Collaboration Agreements

 

The Company assess whether its collaboration agreements are subject to ASC Topic 808, Collaborative Arrangements (Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company will apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If the Company determines a performance obligation within the arrangement is with a customer, the Company applies the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election.

 

The terms of such arrangements typically include payments to the Company for one or more of the following: up-front fees; development and regulatory payments; product supply services; research and development cost reimbursements; profit-sharing arrangements; and royalties on certain products if they are successfully commercialized. As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.

 

Up-front License Fees: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company would recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally would occur at or near the inception of the contract. For licenses that are bundled with other promises, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. The Company will evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

 

Research and Development Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company will evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which the Company will recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis.

 

Research and Development Cost Reimbursements: The Company’s collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer or partner, and they are distinct from the licenses provided to the Company’s collaboration partners, these promises are accounted for as a separate performance obligation which the Company estimates using internal development costs incurred and projections through the term of the arrangements. The Company records revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if the Company concludes that its collaboration partner is not a customer for those collaborative research and development activities, it presents such payments as a reduction of research and development expenses.

 

 F-11 

 

 

Research and Development Arrangement: Under the terms of our research and development agreement with the CFF Agreement, the Company did not account for this arrangement in accordance with Topic 606. However, the Company has determined that it is a partner under a collaboration agreement as it shares in the risks and rewards that would be received if the product is successful and commercialized. Therefore the funds received under the terms of this agreement will be recorded as reimbursements of research and development costs and reduce the research and development expenses in the Company’s Statements of Operations and Comprehensive Income/(Loss). The Company records the reimbursements for certain materials and other research and development costs associated with the agreement when it is probable that a significant reversal in the amount of cumulative costs have been recognized. As of December 31, 2021 and 2020, the Company recognized approximately $2.2 million and $0.1 million, respectively, of reimbursed research and development costs associated with the CFF Agreement. For a complete disclosure of the CFF Agreement, see Note 9 – Collaboration Agreements, License and other Research and Development Agreements.

 

Research and development expenses

 

Research and development expenses primarily consist of costs associated with the preclinical and clinical development of our product candidate portfolio, including the following:

 

● external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and
   
● employee-related expenses, including salaries, benefits and share-based compensation expense.

 

Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.

 

All research and development expenses are charged to operations as incurred in accordance with FASB ASC Topic 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

 

Accrued Research and Development Expenses

 

As part of the process of preparing the Company’s financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. Certain of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and adjust if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

 

The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjust the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

 

 F-12 

 

 

Patent expenses

 

Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.

 

Other comprehensive income/(loss)

 

Other comprehensive income/(loss) consists of net gains/(losses) and unrealized losses on marketable securities available-for-sale and is presented in the Consolidated Statements of Operations.

 

Recently adopted accounting pronouncements

 

In December 2019, the FASB Issued Accounting Standard Update 2019-12, “Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes”. This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted the new standard effective January 1, 2021 with no material impact on the Company’s consolidated financial statements.

 

Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities

 

The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date.

 

Cash, Cash Equivalents and Restricted Cash

 

The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes.

 

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Balance Sheets to the total of the amounts in the Consolidated Statements of Cash Flows as of December 31, 2021, December 31, 2020 and December 31, 2019 (in thousands):

 

   December 31,
2021		   December 31,
2020		   December 31,
2019		 
Cash and cash equivalents  $21,030   $12,432   $22,170 
Restricted cash included in current/long term assets   250    336    586 
Cash, cash equivalents and restricted cash in the statements of cash flows  $21,280   $12,768   $22,756 

 

Marketable Securities

 

The Company has classified its investments in marketable securities as available-for-sale and as a current asset. The Company’s investments in marketable securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized gains and losses are classified as other comprehensive (loss)/income and costs are determined on a specific identification basis. Realized gains and losses from our marketable securities are recorded in other income, net. For the years ended December 31, 2021 and 2020, the Company recorded unrealized (losses)/gains of approximately ($374) thousand and $238 thousand, respectively, and reclassed approximately $0 and $9 thousand to net realized loss from operations from the sale of certain securities during 2021 and 2020, respectively. As of December 31, 2021 and 2020, the Company had net accumulated unrealized losses of approximately $145 thousand and net accumulated unrealized gains of approximately $228 thousand, respectively.

 

 F-13 

 

 

The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following (in thousands):

 

   Amortized Cost   Unrealized Gain   Unrealized (Loss)   Fair Value 
   Amortized Cost  

Unrealized

Gain

   Unrealized (Loss)    
Fair Value		 
U.S. Government Notes  $19,395   $2   $(120)  $19,277 
Corporate Debt Securities   9,092    —    (27)   9,065 
State and Municipal Bonds   250    —    —    250 
Total marketable securities  $28,737   $2   $(147)  $28,592 

 

Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021 (in thousands):

 

   Fair Value   Net Carrying Amount 
Due within one year  $8,257   $8,310 
Due after one year through five years   20,335    20,402 
   $28,592   $28,712 

 

The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following (in thousands):

 

   Amortized Cost   Unrealized Gain   Unrealized (Loss)   Fair Value 
   Amortized Cost   Unrealized Gain   Unrealized (Loss)    
Fair Value		 
U.S. Treasury Bonds  $18,293   $136   $—   $18,429 
U.S. Government Notes   22,148    82    —    22,230 
Corporate Debt Securities   4,303    3    —    4,306 
State and Municipal Bonds   1,275    7    —    1,282 
Total marketable securities  $46,019   $228   $—   $46,247 

 

Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020 (in thousands):

 

   Fair Value   Net Carrying Amount 
Due within one year  $31,438   $31,602 
Due after one year through five years   14,809    14,845 
   $46,247   $46,447 

 

The Company determined that the unrealized (losses) and gains are deemed to be temporary as of December 31, 2021 and 2020. Unrealized (losses) and gains generally are the result of increases in the risk premiums required by market participants rather than an adverse change in cash flows for a fundamental weakness in the credit quality of the issuer or underlying assets. The Company has the ability and intent to hold these investments until maturity. The Company does not consider the investment in marketable securities to be other-than-temporarily impaired at December 31, 2021 and 2020.

 

 F-14 

 

 

Note 5 - Fair Value Measurements

 

The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

● Level 1 – Quoted prices for identical assets or liabilities in active markets.
   
● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable.
   
● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates.

 

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

 

The carrying amounts of certain cash and cash equivalents, current portion of restricted cash, marketable securities, prepaid expenses and other current assets, accounts payable, current portion of lease liability and accrued expenses approximate fair value due to the short-term nature of these instruments.

 

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands):

 

       Fair Value Hierarchy 
December 31, 2021  Total   (Level 1)   (Level 2)   (Level 3) 
Assets                    
Marketable Securities:                    
U.S. Government Notes  $19,277   $—   $19,277   $— 
Corporate Debt Securities   9,065    —    9,065    — 
State and Municipal Bonds   250    —    250    — 
Total  $28,592   $—   $28,592   $— 

 

       Fair Value Hierarchy 
December 31, 2020  Total   (Level 1)   (Level 2)   (Level 3) 
Assets                    
Marketable Securities:                    
U.S. Treasury Bonds  $18,429   $18,429   $—   $— 
U.S. Government Notes   22,230    —    22,230    — 
Corporate Debt Securities   4,306    —    4,306    — 
State and Municipal Bonds   1,282    —    1,282    — 
Total  $46,247   $18,429   $27,818   $— 

 

U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable securities consisting of U.S. government notes, corporate debt securities and state and municipal bonds are classified as Level 2 and are valued using quoted market prices in markets that are not active.

 

 F-15 

 

 

Note 6 – Leasehold Improvements and Equipment

 

Leasehold improvements and equipment, summarized by major category, consist of the following for the years ended December 31, 2021 and 2020 (in thousands):

 

   December 30,
2021		   December 31,
2020		 
Equipment  $1,640   $1,443 
Leasehold improvements   935    878 
Total   2,575    2,321 
Less: accumulated depreciation and amortization   1,037    797 
Leasehold improvements and equipment, net  $1,538   $1,524 

 

Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was approximately $244 thousand and $231 thousand, respectively. During the years ended December 31, 2021 and 2020, the Company purchased equipment and leasehold improvements of approximately $260 thousand and $6 thousand, respectively. During the year ended December 31, 2021, the Company recorded an asset write-off of approximately $6 thousand, including $4 thousand of related accumulated depreciation. The Company had no asset write-offs during the year ended December 31, 2020.

 

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in thousands):

 

     2021       2020 
   As of December 31, 
   2021   2020 
Payroll and incentives  $1,343   $1,094 
General and administrative expenses   195    280 
Research and development expenses   381    778 
Deferred revenue and other deferred liabilities *   932    643 
Total  $2,851   $2,795 

 

* At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement.

 

Note 8 – Leases

 

The Company has various lease agreements with terms up to 10 years, including leases of office space, a laboratory and manufacturing facility, and various equipment. Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

 

Operating lease obligations

 

On November 1, 2013, the Company entered into a 7-year lease for office space in Bedminster, New Jersey which commenced in June 2014 at a monthly rent of approximately $13,000, increasing to approximately $14,000 per month toward the end of the term.

 

On September 23, 2020, the Company entered into an amendment to the Bedminster lease. Pursuant to the amendment, the Company leased an additional 3,034 rentable square feet (“Expansion Premises”). The amendment became effective upon delivery to the Company of the Expansion Premises, which occurred on August 1, 2021, and extends the term of the lease for seven years from such date. There is no renewal option, no security deposit, no residual value or significant restrictions or covenants other than those customary in such arrangements. Except as expressly provided, all other terms, covenants, conditions and agreements as set forth in the lease will remain unchanged and in full force and effect.

 

 F-16 

 

 

On December 15, 2016, the Company entered into a 10-year, 3-month lease to consolidate our locations while expanding our laboratory and manufacturing facilities. The lease began August 2017. The monthly rent will start at approximately $43,000 increasing to approximately $64,000 in the final year. To obtain the laboratory and facility site, the Company was obligated to provide an initial security deposit of $586,000. This deposit was subsequently reduced and is currently $200,000 at December 31, 2021.

 

The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

 

The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s finance leases.

 

The Company incurred lease expense for its operating leases of approximately $852 thousand and $814 thousand for the years ended December 31, 2021 and 2020. The Company incurred amortization expense on its operating lease right-of-use assets of approximately $501 thousand and $485 thousand for the years ended December 31, 2021 and 2020, respectively.

 

Finance Leases

 

The Company incurred interest expense on its finance leases of approximately $3 thousand and $7 thousand for the years ended December 31, 2021 and 2020, respectively. The Company incurred amortization expense on its finance lease right-of-use assets of approximately $36 thousand and $59 thousand for the years ended December 31, 2021 and 2020, respectively.

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021 (in thousands):

 

Maturity of Lease Liabilities  Operating Lease Liabilities   Finance Lease Liabilities 
2022  $883   $22 
2023   922    2 
2024   962    - 
2025   1,004    - 
2026   1,046    - 
Thereafter   1,112    - 
Total undiscounted operating lease payments  $5,929   $24 
Less: Imputed interest   1,250    - 
Present value of operating lease liabilities  $4,679   $24 
           
Weighted average remaining lease term in years   6.1    0.9 
Weighted average discount rate   7.8%   7.8%

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2020 (in thousands):

 

Maturity of Lease Liabilities  Operating Lease Liabilities   Finance Lease Liabilities 
2021  $685   $34 
2022   645    19 
2023   677    2 
2024   710    - 
2025   745    - 
Thereafter   1,458    - 
Total undiscounted operating lease payments  $4,920   $55 
Less: Imputed interest   1,224    - 
Present value of operating lease liabilities  $3,696   $55 
           
Weighted average remaining lease term in years   6.7    1.7 
Weighted average discount rate   8.4%   8.1%

 

 F-17 

 

 

Note 9 - Collaboration Agreements, License and Other Research and Development Agreements

 

Cystic Fibrosis Foundation Therapeutics Development Award

 

On November 19, 2020, the Company entered into an award agreement (the “Agreement”) with CFF, pursuant to which it received a Therapeutics Development Award of up to $4.2 million (the “Award”) (of which $484,249 had been previously received) to support the preclinical development (the “Development Program”) of the Company’s MAT2501 product candidate (the “Product”), a LNC oral formulation of the broad-spectrum aminoglycoside amikacin, for the treatment of pulmonary non-tubercular mycobacteria infections and other pulmonary diseases (the “Field”). On November 19, 2021, the Company and CFF entered into an Amendment to the Agreement which added an additional milestone payment in the amount of $321 thousand. The milestone payment was invoiced and the payment was received in the fourth quarter of 2021.

 

The first payment under the Agreement, in the amount of $650 thousand, became due upon execution of the Agreement. The Company invoiced the CFF in November 2020 and payment was subsequently received in February 2021. During 2021, the Company invoiced and received $2.5 million related to Agreement and the related deferred liability balance of $899 thousand is included in accrued expense and other current liabilities. The remainder of the Award will be paid to the Company upon the achievement of certain milestones related to the development program and progress of the Development Program, as set forth in the Agreement.

 

If the Company ceases to use commercially reasonable efforts directed to the development of MAT2501 in the Field, (an “Interruption”) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the Award actually received by the Company, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Agreement that covers the Product for use in treating infections in CF patients (the “CF Field”), and (2) a non-exclusive, worldwide license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.

 

Pursuant to the terms of the Agreement, the Company is obligated to make royalty payments to CFF contingent upon commercialization of the Product in the Field up to a maximum of five (5) times the Award or approximately $21.2 million (the “Royalty Cap”), payable in three equal annual installments following the first commercial sale of the Product, the first of which is due within 90 days following the first commercial sale of the Product. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction which will be applied against the Royalty Cap. In addition, the Company is also obligated to make up the two royalty payments of CFF of the approximately $4.2 million each, due in the calendar years in which specific net sales milestones are achieved.

 

The term of the Agreement commenced on November 19, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Agreement. Either CFF or the Company may terminate the agreement for cause, which includes the Company’s material failure to achieve certain development milestones. The Company’s payment obligations survive the termination of the Agreement.

 

The Company concluded that the CFF award is in the scope of ASC 808. Accordingly, as discussed in Note 3, the award amounts received from CFF upon achievement of certain milestones are recognized as credits to research and development expenses in the period the Development Program’s expenses are incurred. During the years ended December 31, 2021 and 2020, the Company recognized $2.2 million and $0.1 million, respectively, as credits to research and development expenses related to the CFF award. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.

 

 F-18 

 

 

Genentech Feasibility Study Agreement

 

On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study agreement will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. On December 13, 2019, per Genentech’s request, the Company billed Genentech for the total $100 thousand and recorded the upfront consideration as deferred revenue, which is recorded in accrued expenses on the consolidated balance sheets, and will recognize it over the term of the contract performance obligation period. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $33 thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.

 

Other Research and development agreements

 

The Company has financial obligations resulting from Cooperative Research and Development Agreements (“CRADAs”) entered into with the with the National Institute of Allergy and Infectious Diseases (“NIH”) as follows:

 

● On February 19, 2016, the Company agreed to provide funds in the amount of $200,000 per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of LNC platform drug products in patients with fungal, bacterial, or viral infections. The initial term of the CRADA was three years. On April 16, 2019, the Company renewed the CRADA for an additional three years with an annual funding commitment of $200,000.
   
● On April 2, 2019, the Company agreed to provide funds in the amount of $157,405 per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of LNC platform drug products in patients with fungal, bacterial, or viral infections. The term of the CRADA is three years.

 

License agreement

 

Through the acquisition of Aquarius, the Company acquired a license from Rutgers University, The State University of New Jersey (successor in interest to the University of Medicine and Dentistry of New Jersey) for the LNC platform delivery technology. The Second Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $100,000 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of $50,000 over the term of the license agreement.

 

Note 10 – Commitments

 

Royalty payment rights

 

On September 12, 2016 the Company conducted a final closing of a private placement offering to accredited investors of shares of the Company’s Series A Preferred Stock. As part of this offer, the investors received royalty payment rights if and when the Company generates sales of its MAT2203 or MAT2501 product candidates. Pursuant to the terms of the Series A Certificate of Designation, the Company may be required to pay royalties of up to $35 million per year. If and when the Company obtains FDA or the European Medicines Agency (“EMA”) approval of MAT2203 and/or MAT2501, which the Company does not expect to occur before 2023, if ever, and/or if the Company generates sales of such products, or the Company receives any proceeds from the licensing or other disposition of MAT2203 or MAT2501, the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the “Royalty Payment Rights”) equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $10 million per calendar year. The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033.

 

 F-19 

 

 

Employment agreements

 

The Company also has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur.

 

Other normal business operating agreements

 

In addition, in the course of normal business operations, the Company enters into agreements with contract service providers to assist in the performance of research & development and manufacturing activities. Expenditures to these third parties represent significant costs in clinical development and may require upfront payments and long-term commitments of cash. Subject to required notice periods and obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time.

 

Note 11 – Income Taxes

 

The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2021 and 2020, the Company does not believe any material uncertain tax positions were present. Accordingly, interest and penalties have not been accrued due to an uncertain tax position.

 

The components of the income tax provision are as follows (in thousands):

 

           
    Year Ended December 31, 
    2021    2020 
Current expense (benefit):          
Federal  $-   $- 
State   -    - 
Foreign   -    - 
Total current expense (benefit):  $-   $- 
           
Deferred expense (benefit):          
Federal  $-   $- 
State   -    - 
Foreign   -    - 
Total deferred expense (benefit):  $-   $- 
           
Total income tax expense (benefit):  $-   $- 

 

 F-20 

 

 

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows:

 

         
   Year Ended December 31, 
   2021   2020 
Income at US Statutory Rate   21.00%   21.00%
State Taxes, net of Federal benefit   1.97%   2.95%
Permanent Differences   (0.82)%   (1.28)%
Tax Credits   2.16%   0.75%
Valuation Allowance   (25.21)%   (24.53)%
Discrete items   0.91%   1.11%
 Effective income tax rate   0.00%   0.00%

 

The Company has no current income taxes payable other than certain state minimum taxes which are included in general and administrative expenses.

 

Significant components of the Company’s deferred tax assets (liabilities) for 2021 and 2020 consist of the following (in thousands):

 

         
   Year Ended December 31, 
   2021   2020 
Share-based Compensation  $3,575   $3,220 
Depreciation and Amortization   166    (119)
Accrued Liability   377    307 
Net Operating Loss Carry-forwards   24,076    19,927 
R&D Credit Carryforwards   3,207    2,264 
Other   (1)   (10)
IPR&D   (848)   (848)
ROU Asset   (1,186)   (921)
ROU Liability   1,315    1,045 
Total Deferred tax assets  $30,681   $24,865 
Valuation allowance   (31,023)   (25,206)
Net deferred tax asset (liability)  $(341)  $(341)

 

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law making several changes to the Internal Revenue Code. The changes include but are not limited to: allowing companies to carryback certain net operating losses, and increasing the amount of net operating loss carryforwards that corporations can use to offset taxable income. The tax law changes in the Act did not have a material impact on the Company’s income tax provision.

 

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible, and is impacted by the Company’s ability to carryforward losses to years in which the Company has taxable income. Due to the Company’s history of losses and lack of other positive evidence to support taxable income, the Company has recorded a valuation allowance against those deferred tax assets that are not expected to be realized. The valuation allowances were approximately $31.0 million, $25.2 million and $19.7 million as of December 31, 2021, 2020 and 2019, respectively, representing increases of approximately $5.8 million and $5.5 million for the years ending December 31, 2021 and 2020, respectively.

 

As of December 31, 2021, the Company had Federal net operating loss carryforwards of approximately $38.1 million which will begin to expire in 2032. In addition, the Company has federal net operating loss carryforwards of approximately $63.3 million which have an indefinite carryforward period. The Company also had federal and state research and development tax credit carryforwards of approximately $3.2 million. The federal net operating loss and tax credit carryforwards will expire at various dates beginning in 2033, if not utilized. The difference between the statutory tax rate and the effective tax rate is primarily attributable to the valuation allowance offsetting deferred tax assets.

 

 F-21 

 

 

Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 due to changes in ownership of the Company that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. The Company has not completed a study to determine whether it had undergone an ownership change since the Company’s inception

 

Sale of net operating losses (NOLs)

 

The Company recognized approximately $1.3 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively, in connection with the sale of certain State of New Jersey Net Operating Losses (“NOL”) and Research and Development (“R&D”) tax credits to a third party under the New Jersey Technology Business Tax Certificate Transfer Program. In addition, the Tax Cuts and Jobs Act, signed into law on December 22, 2017 imposes significant additional limitations on the deductibility of interest and limits NOL deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017. This NOL limitation was suspended for years 2018 through 2020 as a result of the CARES Act.

 

Note 12 – Stockholders’ Equity

 

At-The-Market Equity Offering

 

On July 2, 2020, the Company entered into an At-The-Market (“ATM”) Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $50,000,000, subject to certain limitations on the amount of common stock that may be offered and sold by the Company set forth in the Sales Agreement. BTIG will be paid a 3% commission on the gross proceeds from each sale. The Company may terminate the Sales Agreement at any time; BTIG may terminate the Sales Agreement in certain limited circumstances. During 2021, BTIG sold 3,023,147 shares of the Company’s common stock generating gross proceeds of approximately $5.8 million and net proceeds of approximately $5.6 million, after deducting BTIG’s commission on gross proceeds. During 2020, the Company did not sell any shares of its common stock under the ATM Sales Agreement.

 

Common Stock

 

On September 3, 2021, the Company issued 1,500,000 unregistered shares of its common stock pursuant to the Agreement and Plan of Merger by and among the Company, Saffron Merger Sub, Inc., Aquarius Biotechnologies Inc. (“Aquarius”), and J Carl Craft, as holder representative, dated January 19, 2015, as subsequently amended on September 3, 2021 (the “Aquarius Merger Agreement”), to the holders of Aquarius Biotechnologies Inc., as defined in the Aquarius Merger Agreement. The shares were issued in place of certain milestone payments previously included under the Aquarius Merger Agreement upon the achievement of specified development milestones. The Company recorded a $1.2 million research and development expense related to the issuance of the 1,500,000 shares based on the closing price of the Company’s common stock of $0.80 on the date of issuance.

 

On January 14, 2020, the Company closed on an underwritten public offering of 32,260,000 shares of its common stock at a purchase price of $1.55 per share. The Company generated gross proceeds of approximately $50.0 million and net proceeds of approximately $46.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to approximately 4.8 million additional shares of its common stock on the same terms and conditions. No additional shares of the Company’s common stock were sold pursuant to this option.

 

 F-22 

 

 

Preferred Stock

 

In accordance with the Certificate of Incorporation, the Company is authorized to issue 10,000,000 preferred shares at a par value of $0.001. In connection with a private placement of Series A Preferred Stock, on July 26, 2016, the Company filed the Series A Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series A Preferred Stock. Pursuant to the Series A Certificate of Designation, the Company designated 1,600,000 shares of the Company’s previously undesignated preferred shares as Series A Preferred Stock. In connection with a public offering of Series B Preferred Stock, on June 19, 2018, the Company filed the Series B Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Stock. Pursuant to the Series B Certificate of Designation, the Company designated 8,000 shares of the Company’s previously undesignated preferred shares as Series B Preferred Stock.

 

Series B Preferred Stock

 

During 2021 and prior to June 19, 2021, 143 shares of Series B Preferred Stock were converted by shareholders resulting in the issuance of 286,000 shares of common stock. On June 19, 2021, all 4,218 remaining shares of Series B Preferred Stock were automatically converted into 2,000 shares of the Company’s common stock resulting in the issuance of 8,436,000 shares of common stock. As of December 31, 2021 and December 31, 2020, there were 0 and 4,361 shares of Series B Preferred stock outstanding, respectively.

 

Conversion:

 

Prior to the automatic conversion of Series B Preferred Stock on June 19, 2021, and subject to certain ownership limitations, each share of Series B Preferred Stock was convertible into shares of the Company’s common stock at any time at the option of the holder at an initial conversion price of $0.50 per share subject to adjustment for reverse splits, stock combinations and similar changes as provided in the Certificate of Designation. Based on the conversion price and number of shares outstanding on June 19, 2021, the Series B Preferred Stock were converted into 8,436,000 shares of common stock.

 

Dividends:

 

Subject to certain ownership limitations, holders of the Series B Preferred Stock received dividends paid in the Company’s common stock as follows: (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling 1,687,200 and 1,365,600 shares of common stock, respectively.

 

Warrants

 

All warrants issued by the Company are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company’s capital stock or other similar changes to the equity structure of the Company. The warrants do not have a redemption feature. They may be exercised on a cashless basis at the holder’s option.

 

The warrants are classified as equity instruments.

 

 F-23 

 

 

As of December 31, 2021, the Company had outstanding warrants to purchase an aggregate of 988,000 shares of common stock at exercise prices ranging from $0.50 to $0.75 per share, and with expiration dates between December 31, 2022 and June 21, 2023. A summary of warrants outstanding as of December 31, 2021 and 2020 is presented below, all of which are fully vested (in thousands):

 

   Shares 
Outstanding at December 31, 2019   5,397 
Issued   - 
Exercised   (2,549)
Tendered   - 
Expired   (1,493)
Outstanding at December 31, 2020   1,328*
Outstanding at January 01, 2021     
Issued   - 
Exercised   (320)**
Tendered   - 
Expired   (20)
Outstanding at December 31, 2021   988***

 

* Weighted average exercise price for outstanding warrants is $0.55.
** Converted into approximately 115 thousand shares of common stock.
*** Weighted average exercise price for outstanding warrants is $0.56.

 

Note 13 – Accumulated Other Comprehensive (Loss)/Income

 

The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the years ended December 31, 2021 and 2020 (in thousands):

 

Schedule of Components of Accumulated Other Comprehensive (Loss)/Income 

    Net Unrealized (Losses)/Gains on Available-for-Sale Securities     Accumulated Other Comprehensive (Loss)/Gain  
Balance, December 31, 2019   $ (1 )   $ (1 )
Net unrealized gain on securities available-for-sale     237       237  
Reclassification of realized gain on securities available-for-sale to net loss     (8 )     (8 )
Net current period other comprehensive gain     229       229  
Balance, December 31, 2020   $ 228     $ 228  
Net unrealized loss on securities available-for-sale     (373 )     (373 )
Net current period other comprehensive loss     (374 )     (374 )
Balance, December 31, 2021   $ (146 )   $ (146 )

 

All components of accumulated other comprehensive (loss)/income are net of tax.

 

Note 14 – Stock-based Compensation

 

The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”) provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. Options under the Plan may be granted at prices not less than 100% of the fair value of the shares on the date of grant as determined by the Compensation Committee of the Board of Directors. The Compensation Committee determines the period over which the options become exercisable subject to certain restrictions as defined in the Plan, with the current outstanding options generally vesting over three or four years. The term of the options is no longer than ten years. As of December 31, 2021, the Company had 36,952,460 shares of common stock authorized for issuance under the Plan.

 

With the approval of the Board of Directors and a majority of shareholders, effective May 8, 2014, the Plan was amended and restated. The amendment provides for an automatic increase in the number of shares of common stock available for issuance under the Plan each January (with Board approval), commencing January 1, 2015 in an amount up to four percent (4%) of the total number of shares of common stock outstanding on the preceding December 31st.

 

 F-24 

 

 

The Company recognized stock-based compensation expense (options and restricted share grants) in its consolidated statements of operations as follows (in thousands):

 

Schedule of Recognized Stock-Based Compensation 

   Year Ended December 31, 
   2021   2020 
Research and Development  $1,870   $1,897 
General and Administrative   2,422    2,668 
Total  $4,292   $4,565 

 

The following table contains information about the Company’s stock plan at December 31, 2020:

 

Schedule of Equity Compensation Plan by Arrangements 

    Awards Reserved for Issuance     Awards Issued & Exercised     Awards Available for Grant  
2013 Equity Compensation Plan (in thousands)     36,952 *     32,669 **     4,283  

 

* Increased by 8,005 thousand on January 1, 2021, representing 4% of the total number of shares of common stock outstanding on December 31, 2020.
** Includes both stock grants and option grants

 

The following table summarizes the Company’ stock option activity and related information for the period from January 1, 2020 to December 31, 2021 (options in thousands):

 

Schedule of Stock Option Activity 

   Number of Options   Weighted Average Exercise Price   Weighted Average Contractual Term in Years 
Outstanding at December 31, 2019   17,529   $1.11    6.2 
Granted   6,501   $1.59      
Exercised   (826)   0.74      
Forfeited   (72)  $1.11      
Cancelled   -    -      
Expired   (581)  $1.25      
Outstanding at December 31, 2020   22,551   $1.26    6.9 
                
Granted   10,976   $1.11      
Exercised   (1,077)  $0.60      
Forfeited   (2,824)  $1.08      
Cancelled   -    -      
Expired   (1,441)  $1.98      
Outstanding at December 31, 2021   28,184   $1.21    7.2 

 

The following table summarizes outstanding options at December 31, 2021, by their exercise price (options in thousands):

 

Range of Exercise Prices  Number Outstanding   Weighted Average Exercise Price Per Share 
$0.41 - $0.69   1,935   $0.49 
$0.74 - $1.12   15,940   $0.93 
$1.24 - $1.61   6,525   $1.35 
$2.27 - $3.32   3,784   $2.50 
    28,184   $1.21 

 

As of December 31, 2021, the number of vested shares underlying outstanding options was 14,625,397 at a weighted average exercise price of $1.20. The aggregate intrinsic value of in-the-money options outstanding as of December 31, 2021 was $2.5 million. The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price of $1.01 on December 31, 2021, and the exercise price of options, multiplied by the number of options. As of December 31, 2021, there was approximately $11.7 million of total unrecognized share-based compensation. Such costs are expected to be recognized over a weighted average period of approximately 2.9 years.

 

 F-25 

 

 

All outstanding options expire ten years from date of grant. Options granted to employees prior to 2018 vest in equal monthly installments over three years. Beginning in 2018, options granted to employees vest over four years, with 25% of the shares vesting on the first annual anniversary of grant and the remaining shares vesting in 36 equal monthly installments over the following 3 years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives.

 

During the years ended December 31, 2021 and 2020, the Company granted restricted stock awards for 31,769 and 379,385 shares of common stock, respectively. These awards are typically granted to members of the Board of Directors as payment in lieu of cash fees or as payment to a vendor pursuant to a consulting agreement. The Company values restricted stock awards at the fair market value on the date of grant. The Company recorded the value of these restricted awards as general and administrative expense of approximately $100 thousand and $292 thousand in the consolidated statement of operations for the years ended December 31, 2021 and 2020, respectively.

 

The Company recognizes compensation expense for stock option awards and restricted stock awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of awards granted subject to a vendor’s consulting agreement, whereby the award vesting period and the service period defined pursuant to the terms of the consulting agreement may be different. Beginning January 1, 2020, stock options issued to consultants are recorded at fair value on the date of grant and the award is recognized as an expense on a straight-line basis over the requisite service period. The following weighted-average assumptions were used to calculate share-based compensation for the comparative periods presented:

 

 Schedule of Stock Option Awards and Restricted Stock Awards

    For the Year Ended December 31,  
    2021     2020  
Volatility   98.4% -101.6 %   100.5% - 107.4 %
Risk-free interest rate     0.47% - 1.28 %     0.34% - 1.74 %
Dividend yield     0.0 %     0.0 %
Expected life     6.0 years       6.0 years  

 

The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Hence, the Company uses the “simplified method” described in Staff Accounting Bulletin (SAB) 107 to estimated the expected term of share option grants.

 

The expected stock price volatility assumption is based the Company’s historical stock price volatility.

 

Note 15 – Subsequent Events

 

None

 

 F-26 

 

 EX-4.6 2 ex4-6.htm

 

Exhibit 4.6

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT

TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

The following is a description of our common stock and preferred stock as set forth in our certificate of incorporation and bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this Exhibit 4.6 is a part. This summary does not purport to be complete and is qualified in its entirety by the full text of our aforementioned certificate of incorporation and bylaws and by applicable law.

 

Our authorized capital stock consists of 500,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of Preferred Stock, par value $0.0001 per share.

 

The additional shares of our authorized stock available for issuance might be issued at times and under circumstances so as to have a dilutive effect on earnings per share and on the equity ownership of the holders of our common stock. The ability of our board of directors to issue additional shares of stock could enhance the board’s ability to negotiate on behalf of the stockholders in a takeover situation but could also be used by the board to make a change-in-control more difficult, thereby denying stockholders the potential to sell their shares at a premium and entrenching current management. The following description is a summary of the material provisions of our capital stock. You should refer to our amended and restated certificate of incorporation and by-laws, both of which are on file with the SEC as exhibits to previous SEC filings, for additional information. The summary below is qualified by provisions of applicable law.

 

Common Stock

 

Voting. The holders of our common stock are entitled to one vote for each share held of record on all matters on which the holders are entitled to vote (or consent to).

 

Dividends. The holders of our common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock (including the common stock).

 

Liquidation Rights. In the event of our liquidation, dissolution or winding-up, the holders of our common stock are entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the common stock (including the common stock).

 

Conversion Rights. The holders of our common stock have no conversion rights.

 

Preemptive and Similar Rights. The holders of our common stock have no preemptive or similar rights.

 

Redemption/Put Rights. There are no redemption or sinking fund provisions applicable to the common stock. All of the outstanding shares of our common stock are fully-paid and nonassessable.

 

Transfer Agent and Registrar. The transfer agent and registrar for our common stock is VStock Transfer, LLC.

 

Series A Preferred Stock

 

Our board of directors created out of the authorized and unissued shares of our preferred stock, a series of preferred stock comprised of 1,600,000 shares of Series A Preferred Stock. All shares of Series A Preferred Stock have been automatically converted pursuant to the terms of the certificate of designation.

 

Series B Preferred Stock

 

Our board of directors created out of the authorized and unissued shares of our preferred stock, a series of preferred stock comprised of 15,000 shares of Series B Preferred Stock. All shares of Series B Preferred Stock have been automatically converted pursuant to the terms of the certificate of designation.

 

 
 

 

Preferred Stock

 

We are authorized to issue up to 10,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, rights, and preferences as may be determined from time to time by our board of directors. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting, or other rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock could have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying or preventing a change in control of our company, all without further action by our stockholders.

 

Our board of directors has the authority, within the limitations and restrictions prescribed by law and without stockholder approval, to provide by resolution for the issuance of shares of preferred stock, and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference and the number of shares constituting any series of the designation of such series, by delivering an appropriate certificate of amendment to our amended and restated certificate of incorporation to the Delaware Secretary of State pursuant to the Delaware General Corporation Law (the “DGCL”). The issuance of preferred stock could have the effect of decreasing the market price of the common stock, impeding or delaying a possible takeover and adversely affecting the voting and other rights of the holders of our common stock.

 

If we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description will include:

 

● the title and stated value;
● the number of shares offered, the liquidation preference per share and the purchase price;
● the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;
● whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
● the procedures for any auction and remarketing, if any;
● the provisions for a sinking fund, if any;
● the provisions for redemption, if applicable;
● any listing of the preferred stock on any securities exchange or market;
● whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated) and conversion period;
● whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated) and exchange period;
● voting rights, if any, of the preferred stock;
● a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock;
● the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of Matinas; and
● any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of Matinas.

 

Transfer Agent and Registrar for Preferred Stock. The transfer agent and registrar for any series or class of preferred stock will be set forth in each applicable prospectus supplement.

 

Anti-takeover Effects of Delaware Law and of our Amended and Restated Certificate of Incorporation

 

The following paragraphs summarize certain provisions of the DGCL and our amended and restated certificate of incorporation that may have the effect of discouraging an acquisition of Matinas. The summary does not purport to be complete and is subject to and qualified in its entirety by reference to the DGCL and our amended and restated certificate of incorporation and by-laws, copies of which are on file with the SEC. Please refer to “Additional Information” below for directions on obtaining these documents.

 

 
 

 

Section 203 of the Delaware General Corporation Law

 

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

 

● before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
● upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
● on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

 

In general, Section 203 defines business combination to include the following:

 

● any merger or consolidation involving the corporation and the interested stockholder;
● any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;
● subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
● any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
● the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.

 

In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

 

Certificate of Incorporation and Bylaws

 

Our certificate of incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or tender offers or delaying or preventing a change of control of our company. These provisions are as follows:

 

● they provide that special meetings of stockholders may be called only by the board of directors, President or our Chairman of the board of directors, or at the request in writing by stockholders of record owning at least fifty (50%) percent of the issued and outstanding voting shares of common stock;
● they do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority stockholder holding a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative voting may have the effect of limiting the ability of minority stockholders to effect changes in our board of directors; and
● they allow us to issue “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval.

 

Potential Effects of Authorized but Unissued Stock

 

We have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.

 

The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, the board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the DGCL and subject to any limitations set forth in our amended and restated certificate of incorporation. The purpose of authorizing the board of directors to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from acquiring, a majority of our outstanding voting stock.

 

 

 

 EX-10.15 3 ex10-15.htm

 

Exhibit 10.15

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (this “Agreement”), entered into on October 22, 2020 with the commencement of employment to begin as of December 1, 2020 (the “Commencement Date”), is by and between MATINAS BIOPHARMA HOLDINGS, INC., a Delaware corporation (the “Company”) and Dr. Hui Liu (the “Executive”).

 

W I T N E S S E T H:

 

WHEREAS, the Company desires to employ the Executive as its Senior Vice President and Chief Technology Officer and the Executive desires to accept such employment, on the terms and conditions set forth in this Agreement; and

 

WHEREAS, the Company and the Executive have mutually agreed that, as of the Commencement Date, this Agreement shall govern the terms of employment between the Executive and the Company.

 

NOW, THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

 

ARTICLE 1
Employment;TERM OF AGREEMENT

 

Section 1.1. Employment and Acceptance. During the Term (as defined in Section 1.2), the Company shall employ the Executive, and the Executive shall accept such employment and serve the Company, in each case, subject to the terms and conditions of this Agreement.

 

Section 1.2. Term. The employment relationship hereunder shall be for the period commencing on the Commencement Date and continue until it is terminated by either the Company or the Executive in accordance with ARTICLE 4 (the “Term”). In the event that the Executive’s employment with the Company terminates, the Company’s obligation to continue to pay, after the Termination Date (as defined in Section 4.2(b)), Base Salary (as defined in Section 3.1(a)), Annual Bonus (as defined in Section 3.1(c)) and other unaccrued benefits shall terminate, except as may be provided for in ARTICLE 4.

 

ARTICLE 2
TITLE; DUTIES AND OBLIGATIONS; LOCATION

 

Section 2.1. Title. The Company shall employ the Executive to render exclusive and full-time services to the Company. The Executive shall serve in the capacity of Chief Technology Officer.

 

 

 

 

Section 2.2. Duties. The Executive shall report to the Company’s Chief Executive Officer (“CEO”). The Executive agrees to perform to the best of his ability, experience and talent those acts and duties, consistent with his position as the CEO shall from time to time direct. During the Term, the Executive also shall serve in such other executive-level positions or capacities as may, from time to time, be reasonably requested by the Company including, without limitation (subject to election, appointment, re-election or re-appointment, as applicable) as (a) an officer of any of the Company’s subsidiaries or other Affiliates, and/or (b) a member of any committee of the Company and/or any of its subsidiaries or other Affiliates, in each case, for no additional compensation. As used in this Agreement, “Affiliate” of any individual or entity means any other individual or entity that directly or individual controls, is controlled by, or is under common control with, the individual or entity.

 

Section 2.3. Compliance with Policies, etc. During the Term, the Executive shall be bound by, and comply fully with, all of the Company’s policies and procedures for employees and officers in place from time to time, including, but not limited to, all terms and conditions set forth in the Company’s employee handbook, compliance manual, codes of conduct and any other memoranda and communications applicable to the Executive pertaining to the policies, procedures, rules and regulations, as currently in effect and as may be amended from time to time. These policies and procedures include, among other things and without limitation, the Executive’s obligations to comply with the Company’s rules regarding confidential and proprietary information and trade secrets.

 

Section 2.4. Time Commitment. During the Term, the Executive shall use his best efforts to promote the interests of the Company (including its subsidiaries and other Affiliates) and shall devote all of his business time, ability and attention to the performance of his duties for the Company and shall not, directly or indirectly, render any services to any other person or organization, whether for compensation or otherwise, except with the Board’s prior written consent or as specified on Exhibit C of the Covenants Agreement (as defined in Section 5.1), provided that the foregoing shall not prevent the Executive from (i) participating in charitable, civic, educational, professional, community or industry affairs, or (ii) managing the Executive’s passive personal investments, so long as, in each case, such activities individually or in the aggregate do not materially interfere or conflict with the Executive’s duties hereunder or create a potential business or fiduciary conflict (in each case, as determined by the Board).

 

Section 2.5. Location. The Executive’s principal place of business for the performance of his duties under this Agreement shall be at the principal executive office of the Company, currently located in Bedminster, NJ. Notwithstanding, the foregoing, the Executive shall be required to travel as necessary to perform his duties hereunder.

 

ARTICLE 3
COMPENSATION AND BENEFITS; EXPENSES

 

Section 3.1. Compensation and Benefits. For all services rendered by the Executive in any capacity during the Term (including, without limitation, serving as an officer, director or member of any committee of the Company or any of its subsidiaries or other Affiliates), the Executive shall be compensated as follows (subject, in each case, to the provisions of Article 4 below):

 

(a) Base Salary. The Company shall pay the Executive a base salary (the “Base Salary”) at the annualized rate of $350,000, which shall be subject to customary withholdings and authorized deductions and be payable in equal installments in accordance with the Company’s customary payroll practices in place from time to time. The Executive’s Base Salary shall be subject to periodic adjustments as the Board and/or the Compensation Committee of the Board (the “Compensation Committee”) shall in its/their discretion deem appropriate. As used in this Agreement, the term “Base Salary” shall refer to Base Salary as may be adjusted from time to time.

 

-2-

 

 

(b) Signing Bonus. The Company agrees to pay the Executive a signing bonus of $50,000, payable in the first pay period following the Commencement Date.

 

(c) Annual Bonus. For each calendar year ending during the Term, the Executive shall be eligible to receive an annual bonus (the “Annual Bonus”) with a target amount equal to forty percent (40%) of the Base Salary earned by the Executive for such calendar year (the “Target Annual Bonus”). The actual amount of each Annual Bonus will be based upon the level of achievement of the Company’s corporate objectives and the Executive’s individual objectives, in each case, as established by the Board or the Compensation Committee for the calendar year with respect to which such Annual Bonus relates. The determination of the level of achievement of the corporate objectives and the Executive’s individual performance objectives for a year shall be made by the Board or the Compensation Committee, in its sole discretion. Each Annual Bonus for a calendar year, to the extent earned, will be paid in a lump sum in the following calendar year, within the first 75 days of such following year. The Annual Bonus shall not be deemed earned until the date that it is paid. Accordingly, in order for the Executive to receive an Annual Bonus, the Executive must be actively employed by the Company at the time of such payment.

 

(d) Equity Compensation. Subject to the approval of the Board, the Company will recommend a grant to the Executive of options to purchase up to 350,000 shares of the Company’s common stock pursuant to the Company’s 2013 Equity Compensation Plan, as amended and restated (the “2013 Plan”), on the terms and conditions determined by the Compensation Committee (the “Option”). The Option shall vest over four (4) years as follows: 25% of the shares subject to the Option shall vest on the one-year anniversary of the Commencement Date, and the remaining 75% of the shares subject to the Option will vest in equal monthly installments over the following thirty-six (36) months. During the Term, subject to the terms and conditions established within the 2013 Plan or any successor equity compensation plan as may be in place from time to time and separate Award Agreements (as defined in the 2013 Plan), the Executive also shall be eligible to receive from time to time additional Stock Options, Stock Unit Awards, Performance Shares, Performance Units, Incentive Bonus Awards, Other Cash-Based Awards and/or Other Stock-Based Awards (as such capitalized terms are defined in the 2013 Plan), in amounts, if any, to be approved by the Board or the Compensation Committee in its discretion.

 

(e) Benefit Plans. The Executive shall be entitled to participate in all employee benefit plans and programs (excluding severance plans, if any) generally made available by the Company to senior executives of the Company, to the extent permissible under the general terms and provisions of such plans or programs and in accordance with the provisions thereof. The Company may amend, modify or rescind any employee benefit plan or program and/or change employee contribution amounts to benefit costs without notice in its discretion.

 

-3-

 

 

(f) Paid Vacation. The Executive shall be entitled to paid vacation days in accordance with the Company’s vacation policies in effect from time to time for its executive team; provided, however, that the Executive shall be entitled to no less than fifteen (15) paid vacation days per calendar year during the Term.

 

(g) Relocation Benefits. The Company agrees to pay the Executive a relocation expense payment of $50,000 (“Relocation Expense Payment”), payable in the first pay period following the Commencement Date, which is intended to be used towards the following: (a) reimbursement of the Executive’s existing rental obligations in Massachusetts, (b) a portion of the down payment for purchase of the Executive’s new home in New Jersey and (c) closing costs associated with the purchase of the home in New Jersey. If and to the extent that the Relocation Expense Payment is subject to income and/or employment taxes, then the Executive will be entitled to receive an additional payment (a “Gross-Up Payment”) such that, after payment by Executive of all such taxes thereon, including any income and/or employment taxes imposed upon the Gross-Up Payment, the Executive retains an amount equal to the Relocation Expense Payment amount. In the event that the Executive terminates his employment with the Company prior to the two-year anniversary of the Commencement Date, the Executive shall promptly repay in cash to the Company the full amount paid to the Executive in respect of the Relocation Expense Payment.

 

Section 3.2. Expense Reimbursement. The Company shall reimburse the Executive during the Term, in accordance with the Company’s expense reimbursement policies in place from time, for all reasonable out-of-pocket business expenses incurred by the Executive in the performance of his duties hereunder. In order to receive such reimbursement, the Executive shall furnish to the Company documentary evidence of each such expense in the form required to comply with the Company’s policies in place from time to time.

 

ARTICLE 4
TERMINATION OF EMPLOYMENT

 

Section 4.1. Termination Without Cause or Resignation for Good Reason.

 

(a) The Company may terminate the Executive’s employment hereunder at any time without Cause (other than by reason of death or Disability) upon five (5) days prior written notice to the Executive. Executive may terminate his employment hereunder for Good Reason upon written notice to the Company in accordance with the provisions set forth in Section 4.1(c).

 

(b) As used in this Agreement, “Cause” means: (i) a material act, or act of fraud, committed by the Executive that is intended to result in the Executive’s personal enrichment to the detriment or at the expense of the Company or any of its Affiliates; (ii) the Executive is convicted of a felony; (iii) gross negligence or willful misconduct by the Executive, or failure by the Executive to perform the duties or obligations reasonably assigned to the Executive by the Board or the CEO from time to time, which is not cured upon ten (10) days prior written notice (unless such negligence, misconduct or failure is not susceptible to cure, as determined in the reasonable discretion of the Board); or (iv) the Executive violates the Covenants Agreement (as defined in Section 5.1 below).

 

-4-

 

 

(c) As used in this Agreement, “Good Reason” means the occurrence of any of the following: (1) a material breach by the Company of the terms of this Agreement; (2) a material reduction in the Executive’s Base Salary; or (3) a material change in the geographic location at which the Executive performs services for the Company; provided, however, that the Executive must notify the Company within ninety (90) days of the occurrence of any of the foregoing conditions that he considers it to be a “Good Reason” condition and provide the Company with at least thirty (30) days in which to cure the condition. If the Executive fails to provide this notice and cure period prior to his resignation, or resigns more than six (6) months after the initial existence of the condition, his resignation will not be deemed to be for “Good Reason.”

 

(d) If the Executive’s employment is terminated pursuant to Section 4.1(a) other than during the Post-Change in Control Period (as defined in Section 4.1(e)), the Executive shall, in full discharge of all of the Company’s obligations to the Executive, be entitled to receive, and the Company’s sole obligation to the Executive under this Agreement or otherwise shall be to pay or provide to the Executive, the following:

 

(i) the Accrued Obligations (as defined in Section 4.2(b)); and

 

(ii) subject to Section 4.4 and Section 4.5:

 

(A) payments equal to twelve (12) months of the Executive’s Base Salary (at the rate in effect immediately prior to the Termination Date) (less applicable withholdings and authorized deductions), to be paid in equal installments bimonthly in accordance with the Company’s customary payroll practices, commencing sixty (60) days following the Termination Date (the “Pre-CIC Severance Payments”); and

 

(B) if the Executive then participates in the Company’s medical and/or dental plans and the Executive timely elects to continue and maintain group health plan coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will pay monthly, on the Executive’s behalf, a portion of the cost of such coverage for the twelve (12) months after the Termination Date, which payments will be equal to the amount of the monthly premium for such coverage, less the amount that the Executive would have been required to pay if the Executive had remained an active employee of the Company (the “Pre-CIC COBRA Assistance”); provided, however, that if and to the extent that the Company may not provide such Pre-CIC COBRA Assistance without incurring tax penalties or violating any requirement of the law, the Company shall use its commercially reasonable best efforts to provide substantially similar assistance in an alternative manner provided that the cost of doing so does not exceed the cost that the Company would have incurred had the Pre-CIC COBRA Assistance been provided in the manner described above or cause a violation of Section 409A (as defined in Section 5.16).

 

(e) If the Executive’s employment is terminated pursuant to Section 4.1(a) during the twelve (12) months immediately following a Change in Control (as defined below) (the “Post-Change in Control Period”), the Executive shall, in full discharge of all of the Company’s obligations to the Executive (and in lieu of any payments and benefits set forth in Section 4.1(d)), be entitled to receive, and the Company’s sole obligation to the Executive under this Agreement or otherwise shall be to pay or provide to the Executive, the following:

 

(i) the Accrued Obligations;

 

-5-

 

 

(ii) full accelerated vesting of all of the Executive’s outstanding stock options, restricted stock and other equity incentive awards; and

 

(iii) subject to Section 4.4 and Section 4.5:

 

(A) payments equal to twelve (12) months of the Executive’s Base Salary (at the rate in effect immediately prior to the Termination Date) (less applicable withholdings and authorized deductions), to be paid in equal installments bimonthly in accordance with the Company’s customary payroll practices, commencing sixty (60) days following the Termination Date (the “Post-CIC Base Severance”);

 

(B) if the Executive then participates in the Company’s medical and/or dental plans and the Executive timely elects to continue and maintain group health plan coverage pursuant to COBRA, the Company will pay monthly, on the Executive’s behalf, a portion of the cost of such coverage for twelve (12) months after the Termination Date, which payments will be equal to the amount of the monthly premium for such coverage, less the amount that the Executive would have been required to pay if the Executive had remained an active employee of the Company (the “Post-CIC COBRA Assistance”); provided, however, that if and to the extent that the Company may not provide such Post-CIC COBRA Assistance without incurring tax penalties or violating any requirement of the law, the Company shall use its commercially reasonable best efforts to provide substantially similar assistance in an alternative manner provided that the cost of doing so does not exceed the cost that the Company would have incurred had the Post-CIC COBRA Assistance been provided in the manner described above or cause a violation of Section 409A; and

 

(C) a payment equal to the Executive’s Target Annual Bonus for the calendar year in which the Termination Date occurs, payable in a lump sum on the 60th day following the Termination Date (such payment, together with the Post-CIC Base Severance, the “Post-CIC Severance Payments”).

 

(f) As used in this Agreement, “Change in Control” means (x) a change in ownership of the Company under clause (i) below or (y) a change in the ownership of a substantial portion of the assets of the Company under clause (ii) below:

 

(i) Change in the Ownership of the Company. A change in the ownership of the Company shall occur on the date that any one person, or more than one person acting as a group (as defined in clause (iii) below), acquires ownership of capital stock of the Company that, together with capital stock held by such person or group, constitutes more than 50 percent of the total fair market value or total voting power of the capital stock of the Company. However, if any one person or more than one person acting as a group, is considered to own more than 50 percent of the total fair market value or total voting power of the capital stock of the Company, the acquisition of additional capital stock by the same person or persons shall not be considered to be a change in the ownership of the Company. An increase in the percentage of capital stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires capital stock in the Company in exchange for property will be treated as an acquisition of stock for purposes of this paragraph.

 

-6-

 

 

(ii) Change in the Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a substantial portion of the Company’s assets shall occur on the date that any one person, or more than one person acting as a group (as defined in clause (iii) below), acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 80 percent of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. There is no Change in Control under this clause (ii) when there is a transfer to an entity that is controlled by the shareholders of the Company immediately after the transfer, as provided below in this clause (ii). A transfer of assets by the Company is not treated as a change in the ownership of such assets if the assets are transferred to (a) a shareholder of the Company (immediately before the asset transfer) in exchange for or with respect to its capital stock, (b) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (c) a person, or more than one person acting as a group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of all the outstanding capital stock of the Company, or (d) an entity, at least 50 percent of the total value or voting power of which is owned, directly or indirectly, by a person described in clause (ii)(c) of this paragraph. For purposes of this clause (ii), a person’s status is determined immediately after the transfer of the assets.

 

(iii) Persons Acting as a Group. For purposes of clauses (i) and (ii) above, persons will not be considered to be acting as a group solely because they purchase or own capital stock or purchase assets of the Company at the same time. However, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of assets or capital stock, or similar business transaction with the Company. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of assets or capital stock, or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect to the ownership in that corporation before the transaction giving rise to the change and not with respect to the ownership interest in the other corporation. For purposes of this paragraph, the term “corporation” shall have the meaning assigned such term under Treasury Regulation section 1.280G-1, Q&A-45.

 

(iv) Each of clauses (i) through (iii) above shall be construed and interpreted consistent with the requirements of Section 409A and any Treasury Regulations or other guidance issued thereunder.

 

-7-

 

 

Section 4.2. Termination for Cause; Voluntary Termination.

 

(a) The Company may terminate the Executive’s employment hereunder at any time for Cause upon written notice to the Executive. The Executive may voluntarily terminate his employment hereunder at any time without Good Reason upon sixty (60) days prior written notice to the Company; provided, however, the Company reserves the right, upon written notice to the Executive, to accept the Executive’s notice of resignation and to accelerate such notice and make the Executive’s resignation effective immediately, or on such other date prior to Executive’s intended last day of work as the Company deems appropriate. It is understood and agreed that the Company’s election to accelerate Executive’s notice of resignation shall not be deemed a termination by the Company without Cause for purposes of Section 4.1 of this Agreement or otherwise or constitute Good Reason (as defined in Section 4.1) for purposes of Section 4.1 of this Agreement or otherwise.

 

(b) If the Executive’s employment is terminated pursuant to Section 4.2(a), the Executive shall, in full discharge of all of the Company’s obligations to the Executive, be entitled to receive, and the Company’s sole obligation under this Agreement or otherwise shall be to pay or provide to the Executive, the following (collectively, the “Accrued Obligations”):

 

(i) the Executive’s earned, but unpaid, Base Salary through the final date of the Executive’s employment by the Company (the “Termination Date”), payable in accordance with the Company’s standard payroll practices;

 

(ii) the Executive’s accrued, but unused, vacation (in accordance with the Company’s policies);

 

(iii) expenses reimbursable under Section 3.2 above incurred on or prior to the Termination Date but not yet reimbursed; and

 

(iv) any amounts or benefits that are vested amounts or vested benefits or that the Executive is otherwise entitled to receive under any plan, program, policy or practice (with the exception of those, if any, relating to severance) on the Termination Date, in accordance with such plan, program, policy, or practice.

 

Section 4.3. Termination Resulting from Death or Disability.

 

(a) As the result of any Disability suffered by the Executive, the Company may, upon five (5) days prior notice to the Executive, terminate the Executive’s employment under this Agreement. The Executive’s employment shall automatically terminate upon his death.

 

(b) “Disability” means a determination by the Company in accordance with applicable law that as a result of a physical or mental injury or illness, the Executive is unable to perform the essential functions of his job with or without reasonable accommodation for a period of (i) ninety (90) consecutive days; or (ii) one hundred twenty (120) days during any twelve (12) month period.

 

(c) If the Executive’s employment is terminated pursuant to Section 4.3(a), the Executive or the Executive’s estate, as the case may be, shall be entitled to receive, and the Company’s sole obligation under this Agreement or otherwise shall be to pay or provide to the Executive or the Executive’s estate, as the case may be, the Accrued Obligations.

 

-8-

 

 

Section 4.4. Release Agreement. In order to receive the Pre-CIC Severance Payments or the Post-CIC Severance Payments (collectively referred to herein as the “Severance Payments”) or the Pre-CIC COBRA Assistance or the Post-CIC COBRA Assistance (collectively referred to herein as the “COBRA Assistance”) set forth in Section 4.1 (if eligible), the Executive must timely execute (and not revoke) a separation agreement and general release (the “Release Agreement”) in a form as is determined to be necessary by the Company in its discretion. If the Executive is eligible for Severance Payments and COBRA Assistance pursuant to Section 4.1, the Company will deliver the Release Agreement to the Executive within seven (7) calendar days following the Termination Date. The Severance Payments and COBRA Assistance are subject to the Executive’s execution of such Release Agreement within 21 days of the Executive’s receipt of the Release Agreement and the Executive’s non-revocation of such Release Agreement.

 

Section 4.5. Post-Termination Breach. Notwithstanding anything to the contrary contained in this Agreement, the Company’s obligations to provide the Severance Payments and the COBRA Assistance will immediately cease if the Executive breaches any of the provisions of the Covenants Agreement, the Release Agreement or any other agreement the Executive has with the Company.

 

Section 4.6. Removal from any Boards and Position. If the Executive’s employment is terminated for any reason under this Agreement, he shall be deemed (without further action, deed or notice) to resign (i) if a member, from the Board or board of directors (or similar governing body) of any Affiliate of the Company or any other board to which he has been appointed or nominated by or on behalf of the Company and (ii) from all other positions with the Company or any subsidiary or other Affiliate of the Company, including, but not limited to, as an officer of the Company and any of its subsidiaries or other Affiliates.

 

ARTICLE 5
GENERAL PROVISIONS

 

Section 5.1. Company Non-Disclosure and Invention Assignment Agreement. The Executive agrees to sign and be bound by the Company’s Non-Disclosure and Invention Assignment Agreement signed contemporaneously with this Agreement (the “Covenants Agreement”), the terms of which are incorporated herein by reference. The Covenants Agreement shall survive the termination of this Agreement and the Executive’s employment by the Company for the applicable period(s) set forth therein.

 

Section 5.2. Expenses. Each of the Company and the Executive shall bear its/his own costs, fees and expenses in connection with the negotiation, preparation and execution of this Agreement.

 

-9-

 

 

Section 5.3. Entire Agreement. This Agreement and the Covenants Agreement contain the entire agreement of the parties hereto with respect to the terms and conditions of the Executive’s employment during the Term and activities following termination of this Agreement and the Executive’s employment with the Company and supersede any and all prior agreements and understandings, whether written or oral, between the parties hereto with respect to the subject matter of this Agreement or the Covenants Agreement. Each party hereto acknowledges that no representations, inducements, promises or agreements, whether oral or in writing, have been made by any party, or on behalf of any party, which are not embodied herein or in the Covenants Agreement. The Executive acknowledges and agrees that the Company has fully satisfied, and has no further, obligations to the Executive arising under, or relating to, any other employment or consulting arrangement or understanding (including, without limitation, any claims for compensation or benefits of any kind) or otherwise. No agreement, promise or statement not contained in this Agreement or the Covenants Agreement shall be valid and binding, unless agreed to in writing and signed by the parties sought to be bound thereby.

 

Section 5.4. No Other Contracts. The Executive represents and warrants to the Company that neither the execution and delivery of this Agreement by the Executive nor the performance by the Executive of the Executive’s obligations hereunder, shall constitute a default under or a breach of the terms of any other agreement, contract or other arrangement, whether written or oral, to which the Executive is a party or by which the Executive is bound, nor shall the execution and delivery of this Agreement by the Executive nor the performance by the Executive of his duties and obligations hereunder give rise to any claim or charge against either the Executive, the Company or any Affiliate, based upon any other contract or other arrangement, whether written or oral, to which the Executive is a party or by which the Executive is bound. The Executive further represents and warrants to the Company that he is not a party to or subject to any restrictive covenants, legal restrictions or other agreement, contract or arrangement, whether written or oral, in favor of any entity or person which would in any way preclude, inhibit, impair or limit the Executive’s ability to perform his obligations under this Agreement, including, but not limited to, non-competition agreements, non-solicitation agreements or confidentiality agreements. The Executive shall defend, indemnify and hold the Company harmless from and against all claims, actions, losses, liabilities, damages, costs and expenses (including reasonable attorney’s fees and amounts paid in settlement in good faith) arising from or relating to any breach of the representations and warranties made by the Executive in this Section 5.4.

 

Section 5.5. Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally or sent by nationally recognized overnight courier service (with next business day delivery requested). Any such notice or communication shall be deemed given and effective, in the case of personal delivery, upon receipt by the other party, and in the case of a courier service, upon the next business day, after dispatch of the notice or communication. Any such notice or communication shall be addressed as follows:

 

If to the Company, to:

 

Matinas BioPharma Holdings, Inc.

1545 Route 206 South, Suite 302

Bedminster NJ 07921

Attn: Chief Executive Officer

 

-10-

 

 

With a copy to:

 

Lowenstein Sandler LLP

1251 Avenue of the Americas

New York, New York 10020

Attn: Michael J. Lerner, Esq.

 

If to the Executive, to:

 

Dr. Hui Liu

_________________________

_________________________

 

With a copy to:

 

___________________

____________________

 

Any person named above may designate another address or fax number by giving notice in accordance with this Section to the other persons named above.

 

Section 5.6. Governing Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New Jersey, without regard to principles of conflicts of law. Any and all actions arising out of this Agreement or Employee’s employment by Company or termination therefrom shall be brought and heard in the state and federal courts of the State of New Jersey and the parties hereto hereby irrevocably submit to the exclusive jurisdiction of any such courts. The Company and the Executive HEREBY WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY JURY IN ANY ACTION CONCERNING THIS AGREEMENT OR ANY AND ALL MATTERS ARISING DIRECTLY OR INDIRECTLY HEREFROM AND REPRESENT THAT THEY HAVE CONSULTED WITH COUNSEL OF THEIR CHOICE OR HAVE CHOSEN VOLUNTARILY NOT TO DO SO SPECIFICALLY WITH RESEPCT TO THIS WAIVER.

 

Section 5.7. Waiver. Either party hereto may waive compliance by the other party with any provision of this Agreement. The failure of a party to insist on strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. No waiver of any provision shall be construed as a waiver of any other provision. Any waiver must be in writing.

 

Section 5.8. Severability. If any one or more of the terms, provisions, covenants and restrictions of this Agreement shall be determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated and the parties will attempt to agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid and unenforceable provision in light of the tenor of this Agreement, and, upon so agreeing, shall incorporate such substitute provision in this Agreement. In addition, if any one or more of the provisions contained in this Agreement shall for any reason be determined by a court of competent jurisdiction to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed, by limiting or reducing it, so as to be enforceable to the extent compatible with then applicable law.

 

-11-

 

 

Section 5.9. Counterparts. This Agreement may be executed in any number of counterparts and each such duplicate counterpart shall constitute an original, any one of which may be introduced in evidence or used for any other purpose without the production of its duplicate counterpart. Moreover, notwithstanding that any of the parties did not execute the same counterpart, each counterpart shall be deemed for all purposes to be an original, and all such counterparts shall constitute one and the same instrument, binding on all of the parties hereto.

 

Section 5.10. Advice of Counsel. This Agreement was prepared by Lowenstein Sandler LLP in its capacity as legal counsel to the Company. Both parties hereto acknowledge that they have had the opportunity to seek and obtain the advice of counsel before entering into this Agreement and have done so to the extent desired, and have fully read the Agreement and understand the meaning and import of all the terms hereof.

 

Section 5.11. Assignment. This Agreement shall inure to the benefit of the Company and its successors and assigns (including, without limitation, the purchaser of all or substantially all of its assets) and shall be binding upon the Company and its successors and assigns. This Agreement is personal to the Executive, and the Executive shall not assign or delegate his rights or duties under this Agreement, and any such assignment or delegation shall be null and void.

 

Section 5.12. Agreement to Take Actions. Each party to this Agreement shall execute and deliver such documents, certificates, agreements and other instruments, and shall take all other actions, as may be reasonably necessary or desirable in order to perform his or its obligations under this Agreement.

 

Section 5.13. No Attachment. Except as required by law, no right to receive payments under this Agreement shall be subject to anticipation, commutation, alienation, sale, assignment, encumbrance, charge, pledge, or hypothecation or to execution, attachment, levy or similar process or assignment by operation of law, and any attempt, voluntary or involuntary, to effect any such action shall be null, void and of no effect; provided, however, that nothing in this Section 5.13 shall preclude the assumption of such rights by executors, administrators or other legal representatives of the Executive or the Executive’s estate and their assigning any rights hereunder to the person or persons entitled thereto.

 

Section 5.14. Source of Payment. Except as otherwise provided under the terms of any applicable employee benefit plan, all payments provided for under this Agreement shall be paid in cash from the general funds of Company. The Company shall not be required to establish a special or separate fund or other segregation of assets to assure such payments, and, if the Company shall make any investments to aid it in meeting its obligations hereunder, the Executive shall have no right, title or interest whatever in or to any such investments except as may otherwise be expressly provided in a separate written instrument relating to such investments. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship, between Company and the Executive or any other person. To the extent that any person acquires a right to receive payments from Company hereunder, such right, without prejudice to rights which employees may have, shall be no greater than the right of an unsecured creditor of Company. The Executive shall not look to the owners of the Company for the satisfaction of any obligations of the Company under this Agreement.

 

-12-

 

 

Section 5.15. Tax Withholding. The Company or other payor is authorized to withhold from any benefit provided or payment due hereunder, the amount of withholding taxes due any federal, state or local authority in respect of such benefit or payment and to take such other action as may be necessary in the opinion of the Board to satisfy all obligations for the payment of such withholding taxes. The Executive will be solely responsible for all taxes assessed against him with respect to the compensation and benefits described in this Agreement, other than typical employer-paid taxes such as FICA, and the Company makes no representations as to the tax treatment of such compensation and benefits.

 

Section 5.16. 409A Compliance. All payments under this Agreement are intended to comply with or be exempt from the requirements of Section 409A of the Code and regulations promulgated thereunder (“Section 409A”). As used in this Agreement, the “Code” means the Internal Revenue Code of 1986, as amended. To the extent permitted under applicable regulations and/or other guidance of general applicability issued pursuant to Section 409A, the Company reserves the right to modify this Agreement to conform with any or all relevant provisions regarding compensation and/or benefits so that such compensation and benefits are exempt from the provisions of 409A and/or otherwise comply with such provisions so as to avoid the tax consequences set forth in Section 409A and to assure that no payment or benefit shall be subject to an “additional tax” under Section 409A. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A, or to the extent any provision in this Agreement must be modified to comply with Section 409A, such provision shall be read in such a manner so that no payment due to the Executive shall be subject to an “additional tax” within the meaning of Section 409A(a)(1)(B) of the Code. If necessary to comply with the restriction in Section 409A(a)(2)(B) of the Code concerning payments to “specified employees,” any payment on account of the Executive’s separation from service that would otherwise be due hereunder within six (6) months after such separation shall be delayed until the first business day of the seventh month following the Termination Date and the first such payment shall include the cumulative amount of any payments (without interest) that would have been paid prior to such date if not for such restriction. Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no event may the Executive, directly or indirectly, designate the calendar year of payment. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit. Notwithstanding anything contained herein to the contrary, the Executive shall not be considered to have terminated employment with the Company for purposes of Section 4.1 unless the Executive would be considered to have incurred a “termination of employment” from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii). In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Executive by Section 409A or damages for failing to comply with Section 409A.

 

-13-

 

 

Section 5.17. 280G Modified Cutback.

 

(a) If any payment, benefit or distribution of any type to or for the benefit of the Executive, whether paid or payable, provided or to be provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (collectively, the “Parachute Payments”) would subject the Executive to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), the Parachute Payments shall be reduced so that the maximum amount of the Parachute Payments (after reduction) shall be one dollar ($1.00) less than the amount which would cause the Parachute Payments to be subject to the Excise Tax; provided that the Parachute Payments shall only be reduced to the extent the after-tax value of amounts received by the Executive after application of the above reduction would exceed the after-tax value of the amounts received without application of such reduction. For this purpose, the after-tax value of an amount shall be determined taking into account all federal, state, and local income, employment and excise taxes applicable to such amount. Unless the Executive shall have given prior written notice to the Company to effectuate a reduction in the Parachute Payments if such a reduction is required, which notice shall be consistent with the requirements of Section 409A to avoid the imputation of any tax, penalty or interest thereunder, then the Company shall reduce or eliminate the Parachute Payments by first reducing or eliminating accelerated vesting of stock options or similar awards, then reducing or eliminating any cash payments (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any other remaining Parachute Payments; provided, that no such reduction or elimination shall apply to any non-qualified deferred compensation amounts (within the meaning of Section 409A) to the extent such reduction or elimination would accelerate or defer the timing of such payment in manner that does not comply with Section 409A.

 

(b) An initial determination as to whether (x) any of the Parachute Payments received by the Executive in connection with the occurrence of a change in the ownership or control of the Company or in the ownership of a substantial portion of the assets of the Company shall be subject to the Excise Tax, and (y) the amount of any reduction, if any, that may be required pursuant to the previous paragraph, shall be made by an independent accounting firm selected by the Company (the “Accounting Firm”) prior to the consummation of such change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company. The Executive shall be furnished with notice of all determinations made as to the Excise Tax payable with respect to the Executive’s Parachute Payments, together with the related calculations of the Accounting Firm, promptly after such determinations and calculations have been received by the Company.

 

(c) For purposes of this Section 5.17, (i) no portion of the Parachute Payments the receipt or enjoyment of which the Executive shall have effectively waived in writing prior to the date of payment of the Parachute Payments shall be taken into account; (ii) no portion of the Parachute Payments shall be taken into account which in the opinion of the Accounting Firm does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code; (iii) the Parachute Payments shall be reduced only to the extent necessary so that the Parachute Payments (other than those referred to in the immediately preceding clause (i) or (ii)) in their entirety constitute reasonable compensation for services actually rendered within the meaning of Section 280G(b)(4) of the Code or are otherwise not subject to disallowance as deductions, in the opinion of the auditor or tax counsel referred to in such clause (ii); and (iv) the value of any non-cash benefit or any deferred payment or benefit included in the Parachute Payments shall be determined by the Company’s independent auditors based on Sections 280G and 4999 of the Code and the regulations for applying those sections of the Code, or on substantial authority within the meaning of Section 6662 of the Code.

 

[Signature Page Follows]

 

-14-

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

 

  COMPANY
   
  Matinas BioPharma Holdings, Inc.
     
  By:

/s/ Jerome D. Jabbour

  Name:  Jerome D. Jabbour
  Title: Chief Executive Officer
     
  EXECUTIVE
     
     /s/ Dr. Hui Liu
  Dr. Hui Liu

 

[Signature Page to Employment Agreement]

 

 

 

 EX-10.16 4 ex10-16.htm

 

Exhibit 10.16

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (this “Agreement”), entered into on December 3, 2021 with the commencement of employment to begin as of December 6, 2021 (the “Commencement Date”), is by and between MATINAS BIOPHARMA HOLDINGS, INC., a Delaware corporation (the “Company”) and Thomas Hoover (the “Executive”).

 

W I T N E S S E T H:

 

WHEREAS, the Company desires to employ the Executive as its Senior Vice President and Chief Business Officer and the Executive desires to accept such employment, on the terms and conditions set forth in this Agreement; and

 

WHEREAS, the Company and the Executive have mutually agreed that, as of the Commencement Date, this Agreement shall govern the terms of employment between the Executive and the Company.

 

NOW, THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

 

ARTICLE 1
Employment;TERM OF AGREEMENT

 

Section 1.1. Employment and Acceptance. During the Term (as defined in Section 1.2), the Company shall employ the Executive, and the Executive shall accept such employment and serve the Company, in each case, subject to the terms and conditions of this Agreement.

 

Section 1.2. Term. The employment relationship hereunder shall be for the period commencing on the Commencement Date and continue until it is terminated by either the Company or the Executive in accordance with ARTICLE 4 (the “Term”). In the event that the Executive’s employment with the Company terminates, the Company’s obligation to continue to pay, after the Termination Date (as defined in Section 4.2(b)), Base Salary (as defined in Section 3.1(a)), Annual Bonus (as defined in Section 3.1(b)) and other unaccrued benefits shall terminate, except as may be provided for in ARTICLE 4.

 

ARTICLE 2
TITLE; DUTIES AND OBLIGATIONS; LOCATION

 

Section 2.1. Title. The Company shall employ the Executive to render exclusive and full-time services to the Company. The Executive shall serve in the capacity of Senior Vice President and Chief Business Officer.

 

 

 

 

Section 2.2. Duties. The Executive shall report to the Company’s Chief Executive Officer (“CEO”). The Executive agrees to perform to the best of his ability, experience and talent those acts and duties, consistent with his position as the CEO shall from time to time direct. During the Term, the Executive also shall serve in such other executive-level positions or capacities as may, from time to time, be reasonably requested by the Company including, without limitation (subject to election, appointment, re-election or re-appointment, as applicable) as (a) an officer of any of the Company’s subsidiaries or other Affiliates, and/or (b) a member of any committee of the Company and/or any of its subsidiaries or other Affiliates, in each case, for no additional compensation. As used in this Agreement, “Affiliate” of any individual or entity means any other individual or entity that directly or individual controls, is controlled by, or is under common control with, the individual or entity.

 

Section 2.3. Compliance with Policies, etc. During the Term, the Executive shall be bound by, and comply fully with, all of the Company’s policies and procedures for employees and officers in place from time to time, including, but not limited to, all terms and conditions set forth in the Company’s employee handbook, compliance manual, codes of conduct and any other memoranda and communications applicable to the Executive pertaining to the policies, procedures, rules and regulations, as currently in effect and as may be amended from time to time. These policies and procedures include, among other things and without limitation, the Executive’s obligations to comply with the Company’s rules regarding confidential and proprietary information and trade secrets.

 

Section 2.4. Time Commitment. During the Term, the Executive shall use his best efforts to promote the interests of the Company (including its subsidiaries and other Affiliates) and shall devote all of his business time, ability and attention to the performance of his duties for the Company and shall not, directly or indirectly, render any services to any other person or organization, whether for compensation or otherwise, except with the Board’s prior written consent or as specified on Exhibit C of the Covenants Agreement (as defined in Section 5.1), provided that the foregoing shall not prevent the Executive from (i) participating in charitable, civic, educational, professional, community or industry affairs, or (ii) managing the Executive’s passive personal investments, so long as, in each case, such activities individually or in the aggregate do not materially interfere or conflict with the Executive’s duties hereunder or create a potential business or fiduciary conflict (in each case, as determined by the Board).

 

Section 2.5. Location. The Executive’s principal place of business for the performance of his duties under this Agreement shall be remote at his home in Massachusetts but he will periodically commute to the principal executive office of the Company, currently located in Bedminster, NJ. Notwithstanding, the foregoing, the Executive shall be required to travel as necessary to perform his duties hereunder.

 

ARTICLE 3
COMPENSATION AND BENEFITS; EXPENSES

 

Section 3.1. Compensation and Benefits. For all services rendered by the Executive in any capacity during the Term (including, without limitation, serving as an officer, director or member of any committee of the Company or any of its subsidiaries or other Affiliates), the Executive shall be compensated as follows (subject, in each case, to the provisions of Article 4 below):

 

(a) Base Salary. The Company shall pay the Executive a base salary (the “Base Salary”) at the annualized rate of $412,000, which shall be subject to customary withholdings and authorized deductions and be payable in equal installments in accordance with the Company’s customary payroll practices in place from time to time. The Executive’s Base Salary shall be subject to periodic adjustments as the Board and/or the Compensation Committee of the Board (the “Compensation Committee”) shall in its/their discretion deem appropriate. As used in this Agreement, the term “Base Salary” shall refer to Base Salary as may be adjusted from time to time. 

 

2

 

 

(b) Annual Bonus. For each calendar year ending during the Term, the Executive shall be eligible to receive an annual bonus (the “Annual Bonus”) with a target amount equal to forty percent (40%) of the Base Salary earned by the Executive for such calendar year (the “Target Annual Bonus”). The actual amount of each Annual Bonus will be based upon the level of achievement of the Company’s corporate objectives and the Executive’s individual objectives, in each case, as established by the Board or the Compensation Committee for the calendar year with respect to which such Annual Bonus relates. The determination of the level of achievement of the corporate objectives and the Executive’s individual performance objectives for a year shall be made by the Board or the Compensation Committee, in its sole discretion. Each Annual Bonus for a calendar year, to the extent earned, will be paid in a lump sum in the following calendar year, within the first 75 days of such following year. The Annual Bonus shall not be deemed earned until the date that it is paid. Accordingly, in order for the Executive to receive an Annual Bonus, the Executive must be actively employed by the Company at the time of such payment.

 

(c) Equity Compensation. Subject to the approval of the Board or the Compensation Committee, the Company will recommend a grant to the Executive of options to purchase up to 850,000 shares of the Company’s common stock pursuant to the Company’s 2013 Equity Compensation Plan, as amended and restated (the “2013 Plan”), on the terms and conditions determined by the Compensation Committee (the “Option”). The Option shall vest over four (4) years as follows: 25% of the shares subject to the Option shall vest on the one-year anniversary of the Commencement Date, and the remaining 75% of the shares subject to the Option will vest in equal monthly installments over the following thirty-six (36) months. During the Term, subject to the terms and conditions established within the 2013 Plan or any successor equity compensation plan as may be in place from time to time and separate Award Agreements (as defined in the 2013 Plan), the Executive also shall be eligible to receive from time to time additional Stock Options, Stock Unit Awards, Performance Shares, Performance Units, Incentive Bonus Awards, Other Cash-Based Awards and/or Other Stock-Based Awards (as such capitalized terms are defined in the 2013 Plan), in amounts, if any, to be approved by the Board or the Compensation Committee in its discretion.

 

(d) Benefit Plans. The Executive shall be entitled to participate in all employee benefit plans and programs (excluding severance plans, if any) generally made available by the Company to senior executives of the Company, to the extent permissible under the general terms and provisions of such plans or programs and in accordance with the provisions thereof. The Company may amend, modify or rescind any employee benefit plan or program and/or change employee contribution amounts to benefit costs without notice in its discretion.

 

(e) Paid Vacation. The Executive shall be entitled to paid vacation days in accordance with the Company’s vacation policies in effect from time to time for its executive team; provided, however, that the Executive shall be entitled to no less than fifteen (15) paid vacation days per calendar year during the Term.

 

3

 

 

Section 3.2. Expense Reimbursement. The Company shall reimburse the Executive during the Term, in accordance with the Company’s expense reimbursement policies in place from time, for all reasonable out-of-pocket business expenses incurred by the Executive in the performance of his duties hereunder (including without limitation all reasonable and preapproved expenses for commuting between the Executive’s home in Massachusetts and the Company’s offices in New Jersey). In order to receive such reimbursement, the Executive shall furnish to the Company documentary evidence of each such expense in the form required to comply with the Company’s policies in place from time to time.

 

ARTICLE 4
TERMINATION OF EMPLOYMENT

 

Section 4.1. Termination Without Cause or Resignation for Good Reason.

 

(a) The Company may terminate the Executive’s employment hereunder at any time without Cause (other than by reason of death or Disability) upon five (5) days prior written notice to the Executive. Executive may terminate his employment hereunder for Good Reason upon written notice to the Company in accordance with the provisions set forth in Section 4.1(c).

 

(b) As used in this Agreement, “Cause” means: (i) a material act, or act of fraud, committed by the Executive that is intended to result in the Executive’s personal enrichment to the detriment or at the expense of the Company or any of its Affiliates; (ii) the Executive is convicted of a felony; (iii) gross negligence or willful misconduct by the Executive, or failure by the Executive to perform the duties or obligations reasonably assigned to the Executive by the Board or the CEO from time to time, which is not cured upon ten (10) days prior written notice (unless such negligence, misconduct or failure is not susceptible to cure, as determined in the reasonable discretion of the Board); or (iv) the Executive violates the Covenants Agreement (as defined in Section 5.1 below).

 

(c) As used in this Agreement, “Good Reason” means the occurrence of any of the following: (1) a material breach by the Company of the terms of this Agreement; (2) a material reduction in the Executive’s Base Salary; or (3) a material change by the Company in the geographic location at which the Executive performs services for the Company; provided, however, that the Executive must notify the Company within ninety (90) days of the occurrence of any of the foregoing conditions that he considers it to be a “Good Reason” condition and provide the Company with at least thirty (30) days in which to cure the condition. If the Executive fails to provide this notice and cure period prior to his resignation, or resigns more than six (6) months after the initial existence of the condition, his resignation will not be deemed to be for “Good Reason.”

 

4

 

 

(d) If the Executive’s employment is terminated pursuant to Section 4.1(a) other than during the Post-Change in Control Period (as defined in Section 4.1(e)), the Executive shall, in full discharge of all of the Company’s obligations to the Executive, be entitled to receive, and the Company’s sole obligation to the Executive under this Agreement or otherwise shall be to pay or provide to the Executive, the following:

 

(i) the Accrued Obligations (as defined in Section 4.2(b)); and

 

(ii) subject to Section 4.4 and Section 4.5:

 

(A) payments equal to twelve (12) months of the Executive’s Base Salary (at the rate in effect immediately prior to the Termination Date) (less applicable withholdings and authorized deductions), to be paid in equal installments bimonthly in accordance with the Company’s customary payroll practices, commencing sixty (60) days following the Termination Date (the “Pre-CIC Severance Payments”); and

 

(B) if the Executive then participates in the Company’s medical and/or dental plans and the Executive timely elects to continue and maintain group health plan coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will pay monthly, on the Executive’s behalf, a portion of the cost of such coverage for the twelve (12) months after the Termination Date, which payments will be equal to the amount of the monthly premium for such coverage, less the amount that the Executive would have been required to pay if the Executive had remained an active employee of the Company (the “Pre-CIC COBRA Assistance”); provided, however, that if and to the extent that the Company may not provide such Pre-CIC COBRA Assistance without incurring tax penalties or violating any requirement of the law, the Company shall use its commercially reasonable best efforts to provide substantially similar assistance in an alternative manner provided that the cost of doing so does not exceed the cost that the Company would have incurred had the Pre-CIC COBRA Assistance been provided in the manner described above or cause a violation of Section 409A (as defined in Section 5.16).

 

(e) If the Executive’s employment is terminated pursuant to Section 4.1(a) during the twelve (12) months immediately following a Change in Control (as defined below) (the “Post-Change in Control Period”), the Executive shall, in full discharge of all of the Company’s obligations to the Executive (and in lieu of any payments and benefits set forth in Section 4.1(d)), be entitled to receive, and the Company’s sole obligation to the Executive under this Agreement or otherwise shall be to pay or provide to the Executive, the following:

 

(i) the Accrued Obligations;

 

(ii) full accelerated vesting of all of the Executive’s outstanding stock options, restricted stock and other equity incentive awards; and

 

(iii) subject to Section 4.4 and Section 4.5:

 

(A) payments equal to twelve (12) months of the Executive’s Base Salary (at the rate in effect immediately prior to the Termination Date) (less applicable withholdings and authorized deductions), to be paid in equal installments bimonthly in accordance with the Company’s customary payroll practices, commencing sixty (60) days following the Termination Date (the “Post-CIC Base Severance”);

 

5

 

 

(B) if the Executive then participates in the Company’s medical and/or dental plans and the Executive timely elects to continue and maintain group health plan coverage pursuant to COBRA, the Company will pay monthly, on the Executive’s behalf, a portion of the cost of such coverage for twelve (12) months after the Termination Date, which payments will be equal to the amount of the monthly premium for such coverage, less the amount that the Executive would have been required to pay if the Executive had remained an active employee of the Company (the “Post-CIC COBRA Assistance”); provided, however, that if and to the extent that the Company may not provide such Post-CIC COBRA Assistance without incurring tax penalties or violating any requirement of the law, the Company shall use its commercially reasonable best efforts to provide substantially similar assistance in an alternative manner provided that the cost of doing so does not exceed the cost that the Company would have incurred had the Post-CIC COBRA Assistance been provided in the manner described above or cause a violation of Section 409A; and

 

(C) a payment equal to the Executive’s Target Annual Bonus for the calendar year in which the Termination Date occurs, payable in a lump sum on the 60th day following the Termination Date (such payment, together with the Post-CIC Base Severance, the “Post-CIC Severance Payments”).

 

(f) As used in this Agreement, “Change in Control” means (x) a change in ownership of the Company under clause (i) below or (y) a change in the ownership of a substantial portion of the assets of the Company under clause (ii) below:

 

(i) Change in the Ownership of the Company. A change in the ownership of the Company shall occur on the date that any one person, or more than one person acting as a group (as defined in clause (iii) below), acquires ownership of capital stock of the Company that, together with capital stock held by such person or group, constitutes more than 50 percent of the total fair market value or total voting power of the capital stock of the Company. However, if any one person or more than one person acting as a group, is considered to own more than 50 percent of the total fair market value or total voting power of the capital stock of the Company, the acquisition of additional capital stock by the same person or persons shall not be considered to be a change in the ownership of the Company. An increase in the percentage of capital stock owned by any one person, or persons acting as a group, as a result of a transaction in which the Company acquires capital stock in the Company in exchange for property will be treated as an acquisition of stock for purposes of this paragraph.

 

6

 

 

(ii) Change in the Ownership of a Substantial Portion of the Company’s Assets. A change in the ownership of a substantial portion of the Company’s assets shall occur on the date that any one person, or more than one person acting as a group (as defined in clause (iii) below), acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 80 percent of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. There is no Change in Control under this clause (ii) when there is a transfer to an entity that is controlled by the shareholders of the Company immediately after the transfer, as provided below in this clause (ii). A transfer of assets by the Company is not treated as a change in the ownership of such assets if the assets are transferred to (a) a shareholder of the Company (immediately before the asset transfer) in exchange for or with respect to its capital stock, (b) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (c) a person, or more than one person acting as a group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of all the outstanding capital stock of the Company, or (d) an entity, at least 50 percent of the total value or voting power of which is owned, directly or indirectly, by a person described in clause (ii)(c) of this paragraph. For purposes of this clause (ii), a person’s status is determined immediately after the transfer of the assets.

 

(iii) Persons Acting as a Group. For purposes of clauses (i) and (ii) above, persons will not be considered to be acting as a group solely because they purchase or own capital stock or purchase assets of the Company at the same time. However, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of assets or capital stock, or similar business transaction with the Company. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of assets or capital stock, or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a corporation only with respect to the ownership in that corporation before the transaction giving rise to the change and not with respect to the ownership interest in the other corporation. For purposes of this paragraph, the term “corporation” shall have the meaning assigned such term under Treasury Regulation section 1.280G-1, Q&A-45.

 

(iv) Each of clauses (i) through (iii) above shall be construed and interpreted consistent with the requirements of Section 409A and any Treasury Regulations or other guidance issued thereunder.

 

Section 4.2. Termination for Cause; Voluntary Termination.

 

(a) The Company may terminate the Executive’s employment hereunder at any time for Cause upon written notice to the Executive. The Executive may voluntarily terminate his employment hereunder at any time without Good Reason upon sixty (60) days prior written notice to the Company; provided, however, the Company reserves the right, upon written notice to the Executive, to accept the Executive’s notice of resignation and to accelerate such notice and make the Executive’s resignation effective immediately, or on such other date prior to Executive’s intended last day of work as the Company deems appropriate. It is understood and agreed that the Company’s election to accelerate Executive’s notice of resignation shall not be deemed a termination by the Company without Cause for purposes of Section 4.1 of this Agreement or otherwise or constitute Good Reason (as defined in Section 4.1) for purposes of Section 4.1 of this Agreement or otherwise.

 

7

 

 

(b) If the Executive’s employment is terminated pursuant to Section 4.2(a), the Executive shall, in full discharge of all of the Company’s obligations to the Executive, be entitled to receive, and the Company’s sole obligation under this Agreement or otherwise shall be to pay or provide to the Executive, the following (collectively, the “Accrued Obligations”):

 

(i) the Executive’s earned, but unpaid, Base Salary through the final date of the Executive’s employment by the Company (the “Termination Date”), payable in accordance with the Company’s standard payroll practices;

 

(ii) the Executive’s accrued, but unused, vacation (in accordance with the Company’s policies);

 

(iii) expenses reimbursable under Section 3.2 above incurred on or prior to the Termination Date but not yet reimbursed; and

 

(iv) any amounts or benefits that are vested amounts or vested benefits or that the Executive is otherwise entitled to receive under any plan, program, policy or practice (with the exception of those, if any, relating to severance) on the Termination Date, in accordance with such plan, program, policy, or practice.

 

Section 4.3. Termination Resulting from Death or Disability.

 

(a) As the result of any Disability suffered by the Executive, the Company may, upon five (5) days prior notice to the Executive, terminate the Executive’s employment under this Agreement. The Executive’s employment shall automatically terminate upon his death.

 

(b) “Disability” means a determination by the Company in accordance with applicable law that as a result of a physical or mental injury or illness, the Executive is unable to perform the essential functions of his job with or without reasonable accommodation for a period of (i) ninety (90) consecutive days; or (ii) one hundred twenty (120) days during any twelve (12) month period.

 

(c) If the Executive’s employment is terminated pursuant to Section 4.3(a), the Executive or the Executive’s estate, as the case may be, shall be entitled to receive, and the Company’s sole obligation under this Agreement or otherwise shall be to pay or provide to the Executive or the Executive’s estate, as the case may be, the Accrued Obligations.

 

Section 4.4. Release Agreement. In order to receive the Pre-CIC Severance Payments or the Post-CIC Severance Payments (collectively referred to herein as the “Severance Payments”) or the Pre-CIC COBRA Assistance or the Post-CIC COBRA Assistance (collectively referred to herein as the “COBRA Assistance”) set forth in Section 4.1 (if eligible), the Executive must timely execute (and not revoke) a separation agreement and general release (the “Release Agreement”) in a form as is determined to be necessary by the Company in its discretion. If the Executive is eligible for Severance Payments and COBRA Assistance pursuant to Section 4.1, the Company will deliver the Release Agreement to the Executive within seven (7) calendar days following the Termination Date. The Severance Payments and COBRA Assistance are subject to the Executive’s execution of such Release Agreement within 21 days of the Executive’s receipt of the Release Agreement and the Executive’s non-revocation of such Release Agreement.

 

8

 

 

Section 4.5. Post-Termination Breach. Notwithstanding anything to the contrary contained in this Agreement, the Company’s obligations to provide the Severance Payments and the COBRA Assistance will immediately cease if the Executive breaches any of the provisions of the Covenants Agreement, the Release Agreement or any other agreement the Executive has with the Company.

 

Section 4.6. Removal from any Boards and Position. If the Executive’s employment is terminated for any reason under this Agreement, he shall be deemed (without further action, deed or notice) to resign (i) if a member, from the Board or board of directors (or similar governing body) of any Affiliate of the Company or any other board to which he has been appointed or nominated by or on behalf of the Company and (ii) from all other positions with the Company or any subsidiary or other Affiliate of the Company, including, but not limited to, as an officer of the Company and any of its subsidiaries or other Affiliates.

 

ARTICLE 5
GENERAL PROVISIONS

 

Section 5.1. Company Non-Disclosure and Invention Assignment Agreement. The Executive agrees to sign and be bound by the Company’s Non-Disclosure and Invention Assignment Agreement signed contemporaneously with this Agreement (the “Covenants Agreement”), the terms of which are incorporated herein by reference. The Covenants Agreement shall survive the termination of this Agreement and the Executive’s employment by the Company for the applicable period(s) set forth therein.

 

Section 5.2. Expenses. Each of the Company and the Executive shall bear its/his own costs, fees and expenses in connection with the negotiation, preparation and execution of this Agreement.

 

Section 5.3. Entire Agreement. This Agreement and the Covenants Agreement contain the entire agreement of the parties hereto with respect to the terms and conditions of the Executive’s employment during the Term and activities following termination of this Agreement and the Executive’s employment with the Company and supersede any and all prior agreements and understandings, whether written or oral, between the parties hereto with respect to the subject matter of this Agreement or the Covenants Agreement. Each party hereto acknowledges that no representations, inducements, promises or agreements, whether oral or in writing, have been made by any party, or on behalf of any party, which are not embodied herein or in the Covenants Agreement. The Executive acknowledges and agrees that the Company has fully satisfied, and has no further, obligations to the Executive arising under, or relating to, any other employment or consulting arrangement or understanding (including, without limitation, any claims for compensation or benefits of any kind) or otherwise. No agreement, promise or statement not contained in this Agreement or the Covenants Agreement shall be valid and binding, unless agreed to in writing and signed by the parties sought to be bound thereby.

 

9

 

 

Section 5.4. No Other Contracts. The Executive represents and warrants to the Company that neither the execution and delivery of this Agreement by the Executive nor the performance by the Executive of the Executive’s obligations hereunder, shall constitute a default under or a breach of the terms of any other agreement, contract or other arrangement, whether written or oral, to which the Executive is a party or by which the Executive is bound, nor shall the execution and delivery of this Agreement by the Executive nor the performance by the Executive of his duties and obligations hereunder give rise to any claim or charge against either the Executive, the Company or any Affiliate, based upon any other contract or other arrangement, whether written or oral, to which the Executive is a party or by which the Executive is bound. The Executive further represents and warrants to the Company that he is not a party to or subject to any restrictive covenants, legal restrictions or other agreement, contract or arrangement, whether written or oral, in favor of any entity or person which would in any way preclude, inhibit, impair or limit the Executive’s ability to perform his obligations under this Agreement, including, but not limited to, non-competition agreements, non-solicitation agreements or confidentiality agreements. The Executive shall defend, indemnify and hold the Company harmless from and against all claims, actions, losses, liabilities, damages, costs and expenses (including reasonable attorney’s fees and amounts paid in settlement in good faith) arising from or relating to any breach of the representations and warranties made by the Executive in this Section 5.4.

 

Section 5.5. Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally or sent by nationally recognized overnight courier service (with next business day delivery requested). Any such notice or communication shall be deemed given and effective, in the case of personal delivery, upon receipt by the other party, and in the case of a courier service, upon the next business day, after dispatch of the notice or communication. Any such notice or communication shall be addressed as follows:

 

If to the Company, to:

 

Matinas BioPharma Holdings, Inc.

1545 Route 206 South, Suite 302

Bedminster NJ 07921

Attn: Chief Executive Officer

 

With a copy to:

 

Lowenstein Sandler LLP

1251 Avenue of the Americas

New York, New York 10020

Attn: Michael J. Lerner, Esq.

 

If to the Executive, to:

 

Thomas Hoover

141 Southfield Rd.

Concord, MA 01742

 

With a copy to:

 

___________________

____________________

 

10

 

 

Any person named above may designate another address or fax number by giving notice in accordance with this Section to the other persons named above.

 

Section 5.6. Governing Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New Jersey, without regard to principles of conflicts of law. Any and all actions arising out of this Agreement or Employee’s employment by Company or termination therefrom shall be brought and heard in the state and federal courts of the State of New Jersey and the parties hereto hereby irrevocably submit to the exclusive jurisdiction of any such courts. The Company and the Executive HEREBY WAIVE THEIR RESPECTIVE RIGHT TO TRIAL BY JURY IN ANY ACTION CONCERNING THIS AGREEMENT OR ANY AND ALL MATTERS ARISING DIRECTLY OR INDIRECTLY HEREFROM AND REPRESENT THAT THEY HAVE CONSULTED WITH COUNSEL OF THEIR CHOICE OR HAVE CHOSEN VOLUNTARILY NOT TO DO SO SPECIFICALLY WITH RESEPCT TO THIS WAIVER.

 

Section 5.7. Waiver. Either party hereto may waive compliance by the other party with any provision of this Agreement. The failure of a party to insist on strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. No waiver of any provision shall be construed as a waiver of any other provision. Any waiver must be in writing.

 

Section 5.8. Severability. If any one or more of the terms, provisions, covenants and restrictions of this Agreement shall be determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated and the parties will attempt to agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid and unenforceable provision in light of the tenor of this Agreement, and, upon so agreeing, shall incorporate such substitute provision in this Agreement. In addition, if any one or more of the provisions contained in this Agreement shall for any reason be determined by a court of competent jurisdiction to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed, by limiting or reducing it, so as to be enforceable to the extent compatible with then applicable law.

 

Section 5.9. Counterparts. This Agreement may be executed in any number of counterparts and each such duplicate counterpart shall constitute an original, any one of which may be introduced in evidence or used for any other purpose without the production of its duplicate counterpart. Moreover, notwithstanding that any of the parties did not execute the same counterpart, each counterpart shall be deemed for all purposes to be an original, and all such counterparts shall constitute one and the same instrument, binding on all of the parties hereto.

 

Section 5.10. Advice of Counsel. This Agreement was prepared by Lowenstein Sandler LLP in its capacity as legal counsel to the Company. Both parties hereto acknowledge that they have had the opportunity to seek and obtain the advice of counsel before entering into this Agreement and have done so to the extent desired, and have fully read the Agreement and understand the meaning and import of all the terms hereof.

 

11

 

 

Section 5.11. Assignment. This Agreement shall inure to the benefit of the Company and its successors and assigns (including, without limitation, the purchaser of all or substantially all of its assets) and shall be binding upon the Company and its successors and assigns. This Agreement is personal to the Executive, and the Executive shall not assign or delegate his rights or duties under this Agreement, and any such assignment or delegation shall be null and void.

 

Section 5.12. Agreement to Take Actions. Each party to this Agreement shall execute and deliver such documents, certificates, agreements and other instruments, and shall take all other actions, as may be reasonably necessary or desirable in order to perform his or its obligations under this Agreement.

 

Section 5.13. No Attachment. Except as required by law, no right to receive payments under this Agreement shall be subject to anticipation, commutation, alienation, sale, assignment, encumbrance, charge, pledge, or hypothecation or to execution, attachment, levy or similar process or assignment by operation of law, and any attempt, voluntary or involuntary, to effect any such action shall be null, void and of no effect; provided, however, that nothing in this Section 5.13 shall preclude the assumption of such rights by executors, administrators or other legal representatives of the Executive or the Executive’s estate and their assigning any rights hereunder to the person or persons entitled thereto.

 

Section 5.14. Source of Payment. Except as otherwise provided under the terms of any applicable employee benefit plan, all payments provided for under this Agreement shall be paid in cash from the general funds of Company. The Company shall not be required to establish a special or separate fund or other segregation of assets to assure such payments, and, if the Company shall make any investments to aid it in meeting its obligations hereunder, the Executive shall have no right, title or interest whatever in or to any such investments except as may otherwise be expressly provided in a separate written instrument relating to such investments. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship, between Company and the Executive or any other person. To the extent that any person acquires a right to receive payments from Company hereunder, such right, without prejudice to rights which employees may have, shall be no greater than the right of an unsecured creditor of Company. The Executive shall not look to the owners of the Company for the satisfaction of any obligations of the Company under this Agreement.

 

Section 5.15. Tax Withholding. The Company or other payor is authorized to withhold from any benefit provided or payment due hereunder, the amount of withholding taxes due any federal, state or local authority in respect of such benefit or payment and to take such other action as may be necessary in the opinion of the Board to satisfy all obligations for the payment of such withholding taxes. The Executive will be solely responsible for all taxes assessed against him with respect to the compensation and benefits described in this Agreement, other than typical employer-paid taxes such as FICA, and the Company makes no representations as to the tax treatment of such compensation and benefits.

 

12

 

 

Section 5.16. 409A Compliance. All payments under this Agreement are intended to comply with or be exempt from the requirements of Section 409A of the Code and regulations promulgated thereunder (“Section 409A”). As used in this Agreement, the “Code” means the Internal Revenue Code of 1986, as amended. To the extent permitted under applicable regulations and/or other guidance of general applicability issued pursuant to Section 409A, the Company reserves the right to modify this Agreement to conform with any or all relevant provisions regarding compensation and/or benefits so that such compensation and benefits are exempt from the provisions of 409A and/or otherwise comply with such provisions so as to avoid the tax consequences set forth in Section 409A and to assure that no payment or benefit shall be subject to an “additional tax” under Section 409A. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A, or to the extent any provision in this Agreement must be modified to comply with Section 409A, such provision shall be read in such a manner so that no payment due to the Executive shall be subject to an “additional tax” within the meaning of Section 409A(a)(1)(B) of the Code. If necessary to comply with the restriction in Section 409A(a)(2)(B) of the Code concerning payments to “specified employees,” any payment on account of the Executive’s separation from service that would otherwise be due hereunder within six (6) months after such separation shall be delayed until the first business day of the seventh month following the Termination Date and the first such payment shall include the cumulative amount of any payments (without interest) that would have been paid prior to such date if not for such restriction. Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A. In no event may the Executive, directly or indirectly, designate the calendar year of payment. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit. Notwithstanding anything contained herein to the contrary, the Executive shall not be considered to have terminated employment with the Company for purposes of Section 4.1 unless the Executive would be considered to have incurred a “termination of employment” from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii). In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Executive by Section 409A or damages for failing to comply with Section 409A.

 

Section 5.17. 280G Modified Cutback.

 

(a) If any payment, benefit or distribution of any type to or for the benefit of the Executive, whether paid or payable, provided or to be provided, or distributed or distributable pursuant to the terms of this Agreement or otherwise (collectively, the “Parachute Payments”) would subject the Executive to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), the Parachute Payments shall be reduced so that the maximum amount of the Parachute Payments (after reduction) shall be one dollar ($1.00) less than the amount which would cause the Parachute Payments to be subject to the Excise Tax; provided that the Parachute Payments shall only be reduced to the extent the after-tax value of amounts received by the Executive after application of the above reduction would exceed the after-tax value of the amounts received without application of such reduction. For this purpose, the after-tax value of an amount shall be determined taking into account all federal, state, and local income, employment and excise taxes applicable to such amount. Unless the Executive shall have given prior written notice to the Company to effectuate a reduction in the Parachute Payments if such a reduction is required, which notice shall be consistent with the requirements of Section 409A to avoid the imputation of any tax, penalty or interest thereunder, then the Company shall reduce or eliminate the Parachute Payments by first reducing or eliminating accelerated vesting of stock options or similar awards, then reducing or eliminating any cash payments (with the payments to be made furthest in the future being reduced first), then by reducing or eliminating any other remaining Parachute Payments; provided, that no such reduction or elimination shall apply to any non-qualified deferred compensation amounts (within the meaning of Section 409A) to the extent such reduction or elimination would accelerate or defer the timing of such payment in manner that does not comply with Section 409A.

 

13

 

 

(b) An initial determination as to whether (x) any of the Parachute Payments received by the Executive in connection with the occurrence of a change in the ownership or control of the Company or in the ownership of a substantial portion of the assets of the Company shall be subject to the Excise Tax, and (y) the amount of any reduction, if any, that may be required pursuant to the previous paragraph, shall be made by an independent accounting firm selected by the Company (the “Accounting Firm”) prior to the consummation of such change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company. The Executive shall be furnished with notice of all determinations made as to the Excise Tax payable with respect to the Executive’s Parachute Payments, together with the related calculations of the Accounting Firm, promptly after such determinations and calculations have been received by the Company.

 

(c) For purposes of this Section 5.17, (i) no portion of the Parachute Payments the receipt or enjoyment of which the Executive shall have effectively waived in writing prior to the date of payment of the Parachute Payments shall be taken into account; (ii) no portion of the Parachute Payments shall be taken into account which in the opinion of the Accounting Firm does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code; (iii) the Parachute Payments shall be reduced only to the extent necessary so that the Parachute Payments (other than those referred to in the immediately preceding clause (i) or (ii)) in their entirety constitute reasonable compensation for services actually rendered within the meaning of Section 280G(b)(4) of the Code or are otherwise not subject to disallowance as deductions, in the opinion of the auditor or tax counsel referred to in such clause (ii); and (iv) the value of any non-cash benefit or any deferred payment or benefit included in the Parachute Payments shall be determined by the Company’s independent auditors based on Sections 280G and 4999 of the Code and the regulations for applying those sections of the Code, or on substantial authority within the meaning of Section 6662 of the Code.

 

[Signature Page Follows]

 

14

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

 

  COMPANY
   
  Matinas BioPharma Holdings, Inc.
     
  By:

/s/ Jerome D. Jabbour

  Name:  Jerome D. Jabbour
  Title: Chief Executive Officer
     
  EXECUTIVE
     
     /s/ Thomas Hoover
  Thomas Hoover

 

[Signature Page to Employment Agreement]

 

 

 

 EX-21.1 5 ex21-1.htm

 

Exhibit 21.1

 

Subsidiaries of Matinas BioPharma Holdings, Inc.

 

Name   State of Incorporation
     
Matinas BioPharma, Inc.   Delaware
     
Matinas BioPharma Nanotechnologies, Inc.   Delaware

 

 

 

 EX-23.1 6 ex23-1.htm

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements of Matinas BioPharma Holdings, Inc. and Subsidiaries on Form S-3 (No. 333-239675) and Form S-8 (Nos. 333-198488, 333-203141, 333-210495, 333-215456, 333-222912, 333-237315 and 333-253659) of our report dated March 29, 2021, on our audit of the consolidated financial statements as of December 31, 2021 and 2020 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 8, 2022.

 

/s/ EISNERAMPER LLP

 

EISNERAMPER LLP

Iselin, New Jersey

March 8, 2022

 

 

 

 EX-31.1 7 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Jerome D. Jabbour, certify that:

 

1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2021 of Matinas BioPharma Holdings, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 8, 2022 /s/ Jerome D. Jabbour
  Jerome D. Jabbour
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-31.2 8 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Keith A. Kucinski, certify that:

 

1. I have reviewed this annual report on Form 10-K for the year ended December 31, 2021 of Matinas BioPharma Holdings, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 8, 2022

 

  /s/ Keith A. Kucinski
  Keith A. Kucinski
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

 EX-32.1 9 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION OF

THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b)

OF THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350

 

In connection with the Annual Report on Form 10-K of Matinas BioPharma Holdings, Inc. (the “Company”) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jerome D. Jabbour, Chief Executive Officer of the Company, and Keith A. Kucinski, Chief Financial Officer of the Company, hereby certify, to the knowledge of the undersigned, pursuant to 18 U.S.C. Section 1350, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 8, 2022

 

  /s/ Jerome D. Jabbour
  Jerome D. Jabbour
  Chief Executive Officer
  (Principal Executive Officer)

 

Date: March 8, 2022

 

  /s/ Keith A. Kucinski
  Keith A. Kucinski
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

This Certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 GRAPHIC 10 form10k_002.jpg begin 644 form10k_002.jpg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end GRAPHIC 11 form10k_003.jpg begin 644 form10k_003.jpg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� E%+@T8- "44 MN#1@T )12X-� E%+@T8- "44N#1@T )12X-� E%+@T8- "44N#1@T )1 M2X-� E%+@T8- "44N#1@T )12X-�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end GRAPHIC 12 form10k_005.jpg begin 644 form10k_005.jpg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Ǩ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end GRAPHIC 13 form10k_006.jpg begin 644 form10k_006.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG MJUVVGZ-?7J %[>WDE4$<$JI/]*N5E^)?^15UC_KRF_\ 0#0!D:;J>M:CI=O> MK?$)0GV/_ -!%:HZ5 MKRD;K?_ #_6O_@,?_BJM44VN?:V/_P 72>=K>2/M MMKD9_P"78_\ Q5SL)+B9"X1%4D\#'.<5RD7C[7B^ MBMI!&LEQ-$HV1; MEW*">YQ3Y4+F9T'FZY_S_6O_ (#'_P"*H\W7/^?ZU_\ 8__ !5;K?\ S_6O_@,?_BJEMIWN+1)VA:)F4$HQ!(SV MJ6CE%S%7S=;_ .?ZU_\ 8__ !5'FZW_ ,_UK_X#'_XJK5%'*',5?-UO_G^M M?_ 8_P#Q5'FZWG_C^M?_ &/_P 55JBCE'S%33=4U$^(QIMY+!+&]FUPK1QE M""'5<=3_ 'C715RMK_R/\7_8*D_]&I755FRT%%%%(84444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '%:8L^JQ2SW&HWZ,6VA8 MKED P/K5\:3_ -1+4_\ P,<_UJGX8_X\)?\ KI_2MT5DY$&=_9)_Z"6I_P#@ M7)1_9)_Z"6I_^!?\ D):ID=?],?\ QI?[*P,G4=4Q_P!?6Z!KER;+4 MO$=ZFKO)!YTT1:0BV9?NJN/J1732^-M02>6"'3%N+B#2_MLL41)^,W_H!K4K+\2_\BKK'_7C-_P"@&A 8_AG_ )%C M2_\ KVC_ /016J.<>_2LOPR/^*8TOMFVCZ_[HKE8_&^HQ7\T:VPN(3=E%).T MHOFB-<8ZYR#6]S*QWV1C.1STH[ CD'H>U>;-XPU)WN8U=?)E@>2%C@2*SL%3 M;],BG3_$*],5RMG;0^8B*%>0Y.3(J?,/7YL_A1<+(]'].N#WQ1WP1S[5Y]_P ML:2.YO8GTX.EH5C>0-@;RZJ#_NY85#/XLU)?#:ZB9XHY;K4MD66 5(U^8\^F MU6HN!U5_X9M]4\366K7;K*+2!T2%T#*&8K\W/T_6H+_PG%>ZIF> >];B^/[F*-C/IX4!!Y+._ MIF-;J1?/E?&R+Y0H+^807)CU: MXBT^]$1N;940[_+P ,D9 XJU:>$Y]"O[^[LKZ/I+O5;*P6R1)+AE61"_S[B&.1[ +_X]2:MXZGMM0OK*WM8RT+/"69OG!"J= MY'9);?2]#LK6YE.J7<U.;6M1MK^]25K6V#A(%3R\[?FR0-V[2>1TIEQ\/3/87%@NJ.L5WF.S2>U@EN9T$K>6V,HTC*JJ/[PVDDU9U36/$#^)[R'3I?)TZR*+.7C41$E M/\ 4-0CM#!9 MVT32S("7;.GYUY?;:GKTT7V>;S0)X;=6A\E\AI0"6W8[$\_2EE\8^([ZUD:W1K;/D MX)MG)@W. RG(&<#J: /4#]1QUH'3.1CU]*\W_P"$T\0K=ZD@TXBWM&\E&>)A MD[MHDZ($U;44M] M,/DVLNR*)H6W38; VG'?OZ#GI0!Z,#QOK?1^-M<9[8&U.7O/+)2WUJZCU"34K//D6ZS1)& MA#%R&.WD<]!^8KGI_$&O:XD5@&2V6[NHD$BQ,A/#,Z#< 3@)R?>B[ ZRV\#: M%:-:&.W=OLGF%,DG)D&UF;U.,_G4-E\/]"L&D:-+ABT3Q1B24MY2MUV?W>IK M%OX=>N_$=Q);7,]KI]CL7S=QVX56W84#+9)7\JLZ/JVH6/A#4;Z6.ZN[B*?8 M&E+%9%+*-ZJ0&VC=GIV-%V!T%IX6TNRN["XAC<2V,#00;G^ZC-5P",C.]NO]VKOB?5-:BU1;:U(O$&E)!:A& MNI9BD[,8F;S/,W' ;&T;0@[_ ,5- >I\^P]\_P">:,'N, \C)Y->=7GC/7HK M&REMK3S9;R:13B!P+<*1A6R.IW=1Z&M#7/$^L:?J<%G;VHWB".9\QN1*S$A@ M&Q@;=N23CJ*&([7OWQC)S@8I!ZX.#TK@;#4-4L/#=QK4TIGN+^^9(RR,PA0, M5!PNV9+ATN[E(G,D9)0+$B9Y' +*_->E@YR>F>O'H: ,>T_Y*4/ M^P.W_HY:ZZN1M/\ DI0_[ [?^CEKKJVCL:1V"BBBJ&%%%% !1110 4444 %% M%% !1110 5GZ];R7?AW4[:%"\LMI+&BCJ24( K0HH XS1GOM/T2SM)=*NQ+# M"L;83(X&*M+*X/&D72C.1B+H>H-=315\Y/* M8?GSHUQANH\KKSW-=511SARG+>)I%V)YPJNQ4\AP] M.II?/EVN3I%P2YRX$.-W&.?4UU%%/G#E.86XF2)8DTFZ5%&% 3@=^GXTUY&= MI&;19R7&USY?+#W]:ZFBCG#E.0NXUO;>6WET6[*.GEDA,$KW%21L8HA%%HUP MBI\R!8\;?_KUU=%+F#E.6$TD>?+T>Y4[BWRQ8Y]32QW,T*XBTF[0'DA$P,^I M]:ZBBCF#E.6TV&[F\8"]>RF@MUL'AWR#&6,B$#\@:ZFBBI8TK!1110,**** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C=/MM4 MTJ.6W.E3SY;<'B9,'CW8&K8N+X8_XI^ZP/X=T6!Z#[]=/14\J%8YC[1?XQ_8 M%Y_WU%QCH?O4>??'.= N^223NB/_ +-73T4#@;^XSS6S_:5]_T#&_[_ "?X MT?VE??\ 0,;_ +_)_C2Y$'*C.%SJ(S_Q(;O/LT0S]?FI?M-^ - NL=<;HN? M_'^E:']I7W_0,;_O\G^-']I7W_0,;_O\G^-'(@Y49WVG4#UT*[Z8ZQQ(J)X?N@H M 4#,7 '0#YZT_P"T[[_H&-_W^3_&C^TK[_H&M_W^3_&CD0<'KSOK4_M*^_Z!K?]_D_QH_M*^_Z!K?] M_D_QHY$'*C*A>\MK=((?#UTL2+M10T7RC_ONI/M-_NS_ &!=GURT7_Q5:/\ M:5]_T#6_[_)_C1_:5]_T#6_[_)_C1R(.5&;Y]\2"= N]PSSNB[G/]ZG&[U(_ M\P.]'I\\?_Q5:']I7W_0-;_O\G^-']I7Q./[-8?]M4/]:/9H.5&5I=GJ$OC/ M^TY["6VMAI[6^9&4DOYBMT4GMFNKK,L=2FN+M[:>U:!U0/\ ,X.021V/M6G5 M6MH-*P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110!DZK_R$=+_Z[/Q_VS:G7DK6]G-,@RR(S >N!3=5_P"0 MCI?_ %V?_P!%M5CZ\C)XJEL!RC^,C;;UNK"X#J5 6-2=Q/''XXJR_BM(Y#&] ME,KJP1B", GOG/W?4UOE%/55)]2*/+3.2B_E18=C /BR/<%%K("6(R74 >QY MX)[>M0'Q>\7D^?83+YK;?EP=M=/L3^X.N>G>C8IY*@GKT[T6"QRS>-D#@K8S MF,AN<3V]E;F654 [#'4UQVH>))[EV6!L#I@'@ M5<(.1,I)':O>6\7WYXP?]X5#_:EIG'G?C@@?F>*\TN+RY923,P/?!Q63-=W" MDE9W!SV)S6WLEU,_:=CV>.[@E^Y/&3Z;A4N>X((]0:\+7Q!J5JW[NY9P.Q-= M=X;\>B>5;:Y(1_?[I_&H=/70I5%U/2**A@N$N(%ECY#= ?UJ7=GI6;5BUJ+1 M29HS1H.PM'XTF:,\T:"L5;;_ )&*;_KTC_\ 0GK8K'MO^1CF_P"O2/\ ]">M MBH>X!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@#)U7_D(Z7_UV?_T6U6/\35?5?^0CI?\ UV?_ -%M5G_$ MU2 3%&*6BF4)BDIU)@T 5K:-[6]M':#=N7;U!]CTIO<2%N$M[R2*&X$$R MS';'<1#!4_[0KDIXGM9VCS@QN>A]#UK;:^TVRMBL>V_Y M&.;_ *](_P#T)ZV*E[DA1112 **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@#)U7_ )".E_\ 79__ $6U6?\ $U6U M7_D(Z7_UV?\ ]%M5@_U-4@%HIM%,H=13:* /,_%Z[=>SZN?Y51C/"UI>-1C6 M4/J1_(UFI]U?I79#9'+/E9]GJMY'<^1YF^/TD&[\JTM1'^C M;O[I_P#K5@0?+J _+_/YTVM3-;G>:7:0W;KYD47/4^6/\:O:Q:16R;44@8_S MTJMH)^=*TO$']*35I&G03P.GSW[?[O\ 6NQS7*^"5VV]X_JX'Z5U%MBI>Y M(4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&.._UI M * '44@I: "BF!LC(.1U'TI<\T .HH'2B@#)U7_D(Z7_ -=G_P#1;59_ MQ-5M5_Y".E_]=G_]%M5G_$U2 ****HH**** ///',>-4BD/ RH_0U@FZB4[% M;-H=TJMZ%37(:NOV7RI&&U>N5'S,?2M'548:&=.,9UO9L?*_V MBP9\$$CE3U!KG(3_ *>E=/I]K*U@QE8%IB74>@]*YA 4U+81@J2#^=:PGSJY ME5BHS:1Z#H3?.GX5K:_R ?:LC0L;DK9UW'E@^U6VW+42V+'@Q=NES'UF;^0K MI:P/"2[=&8^LK'^5;]6V" M&SP>V*0B"V_Y&.;_ *](_P#T)ZV*QK;_ )&*;@\6J Y_WGK9J6(****0!111 M0 4444 %%%% !1110 4444 %%%(>010 9'J*7(]:QQ)?7.HW<$-Q%#' 5 S' MN/(SZBIA;:IC_D(0_P#@-_\ 94>H&ED>M&1ZUEM%J2#+:A !W)M^G_CU"1:C M(,IJ5NP]1;Y_]FHU%HI:XZ/6=5;_ )>+?_OR?\:L)J.JG_EZM_\ OR?\ M:KVX^\.P^7/7M2&I)F]D>M&:Y+_A*Y[: &[TR<2Y4$(, M\$G_ H7QFC%@EE,X7.2@STQQ]>:!G6YI,CUKE9O%K1HPCL)GD5%D*^JDXI7 M\6D$ :=<$MQN5 PLY;$9Z@ X&??B@#3R*,TW\*/PH%<=13?PH_"@!U%-_"C\*!CJ*;^% M'X4 .HIOX4?A0 ZBF_A1^% "Y'K2TT<4Z@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** &L,C\*YC4#XA@U2:2TC$ML6R@XRIV\=^1FNI-(1[FD! MR:7WBL0(\UG$CL@W*JAMC=_XAFGR7_B@*Q2RC+@_=P .O3=NZ8[X_"MZ]O(K M&W:60G'8#DL?2JVC:Q::U:F>U9L*=CJPY4^E/E=KB,2>7Q./,D@19,RIL1T$ M? Z_Q'@]*&OO%DDD*&SC12P\QL#IZ?>K9\0Q:A+HMPFEN$NR/E/MWQZ''?M6 M5X9U=Y81:W#L9%PH\SJK#L::C="98TN]\22WD"W]G#'"0WF;>H/;O71YI!T% M*.!R=.LU64XZ'&1W MIX Q>3RY M/+5EX$@.1P/:LO4H&M]=8[24TF[MHY0&8PN." M)!@'Z&NAU$_;;9?L^)#C^%A7;[6,G*4QO<1*^,["X!IC:A9*3F\M M^!G'F#)K,O--TR^FDEF\S>ZE25." ^ M*E_X1_2/*=#)=?/D%MZYQZ#BE_X1_1ML(S/^Y"A3Y@!."2,^O6EL?7_?>MFL*PE2;Q!/Y;9"VL8Z@_Q/6[2*"BBB@ HHHH **** "BBB M@ HHHH **** "CM12'H: ,RP_P"0OJO^_'_Z *9KVO6N@V+7-R_/\"=W/I3K M%@-6U3GHT>?^^!7C7CK77U/Q/<0ESY5NYC1?3'>KA'F>I,G=:$FJ>(M4\07# M//&;[4--CEDMYGDB7DB4Y%B6:^(&N;ZY9E9F MVIM& !7.7-I-9M]HCRA_Y9J1U^M=WX;U6&_LUCV)'<(/F1>/QKFJTN5\RV.J M%6#I\C6O%MLJ,C>A'%=IU%,D@BD&'C5A[BA5'8X MY8:/V3F89QG@U>CGSBL;5WMXKZ*VTP[KJ1C^[)^7%2QSR02".9=K^_2E\6PI M49T=9+1FV#D9I156&X#8%60Q7U+_ )!MQ_N&I+R>_@M+/[# LOR# M>#Z,G'%1IJ7B2-&WZ3'E5)!P#WX'6K/]HWU\^87$2>W<5( ML%\.1=OS5Q%87^OO>K#<:;$L#/EGZ8&!V^N:ZAG2-23A5'>L _P!I MKTNW(^@J)K.YN7W7%P[^U'*#KI[(U)=;LXFPKLY_V!D4Q=?M"<,)%'J5JM'9 MPQ K^E2-:P./NT)(CVM2YI0W<-P,Q2JP]CS5C.:YN32UW9C8H?]GBFBSN@, M"Y?'UI\I7MWU1TVX#J: ZGO^MGZG/;W0M[IRR-]UCV-7=J=D^F2$MO=2N1A,G;GCKC&:L/XIN8\L^G-Y> M+;ME$_\ 9CFW\L,<,2EJK87+ M7EA!@M>I9S^%8>H^'_M%[ M'>6D@@F!P_'##U^M97A"6:+4-0LIKB295Q)&SMN.TUU4]]:VHS/3<]/FI%L)9'!ED>0]RYS6CI.H+?&>%X@LD.W)QPP]?K6EY "Y. M.O2HE)V]T)TIQFXU-"E;6H0!57%7FQ'%_>]LTXD)GO\ A46[S7 ^7O65W%: MO4+*>WPH<[D*& YI)8_.7<#VZ=JD*[AMJ-7\OY6!//&*J=U\3%%7UB9EQIL4 M@RR@'T-5/[*D!'E-(N>RL170M&'&-V/<#D5%--%;(9I'X/&._P"%.*G%ZO0% M&,W:-[F'_9ET>?.GQ_OFE_LRZ_Y[S?\ ?9I+OQ% \*DPW,;J_P I.,'ZXK8T M^]^W6WF%2I%:\UW9&E7#U*<4Y7U,D:9W;_ #Z4S!*5MQITJX_YZ2?] M]'_&E72IV./-D_[[--.JZN7#K8[D:-=I]^2?Y@?A4RZAK#D8L%48YR??_"D) MIVW-WP1:O:ZQ>"0DDP1XW'/\3UWMNR 1FWC_FU==5'I4/@04444&P M4444 %%%% !1110 4444 %%%% !2-]T_2EI#T- &5I_.K:ID=6CS_P!\"O,_ MB%X*EAOI=9L$=XI6W2HO)4^OTKN6UC^SO$&H1O$S(QC.Y3T^04:YK:MIP%D_ MF32G CQS]*OF<-43#EJSY%HSQ73IUM9"IX/H>GY5V&FZFB,C+NFE8QTU-*DI5-'J<'^XO\ MJQ]2'_$MN/=#5FXOQ9Z5"0,R,BA ?I4I'3&7)%MFIG S^E*+2?59](:! MV2, 32C@*3[?UIJOJ"(+KSF+#DKV(]*;JNC+J42:OIX$=\%^91TD'<&KBM=0 M53VBT+8TZ:R!EMV$L6,A>^*L1SB9 ZCCH0>H-5O#FI_:H/(=6#)P W5?7/M4 MS!(]5F6,\%=S#WI.Y#@HDN[DD-TXQ33)GIQBHI' SZ_SJJ\^.]"B^IE*:1=, MN.IIGG8/6J!N":896'4&J22T,W5-/SO>E$WO67Y]*L^?6FX$^WL:HFY[4\2+ MU/>LP39J592:3@:QK>0Z\LQ<+D<'VI(+^^M%"21"9!P"3@BI4F4\9YJ97#=1 MTJ;]!IJ]TQ$URWQ^\@E3U. :T+>YMKQ2T3*X/4=ZH20I(.@!K'F5["X$T+$8 M.2/6E8T]LX[G6K!&J@!<*!C;V H%K )?-$:^9C&['.*2WN%N((Y5Y#"IL\5) MTWNKA@#@<"EI*6@84444 %%%% !1110 4444 %%%% !1110 4444 %%)1F@ MS2,1ZTCD ;F( 'J:Y7Q#XB3RVL-/??/S6[=]C5='(!/7%1:@VZ\T_P#ZZM_Z U2BBY%1ML6J MM_:+>V;PD[=_?'7%6:*&KA"(A* M-7?N=.W[P8W<#T]:%0*2>_>HK>#R8\%V+DY;ZU5U5[A4A%OYF&E_>>6!N VG M'7WQ3Y8N7,T>9\,>2)H \<'ZTQHU()!8%AC(K$.I:O!#NEM [Z$WRO0+N_BL80S,S''"+@L:Y[4M6MKQHBD4L MYMP7E;"LN>JY[5+;Z';(8Y&+M@<(_(!J6M;(]&BZ%. M/M-V5-.T6*XLHYI6D5R,NA^Z>:WTCCB0)$@513@N% 4 =A15J-CCKXB=5W; MT$/(( S_ (4HZ#:.F1C]***9@FPX [#Y0,>E+U&#TI** ;9H>&Q_P 3ZZ_Z M]H__ $)ZZVN1\-_\AZZ_Z]H__0GKKJ9ZE#X$%%%%!L%%%% !1110 4444 %% M%% !1110 4'I12'H: .,OHO,\0:CUQ^['_C@JFJ_9+I;F)1YB8JY.Q5P#D8K.5X M/0[\+:I1&+G%SODM2?DD7I^-:6E:FBJ!&0I'I_6O7[FS M@O;=[:YB62)UPP85Y/XD\$7^A.]WI8:>SSDH1ED_^M73"KT9BXVV1U=AJLQDU&Q>"*7RW)R&(R/Q%84D)1A=6C;6!X(Z_ MC6G_ ,)%9P6X>Y)23^)1V]ZY:D4M3HIM\RLM3)B\)I::=.]Y.TTH4N-K$*/P MI=,R%0=\TW+FHG_ M (ED_P#N&J-VQFOK>/JJ0J?H<5=U0A=,N2> (SS^%9VGYN9O.[,%Q^52C.;T M2-G:#"$Q@8ZU6A>?3V8(GF6['.P=5/KFK>1@#TJ-I-O?%%PVV&"_1"TEO8D2 MN.25Q^9[U!9MO669VS,S8?/%2M*0L7^8]32<=ZZ4CAE)WN:=O/96Z9,6]O>DGU-'!5+= *S:S]4U M VH$4>/-8<>U'+U-(5*DGRQ6A8O=1@MFRQ&X_P ZUFMJ-Y<<0((QZGFH[#3 MVN)#)(=Q8Y+-U%;?V40VSB%*!8ZE& M11OI^V%FVNVW&!@QUD;YQSQ4%]")%) [5A:/J[B06EV0''W6/>NG1 M@5PPK.2L9-=&5M#O1 #:3'&#\I-=#D8KG;NQ23YQQ]*98ZI-9SB&Z;?$3@,> MHI2C?5%4ZG*^61TU+2 @XYI:S.H**** "BBB@ HHHH **** "BBB@ HHHH * M*** $-5;^^ATVTDN9VPB#-61[UQGC:8RW-E9 G:V7<>HID5)UO9D_+&G4CW-6;338++'R_,:L6\?EQ)M QS3R3G)Q[4KGGN3DKL#(-QX MYIC/FFEN>:C9B6PO4TF1=(4N/7!II;/7)_"M" 6=M%OF_>2'^$=JJ7-WYI^5 M54>PI#:=KD!#_O[_ /6IBL6J.E5PFHM_RP@_[^G_ J.X;4X(RXM86QZ2_\ UJ-! M\KOH4YXM6-\6@D01!\L''!3M^/6G6B22?>'MQ6V-#U? (2VQVRY_PHL:QIRELLW4DB)<*L)E0KD] .N< M1.VQ[.?\*B?3-0CD6*1[-)&'R* MTO)HL:*G46EC"TRVU"VN4CN9?,B6-_G]?TH.B:M_PJ=BI15@Z3J M0W _9?EP#^]Y'Z4XZ+JH&XK;<=?WAQ_*BP>PGV)?#?\ R'KK_KVC_P#0GKKJ MYO0]+N[/49KJY,0$D:1JL9ST)/\ 6NDH/0HIJ-F%%%%!J%%%% !1110 4444 M %%%% !1110 4'I10>E '/Q_\AO4_P#?C_\ 0!27$6>:6/\ Y#FI?[\?_H J MP5W#%-.QRU%IVW%# ,I!&0>",5EZ?K,-T-KL$D Y!JAXEUV?2%B,"*?,. < M9R>PK*7NGHT/WS]PYOQ/\/6::34-$(20_,]L>C_3WKB[>^OK:X:?H:QE&MK(Y.,&0?P_2B;538B,W1]YO5&+/806U\(;.65H(^J;L@&MVRB*KD MC!JC8VG(.22>23W-;"C QZ4OA7*STY[R8KDD\MZ]JH6=O?ZKJ/V^ M61HK'808WZ/[@?U]JJ23294:+L]2'OFBF1G=N ^Z&(!SG(S4JK6S.&UM!O>N M=U;*:ON?[I7BNHV\5GZKI@OH5(^^O2@WH3Y97(;"Z14 K0:[B ^]7*-%=VSE M2IR.AINZ\?@1D4'H^U@U>YT-QJ:@86J3:@3U-9\5E>2G!R![59?0IS%N4N2. ME!'MX)VN7(KS)ZUI02B08ZUR4#R1SF-P=RG'-=#IY.12-GJM"/5[/'[V/Y67 MD$5NZ'??;;!7+=][:,U-35Z#Z4ZLF=ZV"BB MB@84444 %%%% !1110 4444 %%%% !1110!'*XBC9V(51R2?2O/;BX.M^('N MX^8(_D3/<"MSQK>R0Z?%:QL5-PVTD>@ZUG:?"EO:+L7J*#BQ$WS>U. P2#TJ-V[4F9((3+(< =JS[2UDU M6Z$LQQ%U ["KC!LNE1-(N9.99Y/^^JVL06X6-,! M1U]ZM/ @;Y)5(Y[ULDD=T:48G-G1I4&4FDS[,:B+ZA9'YCYBCLU=6+0-]V5< MTU[#?$=[*>#0TF.5.+T,*UOTNCM^XXZJ>]6O8UCZG9&WD\R-BKJ<@UH:==_: M[<,PPXX;ZUC.-CBK4>5W18Q4BG%)BG!:S,"4$^M.4EAM;+#WI@/-29PI!Z>U M!9DZMIT;)YB@JX.00<8/M6[X.U>:\MYK.Y;?+ 1ACW4UG:B5CML!(BUQ MJ$Y^[E5'ZU1K0C MJ<,W@S5))4>77I?NC*%\-SV=Q'-<^(''E,TA3<0.2#DC=Z!AC MIST%=QMR,5S^L>#=-UK4A?7+SK*(_+Q&^ 1SU'X_RH"[,4:79ZEX@,YUU9T% MPL_V8$\X7 !Y[9!X ]\TE]X=GD:9U\2& &178%SD;6)Q][C@X_"M:U\"Z7:7 MR7D;S>;')YB?=X.T+Z9Z"H[GP#I=VQ,LUR!YAD 5E&">HSC)_')H"[,F/0C< MP^=;>*7$8D<-(2?E=MIX);'0#CD00>?>ED\+3O&L1\5$HC$D;N2#T!.[V_G6L?A MUI!D#!YUP1PI4<;0N.F1TSQWIQ^'NCFX>;=."P0;G4_3\!72UBZ#X8L?#QG-HTK&8Y;S&S6U0(**** "BBB@ MHHHH **** "BBB@ HHHH **** .?3_D.:G_OQ_\ H JT*JQC_B>:GD?QQ_\ MH K/U._U2"_$=G;"2%8][EO0'G'X51SRW-EE##%5IK0,*QCXDNHH\2Z;*)%! MSQU/M4:^)[FX %O8.7#H&4]@2,Y_"A.Q$H*1;GT_)SMY'0U1OK2ZN1$'G)$3 M!EW'.".12MXFN7F6)--FV@G>Y7IQ31K\S>:/[.?S'CW0CWVDD'\J=Q4X3IN\ M6:5OXBO IBDAAWJ.I. 1ZU1U&[N]$P<"J;:U M,EE#.NG3$NN]EQT&0/ZY_ U"WB>98!)_9DPS_"1C'U_SWHOV)]G*_,V=&D80 M< 4ZN7_X2JX;RV33I/+8[2?3/K]*L0>(IY9H0]A(B2.4!(Z8[TMS5+2QIZM_ MR";H_P#3)OY4ZQ8O809_N#^0J+49HYM.N8D;+E"N/?%36I"V<*=U09'X46,[ MIL=)61)J5FUQ)%YHRA^8G@*<=ST[BMB0'&0"*P9_#MO-<3S'G_ .NLV3PI:&4/ M^\R&)')[\&HCX2MED("3['7:<-Q571"*<$IX '6G94#K1WSS[>';@5TMK;>4@SUJCHT*QJO'(% M;,C9)9JM'HI:6,_4& C(/3%4O#&6U>9QTVXJ+5KK&X UH^$;-EB>Y;^*HD9U M9:6.I49&*Q[^%XI1*G5&W"ME0!6?J##!K*&YRU-C;L+M;NTCD4\X ;V-7*Y_ MPWN^S3G/'F.;!T^E:_C&=(M"=#@M*P116'I,'E M6 R>@H."O_$+ASCDYJ%NM3$@U$W>DS![&+JCL\\=OV/)K7A00VH XP*QKPD: MSAAP%&*W N^W_"NB.QZ%&-H(R;NZ*$D&LUM3/(!/<<&IM3B==W6I=&LHYK<. MV"?XCBANQ4ZG(KC(=7,;??/YU>76T*'@/NN^/K M4^T1G#%*UV07VH+,,;LGL*M:)"R*S,/O&!84VC!J:D[ MZ&-:MSZ(H/_U\514'RU4>GBEIJ]33 MJ#TD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4'@$T4'I0!B2Z??#4+FYMW@*3[6Q(2",#'I2"SU4'/^A^ARS?X5M >_-. MH)<4S"^Q:KSC['^+,?Z4+8ZFIW!;$'U!;GZ\5NT4!R(P_L6J9R19'G^\W^%- M^P:F6W$66[&,Y;KZ]*WJ* Y48?V/5#P198]-S?X4&SU4G_ERYZ\MS^E;E% < MB,/['JO_ $Y8Z$9;_"C['JO_ $Y>PRW^%;E% *$48(L-24$*MB >V6_PH>UU M14)VV1VC(&YO\*WJ:PS_ (47L#BCA(IB\K%L;B?FQTS6I!)D]>>_O5/5["33 M[PRJI^SR'(('0^],@G YS^-;I*2T/.=X3=SH$.Y.:4 50AN1@9.*N)(K=Q63 MBT;1FF*Z[1DU&,,,8J;@]P: H%%RFET*VPC(/2F;<#%6BOK3-M4F0XE4K[4P MI[5:9<4PK5)DN"*ICIAC'I5LI3"M.YFXC+9 ).E9'BV!S;P7"KD1GFMZV7YS M4D]JES"\,@RKTN;4UIZ:G$6.H+& PZ58N=6&W&['O27GA:>"1C;[BO;%16W MARYED D1_P#@7 J^96.E5TNA3M+>;4[L<';G\Z]!L[46MND2@8 YJ#3=+AT^ M/ "E\=?2KRG/-92DWL8W@H6BN3;VDDD:&G6(LK)(<_-CYB/4U=I*6LV=J5E8****!A1 M110 4444 %%%% !1110 4444 %%%% '">,;DRZU:6C']VB;R/<\59A -JF!C M YJ7Q7HD]ZT=_9C=/"N&C_O"L#3]7,6(9E9&7@JW44'G5E)5-39) (XZ]*0C M.?<5(CK*@84U@:5M;F=KZG/ZPABOHI^S+@UL6,PD@%1ZC9?:[4QC <O;R&&<;2O!%;PD=U&=URFOJ%JLT)('-9.C3_9;]K9^C=*U9;V)K<[6YKGP M^[4T9.N3FJG'0NK&\#K=M 6G)RN?6E"\5S6L>*SHKG69;U4DM5C@5L;O[P]?K2'8UR .3TI=@W9!IV.#D<4NTXXX% M #=I/2E4 L00:=MINX"/*D].] %2_NDMXMH/:L_PW9/JFOQW./W%MDGW)Z53 MO/-O=1BM(VP\K[<^@[UZ1I>G6^F626\" !>I]3W-4:8>'/*[+RTM(!2T'H!1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% ""E[4@I>U !1110 4444 %%%% !1110 4AI:* (I(4FC,QD"KU,;]/PKIZ#R*:DUL1.G&>YPKQWUJV)K>10/XE&X'\J!J(3[Q*_4$ M5W!4'J*A>T@D^_$A^JU7.V<\L,OLLY2/4@Q^^#^-65O_ %/YUJRZ'839S;JO MNO!K.N/#!3+6EPRG^Z_(J^:)#IU%L/CO :L+*CBN?FCO+)]MQ"RXYW#D8]@!II"J-.TC9V9^E1R(<<"B&7@G.#R:3J*4<"GY#T$ M"@YX J*201)C(_.J]U>>5D UG*US>MLMXBW/WCTJDEU(<^D1+R8RML499CP* MZRQMS:V4,)Y*(!6?IFBBU?S[AO,F[>BUL]J4GT1O1IN*U9NOQM+H-_&H))A8 #OQ3(J*Z9R>B2&2U!8YJ^O/ Y.><^])&-D?/ M;IFE=IEQE;8XUK/4$;RR !6CI>E2>;YCC+=2:Z'"/U4'ZBE3*XYSCT&*MS*IZCJOD[E'T^M5K+2 M-5UTAE3R;8GF1^X]JH$G/8?X7<]6-:8%!W4:;@M1:***#8**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH 04O:D%+VH **** "BBB@ HHHH * M*** "BBB@ HHHH *2EHH 2BEHH AGA2>-HY "K#!KBKNV?2[\PODQMS&Q[^U M=T>M9VL:8 ^8&J<;G'&?+I(VV4>F:=66E][U(+X>M+E9K[6'4I_=KRQKJH8(K=5CC0*/056TO3UL(,$[I&Y9JT*F3.FC3 MY5=A12T5!N)WI:3O2T %%%% !1110 4444 %%%% !1110 4444 %%%% "8I& M4,"#T/6G44 (( %O\Z6@ HHHH **** "BBB@ HHHH M **** #O3&SD8%/HQ0!4N;*WNUQ-$K^__P!>LR7PO:')BDFB)Z $$5NX%&!3 M4FB)0C+=',-X8N!_J[T?\"C_ /KTW_A&[W_G]C_[]_\ UZZK%&!Z4^=D>PAV M.8'ANXX_TL$=\)C^M:-MH5E#RR>:_JU:I4&E Q0Y-C5&"Z%<6=L.EO'_ -\B MI5C11A5 ^@IV*,"INS112V08HI<48H&%%%% #2><4ZDP.:6@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!",CI44MM%,/WL,;_P"\H-34 M4 5UL[=/N01+]$ I[0JZ[612/<5+10+E78PM1\)Z9J&7,/E3=I(N#7.S^"M4 MA)^S74BG<(480V0PJ<\?SI2#3J*1J)12T4 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D! end GRAPHIC 14 form10k_008.jpg begin 644 form10k_008.jpg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end GRAPHIC 15 form10k_009.jpg begin 644 form10k_009.jpg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end EX-101.SCH 16 mtnb-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Stockholders Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Liquidity and Plan of Operations link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Leasehold Improvements and Equipment link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses and Other Liabilities link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Collaboration Agreements, License and Other Research and Development Agreements link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Accumulated Other Comprehensive (Loss)/Income link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leasehold Improvements and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accrued Expenses and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Accumulated Other Comprehensive (Loss)/Income (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Liquidity and Plan of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Summary of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Maturities of Debt Securities Available-for-sale (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Fair Value Measurement of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Leasehold Improvements and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Leasehold Improvements and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Accrued Expenses (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Maturity of Operating and Finance Leases Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Summary of Shareholders Equity Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Schedule of Recognized Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Schedule of Equity Compensation Plan by Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Summary of Outstanding Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Schedule of Stock Option Awards and Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 17 mtnb-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 18 mtnb-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 19 mtnb-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Redeemable Convertible Preferred Stock B [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] At The Market Sales Agreement [Member] Sale of Stock [Axis] Underwritten Public Offering [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Series B Preferred Stock [Member] First Anniversary [Member] Second Anniversary [Member] Third Anniversary [Member] Product and Service [Axis] CFF Research Grant Revenue [Member] Award Type [Axis] Three Molecules [Member] Feasibility Study Agreement [Member] Legal Entity [Axis] Genentech [Member] Per Molecules [Member] Project [Axis] CFF Agreement [Member] Antidilutive Securities [Axis] Stock Options [Member] Preferred Stock and Accrued Dividend Upon Conversion [Member] Warrant [Member] Financial Instrument [Axis] US Government Agencies Debt Securities [Member] Corporate Debt Securities [Member] US States and Political Subdivisions Debt Securities [Member] US Treasury Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] State and Municipal Bonds [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Leasehold Improvements [Member] Genentech Feasibility Study Agreement [Member] Award Agreement [Member] Cystic Fibrosis Foundation [Member] Balance Sheet Location [Axis] Prepaid Expenses and Other Current Assets [Member] Accrued Expense And Other Current Liabilities [Member] Scenario [Axis] Upon Achievement Of Sales Milestones [Member] Other Commitments [Axis] Cooperative Research And Development Agreements [Member] License Agreement [Member] Series A Preferred Stock [Member] Net Sales [Member] Net Sales [Member] Tax Credit Carryforward [Axis] Federal and State research and development tax credit carry forwards [Member] Sales Agreement [Member] Aquarius Merger Agreement [Member] Business Acquisition [Axis] Holders Of Aquarius Biotechnologies Inc [Member] Unregistered Shares [Member] Designated [Member] Title of Individual [Axis] Holders [Member] Plan Name [Axis] 2013 Equity Compensation Plan [Member] Option Indexed to Issuer's Equity, Type [Axis] Share-based Payment Arrangement, Option [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Exercise Price Range [Axis] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS: Current assets: Cash and cash equivalents Marketable securities Restricted cash Prepaid expenses and other current assets Total current assets Non-current assets: Leasehold improvements and equipment - net Operating lease right-of-use assets - net Finance lease right-of-use assets - net In-process research and development Goodwill Restricted cash - security deposits Total non-current assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable Accrued expenses and other liabilities Operating lease liabilities - current Financing lease liabilities - current Total current liabilities Non-current liabilities: Deferred tax liability Operating lease liabilities - net of current portion Financing lease liabilities - net of current portion Total non-current liabilities Total liabilities Stockholders’ equity: Series B Convertible preferred stock, stated value $1,000 per share, 8,000 shares authorized as of December 31, 2021 and 2020, respectively; 0 and 4,361 shares issued and outstanding as of December 31, 2021 and 2020, respectively Common stock par value $0.0001 per share, 500,000,000 shares authorized at December 31, 2021 and 2020, respectively; 216,269,450 and 200,113,431 issued and outstanding as of December 31, 2021 and 2020, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive (loss)/income Total stockholders’ equity Total liabilities and stockholders’ equity Series B Convertible preferred stock, par value Series B Convertible preferred stock, shares authorized Series B Convertible preferred stock, shares issued Series B Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue: Contract research revenue Costs and Expenses: Research and development General and administrative Total costs and expenses Loss from operations Sale of New Jersey net operating loss Other income, net Net loss Preferred stock series B accumulated dividends Net loss attributable to common shareholders Net loss attributable to common shareholders per share – basic and diluted Basic and diluted Other comprehensive (loss)/income, net of tax Net unrealized (loss)/gain on securities available-for-sale Reclassification of realized gain on securities available-for-sale to net loss Other comprehensive (loss)/income, net of tax Comprehensive loss attributable to shareholders Statement [Table] Statement [Line Items] Beginning balance, value Balance, shares Stock-based compensation Issuance of common stock as compensation for services Issuance of common stock as compensation for services, shares Issuance of common stock in exchange for preferred shares B Issuance of common stock in exchange for preferred shares B, shares Issuance of common stock in public offering, net of stock issuance costs Issuance of common stock in public offering, net of stock issuance costs, shares Issuance of common stock in exchange for Options Issuance of common stock in exchange for Options, shares Issuance of common stock in exchange for Warrants Issuance of common stock in exchange for Warrants, shares Stock dividends Stock dividend, shares Other comprehensive income loss Issuance of common stock pursuant to the Aquarius Merger Issuance of common stock pursuant to the Aquarius Merger, shares Net loss Ending balance, value Balance, shares Stock issuance cost Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on disposal of equipment Stock-based compensation expense Amortization of operating lease right-of-use assets Amortization of finance lease right-of-use assets Amortization of bond discount Realized gain on sale of marketable securities Stock issued pursuant to the Aquarius Merger Agreement charged to Research and Development Changes in operating assets and liabilities: Operating lease liabilities Prepaid expenses and other current assets Accounts payable Accrued expenses and other liabilities Net cash used in operating activities Cash flows from investing activities: Purchases of marketable securities Proceeds from sales of marketable securities Purchases of leasehold improvements and equipment Net cash provided by/(used in) investing activities Cash flows from financing activities: Net proceeds from public offering of common stock Proceeds from exercise of warrants Proceeds from exercise of options Payments of capital lease liability – principal Net cash provided by financing activities Net increase/(decrease) in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental non-cash financing and investing activities: Unrealized (loss)/gain on marketable securities Cashless exercise of warrants Stock dividends issued Non-cash prepaid from exercise of options Preferred stock conversion into common stock - series B Unearned restricted stock grants Right-of-use asset in exchange from liabilities from operating lease Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Liquidity and Plan of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies Cash and Cash Equivalents [Abstract] Cash, Cash Equivalents, Restricted Cash and Marketable Securities Fair Value Disclosures [Abstract] Fair Value Measurements Property, Plant and Equipment [Abstract] Leasehold Improvements and Equipment Payables and Accruals [Abstract] Accrued Expenses and Other Liabilities Leases Leases Research and Development [Abstract] Collaboration Agreements, License and Other Research and Development Agreements Commitments and Contingencies Disclosure [Abstract] Commitments Income Tax Disclosure [Abstract] Income Taxes Equity [Abstract] Stockholders’ Equity Accumulated Other Comprehensive (Loss)/Income Share-based Payment Arrangement [Abstract] Stock-based Compensation Subsequent Events [Abstract] Subsequent Events Basis of presentation and principles of consolidation COVID-19 Use of estimates Segment and geographic information Cash, cash equivalents and restricted cash Marketable Securities Concentration of credit risk Leasehold improvements and equipment Goodwill and other intangible assets Leases Preferred stock dividends Income taxes Fair Value Measurements Stock-based compensation Basic and diluted net loss per common share Revenue recognition Collaboration Agreements Research and development expenses Patent expenses Other comprehensive income/(loss) Recently adopted accounting pronouncements Schedule of Anti-dilutive Securities Schedule of Cash, Cash Equivalents and Restricted Cash Summary of Marketable Securities Schedule of Maturities of Debt Securities Available-for-sale Schedule of Fair Value Measurement of Assets and Liabilities Schedule of Leasehold Improvements and Equipment Schedule of Accrued Expenses Schedule of Maturity of Operating and Finance Leases Liabilities Schedule of Income Tax Provision Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities Summary of Shareholders Equity Warrants Outstanding Schedule of Components of Accumulated Other Comprehensive (Loss)/Income Schedule of Recognized Stock-Based Compensation Schedule of Equity Compensation Plan by Arrangements Schedule of Stock Option Activity Summary of Outstanding Options Schedule of Stock Option Awards and Restricted Stock Awards Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accumulated deficit Net loss Number of underwritten public offering of common stock Proceeds from public offering, gross Gross proceeds from public offering of common stock Net proceeds from public offering of common stock Restricted cash Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive earnings per share, amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Number of operating segment Leasehold improvements and equipment, useful life Goodwill impairments Preferred Stock, Dividend Rate, Percentage Accrual for interest or penalties Revenue Proceeds from sale of productive assets Research and Development, costs incurred Restricted cash included in current/long term assets Cash, cash equivalents and restricted cash in the statements of cash flows Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items] Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Due within one year, fair value Due within one year, net carrying amount Due after one year through five years, fair value Due after one year through five years, net carrying amount Debt Securities Available-for-sale, fair value Debt Securities Available-for-sale, net carrying amount Marketable securities, unrealized gain loss Net realized loss Net accumulated unrealized gain Schedule of Fair Value, Off-balance Sheet Risks [Table] Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Marketable Securities Total Less: accumulated depreciation and amortization Leasehold improvements and equipment, net Depreciation and amortization expenses Purchase of equipment and leasehold improvements Asset write-off Accumulated depreciation expense Payroll and incentives General and administrative expenses Research and development expenses Other Accrued Liabilities, Current Total Deferred liability Deferred revenue Schedule Of Maturity Of Operating And Finance Leases Liabilities Operating Lease Liabilities, 2022 Finance Lease Liabilities, 2022 Operating Lease Liabilities, 2023 Finance Lease Liabilities, 2023 Operating Lease Liabilities, 2024 Finance Lease Liabilities, 2024 Operating Lease Liabilities, 2025 Finance Lease Liabilities, 2025 Operating Lease Liabilities, 2026 Finance Lease Liabilities, 2026 Operating Lease Liabilities, Thereafter Finance Lease Liabilities, Thereafter Total undiscounted operating lease payments Total undiscounted finance lease payments Operating Lease Liabilities, less: Imputed interest Finance Lease Liabilities, less: Imputed interest Present value of operating lease liabilities Present value of finance lease liabilities Operating Lease Liabilities, weighted average remaining lease term in years Finance Lease Liabilities, weighted average remaining lease term in years Operating Lease Liabilities, weighted average discount rate Finance Lease Liabilities, weighted average discount rate Operating lease, Terms Operating lease, description Lease monthly rent expense Increase of rent expenses Area of land Operating lease extended term Security deposit Security deposit at present Lease expense Operating lease right-of-use assets amortization expenses Finance lease, interest expense Finance lease right-of-use assets amortization expenses Therapeutics development award Proceeds from award Additional milestone payment Grants Receivable Amount received from agreement Other Liabilities Royalty payable Research and development expenses Agreement description Deferred revenue Remaining balance lease term amount Initial term Other commitment Funds provide for support Milestone fee Annual license fee Loss Contingencies [Table] Loss Contingencies [Line Items] Accrued royalties Royalty payment rights, description Royalty payment rights expire description Federal State Foreign Total current expense (benefit): Federal State Foreign Total deferred expense (benefit): Total income tax expense (benefit): Income at US Statutory Rate State Taxes, net of Federal benefit Permanent Differences Tax Credits Valuation Allowance Discrete items  Effective income tax rate Share-based Compensation Depreciation and Amortization Accrued Liability Net Operating Loss Carry-forwards R&D Credit Carryforwards Other IPR&D ROU Asset ROU Liability Total Deferred tax assets Valuation allowance Net deferred tax asset (liability) Tax Credit Carryforward [Table] Tax Credit Carryforward [Line Items] Deferred Tax Assets, Valuation Allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Operating loss carryforwards Operating loss carryforwards, expiration year Operating loss carryforwards with no expiration Sale of net operating losses [custom:LimitationsOnNetOperatingLossDeductibilityDescription] Shares Outstanding, beginning Shares Issued Shares Exercised Shares Tendered Shares Expired Shares Outstanding, ending Weighted average of exercise price for outstanding warrants Number of warrant common stock converted Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized gain (loss) on securities available-for-sale Accumulated Other Comprehensive (Loss)/Gain, Net unrealized gain (loss) on securities available-for-sale Net Unrealized Gains (Losses) on Available-for-Sale Securities, Reclassification of realized gain on securities available-for-sale to net loss Accumulated Other Comprehensive (Loss)/Gain, Reclassification of realized gain on securities available-for-sale to net loss Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net current period other comprehensive loss Accumulated Other Comprehensive (Loss)/Gain, Net current period other comprehensive loss Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance Accumulated Other Comprehensive (Loss)/Gain, Ending Balance Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Aggregate offering price for sale of stock Sale of stock percentage Sale of stock shares Proceeds from issuance of common stock Business acquisition, equity iterest issued or issuable, shares Research and Development Expense Share price Issuance of common stock in public offering, shares Preferred stock shares authorized Preferred stock par value Shares converted Shares issued upon conversion Preferred stock, shares outstanding Conversion price per share Number of preferred stock shares converted Liquidity value and dividends description Number of warrant to purchase of common stock Class of warrant or right, exercise price of warrants or rights Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based compensation expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Awards Reserved for Issuance Awards Issued Awards Available for Grant Increased shares of common stock outstanding Percentage for common stock outstanding Number of Options, Outstanding at Beginning Weighted average Exercise Price, Outstanding at Beginning Weighted Average Contractual Term in Years, Ending Number of Options, Granted Weighted average Exercise Price, Granted Number of Options, Exercised Weighted average Exercise Price, Exercised Number of Options, Forfeited Weighted average Exercise Price, Forfeited Number of Options, Cancelled Weighted average Exercise Price, Cancelled Number of Options, Expired Weighted average Exercise Price, Expired Number of Options, Outstanding at Ending Weighted average Exercise Price, Outstanding at Ending Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price, minimum Exercise price, maximum Number of options outstanding Weighted Average Exercise Price Per Share Volatility, minimum Volatility, maximum Risk-free interest rate, minimum Risk-free interest rate, maximum Dividend yield Expected life Option granted description Option vested period Option term Number of common stock issued under plan Share-based payment award increase of shares offering date Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Number of option vested Option vested price per share Option intrinsic value Aggregate intrinsic price Unrecognized share-based compensation Share-based compensation weighted average period Vesting description Stock options expire term Stock option shares vesting percentage Number of restricted stock awards granted General and administrative expense Redeemable Convertible Preferred Stock B [Member] Issuance of common stock in exchange for preferred shares B. Issuance of common stock in exchange for options. Issuance of common stock in exchange for warrants. Stock dividend. Issuance of common stock in exchange for preferred shares B, shares. Issuance of common stock from the exercise of Warrants, shares. Issuance of common stock in exchange for options, shares. Unrealized (loss)/gains on securities for sale. Cashless exercise of warrants. Preferred stock conversion into common stock - Series B. Unearned restricted stock grants. Non-Cash prepaid from exercise of options. At The Market Sales Agreement [Member] Proceeds From Issuance Initial Public Offering Gross. Unusual Risks And Uncertainties [PolicyTextBlock] Preferred Stock Dividends [PolicyTextBlock] Collaboration Agreements Policy [Text Block] Patent Expenses Policy [TextBlock] Other Comprehensive Loss [PolicyTextBlock] First Anniversary [Member] Second Anniversary [Member] Third Anniversary [Member] CFF Research Grant Revenue [Member] Three Molecules [Member] Feasibility Study Agreement [Member] Genentech [Member] Per Molecules [Member] CFF Agreement [Member] Stock Options [Member] Preferred Stock and Accrued Dividend Upon Conversion [Member] Schedule of cash and cash equivalents and restricted cash [Table Text Block]. Net carrying value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date. Net carrying value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date. Net carrying value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date. Accumulated unrealized gain. Accrued general and administrative expenses current. Accrued research and development expenses current. Genentech Feasibility Study Agreement [Member] Net unrealized gains losses on available-for-sale securities. Net unrealized gains losses on available-for-sale-securities net unrealized loss on securities available-for-sale. Accumulated other comprehensive loss gain net unrealized loss on securities available for sale Net unrealized gains losses on available for sale securities reclassification net loss. Accumulated other comprehensive loss gain re-classifications net loss. Accumulated other comprehensive income loss adjustment net of tax. Deferred tax assets Right-Of-Use asset. State and Municipal Bonds [Member] ROU Liability. Operating loss carryforwards, expiration year. Operating loss carryforwards with no expiration. Share-based compensation arrangement by share based payment award increase of shares offering date. Federal and State research and development tax credit carry forwards [Member]. 2013 Equity Compensation Plan [Member]. Sale of net operating losses. Underwritten Public Offering [Member]. Sales Agreement [Member]. Increased shares of common stock outstanding. Lessee operating and financing leases [Text Block]. Aquarius Merger Agreement. Holders Of Aquarius Biotechnologies Inc. Unregistered Shares [Member] Schedule of maturity of operating and finance leases liabilities [Table Text Block]. Designated [Member]. Holders [Member] Liquidity value and dividends description. Share-based compensation arrangement by share based payment award options cancelled in period. Share-based compensation arrangements by share based payment award options cancelled in period weighted average exercise price. Increase of rent expenses. Operating leases extended term. Share-based compensation arrangement by share based payment award non-option equity instruments tendered. Exercise Price One [Member]. Exercise Price Two [Member]. Exercise Price Three [Member]. Exercise price four [Member]. Reduced in security deposit. Share based compensation arrangement by share based payment award non-options equity instruments weighted average exercise price. Proceeds from award. Award Agreement [Member] Cystic Fibrosis Foundation [Member] Therapeutics development award. Accrued Expense and Other Current Liabilities [Member] Royalty payable. Upon Achievement of Sales Milestones [Member] Limitations on Net operating loss deductibility, description. Milestone fee. License Agreement [Member] Remaining balance lease term amount. Funds provide for support. Agreement description. Royalty payment rights, description. Royalty payment rights expire description. Additional milestone payment. Cooperative Research and Development Agreements [Member] Net Sales [Member] Net Sales [Member] Net proceeds from public offering of common stock. Deferred tax assets depreciation and amortization. Net Sales [Member] [Default Label] Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Costs and Expenses Operating Income (Loss) Preferred Stock Dividends and Other Adjustments Net Income (Loss) Available to Common Stockholders, Basic Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Gain (Loss) on Disposition of Property Plant Equipment Marketable Securities, Realized Gain (Loss) Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Marketable Securities Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations LesseeOperatingAndFinancingLeasesTextBlock Lessee, Leases [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Share-based Payment Arrangement [Policy Text Block] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest NetProceedsFromPublicOfferingOfCommonStock Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Marketable Securities [Default Label] AccruedResearchAndDevelopmentExpensesCurrent Deferred Revenue Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Percent Deferred Tax Liabilities, Intangible Assets DeferredTaxAssetsRIghtOfUseAsset Deferred Tax Assets, Gross Deferred Tax Assets, Net Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations NetUnrealizedGainsLossesOnAvailableforsaleSecurities AccumulatedOtherComprehensiveIncomeLossNetOfTaxes Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period EX-101.PRE 20 mtnb-20211231_pre.xml XBRL PRESENTATION FILE XML 21 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Mar. 04, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 001-38022    
Entity Registrant Name MATINAS BIOPHARMA HOLDINGS, INC.    
Entity Central Index Key 0001582554    
Entity Tax Identification Number 46-3011414    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1545 Route 206 South    
Entity Address, Address Line Two Suite 302    
Entity Address, City or Town Bedminster    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07921    
City Area Code 908    
Local Phone Number 484-8805    
Title of 12(b) Security Common Stock, par value $0.0001    
Trading Symbol MTNB    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 160.0
Entity Common Stock, Shares Outstanding   216,864,526  
Documents Incorporated by Reference [Text Block] None.    
Auditor Firm ID 247    
Auditor Name EISNERAMPER LLP    
Auditor Location Iselin, New Jersey    
XML 22 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 21,029,806 $ 12,432,481
Marketable securities 28,592,049 46,246,573
Restricted cash 50,000 136,000
Prepaid expenses and other current assets 1,321,466 2,739,791
Total current assets 50,993,321 61,554,845
Non-current assets:    
Leasehold improvements and equipment - net 1,537,728 1,523,950
Operating lease right-of-use assets - net 4,218,890 3,276,639
Finance lease right-of-use assets - net 22,270 58,007
In-process research and development 3,017,377 3,017,377
Goodwill 1,336,488 1,336,488
Restricted cash - security deposits 200,000 200,000
Total non-current assets 10,332,753 9,412,461
Total assets 61,326,074 70,967,306
Current liabilities:    
Accounts payable 938,270 349,941
Accrued expenses and other liabilities 2,850,888 2,795,329
Operating lease liabilities - current 538,546 391,498
Financing lease liabilities - current 21,039 30,853
Total current liabilities 4,348,743 3,567,621
Non-current liabilities:    
Deferred tax liability 341,265 341,265
Operating lease liabilities - net of current portion 4,140,387 3,304,063
Financing lease liabilities - net of current portion 2,621 23,660
Total non-current liabilities 4,484,273 3,668,988
Total liabilities 8,833,016 7,236,609
Stockholders’ equity:    
Series B Convertible preferred stock, stated value $1,000 per share, 8,000 shares authorized as of December 31, 2021 and 2020, respectively; 0 and 4,361 shares issued and outstanding as of December 31, 2021 and 2020, respectively 3,797,705
Common stock par value $0.0001 per share, 500,000,000 shares authorized at December 31, 2021 and 2020, respectively; 216,269,450 and 200,113,431 issued and outstanding as of December 31, 2021 and 2020, respectively 21,627 20,010
Additional paid-in capital 184,251,138 167,192,003
Accumulated deficit (131,634,208) (107,507,193)
Accumulated other comprehensive (loss)/income (145,499) 228,172
Total stockholders’ equity 52,493,058 63,730,697
Total liabilities and stockholders’ equity $ 61,326,074 $ 70,967,306
XML 23 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Series B Convertible preferred stock, par value $ 1,000 $ 1,000
Series B Convertible preferred stock, shares authorized 8,000 8,000
Series B Convertible preferred stock, shares issued 0 4,361
Series B Convertible preferred stock, shares outstanding 0 4,361
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 216,269,450 200,113,431
Common stock, shares outstanding 216,269,450 200,113,431
XML 24 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue:    
Contract research revenue $ 33,333 $ 158,333
Costs and Expenses:    
Research and development 14,583,283 14,358,918
General and administrative 10,184,805 10,005,967
Total costs and expenses 24,768,088 24,364,885
Loss from operations (24,734,755) (24,206,552)
Sale of New Jersey net operating loss 1,328,470 1,073,289
Other income, net 122,870 686,425
Net loss (23,283,415) (22,446,838)
Preferred stock series B accumulated dividends (395,799) (793,442)
Net loss attributable to common shareholders $ (23,679,214) $ (23,240,280)
Net loss attributable to common shareholders per share – basic and diluted $ (0.11) $ (0.12)
Basic and diluted 210,178,332 196,894,628
Other comprehensive (loss)/income, net of tax    
Net unrealized (loss)/gain on securities available-for-sale $ (373,671) $ 237,537
Reclassification of realized gain on securities available-for-sale to net loss (8,485)
Other comprehensive (loss)/income, net of tax (373,671) 229,052
Comprehensive loss attributable to shareholders $ (23,657,086) $ (22,217,786)
XML 25 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Changes in Stockholders Equity - USD ($)
Redeemable Convertible Preferred Stock B [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 3,985,805 $ 16,315 $ 113,427,897 $ (84,377,555) $ (880) $ 33,051,582
Balance, shares at Dec. 31, 2019 4,577 163,156,984        
Stock-based compensation 4,184,141 4,184,141
Issuance of common stock as compensation for services $ 38 390,604 390,642
Issuance of common stock as compensation for services, shares   379,385        
Issuance of common stock in exchange for preferred shares B $ (188,100) $ 43 188,057
Issuance of common stock in exchange for preferred shares B, shares (216) 432,000        
Issuance of common stock in public offering, net of stock issuance costs $ 3,226 46,700,984 46,704,210
Issuance of common stock in public offering, net of stock issuance costs, shares   32,260,000        
Issuance of common stock in exchange for Options $ 79 820,248 820,327
Issuance of common stock in exchange for Options, shares   782,073        
Issuance of common stock in exchange for Warrants $ 172 797,409 797,581
Issuance of common stock in exchange for Warrants, shares   1,737,389        
Stock dividends $ 137 682,663 (682,800)
Stock dividend, shares   1,365,600        
Other comprehensive income loss   229,052 229,052
Issuance of common stock pursuant to the Aquarius Merger          
Issuance of common stock pursuant to the Aquarius Merger, shares          
Net loss (22,446,838) (22,446,838)
Ending balance, value at Dec. 31, 2020 $ 3,797,705 $ 20,010 167,192,003 (107,507,193) 228,172 63,730,697
Balance, shares at Dec. 31, 2020 4,361 200,113,431        
Stock-based compensation 4,192,082 4,192,082
Issuance of common stock as compensation for services $ 4 31,748 31,752
Issuance of common stock as compensation for services, shares   31,769        
Issuance of common stock in exchange for preferred shares B $ (3,797,705) $ 873 3,796,832
Issuance of common stock in exchange for preferred shares B, shares (4,361) 8,722,000        
Issuance of common stock in public offering, net of stock issuance costs $ 302 5,580,169 5,580,471
Issuance of common stock in public offering, net of stock issuance costs, shares   3,023,147        
Issuance of common stock in exchange for Options $ 107 1,415,035 1,415,142
Issuance of common stock in exchange for Options, shares   1,076,946        
Issuance of common stock in exchange for Warrants $ 12 (12)
Issuance of common stock in exchange for Warrants, shares   114,957        
Stock dividends $ 169 843,431 (843,600)
Stock dividend, shares   1,687,200        
Other comprehensive income loss (373,671) (373,671)
Issuance of common stock pursuant to the Aquarius Merger $ 150 1,199,850 1,200,000
Issuance of common stock pursuant to the Aquarius Merger, shares   1,500,000        
Net loss (23,283,415) (23,283,415)
Ending balance, value at Dec. 31, 2021 $ 21,627 $ 184,251,138 $ (131,634,208) $ (145,499) $ 52,493,058
Balance, shares at Dec. 31, 2021 216,269,450        
XML 26 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Changes in Stockholders Equity (Parenthetical) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Common Stock [Member]    
Stock issuance cost $ 172,592 $ 3,308,790
XML 27 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (23,283,415) $ (22,446,838)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 244,395 231,058
Loss on disposal of equipment 2,207
Stock-based compensation expense 4,292,355 4,564,787
Amortization of operating lease right-of-use assets 501,359 484,568
Amortization of finance lease right-of-use assets 35,737 58,961
Amortization of bond discount 250,453 239,831
Realized gain on sale of marketable securities 8,485
Stock issued pursuant to the Aquarius Merger Agreement charged to Research and Development 1,200,000
Changes in operating assets and liabilities:    
Operating lease liabilities (460,239) (423,741)
Prepaid expenses and other current assets 1,349,804 (611,397)
Accounts payable 588,329 (329,369)
Accrued expenses and other liabilities 55,560 855,819
Net cash used in operating activities (15,223,455) (17,367,836)
Cash flows from investing activities:    
Purchases of marketable securities (23,194,600) (72,106,359)
Proceeds from sales of marketable securities 40,225,000 31,445,156
Purchases of leasehold improvements and equipment (260,380) (5,749)
Net cash provided by/(used in) investing activities 16,770,020 (40,666,952)
Cash flows from financing activities:    
Net proceeds from public offering of common stock 5,580,471 46,704,210
Proceeds from exercise of warrants 797,581
Proceeds from exercise of options 1,415,142 599,713
Payments of capital lease liability – principal (30,853) (54,673)
Net cash provided by financing activities 6,964,760 48,046,831
Net increase/(decrease) in cash, cash equivalents and restricted cash 8,511,325 (9,987,957)
Cash, cash equivalents and restricted cash at beginning of period 12,768,481 22,756,438
Cash, cash equivalents and restricted cash at end of period 21,279,806 12,768,481
Supplemental non-cash financing and investing activities:    
Unrealized (loss)/gain on marketable securities (373,671) 229,052
Cashless exercise of warrants 12
Stock dividends issued 843,600 682,800
Non-cash prepaid from exercise of options 220,614
Preferred stock conversion into common stock - series B 3,797,705 188,100
Unearned restricted stock grants 68,521
Right-of-use asset in exchange from liabilities from operating lease $ 1,443,610
XML 28 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

Note 1 – Description of Business

 

Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma” or “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

 
XML 29 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Liquidity and Plan of Operations
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity and Plan of Operations

Note 2 – Liquidity and Plan of Operations

 

The Company has experienced net losses and negative cash flows from operations each period since its inception. Through December 31, 2021, the Company had an accumulated deficit of approximately $131.6 million. The Company’s net loss for the years ended December 31, 2021 and 2020 were approximately $23.3 million and $22.4 million, respectively.

 

The Company has been engaged in developing LYPDISO (formerly MAT9001) as well as its lipid nanocrystal (“LNC”) platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501, since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales, and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability.

 

Assuming the Company obtains Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.

 

To continue to fund operations, during January 2021, the Company sold 3,023,147 shares of common stock under its At-The-Market Sales Agreement with BTIG, LLC, generating gross proceeds of approximately $5.8 million and net proceeds of approximately $5.6 million. In addition, on January 14, 2020, the Company completed an underwritten public offering of 32,600,000 shares of common stock, generating gross cash proceeds of approximately $50.0 million and net proceeds of approximately $46.7 million. (See Note 12 – Stockholders’ Equity).

 

As of December 31, 2021, the Company had cash and cash equivalents of approximately $21.0 million, marketable securities of approximately $28.6 million and restricted cash of approximately $0.3 million. The Company believes the cash and cash equivalents and marketable securities on hand are sufficient to fund planned operations through 2023.

 
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

 

Basis of presentation and principles of consolidation

 

The accompanying audited consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.

 

 

COVID-19

 

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn.

 

The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the year ended December 31, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant items subject to such estimates and assumptions include, but are not limited to, the Company’s research and development expenses, the assessment of the impairment of goodwill and intangible assets, level 3 fair value measurement of financial instruments, income tax valuations, the determination of stock-based compensation and contingent consideration.

 

Segment and geographic information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

 

Cash, cash equivalents and restricted cash

 

The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. For a complete disclosure of the Company’s cash, cash equivalents and restricted cash, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.

 

Marketable Securities

 

Marketable securities, all of which are available-for-sale, consist of U.S. treasury bonds, U.S. government notes, corporate debt securities and state and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive (loss)/income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in other income, net. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in other income, net. For a complete disclosure of the Company’s marketable securities, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.

 

 

Concentration of credit risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company’s investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. Balances are maintained at U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. The Company has not experienced any credit losses associated with its balances in such accounts.

 

Leasehold improvements and equipment

 

Equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation on equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Capitalized costs associated with leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining term of the lease.

 

Goodwill and other intangible assets

 

Goodwill is recorded when consideration paid for an acquired entity exceeds the fair value of the net assets acquired. Goodwill is not amortized but rather is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances indicate the goodwill may be impaired. U.S. GAAP provides that the Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If the Company determine this is the case, the Company can perform further analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any.

 

A reporting unit is an operating segment, or one level below an operating segment. Historically, the Company has conducted its business in a single operating segment and reporting unit. For the years ended December 31, 2021 and 2020, the Company assessed goodwill impairment by performing a qualitative test for its reporting unit. As part of the qualitative review, the Company considered its cash position and its ability to obtain additional financing in the near term to meet its operational and strategic goals and substantiate the value of its business. Based on the results of the Company’s assessment, it was determined that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amount. There were no impairments of goodwill during the years ended December 31, 2021 and 2020. If a nonrecurring fair value measurement for a goodwill impairment was required, sufficient information will be provided to permit reconciliation of the fair value of the asset categorized within the fair value hierarchy as level 3 to the amounts presented in the statement of financial position.

 

Indefinite lived intangible assets are composed of in-process research and development (“IPR&D”) and represent projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition. These IPR&D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020.

 

Leases

 

The Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, “Leases”, establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required.

 

 

Preferred stock dividends

 

Subject to provisions detailed more fully in Note 12, Stockholders’ Equity, shares of Series B Preferred Stock earned dividends at rates of 10%, 15% and 20% once per year on the first, second and third anniversary, respectively, of June 19, 2018. The dividends were paid when earned to the holders of the Series B Preferred Stock in the form of shares of the Company’s common stock.

 

Income taxes

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

The Company adopted the provisions of Accounting Standard Codification 740-10 and has analyzed its filing positions in 2021 and 2020 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2021.

 

Since the Company incurred net operating losses in every tax year since inception, the 2014 through 2020 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.

 

Fair Value Measurements

 

As defined in ASC 820 “Fair Value Measurement”, fair value measurements should be disclosed separately by three levels of the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs (quoted prices in active markets) and minimized the use of unobservable inputs (the Company’s assumptions) when developing fair value measurements, in accordance with the established fair value hierarchy. For a complete disclosure of the Company’s fair value measurements, see Note 5 – Fair Value Measurements.

 

Stock-based compensation

 

Stock-based compensation to employees consist of stock option grants and restricted shares that are recognized in the consolidated statement of operations based on their fair values at the date of grant.

 

The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, Equity-Based Payments to Non-Employees based upon the fair-value of the underlying instrument. The equity instruments, consisting of stock options granted to consultants, are valued using the Black-Scholes valuation model. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.

 

The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.

 

 

Basic and diluted net loss per common share

 

Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a “participating security”). The Company considered its Preferred Stock to be participating securities because they included rights to participate in dividends with the common stock.

 

Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.

 

During the years ended December 31, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The reconciliation of the diluted shares as of December 31, 2021 and 2020 are as follows (in thousands):

 

   As of December 31, 
   2021   2020 
Stock options   28,184    22,551 
Preferred Stock and accrued dividend upon conversion   -    8,722 
Warrants   988    1,328 
Total   29,172    32,601 

 

Revenue recognition

 

Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied.

 

At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

 

For the years ended December 31, 2020, the Company’s revenues primarily consist of a research grant to provide research and development services to the Cystic Fibrosis Foundation (“CFF”). The grant contract has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this grant. The Company had approximately $125 thousand of CFF research grant revenue for the year ended December 31, 2020.

 

On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech paid the Company a total of $100 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. The Agreement has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this Agreement. As certain Agreement performance obligations in this agreement were completed, disaggregation of revenue is not required. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $33 thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.

 

 

Collaboration Agreements

 

The Company assess whether its collaboration agreements are subject to ASC Topic 808, Collaborative Arrangements (Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company will apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If the Company determines a performance obligation within the arrangement is with a customer, the Company applies the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election.

 

The terms of such arrangements typically include payments to the Company for one or more of the following: up-front fees; development and regulatory payments; product supply services; research and development cost reimbursements; profit-sharing arrangements; and royalties on certain products if they are successfully commercialized. As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.

 

Up-front License Fees: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company would recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally would occur at or near the inception of the contract. For licenses that are bundled with other promises, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. The Company will evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

 

Research and Development Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company will evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which the Company will recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis.

 

Research and Development Cost Reimbursements: The Company’s collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer or partner, and they are distinct from the licenses provided to the Company’s collaboration partners, these promises are accounted for as a separate performance obligation which the Company estimates using internal development costs incurred and projections through the term of the arrangements. The Company records revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if the Company concludes that its collaboration partner is not a customer for those collaborative research and development activities, it presents such payments as a reduction of research and development expenses.

 

 

Research and Development Arrangement: Under the terms of our research and development agreement with the CFF Agreement, the Company did not account for this arrangement in accordance with Topic 606. However, the Company has determined that it is a partner under a collaboration agreement as it shares in the risks and rewards that would be received if the product is successful and commercialized. Therefore the funds received under the terms of this agreement will be recorded as reimbursements of research and development costs and reduce the research and development expenses in the Company’s Statements of Operations and Comprehensive Income/(Loss). The Company records the reimbursements for certain materials and other research and development costs associated with the agreement when it is probable that a significant reversal in the amount of cumulative costs have been recognized. As of December 31, 2021 and 2020, the Company recognized approximately $2.2 million and $0.1 million, respectively, of reimbursed research and development costs associated with the CFF Agreement. For a complete disclosure of the CFF Agreement, see Note 9 – Collaboration Agreements, License and other Research and Development Agreements.

 

Research and development expenses

 

Research and development expenses primarily consist of costs associated with the preclinical and clinical development of our product candidate portfolio, including the following:

 

● external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and
   
● employee-related expenses, including salaries, benefits and share-based compensation expense.

 

Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.

 

All research and development expenses are charged to operations as incurred in accordance with FASB ASC Topic 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

 

Accrued Research and Development Expenses

 

As part of the process of preparing the Company’s financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. Certain of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and adjust if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

 

The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjust the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

 

 

Patent expenses

 

Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.

 

Other comprehensive income/(loss)

 

Other comprehensive income/(loss) consists of net gains/(losses) and unrealized losses on marketable securities available-for-sale and is presented in the Consolidated Statements of Operations.

 

Recently adopted accounting pronouncements

 

In December 2019, the FASB Issued Accounting Standard Update 2019-12, “Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes”. This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted the new standard effective January 1, 2021 with no material impact on the Company’s consolidated financial statements.

 
XML 31 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
 12 Months Ended
Dec. 31, 2021
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Marketable Securities

Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities

 

The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date.

 

Cash, Cash Equivalents and Restricted Cash

 

The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes.

 

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Balance Sheets to the total of the amounts in the Consolidated Statements of Cash Flows as of December 31, 2021, December 31, 2020 and December 31, 2019 (in thousands):

 

   December 31,
2021		   December 31,
2020		   December 31,
2019		 
Cash and cash equivalents  $21,030   $12,432   $22,170 
Restricted cash included in current/long term assets   250    336    586 
Cash, cash equivalents and restricted cash in the statements of cash flows  $21,280   $12,768   $22,756 

 

Marketable Securities

 

The Company has classified its investments in marketable securities as available-for-sale and as a current asset. The Company’s investments in marketable securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized gains and losses are classified as other comprehensive (loss)/income and costs are determined on a specific identification basis. Realized gains and losses from our marketable securities are recorded in other income, net. For the years ended December 31, 2021 and 2020, the Company recorded unrealized (losses)/gains of approximately ($374) thousand and $238 thousand, respectively, and reclassed approximately $0 and $9 thousand to net realized loss from operations from the sale of certain securities during 2021 and 2020, respectively. As of December 31, 2021 and 2020, the Company had net accumulated unrealized losses of approximately $145 thousand and net accumulated unrealized gains of approximately $228 thousand, respectively.

 

 

The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following (in thousands):

 

   Amortized Cost   Unrealized Gain   Unrealized (Loss)   Fair Value 
   Amortized Cost  

Unrealized

Gain

   Unrealized (Loss)    
Fair Value		 
U.S. Government Notes  $19,395   $2   $(120)  $19,277 
Corporate Debt Securities   9,092    —    (27)   9,065 
State and Municipal Bonds   250    —    —    250 
Total marketable securities  $28,737   $2   $(147)  $28,592 

 

Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021 (in thousands):

 

   Fair Value   Net Carrying Amount 
Due within one year  $8,257   $8,310 
Due after one year through five years   20,335    20,402 
   $28,592   $28,712 

 

The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following (in thousands):

 

   Amortized Cost   Unrealized Gain   Unrealized (Loss)   Fair Value 
   Amortized Cost   Unrealized Gain   Unrealized (Loss)    
Fair Value		 
U.S. Treasury Bonds  $18,293   $136   $—   $18,429 
U.S. Government Notes   22,148    82    —    22,230 
Corporate Debt Securities   4,303    3    —    4,306 
State and Municipal Bonds   1,275    7    —    1,282 
Total marketable securities  $46,019   $228   $—   $46,247 

 

Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020 (in thousands):

 

   Fair Value   Net Carrying Amount 
Due within one year  $31,438   $31,602 
Due after one year through five years   14,809    14,845 
   $46,247   $46,447 

 

The Company determined that the unrealized (losses) and gains are deemed to be temporary as of December 31, 2021 and 2020. Unrealized (losses) and gains generally are the result of increases in the risk premiums required by market participants rather than an adverse change in cash flows for a fundamental weakness in the credit quality of the issuer or underlying assets. The Company has the ability and intent to hold these investments until maturity. The Company does not consider the investment in marketable securities to be other-than-temporarily impaired at December 31, 2021 and 2020.

 

 
XML 32 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 5 - Fair Value Measurements

 

The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

● Level 1 – Quoted prices for identical assets or liabilities in active markets.
   
● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable.
   
● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates.

 

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

 

The carrying amounts of certain cash and cash equivalents, current portion of restricted cash, marketable securities, prepaid expenses and other current assets, accounts payable, current portion of lease liability and accrued expenses approximate fair value due to the short-term nature of these instruments.

 

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands):

 

       Fair Value Hierarchy 
December 31, 2021  Total   (Level 1)   (Level 2)   (Level 3) 
Assets                    
Marketable Securities:                    
U.S. Government Notes  $19,277   $—   $19,277   $— 
Corporate Debt Securities   9,065    —    9,065    — 
State and Municipal Bonds   250    —    250    — 
Total  $28,592   $—   $28,592   $— 

 

       Fair Value Hierarchy 
December 31, 2020  Total   (Level 1)   (Level 2)   (Level 3) 
Assets                    
Marketable Securities:                    
U.S. Treasury Bonds  $18,429   $18,429   $—   $— 
U.S. Government Notes   22,230    —    22,230    — 
Corporate Debt Securities   4,306    —    4,306    — 
State and Municipal Bonds   1,282    —    1,282    — 
Total  $46,247   $18,429   $27,818   $— 

 

U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable securities consisting of U.S. government notes, corporate debt securities and state and municipal bonds are classified as Level 2 and are valued using quoted market prices in markets that are not active.

 

 
XML 33 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leasehold Improvements and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Leasehold Improvements and Equipment

Note 6 – Leasehold Improvements and Equipment

 

Leasehold improvements and equipment, summarized by major category, consist of the following for the years ended December 31, 2021 and 2020 (in thousands):

 

   December 30,
2021		   December 31,
2020		 
Equipment  $1,640   $1,443 
Leasehold improvements   935    878 
Total   2,575    2,321 
Less: accumulated depreciation and amortization   1,037    797 
Leasehold improvements and equipment, net  $1,538   $1,524 

 

Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was approximately $244 thousand and $231 thousand, respectively. During the years ended December 31, 2021 and 2020, the Company purchased equipment and leasehold improvements of approximately $260 thousand and $6 thousand, respectively. During the year ended December 31, 2021, the Company recorded an asset write-off of approximately $6 thousand, including $4 thousand of related accumulated depreciation. The Company had no asset write-offs during the year ended December 31, 2020.

 
XML 34 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses and Other Liabilities
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in thousands):

 

     2021       2020 
   As of December 31, 
   2021   2020 
Payroll and incentives  $1,343   $1,094 
General and administrative expenses   195    280 
Research and development expenses   381    778 
Deferred revenue and other deferred liabilities *   932    643 
Total  $2,851   $2,795 

 

* At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement.

 
XML 35 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
 12 Months Ended
Dec. 31, 2021
Leases  
Leases

Note 8 – Leases

 

The Company has various lease agreements with terms up to 10 years, including leases of office space, a laboratory and manufacturing facility, and various equipment. Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

 

Operating lease obligations

 

On November 1, 2013, the Company entered into a 7-year lease for office space in Bedminster, New Jersey which commenced in June 2014 at a monthly rent of approximately $13,000, increasing to approximately $14,000 per month toward the end of the term.

 

On September 23, 2020, the Company entered into an amendment to the Bedminster lease. Pursuant to the amendment, the Company leased an additional 3,034 rentable square feet (“Expansion Premises”). The amendment became effective upon delivery to the Company of the Expansion Premises, which occurred on August 1, 2021, and extends the term of the lease for seven years from such date. There is no renewal option, no security deposit, no residual value or significant restrictions or covenants other than those customary in such arrangements. Except as expressly provided, all other terms, covenants, conditions and agreements as set forth in the lease will remain unchanged and in full force and effect.

 

 

On December 15, 2016, the Company entered into a 10-year, 3-month lease to consolidate our locations while expanding our laboratory and manufacturing facilities. The lease began August 2017. The monthly rent will start at approximately $43,000 increasing to approximately $64,000 in the final year. To obtain the laboratory and facility site, the Company was obligated to provide an initial security deposit of $586,000. This deposit was subsequently reduced and is currently $200,000 at December 31, 2021.

 

The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

 

The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s finance leases.

 

The Company incurred lease expense for its operating leases of approximately $852 thousand and $814 thousand for the years ended December 31, 2021 and 2020. The Company incurred amortization expense on its operating lease right-of-use assets of approximately $501 thousand and $485 thousand for the years ended December 31, 2021 and 2020, respectively.

 

Finance Leases

 

The Company incurred interest expense on its finance leases of approximately $3 thousand and $7 thousand for the years ended December 31, 2021 and 2020, respectively. The Company incurred amortization expense on its finance lease right-of-use assets of approximately $36 thousand and $59 thousand for the years ended December 31, 2021 and 2020, respectively.

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021 (in thousands):

 

Maturity of Lease Liabilities  Operating Lease Liabilities   Finance Lease Liabilities 
2022  $883   $22 
2023   922    2 
2024   962    - 
2025   1,004    - 
2026   1,046    - 
Thereafter   1,112    - 
Total undiscounted operating lease payments  $5,929   $24 
Less: Imputed interest   1,250    - 
Present value of operating lease liabilities  $4,679   $24 
           
Weighted average remaining lease term in years   6.1    0.9 
Weighted average discount rate   7.8%   7.8%

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2020 (in thousands):

 

Maturity of Lease Liabilities  Operating Lease Liabilities   Finance Lease Liabilities 
2021  $685   $34 
2022   645    19 
2023   677    2 
2024   710    - 
2025   745    - 
Thereafter   1,458    - 
Total undiscounted operating lease payments  $4,920   $55 
Less: Imputed interest   1,224    - 
Present value of operating lease liabilities  $3,696   $55 
           
Weighted average remaining lease term in years   6.7    1.7 
Weighted average discount rate   8.4%   8.1%

 

 
XML 36 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements, License and Other Research and Development Agreements
 12 Months Ended
Dec. 31, 2021
Research and Development [Abstract]  
Collaboration Agreements, License and Other Research and Development Agreements

Note 9 - Collaboration Agreements, License and Other Research and Development Agreements

 

Cystic Fibrosis Foundation Therapeutics Development Award

 

On November 19, 2020, the Company entered into an award agreement (the “Agreement”) with CFF, pursuant to which it received a Therapeutics Development Award of up to $4.2 million (the “Award”) (of which $484,249 had been previously received) to support the preclinical development (the “Development Program”) of the Company’s MAT2501 product candidate (the “Product”), a LNC oral formulation of the broad-spectrum aminoglycoside amikacin, for the treatment of pulmonary non-tubercular mycobacteria infections and other pulmonary diseases (the “Field”). On November 19, 2021, the Company and CFF entered into an Amendment to the Agreement which added an additional milestone payment in the amount of $321 thousand. The milestone payment was invoiced and the payment was received in the fourth quarter of 2021.

 

The first payment under the Agreement, in the amount of $650 thousand, became due upon execution of the Agreement. The Company invoiced the CFF in November 2020 and payment was subsequently received in February 2021. During 2021, the Company invoiced and received $2.5 million related to Agreement and the related deferred liability balance of $899 thousand is included in accrued expense and other current liabilities. The remainder of the Award will be paid to the Company upon the achievement of certain milestones related to the development program and progress of the Development Program, as set forth in the Agreement.

 

If the Company ceases to use commercially reasonable efforts directed to the development of MAT2501 in the Field, (an “Interruption”) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the Award actually received by the Company, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Agreement that covers the Product for use in treating infections in CF patients (the “CF Field”), and (2) a non-exclusive, worldwide license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.

 

Pursuant to the terms of the Agreement, the Company is obligated to make royalty payments to CFF contingent upon commercialization of the Product in the Field up to a maximum of five (5) times the Award or approximately $21.2 million (the “Royalty Cap”), payable in three equal annual installments following the first commercial sale of the Product, the first of which is due within 90 days following the first commercial sale of the Product. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction which will be applied against the Royalty Cap. In addition, the Company is also obligated to make up the two royalty payments of CFF of the approximately $4.2 million each, due in the calendar years in which specific net sales milestones are achieved.

 

The term of the Agreement commenced on November 19, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Agreement. Either CFF or the Company may terminate the agreement for cause, which includes the Company’s material failure to achieve certain development milestones. The Company’s payment obligations survive the termination of the Agreement.

 

The Company concluded that the CFF award is in the scope of ASC 808. Accordingly, as discussed in Note 3, the award amounts received from CFF upon achievement of certain milestones are recognized as credits to research and development expenses in the period the Development Program’s expenses are incurred. During the years ended December 31, 2021 and 2020, the Company recognized $2.2 million and $0.1 million, respectively, as credits to research and development expenses related to the CFF award. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.

 

 

Genentech Feasibility Study Agreement

 

On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study agreement will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. On December 13, 2019, per Genentech’s request, the Company billed Genentech for the total $100 thousand and recorded the upfront consideration as deferred revenue, which is recorded in accrued expenses on the consolidated balance sheets, and will recognize it over the term of the contract performance obligation period. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $33 thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.

 

Other Research and development agreements

 

The Company has financial obligations resulting from Cooperative Research and Development Agreements (“CRADAs”) entered into with the with the National Institute of Allergy and Infectious Diseases (“NIH”) as follows:

 

● On February 19, 2016, the Company agreed to provide funds in the amount of $200,000 per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of LNC platform drug products in patients with fungal, bacterial, or viral infections. The initial term of the CRADA was three years. On April 16, 2019, the Company renewed the CRADA for an additional three years with an annual funding commitment of $200,000.
   
● On April 2, 2019, the Company agreed to provide funds in the amount of $157,405 per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of LNC platform drug products in patients with fungal, bacterial, or viral infections. The term of the CRADA is three years.

 

License agreement

 

Through the acquisition of Aquarius, the Company acquired a license from Rutgers University, The State University of New Jersey (successor in interest to the University of Medicine and Dentistry of New Jersey) for the LNC platform delivery technology. The Second Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $100,000 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of $50,000 over the term of the license agreement.

 
XML 37 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments

Note 10 – Commitments

 

Royalty payment rights

 

On September 12, 2016 the Company conducted a final closing of a private placement offering to accredited investors of shares of the Company’s Series A Preferred Stock. As part of this offer, the investors received royalty payment rights if and when the Company generates sales of its MAT2203 or MAT2501 product candidates. Pursuant to the terms of the Series A Certificate of Designation, the Company may be required to pay royalties of up to $35 million per year. If and when the Company obtains FDA or the European Medicines Agency (“EMA”) approval of MAT2203 and/or MAT2501, which the Company does not expect to occur before 2023, if ever, and/or if the Company generates sales of such products, or the Company receives any proceeds from the licensing or other disposition of MAT2203 or MAT2501, the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the “Royalty Payment Rights”) equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $10 million per calendar year. The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033.

 

 

Employment agreements

 

The Company also has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur.

 

Other normal business operating agreements

 

In addition, in the course of normal business operations, the Company enters into agreements with contract service providers to assist in the performance of research & development and manufacturing activities. Expenditures to these third parties represent significant costs in clinical development and may require upfront payments and long-term commitments of cash. Subject to required notice periods and obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time.

 
XML 38 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 11 – Income Taxes

 

The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2021 and 2020, the Company does not believe any material uncertain tax positions were present. Accordingly, interest and penalties have not been accrued due to an uncertain tax position.

 

The components of the income tax provision are as follows (in thousands):

 

           
    Year Ended December 31, 
    2021    2020 
Current expense (benefit):          
Federal  $-   $- 
State   -    - 
Foreign   -    - 
Total current expense (benefit):  $-   $- 
           
Deferred expense (benefit):          
Federal  $-   $- 
State   -    - 
Foreign   -    - 
Total deferred expense (benefit):  $-   $- 
           
Total income tax expense (benefit):  $-   $- 

 

 

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows:

 

         
   Year Ended December 31, 
   2021   2020 
Income at US Statutory Rate   21.00%   21.00%
State Taxes, net of Federal benefit   1.97%   2.95%
Permanent Differences   (0.82)%   (1.28)%
Tax Credits   2.16%   0.75%
Valuation Allowance   (25.21)%   (24.53)%
Discrete items   0.91%   1.11%
 Effective income tax rate   0.00%   0.00%

 

The Company has no current income taxes payable other than certain state minimum taxes which are included in general and administrative expenses.

 

Significant components of the Company’s deferred tax assets (liabilities) for 2021 and 2020 consist of the following (in thousands):

 

         
   Year Ended December 31, 
   2021   2020 
Share-based Compensation  $3,575   $3,220 
Depreciation and Amortization   166    (119)
Accrued Liability   377    307 
Net Operating Loss Carry-forwards   24,076    19,927 
R&D Credit Carryforwards   3,207    2,264 
Other   (1)   (10)
IPR&D   (848)   (848)
ROU Asset   (1,186)   (921)
ROU Liability   1,315    1,045 
Total Deferred tax assets  $30,681   $24,865 
Valuation allowance   (31,023)   (25,206)
Net deferred tax asset (liability)  $(341)  $(341)

 

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law making several changes to the Internal Revenue Code. The changes include but are not limited to: allowing companies to carryback certain net operating losses, and increasing the amount of net operating loss carryforwards that corporations can use to offset taxable income. The tax law changes in the Act did not have a material impact on the Company’s income tax provision.

 

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible, and is impacted by the Company’s ability to carryforward losses to years in which the Company has taxable income. Due to the Company’s history of losses and lack of other positive evidence to support taxable income, the Company has recorded a valuation allowance against those deferred tax assets that are not expected to be realized. The valuation allowances were approximately $31.0 million, $25.2 million and $19.7 million as of December 31, 2021, 2020 and 2019, respectively, representing increases of approximately $5.8 million and $5.5 million for the years ending December 31, 2021 and 2020, respectively.

 

As of December 31, 2021, the Company had Federal net operating loss carryforwards of approximately $38.1 million which will begin to expire in 2032. In addition, the Company has federal net operating loss carryforwards of approximately $63.3 million which have an indefinite carryforward period. The Company also had federal and state research and development tax credit carryforwards of approximately $3.2 million. The federal net operating loss and tax credit carryforwards will expire at various dates beginning in 2033, if not utilized. The difference between the statutory tax rate and the effective tax rate is primarily attributable to the valuation allowance offsetting deferred tax assets.

 

 

Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 due to changes in ownership of the Company that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. The Company has not completed a study to determine whether it had undergone an ownership change since the Company’s inception

 

Sale of net operating losses (NOLs)

 

The Company recognized approximately $1.3 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively, in connection with the sale of certain State of New Jersey Net Operating Losses (“NOL”) and Research and Development (“R&D”) tax credits to a third party under the New Jersey Technology Business Tax Certificate Transfer Program. In addition, the Tax Cuts and Jobs Act, signed into law on December 22, 2017 imposes significant additional limitations on the deductibility of interest and limits NOL deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017. This NOL limitation was suspended for years 2018 through 2020 as a result of the CARES Act.

 
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders’ Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 12 – Stockholders’ Equity

 

At-The-Market Equity Offering

 

On July 2, 2020, the Company entered into an At-The-Market (“ATM”) Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $50,000,000, subject to certain limitations on the amount of common stock that may be offered and sold by the Company set forth in the Sales Agreement. BTIG will be paid a 3% commission on the gross proceeds from each sale. The Company may terminate the Sales Agreement at any time; BTIG may terminate the Sales Agreement in certain limited circumstances. During 2021, BTIG sold 3,023,147 shares of the Company’s common stock generating gross proceeds of approximately $5.8 million and net proceeds of approximately $5.6 million, after deducting BTIG’s commission on gross proceeds. During 2020, the Company did not sell any shares of its common stock under the ATM Sales Agreement.

 

Common Stock

 

On September 3, 2021, the Company issued 1,500,000 unregistered shares of its common stock pursuant to the Agreement and Plan of Merger by and among the Company, Saffron Merger Sub, Inc., Aquarius Biotechnologies Inc. (“Aquarius”), and J Carl Craft, as holder representative, dated January 19, 2015, as subsequently amended on September 3, 2021 (the “Aquarius Merger Agreement”), to the holders of Aquarius Biotechnologies Inc., as defined in the Aquarius Merger Agreement. The shares were issued in place of certain milestone payments previously included under the Aquarius Merger Agreement upon the achievement of specified development milestones. The Company recorded a $1.2 million research and development expense related to the issuance of the 1,500,000 shares based on the closing price of the Company’s common stock of $0.80 on the date of issuance.

 

On January 14, 2020, the Company closed on an underwritten public offering of 32,260,000 shares of its common stock at a purchase price of $1.55 per share. The Company generated gross proceeds of approximately $50.0 million and net proceeds of approximately $46.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to approximately 4.8 million additional shares of its common stock on the same terms and conditions. No additional shares of the Company’s common stock were sold pursuant to this option.

 

 

Preferred Stock

 

In accordance with the Certificate of Incorporation, the Company is authorized to issue 10,000,000 preferred shares at a par value of $0.001. In connection with a private placement of Series A Preferred Stock, on July 26, 2016, the Company filed the Series A Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series A Preferred Stock. Pursuant to the Series A Certificate of Designation, the Company designated 1,600,000 shares of the Company’s previously undesignated preferred shares as Series A Preferred Stock. In connection with a public offering of Series B Preferred Stock, on June 19, 2018, the Company filed the Series B Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Stock. Pursuant to the Series B Certificate of Designation, the Company designated 8,000 shares of the Company’s previously undesignated preferred shares as Series B Preferred Stock.

 

Series B Preferred Stock

 

During 2021 and prior to June 19, 2021, 143 shares of Series B Preferred Stock were converted by shareholders resulting in the issuance of 286,000 shares of common stock. On June 19, 2021, all 4,218 remaining shares of Series B Preferred Stock were automatically converted into 2,000 shares of the Company’s common stock resulting in the issuance of 8,436,000 shares of common stock. As of December 31, 2021 and December 31, 2020, there were 0 and 4,361 shares of Series B Preferred stock outstanding, respectively.

 

Conversion:

 

Prior to the automatic conversion of Series B Preferred Stock on June 19, 2021, and subject to certain ownership limitations, each share of Series B Preferred Stock was convertible into shares of the Company’s common stock at any time at the option of the holder at an initial conversion price of $0.50 per share subject to adjustment for reverse splits, stock combinations and similar changes as provided in the Certificate of Designation. Based on the conversion price and number of shares outstanding on June 19, 2021, the Series B Preferred Stock were converted into 8,436,000 shares of common stock.

 

Dividends:

 

Subject to certain ownership limitations, holders of the Series B Preferred Stock received dividends paid in the Company’s common stock as follows: (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling 1,687,200 and 1,365,600 shares of common stock, respectively.

 

Warrants

 

All warrants issued by the Company are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company’s capital stock or other similar changes to the equity structure of the Company. The warrants do not have a redemption feature. They may be exercised on a cashless basis at the holder’s option.

 

The warrants are classified as equity instruments.

 

 

As of December 31, 2021, the Company had outstanding warrants to purchase an aggregate of 988,000 shares of common stock at exercise prices ranging from $0.50 to $0.75 per share, and with expiration dates between December 31, 2022 and June 21, 2023. A summary of warrants outstanding as of December 31, 2021 and 2020 is presented below, all of which are fully vested (in thousands):

 

   Shares 
Outstanding at December 31, 2019   5,397 
Issued   - 
Exercised   (2,549)
Tendered   - 
Expired   (1,493)
Outstanding at December 31, 2020   1,328*
Outstanding at January 01, 2021     
Issued   - 
Exercised   (320)**
Tendered   - 
Expired   (20)
Outstanding at December 31, 2021   988***

 

* Weighted average exercise price for outstanding warrants is $0.55.
** Converted into approximately 115 thousand shares of common stock.
*** Weighted average exercise price for outstanding warrants is $0.56.

 
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accumulated Other Comprehensive (Loss)/Income
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Accumulated Other Comprehensive (Loss)/Income

Note 13 – Accumulated Other Comprehensive (Loss)/Income

 

The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the years ended December 31, 2021 and 2020 (in thousands):

 

Schedule of Components of Accumulated Other Comprehensive (Loss)/Income 

    Net Unrealized (Losses)/Gains on Available-for-Sale Securities     Accumulated Other Comprehensive (Loss)/Gain  
Balance, December 31, 2019   $ (1 )   $ (1 )
Net unrealized gain on securities available-for-sale     237       237  
Reclassification of realized gain on securities available-for-sale to net loss     (8 )     (8 )
Net current period other comprehensive gain     229       229  
Balance, December 31, 2020   $ 228     $ 228  
Net unrealized loss on securities available-for-sale     (373 )     (373 )
Net current period other comprehensive loss     (374 )     (374 )
Balance, December 31, 2021   $ (146 )   $ (146 )

 

All components of accumulated other comprehensive (loss)/income are net of tax.

 
XML 41 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation

Note 14 – Stock-based Compensation

 

The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”) provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. Options under the Plan may be granted at prices not less than 100% of the fair value of the shares on the date of grant as determined by the Compensation Committee of the Board of Directors. The Compensation Committee determines the period over which the options become exercisable subject to certain restrictions as defined in the Plan, with the current outstanding options generally vesting over three or four years. The term of the options is no longer than ten years. As of December 31, 2021, the Company had 36,952,460 shares of common stock authorized for issuance under the Plan.

 

With the approval of the Board of Directors and a majority of shareholders, effective May 8, 2014, the Plan was amended and restated. The amendment provides for an automatic increase in the number of shares of common stock available for issuance under the Plan each January (with Board approval), commencing January 1, 2015 in an amount up to four percent (4%) of the total number of shares of common stock outstanding on the preceding December 31st.

 

 

The Company recognized stock-based compensation expense (options and restricted share grants) in its consolidated statements of operations as follows (in thousands):

 

Schedule of Recognized Stock-Based Compensation 

   Year Ended December 31, 
   2021   2020 
Research and Development  $1,870   $1,897 
General and Administrative   2,422    2,668 
Total  $4,292   $4,565 

 

The following table contains information about the Company’s stock plan at December 31, 2020:

 

Schedule of Equity Compensation Plan by Arrangements 

    Awards Reserved for Issuance     Awards Issued & Exercised     Awards Available for Grant  
2013 Equity Compensation Plan (in thousands)     36,952 *     32,669 **     4,283  

 

* Increased by 8,005 thousand on January 1, 2021, representing 4% of the total number of shares of common stock outstanding on December 31, 2020.
** Includes both stock grants and option grants

 

The following table summarizes the Company’ stock option activity and related information for the period from January 1, 2020 to December 31, 2021 (options in thousands):

 

Schedule of Stock Option Activity 

   Number of Options   Weighted Average Exercise Price   Weighted Average Contractual Term in Years 
Outstanding at December 31, 2019   17,529   $1.11    6.2 
Granted   6,501   $1.59      
Exercised   (826)   0.74      
Forfeited   (72)  $1.11      
Cancelled   -    -      
Expired   (581)  $1.25      
Outstanding at December 31, 2020   22,551   $1.26    6.9 
                
Granted   10,976   $1.11      
Exercised   (1,077)  $0.60      
Forfeited   (2,824)  $1.08      
Cancelled   -    -      
Expired   (1,441)  $1.98      
Outstanding at December 31, 2021   28,184   $1.21    7.2 

 

The following table summarizes outstanding options at December 31, 2021, by their exercise price (options in thousands):

 

Range of Exercise Prices  Number Outstanding   Weighted Average Exercise Price Per Share 
$0.41 - $0.69   1,935   $0.49 
$0.74 - $1.12   15,940   $0.93 
$1.24 - $1.61   6,525   $1.35 
$2.27 - $3.32   3,784   $2.50 
    28,184   $1.21 

 

As of December 31, 2021, the number of vested shares underlying outstanding options was 14,625,397 at a weighted average exercise price of $1.20. The aggregate intrinsic value of in-the-money options outstanding as of December 31, 2021 was $2.5 million. The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price of $1.01 on December 31, 2021, and the exercise price of options, multiplied by the number of options. As of December 31, 2021, there was approximately $11.7 million of total unrecognized share-based compensation. Such costs are expected to be recognized over a weighted average period of approximately 2.9 years.

 

 

All outstanding options expire ten years from date of grant. Options granted to employees prior to 2018 vest in equal monthly installments over three years. Beginning in 2018, options granted to employees vest over four years, with 25% of the shares vesting on the first annual anniversary of grant and the remaining shares vesting in 36 equal monthly installments over the following 3 years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives.

 

During the years ended December 31, 2021 and 2020, the Company granted restricted stock awards for 31,769 and 379,385 shares of common stock, respectively. These awards are typically granted to members of the Board of Directors as payment in lieu of cash fees or as payment to a vendor pursuant to a consulting agreement. The Company values restricted stock awards at the fair market value on the date of grant. The Company recorded the value of these restricted awards as general and administrative expense of approximately $100 thousand and $292 thousand in the consolidated statement of operations for the years ended December 31, 2021 and 2020, respectively.

 

The Company recognizes compensation expense for stock option awards and restricted stock awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of awards granted subject to a vendor’s consulting agreement, whereby the award vesting period and the service period defined pursuant to the terms of the consulting agreement may be different. Beginning January 1, 2020, stock options issued to consultants are recorded at fair value on the date of grant and the award is recognized as an expense on a straight-line basis over the requisite service period. The following weighted-average assumptions were used to calculate share-based compensation for the comparative periods presented:

 

 Schedule of Stock Option Awards and Restricted Stock Awards

    For the Year Ended December 31,  
    2021     2020  
Volatility   98.4% -101.6 %   100.5% - 107.4 %
Risk-free interest rate     0.47% - 1.28 %     0.34% - 1.74 %
Dividend yield     0.0 %     0.0 %
Expected life     6.0 years       6.0 years  

 

The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Hence, the Company uses the “simplified method” described in Staff Accounting Bulletin (SAB) 107 to estimated the expected term of share option grants.

 

The expected stock price volatility assumption is based the Company’s historical stock price volatility.

 
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 15 – Subsequent Events

 

None
XML 43 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of presentation and principles of consolidation

Basis of presentation and principles of consolidation

 

The accompanying audited consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.

 

 
COVID-19

COVID-19

 

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn.

 

The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the year ended December 31, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.

 
Use of estimates

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Significant items subject to such estimates and assumptions include, but are not limited to, the Company’s research and development expenses, the assessment of the impairment of goodwill and intangible assets, level 3 fair value measurement of financial instruments, income tax valuations, the determination of stock-based compensation and contingent consideration.

 
Segment and geographic information

Segment and geographic information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment.

 
Cash, cash equivalents and restricted cash

Cash, cash equivalents and restricted cash

 

The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. For a complete disclosure of the Company’s cash, cash equivalents and restricted cash, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.

 
Marketable Securities

Marketable Securities

 

Marketable securities, all of which are available-for-sale, consist of U.S. treasury bonds, U.S. government notes, corporate debt securities and state and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive (loss)/income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in other income, net. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in other income, net. For a complete disclosure of the Company’s marketable securities, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.

 

 
Concentration of credit risk

Concentration of credit risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company’s investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. Balances are maintained at U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. The Company has not experienced any credit losses associated with its balances in such accounts.

 
Leasehold improvements and equipment

Leasehold improvements and equipment

 

Equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation on equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Capitalized costs associated with leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining term of the lease.

 
Goodwill and other intangible assets

Goodwill and other intangible assets

 

Goodwill is recorded when consideration paid for an acquired entity exceeds the fair value of the net assets acquired. Goodwill is not amortized but rather is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances indicate the goodwill may be impaired. U.S. GAAP provides that the Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If the Company determine this is the case, the Company can perform further analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any.

 

A reporting unit is an operating segment, or one level below an operating segment. Historically, the Company has conducted its business in a single operating segment and reporting unit. For the years ended December 31, 2021 and 2020, the Company assessed goodwill impairment by performing a qualitative test for its reporting unit. As part of the qualitative review, the Company considered its cash position and its ability to obtain additional financing in the near term to meet its operational and strategic goals and substantiate the value of its business. Based on the results of the Company’s assessment, it was determined that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amount. There were no impairments of goodwill during the years ended December 31, 2021 and 2020. If a nonrecurring fair value measurement for a goodwill impairment was required, sufficient information will be provided to permit reconciliation of the fair value of the asset categorized within the fair value hierarchy as level 3 to the amounts presented in the statement of financial position.

 

Indefinite lived intangible assets are composed of in-process research and development (“IPR&D”) and represent projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition. These IPR&D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020.

 
Leases

Leases

 

The Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, “Leases”, establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required.

 

 
Preferred stock dividends

Preferred stock dividends

 

Subject to provisions detailed more fully in Note 12, Stockholders’ Equity, shares of Series B Preferred Stock earned dividends at rates of 10%, 15% and 20% once per year on the first, second and third anniversary, respectively, of June 19, 2018. The dividends were paid when earned to the holders of the Series B Preferred Stock in the form of shares of the Company’s common stock.

 
Income taxes

Income taxes

 

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.

 

The Company adopted the provisions of Accounting Standard Codification 740-10 and has analyzed its filing positions in 2021 and 2020 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2021.

 

Since the Company incurred net operating losses in every tax year since inception, the 2014 through 2020 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.

 
Fair Value Measurements

Fair Value Measurements

 

As defined in ASC 820 “Fair Value Measurement”, fair value measurements should be disclosed separately by three levels of the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs (quoted prices in active markets) and minimized the use of unobservable inputs (the Company’s assumptions) when developing fair value measurements, in accordance with the established fair value hierarchy. For a complete disclosure of the Company’s fair value measurements, see Note 5 – Fair Value Measurements.

 
Stock-based compensation

Stock-based compensation

 

Stock-based compensation to employees consist of stock option grants and restricted shares that are recognized in the consolidated statement of operations based on their fair values at the date of grant.

 

The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, Equity-Based Payments to Non-Employees based upon the fair-value of the underlying instrument. The equity instruments, consisting of stock options granted to consultants, are valued using the Black-Scholes valuation model. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.

 

The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.

 

 
Basic and diluted net loss per common share

Basic and diluted net loss per common share

 

Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a “participating security”). The Company considered its Preferred Stock to be participating securities because they included rights to participate in dividends with the common stock.

 

Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.

 

During the years ended December 31, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The reconciliation of the diluted shares as of December 31, 2021 and 2020 are as follows (in thousands):

 

   As of December 31, 
   2021   2020 
Stock options   28,184    22,551 
Preferred Stock and accrued dividend upon conversion   -    8,722 
Warrants   988    1,328 
Total   29,172    32,601 

 
Revenue recognition

Revenue recognition

 

Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied.

 

At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

 

For the years ended December 31, 2020, the Company’s revenues primarily consist of a research grant to provide research and development services to the Cystic Fibrosis Foundation (“CFF”). The grant contract has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this grant. The Company had approximately $125 thousand of CFF research grant revenue for the year ended December 31, 2020.

 

On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech paid the Company a total of $100 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. The Agreement has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this Agreement. As certain Agreement performance obligations in this agreement were completed, disaggregation of revenue is not required. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $33 thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.

 

 
Collaboration Agreements

Collaboration Agreements

 

The Company assess whether its collaboration agreements are subject to ASC Topic 808, Collaborative Arrangements (Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company will apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If the Company determines a performance obligation within the arrangement is with a customer, the Company applies the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election.

 

The terms of such arrangements typically include payments to the Company for one or more of the following: up-front fees; development and regulatory payments; product supply services; research and development cost reimbursements; profit-sharing arrangements; and royalties on certain products if they are successfully commercialized. As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.

 

Up-front License Fees: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company would recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally would occur at or near the inception of the contract. For licenses that are bundled with other promises, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. The Company will evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

 

Research and Development Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company will evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which the Company will recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis.

 

Research and Development Cost Reimbursements: The Company’s collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer or partner, and they are distinct from the licenses provided to the Company’s collaboration partners, these promises are accounted for as a separate performance obligation which the Company estimates using internal development costs incurred and projections through the term of the arrangements. The Company records revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if the Company concludes that its collaboration partner is not a customer for those collaborative research and development activities, it presents such payments as a reduction of research and development expenses.

 

 

Research and Development Arrangement: Under the terms of our research and development agreement with the CFF Agreement, the Company did not account for this arrangement in accordance with Topic 606. However, the Company has determined that it is a partner under a collaboration agreement as it shares in the risks and rewards that would be received if the product is successful and commercialized. Therefore the funds received under the terms of this agreement will be recorded as reimbursements of research and development costs and reduce the research and development expenses in the Company’s Statements of Operations and Comprehensive Income/(Loss). The Company records the reimbursements for certain materials and other research and development costs associated with the agreement when it is probable that a significant reversal in the amount of cumulative costs have been recognized. As of December 31, 2021 and 2020, the Company recognized approximately $2.2 million and $0.1 million, respectively, of reimbursed research and development costs associated with the CFF Agreement. For a complete disclosure of the CFF Agreement, see Note 9 – Collaboration Agreements, License and other Research and Development Agreements.

 
Research and development expenses

Research and development expenses

 

Research and development expenses primarily consist of costs associated with the preclinical and clinical development of our product candidate portfolio, including the following:

 

● external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and
   
● employee-related expenses, including salaries, benefits and share-based compensation expense.

 

Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.

 

All research and development expenses are charged to operations as incurred in accordance with FASB ASC Topic 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.

 

Accrued Research and Development Expenses

 

As part of the process of preparing the Company’s financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. Certain of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and adjust if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.

 

The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjust the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

 

 
Patent expenses

Patent expenses

 

Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.

 
Other comprehensive income/(loss)

Other comprehensive income/(loss)

 

Other comprehensive income/(loss) consists of net gains/(losses) and unrealized losses on marketable securities available-for-sale and is presented in the Consolidated Statements of Operations.

 
Recently adopted accounting pronouncements

Recently adopted accounting pronouncements

 

In December 2019, the FASB Issued Accounting Standard Update 2019-12, “Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes”. This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted the new standard effective January 1, 2021 with no material impact on the Company’s consolidated financial statements.

 
XML 44 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Anti-dilutive Securities

   As of December 31, 
   2021   2020 
Stock options   28,184    22,551 
Preferred Stock and accrued dividend upon conversion   -    8,722 
Warrants   988    1,328 
Total   29,172    32,601 
XML 45 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)
 12 Months Ended
Dec. 31, 2021
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Balance Sheets to the total of the amounts in the Consolidated Statements of Cash Flows as of December 31, 2021, December 31, 2020 and December 31, 2019 (in thousands):

 

   December 31,
2021		   December 31,
2020		   December 31,
2019		 
Cash and cash equivalents  $21,030   $12,432   $22,170 
Restricted cash included in current/long term assets   250    336    586 
Cash, cash equivalents and restricted cash in the statements of cash flows  $21,280   $12,768   $22,756 
Summary of Marketable Securities

The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following (in thousands):

 

   Amortized Cost   Unrealized Gain   Unrealized (Loss)   Fair Value 
   Amortized Cost  

Unrealized

Gain

   Unrealized (Loss)    
Fair Value		 
U.S. Government Notes  $19,395   $2   $(120)  $19,277 
Corporate Debt Securities   9,092    —    (27)   9,065 
State and Municipal Bonds   250    —    —    250 
Total marketable securities  $28,737   $2   $(147)  $28,592 
 

The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following (in thousands):

 

   Amortized Cost   Unrealized Gain   Unrealized (Loss)   Fair Value 
   Amortized Cost   Unrealized Gain   Unrealized (Loss)    
Fair Value		 
U.S. Treasury Bonds  $18,293   $136   $—   $18,429 
U.S. Government Notes   22,148    82    —    22,230 
Corporate Debt Securities   4,303    3    —    4,306 
State and Municipal Bonds   1,275    7    —    1,282 
Total marketable securities  $46,019   $228   $—   $46,247 
 
Schedule of Maturities of Debt Securities Available-for-sale

Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021 (in thousands):

 

   Fair Value   Net Carrying Amount 
Due within one year  $8,257   $8,310 
Due after one year through five years   20,335    20,402 
   $28,592   $28,712 
 

Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020 (in thousands):

 

   Fair Value   Net Carrying Amount 
Due within one year  $31,438   $31,602 
Due after one year through five years   14,809    14,845 
   $46,247   $46,447 
 
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurement of Assets and Liabilities

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands):

 

       Fair Value Hierarchy 
December 31, 2021  Total   (Level 1)   (Level 2)   (Level 3) 
Assets                    
Marketable Securities:                    
U.S. Government Notes  $19,277   $—   $19,277   $— 
Corporate Debt Securities   9,065    —    9,065    — 
State and Municipal Bonds   250    —    250    — 
Total  $28,592   $—   $28,592   $— 

 

       Fair Value Hierarchy 
December 31, 2020  Total   (Level 1)   (Level 2)   (Level 3) 
Assets                    
Marketable Securities:                    
U.S. Treasury Bonds  $18,429   $18,429   $—   $— 
U.S. Government Notes   22,230    —    22,230    — 
Corporate Debt Securities   4,306    —    4,306    — 
State and Municipal Bonds   1,282    —    1,282    — 
Total  $46,247   $18,429   $27,818   $— 
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leasehold Improvements and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Leasehold Improvements and Equipment

Leasehold improvements and equipment, summarized by major category, consist of the following for the years ended December 31, 2021 and 2020 (in thousands):

 

   December 30,
2021		   December 31,
2020		 
Equipment  $1,640   $1,443 
Leasehold improvements   935    878 
Total   2,575    2,321 
Less: accumulated depreciation and amortization   1,037    797 
Leasehold improvements and equipment, net  $1,538   $1,524 
XML 48 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses and Other Liabilities (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in thousands):

 

     2021       2020 
   As of December 31, 
   2021   2020 
Payroll and incentives  $1,343   $1,094 
General and administrative expenses   195    280 
Research and development expenses   381    778 
Deferred revenue and other deferred liabilities *   932    643 
Total  $2,851   $2,795 

 

* At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement.
XML 49 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Leases  
Schedule of Maturity of Operating and Finance Leases Liabilities

The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021 (in thousands):

 

Maturity of Lease Liabilities  Operating Lease Liabilities   Finance Lease Liabilities 
2022  $883   $22 
2023   922    2 
2024   962    - 
2025   1,004    - 
2026   1,046    - 
Thereafter   1,112    - 
Total undiscounted operating lease payments  $5,929   $24 
Less: Imputed interest   1,250    - 
Present value of operating lease liabilities  $4,679   $24 
           
Weighted average remaining lease term in years   6.1    0.9 
Weighted average discount rate   7.8%   7.8%

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2020 (in thousands):

 

Maturity of Lease Liabilities  Operating Lease Liabilities   Finance Lease Liabilities 
2021  $685   $34 
2022   645    19 
2023   677    2 
2024   710    - 
2025   745    - 
Thereafter   1,458    - 
Total undiscounted operating lease payments  $4,920   $55 
Less: Imputed interest   1,224    - 
Present value of operating lease liabilities  $3,696   $55 
           
Weighted average remaining lease term in years   6.7    1.7 
Weighted average discount rate   8.4%   8.1%
XML 50 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Provision

The components of the income tax provision are as follows (in thousands):

 

           
    Year Ended December 31, 
    2021    2020 
Current expense (benefit):          
Federal  $-   $- 
State   -    - 
Foreign   -    - 
Total current expense (benefit):  $-   $- 
           
Deferred expense (benefit):          
Federal  $-   $- 
State   -    - 
Foreign   -    - 
Total deferred expense (benefit):  $-   $- 
           
Total income tax expense (benefit):  $-   $- 
Schedule of Effective Income Tax Rate Reconciliation

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows:

 

         
   Year Ended December 31, 
   2021   2020 
Income at US Statutory Rate   21.00%   21.00%
State Taxes, net of Federal benefit   1.97%   2.95%
Permanent Differences   (0.82)%   (1.28)%
Tax Credits   2.16%   0.75%
Valuation Allowance   (25.21)%   (24.53)%
Discrete items   0.91%   1.11%
 Effective income tax rate   0.00%   0.00%
Schedule of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets (liabilities) for 2021 and 2020 consist of the following (in thousands):

 

         
   Year Ended December 31, 
   2021   2020 
Share-based Compensation  $3,575   $3,220 
Depreciation and Amortization   166    (119)
Accrued Liability   377    307 
Net Operating Loss Carry-forwards   24,076    19,927 
R&D Credit Carryforwards   3,207    2,264 
Other   (1)   (10)
IPR&D   (848)   (848)
ROU Asset   (1,186)   (921)
ROU Liability   1,315    1,045 
Total Deferred tax assets  $30,681   $24,865 
Valuation allowance   (31,023)   (25,206)
Net deferred tax asset (liability)  $(341)  $(341)
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders’ Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Summary of Shareholders Equity Warrants Outstanding

   Shares 
Outstanding at December 31, 2019   5,397 
Issued   - 
Exercised   (2,549)
Tendered   - 
Expired   (1,493)
Outstanding at December 31, 2020   1,328*
Outstanding at January 01, 2021     
Issued   - 
Exercised   (320)**
Tendered   - 
Expired   (20)
Outstanding at December 31, 2021   988***

 

* Weighted average exercise price for outstanding warrants is $0.55.
** Converted into approximately 115 thousand shares of common stock.
*** Weighted average exercise price for outstanding warrants is $0.56.

 
XML 52 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accumulated Other Comprehensive (Loss)/Income (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive (Loss)/Income

The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the years ended December 31, 2021 and 2020 (in thousands):

 

Schedule of Components of Accumulated Other Comprehensive (Loss)/Income 

    Net Unrealized (Losses)/Gains on Available-for-Sale Securities     Accumulated Other Comprehensive (Loss)/Gain  
Balance, December 31, 2019   $ (1 )   $ (1 )
Net unrealized gain on securities available-for-sale     237       237  
Reclassification of realized gain on securities available-for-sale to net loss     (8 )     (8 )
Net current period other comprehensive gain     229       229  
Balance, December 31, 2020   $ 228     $ 228  
Net unrealized loss on securities available-for-sale     (373 )     (373 )
Net current period other comprehensive loss     (374 )     (374 )
Balance, December 31, 2021   $ (146 )   $ (146 )
XML 53 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Recognized Stock-Based Compensation

The Company recognized stock-based compensation expense (options and restricted share grants) in its consolidated statements of operations as follows (in thousands):

 

Schedule of Recognized Stock-Based Compensation 

   Year Ended December 31, 
   2021   2020 
Research and Development  $1,870   $1,897 
General and Administrative   2,422    2,668 
Total  $4,292   $4,565 
Schedule of Equity Compensation Plan by Arrangements

The following table contains information about the Company’s stock plan at December 31, 2020:

 

Schedule of Equity Compensation Plan by Arrangements 

    Awards Reserved for Issuance     Awards Issued & Exercised     Awards Available for Grant  
2013 Equity Compensation Plan (in thousands)     36,952 *     32,669 **     4,283  

 

* Increased by 8,005 thousand on January 1, 2021, representing 4% of the total number of shares of common stock outstanding on December 31, 2020.
** Includes both stock grants and option grants
Schedule of Stock Option Activity

The following table summarizes the Company’ stock option activity and related information for the period from January 1, 2020 to December 31, 2021 (options in thousands):

 

Schedule of Stock Option Activity 

   Number of Options   Weighted Average Exercise Price   Weighted Average Contractual Term in Years 
Outstanding at December 31, 2019   17,529   $1.11    6.2 
Granted   6,501   $1.59      
Exercised   (826)   0.74      
Forfeited   (72)  $1.11      
Cancelled   -    -      
Expired   (581)  $1.25      
Outstanding at December 31, 2020   22,551   $1.26    6.9 
                
Granted   10,976   $1.11      
Exercised   (1,077)  $0.60      
Forfeited   (2,824)  $1.08      
Cancelled   -    -      
Expired   (1,441)  $1.98      
Outstanding at December 31, 2021   28,184   $1.21    7.2 
Summary of Outstanding Options

The following table summarizes outstanding options at December 31, 2021, by their exercise price (options in thousands):

 

Range of Exercise Prices  Number Outstanding   Weighted Average Exercise Price Per Share 
$0.41 - $0.69   1,935   $0.49 
$0.74 - $1.12   15,940   $0.93 
$1.24 - $1.61   6,525   $1.35 
$2.27 - $3.32   3,784   $2.50 
    28,184   $1.21 
Schedule of Stock Option Awards and Restricted Stock Awards

 Schedule of Stock Option Awards and Restricted Stock Awards

    For the Year Ended December 31,  
    2021     2020  
Volatility   98.4% -101.6 %   100.5% - 107.4 %
Risk-free interest rate     0.47% - 1.28 %     0.34% - 1.74 %
Dividend yield     0.0 %     0.0 %
Expected life     6.0 years       6.0 years  
XML 54 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Liquidity and Plan of Operations (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 14, 2020
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accumulated deficit     $ 131,634,208 $ 107,507,193  
Net loss     23,300,000 22,400,000  
Gross proceeds from public offering of common stock $ 50,000,000.0   5,580,471 46,704,210  
Net proceeds from public offering of common stock 46,700,000        
Cash and cash equivalents     21,029,806 12,432,481 $ 22,170,000
Marketable securities     28,592,049 $ 46,246,573  
Restricted cash     $ 300,000    
Underwritten Public Offering [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Gross proceeds from public offering of common stock 50,000,000.0        
Net proceeds from public offering of common stock $ 46,700,000        
At The Market Sales Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from public offering, gross   $ 5,800,000      
Gross proceeds from public offering of common stock   $ 5,600,000      
Common Stock [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of underwritten public offering of common stock 32,260,000   3,023,147 32,260,000  
Common Stock [Member] | Underwritten Public Offering [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of underwritten public offering of common stock 32,600,000        
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Anti-dilutive Securities (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive earnings per share, amount 29,172 32,601
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive earnings per share, amount 28,184 22,551
Preferred Stock and Accrued Dividend Upon Conversion [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive earnings per share, amount 8,722
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive earnings per share, amount 988 1,328
XML 56 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Details Narrative)
 12 Months Ended
Dec. 12, 2019
USD ($)
Jun. 19, 2018
Dec. 31, 2021
USD ($)
Segment
Dec. 31, 2020
USD ($)
Property, Plant and Equipment [Line Items]        
Number of operating segment | Segment     1  
Goodwill impairments     $ 0 $ 0
Accrual for interest or penalties     0  
Revenue     33,333 158,333
CFF Agreement [Member]        
Property, Plant and Equipment [Line Items]        
Research and Development, costs incurred     2,200,000 100,000
Genentech [Member]        
Property, Plant and Equipment [Line Items]        
Revenue     33,000 33,000
Per Molecules [Member] | Genentech [Member]        
Property, Plant and Equipment [Line Items]        
Revenue     $ 33,000 33,000
CFF Research Grant Revenue [Member]        
Property, Plant and Equipment [Line Items]        
Revenue       $ 125,000
Feasibility Study Agreement [Member] | Three Molecules [Member] | Genentech [Member]        
Property, Plant and Equipment [Line Items]        
Proceeds from sale of productive assets $ 100,000      
Feasibility Study Agreement [Member] | Per Molecules [Member] | Genentech [Member]        
Property, Plant and Equipment [Line Items]        
Proceeds from sale of productive assets $ 33,000      
Series B Preferred Stock [Member] | First Anniversary [Member]        
Property, Plant and Equipment [Line Items]        
Preferred Stock, Dividend Rate, Percentage   10.00%    
Series B Preferred Stock [Member] | Second Anniversary [Member]        
Property, Plant and Equipment [Line Items]        
Preferred Stock, Dividend Rate, Percentage   15.00%    
Series B Preferred Stock [Member] | Third Anniversary [Member]        
Property, Plant and Equipment [Line Items]        
Preferred Stock, Dividend Rate, Percentage   20.00%    
Minimum [Member]        
Property, Plant and Equipment [Line Items]        
Leasehold improvements and equipment, useful life     3 years  
Maximum [Member]        
Property, Plant and Equipment [Line Items]        
Leasehold improvements and equipment, useful life     10 years  
XML 57 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash and Cash Equivalents [Abstract]      
Cash and cash equivalents $ 21,029,806 $ 12,432,481 $ 22,170,000
Restricted cash included in current/long term assets 250,000 336,000 586,000
Cash, cash equivalents and restricted cash in the statements of cash flows $ 21,280,000 $ 12,768,000 $ 22,756,000
XML 58 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Marketable Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost $ 28,737 $ 46,019
Unrealized Gain 2 228
Unrealized (Loss) 147
Fair Value 28,592 46,247
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (147)
US Government Agencies Debt Securities [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 19,395 22,148
Unrealized Gain 2 82
Unrealized (Loss) 120
Fair Value 19,277 22,230
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (120)
Corporate Debt Securities [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 9,092 4,303
Unrealized Gain 3
Unrealized (Loss) 27
Fair Value 9,065 4,306
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (27)
US States and Political Subdivisions Debt Securities [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost 250 1,275
Unrealized Gain 7
Unrealized (Loss)
Fair Value 250 1,282
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax
US Treasury Securities [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Amortized Cost   18,293
Unrealized Gain   136
Unrealized (Loss)  
Fair Value   18,429
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax  
XML 59 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Maturities of Debt Securities Available-for-sale (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents [Abstract]    
Due within one year, fair value $ 8,257 $ 31,438
Due within one year, net carrying amount 8,310 31,602
Due after one year through five years, fair value 20,335 14,809
Due after one year through five years, net carrying amount 20,402 14,845
Debt Securities Available-for-sale, fair value 28,592 46,247
Debt Securities Available-for-sale, net carrying amount $ 28,712 $ 46,447
XML 60 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents [Abstract]    
Marketable securities, unrealized gain loss $ 374 $ 238
Net realized loss 0 9
Net accumulated unrealized gain $ 145 $ 228
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Fair Value Measurement of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities $ 28,592 $ 46,247
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 18,429
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 28,592 27,818
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities
US Government Agencies Debt Securities [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 19,277 22,230
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 19,277 22,230
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities
Corporate Debt Securities [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 9,065 4,306
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 9,065 4,306
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities  
State and Municipal Bonds [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities  
US States and Political Subdivisions Debt Securities [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 250 1,282
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities 250 1,282
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities
US Treasury Securities [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities   18,429
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities   18,429
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities  
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]    
Marketable Securities  
XML 62 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Leasehold Improvements and Equipment (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total $ 2,575,000 $ 2,321,000
Less: accumulated depreciation and amortization 1,037,000 797,000
Leasehold improvements and equipment, net 1,537,728 1,523,950
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total 1,640,000 1,443,000
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Total $ 935,000 $ 878,000
XML 63 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leasehold Improvements and Equipment (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation and amortization expenses $ 244,000 $ 231,000
Purchase of equipment and leasehold improvements 260,380 5,749
Asset write-off 6,000 $ 0
Accumulated depreciation expense $ 4,000  
XML 64 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Accrued Expenses (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and incentives $ 1,343,000 $ 1,094,000
General and administrative expenses 195,000 280,000
Research and development expenses 381,000 778,000
Other Accrued Liabilities, Current [1] 932,000 643,000
Total $ 2,850,888 $ 2,795,329
[1] At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement.
XML 65 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Accrued Expenses (Details) (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
CFF Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Deferred liability $ 899 $ 577
Genentech Feasibility Study Agreement [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Deferred revenue $ 33 $ 67
XML 66 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Maturity of Operating and Finance Leases Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Leases    
Operating Lease Liabilities, 2022 $ 883,000 $ 685,000
Finance Lease Liabilities, 2022 22,000 34,000
Operating Lease Liabilities, 2023 922,000 645,000
Finance Lease Liabilities, 2023 2,000 19,000
Operating Lease Liabilities, 2024 962,000 677,000
Finance Lease Liabilities, 2024 2,000
Operating Lease Liabilities, 2025 1,004,000 710,000
Finance Lease Liabilities, 2025
Operating Lease Liabilities, 2026 1,046 745,000
Finance Lease Liabilities, 2026
Operating Lease Liabilities, Thereafter 1,112,000 1,458,000
Finance Lease Liabilities, Thereafter
Total undiscounted operating lease payments 5,929,000 4,920,000
Total undiscounted finance lease payments 24,000 55,000
Operating Lease Liabilities, less: Imputed interest 1,250,000 1,224,000
Finance Lease Liabilities, less: Imputed interest
Present value of operating lease liabilities 4,679,000 3,696,000
Present value of finance lease liabilities $ 24,000 $ 55,000
Operating Lease Liabilities, weighted average remaining lease term in years 6 years 1 month 6 days 6 years 8 months 12 days
Finance Lease Liabilities, weighted average remaining lease term in years 10 months 24 days 1 year 8 months 12 days
Operating Lease Liabilities, weighted average discount rate 7.80% 8.40%
Finance Lease Liabilities, weighted average discount rate 7.80% 8.10%
XML 67 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Details Narrative)
 12 Months Ended
Sep. 23, 2020
ft²
Dec. 15, 2016
USD ($)
Nov. 01, 2013
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Leases          
Operating lease, Terms   10 years 3 months 7 years 10 years  
Operating lease, description       Some leases include purchase, termination or extension options for one or more years.  
Lease monthly rent expense   $ 43,000 $ 13,000    
Increase of rent expenses   64,000 $ 14,000    
Area of land | ft² 3,034        
Operating lease extended term seven years        
Security deposit   $ 586,000      
Security deposit at present       $ 200,000  
Lease expense       852,000 $ 814,000
Operating lease right-of-use assets amortization expenses       501,359 484,568
Finance lease, interest expense       3,000 7,000
Finance lease right-of-use assets amortization expenses       $ 35,737 $ 58,961
XML 68 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative) - USD ($)
 12 Months Ended
Nov. 19, 2021
Nov. 19, 2020
Dec. 12, 2019
Apr. 16, 2019
Feb. 19, 2016
Dec. 31, 2021
Dec. 31, 2020
Dec. 13, 2019
Apr. 02, 2019
Research and development expenses           $ 14,583,283 $ 14,358,918    
Revenue           33,333 158,333    
Cooperative Research And Development Agreements [Member]                  
Remaining balance lease term amount         $ 200,000        
Initial term       3 years          
Other commitment       $ 200,000          
Funds provide for support                 $ 157,405
Cystic Fibrosis Foundation [Member]                  
Amount received from agreement           2,500,000      
Genentech [Member]                  
Revenue           33,000 33,000    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]                  
Therapeutics development award   $ 4,200,000              
Proceeds from award   484,249              
Additional milestone payment $ 321,000                
Royalty payable   21,200,000              
Research and development expenses           2,200,000 100,000    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Upon Achievement Of Sales Milestones [Member]                  
Royalty payable   $ 4,200,000              
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Prepaid Expenses and Other Current Assets [Member]                  
Grants Receivable             650,000    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Accrued Expense And Other Current Liabilities [Member]                  
Other Liabilities             $ 899,000    
Genentech Feasibility Study Agreement [Member] | Genentech [Member]                  
Agreement description     Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement.            
Deferred revenue               $ 100,000  
License Agreement [Member]                  
Milestone fee           100,000      
Annual license fee           $ 50,000      
XML 69 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments (Details Narrative) - Series A Preferred Stock [Member]
$ in Millions
Sep. 12, 2016
USD ($)
Loss Contingencies [Line Items]  
Royalty payment rights, description the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the “Royalty Payment Rights”) equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $10 million per calendar year.
Royalty payment rights expire description The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033
Maximum [Member]  
Loss Contingencies [Line Items]  
Accrued royalties $ 35
Maximum [Member] | Net Sales [Member]  
Loss Contingencies [Line Items]  
Accrued royalties 25
Maximum [Member] | Net Sales [Member]  
Loss Contingencies [Line Items]  
Accrued royalties $ 10
XML 70 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Income Tax Provision (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal
State
Foreign
Total current expense (benefit):
Federal
State
Foreign
Total deferred expense (benefit):
Total income tax expense (benefit):
XML 71 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Income at US Statutory Rate 21.00% 21.00%
State Taxes, net of Federal benefit 1.97% 2.95%
Permanent Differences (0.82%) (1.28%)
Tax Credits 2.16% 0.75%
Valuation Allowance (25.21%) (24.53%)
Discrete items 0.91% 1.11%
 Effective income tax rate 0.00% 0.00%
XML 72 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Share-based Compensation $ 3,575 $ 3,220  
Depreciation and Amortization 166 (119)  
Accrued Liability 377 307  
Net Operating Loss Carry-forwards 24,076 19,927  
R&D Credit Carryforwards 3,207 2,264  
Other (1) (10)  
IPR&D (848) (848)  
ROU Asset (1,186) (921)  
ROU Liability 1,315 1,045  
Total Deferred tax assets 30,681 24,865  
Valuation allowance (31,023) (25,206) $ (19,700)
Net deferred tax asset (liability) $ (341) $ (341)  
XML 73 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Tax Credit Carryforward [Line Items]      
Deferred Tax Assets, Valuation Allowance $ 31,023 $ 25,206 $ 19,700
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 5,800 5,500  
Operating loss carryforwards $ 38,100    
Operating loss carryforwards, expiration year 2032    
Operating loss carryforwards with no expiration $ 63,300    
Sale of net operating losses $ 1,300 $ 1,100  
[custom:LimitationsOnNetOperatingLossDeductibilityDescription] In addition, the Tax Cuts and Jobs Act, signed into law on December 22, 2017 imposes significant additional limitations on the deductibility of interest and limits NOL deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017    
Federal and State research and development tax credit carry forwards [Member]      
Tax Credit Carryforward [Line Items]      
Operating loss carryforwards $ 3,200    
XML 74 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Shareholders Equity Warrants Outstanding (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Shares Outstanding, beginning 1,328,000 [1] 5,397,000
Shares Issued
Shares Exercised (320,000) [2] (2,549,000)
Shares Tendered
Shares Expired (20,000) (1,493,000)
Shares Outstanding, ending 988,000 [3] 1,328,000 [1]
[1] Weighted average exercise price for outstanding warrants is $0.55.
[2] Converted into approximately 115 thousand shares of common stock.
[3] Weighted average exercise price for outstanding warrants is $0.56.
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Weighted average of exercise price for outstanding warrants $ 0.56 $ 0.55
Number of warrant common stock converted 115,000  
XML 76 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance $ 228,000 $ (1,000)
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance 228,172 (1,000)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized gain (loss) on securities available-for-sale (373,000) 237,000
Accumulated Other Comprehensive (Loss)/Gain, Net unrealized gain (loss) on securities available-for-sale (373,000) 237,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Reclassification of realized gain on securities available-for-sale to net loss   (8,000)
Accumulated Other Comprehensive (Loss)/Gain, Reclassification of realized gain on securities available-for-sale to net loss   (8,000)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net current period other comprehensive loss (374,000) 229,000
Accumulated Other Comprehensive (Loss)/Gain, Net current period other comprehensive loss (374,000) 229,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance (146,000) $ 228,000
Accumulated Other Comprehensive (Loss)/Gain, Ending Balance $ (146,000)  
XML 77 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 03, 2021
Jul. 19, 2021
Jun. 19, 2021
Jun. 19, 2021
Jun. 18, 2021
Jul. 02, 2020
Jan. 14, 2020
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Jun. 19, 2020
Jun. 19, 2018
Subsidiary, Sale of Stock [Line Items]                        
Net proceeds from public offering of common stock             $ 50,000,000.0   $ 5,580,471 $ 46,704,210    
Research and Development Expense                 $ 14,583,283 $ 14,358,918    
Net proceeds from public offering of common stock             $ 46,700,000          
Preferred stock shares authorized                 8,000 8,000    
Preferred stock par value                 $ 1,000 $ 1,000    
Preferred stock, shares outstanding                 0 4,361    
Common stock, shares outstanding                 216,269,450 200,113,431    
Number of warrant to purchase of common stock                 988,000      
Maximum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Class of warrant or right, exercise price of warrants or rights                 $ 0.50      
Minimum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Class of warrant or right, exercise price of warrants or rights                 $ 0.75      
Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Share price             $ 1.55          
Issuance of common stock in public offering, shares             32,260,000   3,023,147 32,260,000    
Shares converted   2,000                    
Shares issued upon conversion   8,436,000                    
Series A Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock shares authorized                 10,000,000      
Preferred stock par value                 $ 0.001      
Series A Preferred Stock [Member] | Designated [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock shares authorized                 1,600,000      
Series B Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock shares authorized                       8,000
Shares converted     4,218   143       143      
Preferred stock, shares outstanding                 4,361 0    
Liquidity value and dividends description                 (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling 1,687,200 and 1,365,600 shares of common stock, respectively      
Common stock, shares outstanding     1,687,200 1,687,200             1,365,600  
Series B Preferred Stock [Member] | Holders [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of preferred stock shares converted       8,436,000                
Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Shares converted         286,000       286,000      
Aquarius Merger Agreement [Member] | Holders Of Aquarius Biotechnologies Inc [Member] | Unregistered Shares [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Business acquisition, equity iterest issued or issuable, shares 1,500,000                      
Research and Development Expense $ 1,200,000                      
Share price $ 0.80                      
Conversion price per share     $ 0.50 $ 0.50                
Underwritten Public Offering [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Net proceeds from public offering of common stock             $ 50,000,000.0          
Net proceeds from public offering of common stock             $ 46,700,000          
Underwritten Public Offering [Member] | Common Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Issuance of common stock in public offering, shares             32,600,000          
Underwritten Public Offering [Member] | Sales Agreement [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Aggregate offering price for sale of stock           $ 50,000,000            
Sale of stock percentage           3.00%            
Sale of stock shares               3,023,147        
Proceeds from issuance of common stock               $ 5,800,000        
Net proceeds from public offering of common stock               $ 5,600,000        
XML 78 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Recognized Stock-Based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Share-based compensation expense $ 4,292,355 $ 4,564,787
Research and Development Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Share-based compensation expense 1,870,000 1,897,000
General and Administrative Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Share-based compensation expense $ 2,422,000 $ 2,668,000
XML 79 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Equity Compensation Plan by Arrangements (Details) - 2013 Equity Compensation Plan [Member]
shares in Thousands
 12 Months Ended
Dec. 31, 2020
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Awards Reserved for Issuance 36,952 [1]
Awards Issued 32,669 [2]
Awards Available for Grant 4,283
[1] Increased by 8,005 thousand on January 1, 2021, representing 4% of the total number of shares of common stock outstanding on December 31, 2020.
[2] Includes both stock grants and option grants
XML 80 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical) - shares
shares in Thousands
 12 Months Ended
May 08, 2014
Dec. 31, 2020
Jan. 02, 2021
Share-based Payment Arrangement [Abstract]      
Increased shares of common stock outstanding     8,005
Percentage for common stock outstanding 4.00% 4.00%  
XML 81 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Stock Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]      
Number of Options, Outstanding at Beginning 22,551,000 17,529,000  
Weighted average Exercise Price, Outstanding at Beginning $ 1.26 $ 1.11  
Weighted Average Contractual Term in Years, Ending 7 years 2 months 12 days 6 years 10 months 24 days 6 years 2 months 12 days
Number of Options, Granted 10,976,000 6,501,000  
Weighted average Exercise Price, Granted $ 1.11 $ 1.59  
Number of Options, Exercised (1,077,000) (826,000)  
Weighted average Exercise Price, Exercised $ 0.60 $ 0.74  
Number of Options, Forfeited (2,824,000) (72,000)  
Weighted average Exercise Price, Forfeited $ 1.08 $ 1.11  
Number of Options, Cancelled  
Weighted average Exercise Price, Cancelled  
Number of Options, Expired (1,441,000) (581,000)  
Weighted average Exercise Price, Expired $ 1.98 $ 1.25  
Number of Options, Outstanding at Ending 28,184,000 22,551,000 17,529,000
Weighted average Exercise Price, Outstanding at Ending $ 1.21 $ 1.26 $ 1.11
XML 82 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Outstanding Options (Details)
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of options outstanding | shares 28,184,000
Weighted Average Exercise Price Per Share $ 1.21
Exercise Price One [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, minimum 0.41
Exercise price, maximum $ 0.69
Number of options outstanding | shares 1,935,000
Weighted Average Exercise Price Per Share $ 0.49
Exercise Price Two [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, minimum 0.74
Exercise price, maximum $ 1.12
Number of options outstanding | shares 15,940,000
Weighted Average Exercise Price Per Share $ 0.93
Exercise Price Three [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, minimum 1.24
Exercise price, maximum $ 1.61
Number of options outstanding | shares 6,525,000
Weighted Average Exercise Price Per Share $ 1.35
Exercise Price Four [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, minimum 2.27
Exercise price, maximum $ 3.32
Number of options outstanding | shares 3,784,000
Weighted Average Exercise Price Per Share $ 2.50
XML 83 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Schedule of Stock Option Awards and Restricted Stock Awards (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Volatility, minimum 98.40% 100.50%
Volatility, maximum 101.60% 107.40%
Risk-free interest rate, minimum 0.47% 0.34%
Risk-free interest rate, maximum 1.28% 1.74%
Dividend yield 0.00% 0.00%
Expected life 6 years 6 years
XML 84 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation (Details Narrative) - USD ($)
 12 Months Ended
May 08, 2014
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based payment award increase of shares offering date January 1, 2015    
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum 4.00%   4.00%
Number of option vested   14,625,397  
Option vested price per share   $ 1.20  
Option intrinsic value   $ 2,500  
Aggregate intrinsic price   $ 1.01  
Unrecognized share-based compensation   $ 11,700,000  
Share-based compensation weighted average period   2 years 10 months 24 days  
Vesting description   All outstanding options expire ten years from date of grant. Options granted to employees prior to 2018 vest in equal monthly installments over three years. Beginning in 2018, options granted to employees vest over four years, with 25% of the shares vesting on the first annual anniversary of grant and the remaining shares vesting in 36 equal monthly installments over the following 3 years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives  
Stock options expire term   10 years  
Number of restricted stock awards granted   31,769 379,385
General and administrative expense   $ 100,000 $ 292,000
Share-based Payment Arrangement, Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock option shares vesting percentage   25.00%  
2013 Equity Compensation Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Option granted description   granted at prices not less than 100% of the fair value of the shares  
Option term   The term of the options is no longer than ten years  
Number of common stock issued under plan   36,952,460  
2013 Equity Compensation Plan [Member] | Minimum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Option vested period   3 years  
2013 Equity Compensation Plan [Member] | Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Option vested period   4 years  
XML 85 form10k_htm.xml IDEA: XBRL DOCUMENT 0001582554 2021-01-01 2021-12-31 0001582554 2021-06-30 0001582554 2022-03-04 0001582554 2021-12-31 0001582554 2020-12-31 0001582554 2020-01-01 2020-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2019-12-31 0001582554 us-gaap:CommonStockMember 2019-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001582554 us-gaap:RetainedEarningsMember 2019-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001582554 2019-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2020-12-31 0001582554 us-gaap:CommonStockMember 2020-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001582554 us-gaap:RetainedEarningsMember 2020-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001582554 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001582554 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001582554 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001582554 MTNB:RedeemableConvertiblePreferredStockBMember us-gaap:PreferredStockMember 2021-12-31 0001582554 us-gaap:CommonStockMember 2021-12-31 0001582554 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001582554 us-gaap:RetainedEarningsMember 2021-12-31 0001582554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001582554 MTNB:AtTheMarketSalesAgreementMember 2021-01-01 2021-01-31 0001582554 us-gaap:CommonStockMember MTNB:UnderwrittenPublicOfferingMember 2020-01-12 2020-01-14 0001582554 MTNB:UnderwrittenPublicOfferingMember 2020-01-12 2020-01-14 0001582554 srt:MinimumMember 2021-01-01 2021-12-31 0001582554 srt:MaximumMember 2021-01-01 2021-12-31 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:FirstAnniversaryMember 2018-06-18 2018-06-19 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:SecondAnniversaryMember 2018-06-18 2018-06-19 0001582554 us-gaap:SeriesBPreferredStockMember MTNB:ThirdAnniversaryMember 2018-06-18 2018-06-19 0001582554 MTNB:CFFResearchGrantRevenueMember 2020-01-01 2020-12-31 0001582554 MTNB:ThreeMoleculesMember MTNB:FeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-11 2019-12-12 0001582554 MTNB:PerMoleculesMember MTNB:FeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-11 2019-12-12 0001582554 MTNB:PerMoleculesMember MTNB:GenentechMember 2021-01-01 2021-12-31 0001582554 MTNB:PerMoleculesMember MTNB:GenentechMember 2020-01-01 2020-12-31 0001582554 MTNB:CFFAgreementMember 2021-01-01 2021-12-31 0001582554 MTNB:CFFAgreementMember 2020-01-01 2020-12-31 0001582554 MTNB:StockOptionsMember 2021-01-01 2021-12-31 0001582554 MTNB:StockOptionsMember 2020-01-01 2020-12-31 0001582554 MTNB:PreferredStockAndAccruedDividendUponConversionMember 2021-01-01 2021-12-31 0001582554 MTNB:PreferredStockAndAccruedDividendUponConversionMember 2020-01-01 2020-12-31 0001582554 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001582554 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001582554 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member MTNB:StateAndMunicipalBondsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001582554 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001582554 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2020-12-31 0001582554 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001582554 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001582554 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001582554 us-gaap:EquipmentMember 2021-12-31 0001582554 us-gaap:EquipmentMember 2020-12-31 0001582554 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001582554 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001582554 MTNB:CFFAgreementMember 2021-12-31 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember 2021-12-31 0001582554 MTNB:CFFAgreementMember 2020-12-31 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember 2020-12-31 0001582554 2013-11-01 0001582554 2013-11-01 2013-11-01 0001582554 2020-09-23 0001582554 2020-09-22 2020-09-23 0001582554 2016-12-15 0001582554 2016-12-14 2016-12-15 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-11-19 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-11-18 2020-11-19 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2021-11-18 2021-11-19 0001582554 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-12-31 0001582554 MTNB:CysticFibrosisFoundationMember 2021-01-01 2021-12-31 0001582554 MTNB:AccruedExpenseAndOtherCurrentLiabilitiesMember MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-12-31 0001582554 MTNB:UponAchievementOfSalesMilestonesMember MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-11-19 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2021-01-01 2021-12-31 0001582554 MTNB:AwardAgreementMember MTNB:CysticFibrosisFoundationMember 2020-01-01 2020-12-31 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-01 2019-12-12 0001582554 MTNB:GenentechFeasibilityStudyAgreementMember MTNB:GenentechMember 2019-12-13 0001582554 MTNB:GenentechMember 2020-01-01 2020-12-31 0001582554 MTNB:GenentechMember 2021-01-01 2021-12-31 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2016-02-16 2016-02-19 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2019-04-15 2019-04-16 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2019-04-16 0001582554 MTNB:CooperativeResearchAndDevelopmentAgreementsMember 2019-04-02 0001582554 MTNB:LicenseAgreementMember 2021-01-01 2021-12-31 0001582554 srt:MaximumMember us-gaap:SeriesAPreferredStockMember 2016-09-12 0001582554 us-gaap:SeriesAPreferredStockMember 2016-09-01 2016-09-12 0001582554 srt:MaximumMember MTNB:FourPointFivePercentOfNetSalesMember us-gaap:SeriesAPreferredStockMember 2016-09-12 0001582554 srt:MaximumMember MTNB:SevenPointFivePercentOfNetSalesMember us-gaap:SeriesAPreferredStockMember 2016-09-12 0001582554 MTNB:FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsMember 2021-12-31 0001582554 MTNB:UnderwrittenPublicOfferingMember MTNB:SalesAgreementMember 2020-06-29 2020-07-02 0001582554 MTNB:UnderwrittenPublicOfferingMember MTNB:SalesAgreementMember 2021-01-02 2021-01-31 0001582554 MTNB:HoldersOfAquariusBiotechnologiesIncMember MTNB:UnregisteredSharesMember MTNB:AquariusMergerAgreementMember 2021-09-01 2021-09-03 0001582554 MTNB:HoldersOfAquariusBiotechnologiesIncMember MTNB:UnregisteredSharesMember MTNB:AquariusMergerAgreementMember 2021-09-03 0001582554 us-gaap:CommonStockMember 2020-01-12 2020-01-14 0001582554 us-gaap:CommonStockMember 2020-01-14 0001582554 2020-01-12 2020-01-14 0001582554 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582554 us-gaap:SeriesAPreferredStockMember MTNB:DesignatedMember 2021-12-31 0001582554 us-gaap:SeriesBPreferredStockMember 2018-06-19 0001582554 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:SeriesBPreferredStockMember 2021-06-16 2021-06-18 0001582554 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001582554 us-gaap:CommonStockMember 2021-06-16 2021-06-18 0001582554 us-gaap:SeriesBPreferredStockMember 2021-06-19 2021-06-19 0001582554 us-gaap:CommonStockMember 2021-07-19 2021-07-19 0001582554 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001582554 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001582554 MTNB:HoldersOfAquariusBiotechnologiesIncMember MTNB:UnregisteredSharesMember MTNB:AquariusMergerAgreementMember 2021-06-19 0001582554 MTNB:HoldersMember us-gaap:SeriesBPreferredStockMember 2021-06-17 2021-06-19 0001582554 us-gaap:SeriesBPreferredStockMember 2021-06-19 0001582554 us-gaap:SeriesBPreferredStockMember 2020-06-19 0001582554 srt:MaximumMember 2021-12-31 0001582554 srt:MinimumMember 2021-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2021-01-01 2021-12-31 0001582554 srt:MinimumMember MTNB:TwoThousandThirteenEquityCompensationPlanMember 2021-01-01 2021-12-31 0001582554 srt:MaximumMember MTNB:TwoThousandThirteenEquityCompensationPlanMember 2021-01-01 2021-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2021-12-31 0001582554 2014-05-07 2014-05-08 0001582554 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001582554 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001582554 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001582554 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001582554 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2020-12-31 0001582554 MTNB:TwoThousandThirteenEquityCompensationPlanMember 2020-01-01 2020-12-31 0001582554 2021-01-02 0001582554 2019-01-01 2019-12-31 0001582554 MTNB:ExercisePriceOneMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceOneMember 2021-12-31 0001582554 MTNB:ExercisePriceTwoMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceTwoMember 2021-12-31 0001582554 MTNB:ExercisePriceThreeMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceThreeMember 2021-12-31 0001582554 MTNB:ExercisePriceFourMember 2021-01-01 2021-12-31 0001582554 MTNB:ExercisePriceFourMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure utr:sqft MTNB:Segment 0001582554 false FY P3Y P10Y3M P3Y 10-K true 2021-12-31 --12-31 2021 false 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. DE 46-3011414 1545 Route 206 South Suite 302 Bedminster NJ 07921 908 484-8805 Common Stock, par value $0.0001 MTNB NYSE No No Yes Yes Non-accelerated Filer true false false 160000000.0 216864526 None. 247 EISNERAMPER LLP Iselin, New Jersey 21029806 12432481 28592049 46246573 50000 136000 1321466 2739791 50993321 61554845 1537728 1523950 4218890 3276639 22270 58007 3017377 3017377 1336488 1336488 200000 200000 10332753 9412461 61326074 70967306 938270 349941 2850888 2795329 538546 391498 21039 30853 4348743 3567621 341265 341265 4140387 3304063 2621 23660 4484273 3668988 8833016 7236609 1000 1000 8000 8000 0 0 4361 4361 3797705 0.0001 0.0001 500000000 500000000 216269450 216269450 200113431 200113431 21627 20010 184251138 167192003 -131634208 -107507193 -145499 228172 52493058 63730697 61326074 70967306 33333 158333 14583283 14358918 10184805 10005967 24768088 24364885 -24734755 -24206552 1328470 1073289 122870 686425 -23283415 -22446838 395799 793442 -23679214 -23240280 -0.11 -0.12 210178332 196894628 -373671 237537 8485 -373671 229052 -23657086 -22217786 4577 3985805 163156984 16315 113427897 -84377555 -880 33051582 4184141 4184141 379385 38 390604 390642 -216 -188100 432000 43 188057 3308790 32260000 3226 46700984 46704210 782073 79 820248 820327 1737389 172 797409 797581 1365600 137 682663 -682800 229052 229052 -22446838 -22446838 4361 3797705 200113431 20010 167192003 -107507193 228172 63730697 4192082 4192082 31769 4 31748 31752 -4361 -3797705 8722000 873 3796832 172592 3023147 302 5580169 5580471 3023147 302 5580169 5580471 1076946 107 1415035 1415142 114957 12 -12 1500000 150 1199850 1200000 1687200 169 843431 -843600 -373671 -373671 -373671 -373671 -23283415 -23283415 216269450 21627 184251138 -131634208 -145499 52493058 -23283415 -22446838 244395 231058 -2207 4292355 4564787 501359 484568 35737 58961 250453 239831 -8485 1200000 -460239 -423741 -1349804 611397 588329 -329369 55560 855819 -15223455 -17367836 23194600 72106359 40225000 31445156 260380 5749 16770020 -40666952 5580471 46704210 797581 1415142 599713 30853 54673 6964760 48046831 8511325 -9987957 12768481 22756438 21279806 12768481 -373671 229052 12 843600 682800 220614 3797705 188100 68521 1443610 <p id="xdx_80C_eus-gaap--NatureOfOperations_z0DDL4xaqtw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_826_zGgFUmCdjqCe">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma” or “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_801_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ztZsyxFPxwB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_82D_z6nAVgZwB3Hf">Liquidity and Plan of Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has experienced net losses and negative cash flows from operations each period since its inception. Through December 31, 2021, the Company had an accumulated deficit of approximately $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20211231_zYgYBh4TJRrb" title="Accumulated deficit">131.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. The Company’s net loss for the years ended December 31, 2021 and 2020 were approximately $<span id="xdx_909_eus-gaap--ProfitLoss_pn5n6_c20210101__20211231_zeDxbJMIotY4" title="Net loss">23.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90C_eus-gaap--ProfitLoss_pn5n6_c20200101__20201231_zqOhW8gOztY7" title="Net loss">22.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been engaged in developing LYPDISO (formerly MAT9001) as well as its lipid nanocrystal (“LNC”) platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501, since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales, and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming the Company obtains Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To continue to fund operations, during January 2021, the Company sold <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGoblHmleMe" title="Issuance of common stock in public offering, net of stock issuance costs, shares">3,023,147</span> shares of common stock under its At-The-Market Sales Agreement with BTIG, LLC, generating gross proceeds of approximately $<span id="xdx_901_ecustom--ProceedsFromIssuanceInitialPublicOfferingGross_pn5n6_c20210101__20210131__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember_zZWJ1K61pTVc" title="Proceeds from public offering, gross">5.8</span> million and net proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20210101__20210131__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember_z9dXha2m4R5a" title="Proceeds from public offering">5.6</span> million. In addition, on January 14, 2020, the Company completed an underwritten public offering of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200112__20200114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zm9VtvpOOfQc" title="Number of underwritten public offering of common stock">32,600,000</span> shares of common stock, generating gross cash proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20200112__20200114__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zVQ27jDMtqo8" title="Gross proceeds from public offering of common stock">50.0</span> million and net proceeds of approximately $<span id="xdx_905_ecustom--NetProceedsFromPublicOfferingOfCommonStock_pn5n6_c20200112__20200114__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zYmzU1vNiaPf" title="Net proceeds from public offering of common stock">46.7</span> million. (See Note 12 – Stockholders’ Equity).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had cash and cash equivalents of approximately $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20211231_zLjVmJumAPof" title="Cash and cash equivalents">21.0</span> million, marketable securities of approximately $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_pn5n6_c20211231_z26tsX79237g" title="Marketable securities">28.6</span> million and restricted cash of approximately $<span id="xdx_90C_eus-gaap--RestrictedCash_iI_pn5n6_c20211231_zP7vrb4aLBDb" title="Restricted cash">0.3</span> million. The Company believes the cash and cash equivalents and marketable securities on hand are sufficient to fund planned operations through 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -131600000 23300000 22400000 3023147 5800000 5600000 32600000 50000000.0 46700000 21000000.0 28600000 300000 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zL7GBBrM8oF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_828_zXa4mT2jDCR">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zN1w3mOf1TCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of presentation and principles of consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying audited consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zKrjhA8twawh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the year ended December 31, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zjquVwlWrjO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant items subject to such estimates and assumptions include, but are not limited to, the Company’s research and development expenses, the assessment of the impairment of goodwill and intangible assets, level 3 fair value measurement of financial instruments, income tax valuations, the determination of stock-based compensation and contingent consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq8FVAOAfsU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment and geographic information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <span id="xdx_900_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20210101__20211231_zwkxOQXwFxHh" title="Number of operating segment">one</span> operating and reporting segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zsLY94BG6Llb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash, cash equivalents and restricted cash</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. For a complete disclosure of the Company’s cash, cash equivalents and restricted cash, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zvFglrIOSCwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketable Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities, all of which are available-for-sale, consist of U.S. treasury bonds, U.S. government notes, corporate debt securities and state and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive (loss)/income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in other income, net. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in other income, net. For a complete disclosure of the Company’s marketable securities, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z0yycBKwI26a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of credit risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company’s investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. Balances are maintained at U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. The Company has not experienced any credit losses associated with its balances in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWVPSMfcjt92" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leasehold improvements and equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation on equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zMyC5RnAVATh" title="Leasehold improvements and equipment, useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0642">three</span></span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zOdhwkzhiB4d" title="Leasehold improvements and equipment, useful life">ten years</span>. Capitalized costs associated with leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining term of the lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zfolkKRnnxS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill and other intangible assets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill is recorded when consideration paid for an acquired entity exceeds the fair value of the net assets acquired. Goodwill is not amortized but rather is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances indicate the goodwill may be impaired. U.S. GAAP provides that the Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If the Company determine this is the case, the Company can perform further analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reporting unit is an operating segment, or one level below an operating segment. Historically, the Company has conducted its business in a single operating segment and reporting unit. For the years ended December 31, 2021 and 2020, the Company assessed goodwill impairment by performing a qualitative test for its reporting unit. As part of the qualitative review, the Company considered its cash position and its ability to obtain additional financing in the near term to meet its operational and strategic goals and substantiate the value of its business. Based on the results of the Company’s assessment, it was determined that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amount. There were <span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_pp0p0_do_c20200101__20201231_z4OcyIeVXcvk" title="Goodwill impairments"><span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_pp0p0_do_c20210101__20211231_z3nwUUo2Fxnd">no</span></span> impairments of goodwill during the years ended December 31, 2021 and 2020. If a nonrecurring fair value measurement for a goodwill impairment was required, sufficient information will be provided to permit reconciliation of the fair value of the asset categorized within the fair value hierarchy as level 3 to the amounts presented in the statement of financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite lived intangible assets are composed of in-process research and development (“IPR&amp;D”) and represent projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition. These IPR&amp;D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zgmKq20FTWkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, “Leases”, establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--PreferredStockDividendsPolicyTextBlock_zbSAqaVS7Csf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred stock dividends</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">S<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ubject </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to provisions detailed more fully in Note 12, Stockholders’ Equity, shares of Series B Preferred Stock earned dividends at rates of <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_c20180618__20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--FirstAnniversaryMember_pdd">10%</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_c20180618__20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecondAnniversaryMember_pdd">15% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_c20180618__20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ThirdAnniversaryMember_pdd">20% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">once per year on the first, second and third anniversary, respectively, of June 19, 2018. The dividends were paid when earned to the holders of the Series B Preferred Stock in the form of shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_z974AjQUTlAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of Accounting Standard Codification 740-10 and has analyzed its filing positions in 2021 and 2020 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had <span id="xdx_900_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_pp0p0_do_c20210101__20211231_zuilpgBvQOBh" title="Accrual for interest or penalties">no</span> accrual for interest or penalties as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the Company incurred net operating losses in every tax year since inception, the 2014 through 2020 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXe8MjQZ3SM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in ASC 820 “Fair Value Measurement”, fair value measurements should be disclosed separately by three levels of the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs (quoted prices in active markets) and minimized the use of unobservable inputs (the Company’s assumptions) when developing fair value measurements, in accordance with the established fair value hierarchy. For a complete disclosure of the Company’s fair value measurements, see Note 5 – Fair Value Measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zjjftByG8iOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation to employees consist of stock option grants and restricted shares that are recognized in the consolidated statement of operations based on their fair values at the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, <i>Equity-Based Payments to Non-Employees </i>based upon the fair-value of the underlying instrument. The equity instruments, consisting of stock options granted to consultants, are valued using the Black-Scholes valuation model. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zA4Qtd5Iwphl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and diluted net loss per common share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a “participating security”). The Company considered its Preferred Stock to be participating securities because they included rights to participate in dividends with the common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The reconciliation of the diluted shares as of December 31, 2021 and 2020 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z6krGQqR3Vf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zfYXsqblA8f2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Anti-dilutive Securities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zYj87byNmtzi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z7USym8SjpUa" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">22,551</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock and accrued dividend upon conversion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredStockAndAccruedDividendUponConversionMember_zym9SN6ktefi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredStockAndAccruedDividendUponConversionMember_zfK9kWV8PtLb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">8,722</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgtkbD5b8se3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8bZ6AKUT1X7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231_zbiUoVBTn0Rc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">29,172</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231_zHWfJ2JCmIfb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,601</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_znAbd7YzqhEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zz6LXs9TLcQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue recognition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2020, the Company’s revenues primarily consist of a research grant to provide research and development services to the Cystic Fibrosis Foundation (“CFF”). The grant contract has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this grant. The Company had approximately $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CFFResearchGrantRevenueMember_zbFniMpfME89" title="Revenue">125</span> thousand of CFF research grant revenue for the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech paid the Company a total of $<span id="xdx_90D_eus-gaap--ProceedsFromSaleOfProductiveAssets_pn3n3_c20191211__20191212__us-gaap--AwardTypeAxis__custom--ThreeMoleculesMember__us-gaap--TypeOfArrangementAxis__custom--FeasibilityStudyAgreementMember__dei--LegalEntityAxis__custom--GenentechMember_ziqK41Y3RYqi" title="Proceeds from sale of productive assets">100</span> thousand for three molecules, or approximately $<span id="xdx_901_eus-gaap--ProceedsFromSaleOfProductiveAssets_pn3n3_c20191211__20191212__us-gaap--AwardTypeAxis__custom--PerMoleculesMember__us-gaap--TypeOfArrangementAxis__custom--FeasibilityStudyAgreementMember__dei--LegalEntityAxis__custom--GenentechMember_zh9ATdBbVq55" title="Proceeds from sale of productive assets">33</span> thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. The Agreement has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this Agreement. As certain Agreement performance obligations in this agreement were completed, disaggregation of revenue is not required. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--GenentechMember__us-gaap--AwardTypeAxis__custom--PerMoleculesMember_zFExQ2RqxFB6" title="Revenue"><span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__dei--LegalEntityAxis__custom--GenentechMember__us-gaap--AwardTypeAxis__custom--PerMoleculesMember_zLNEdgpjtzAi">33</span></span> thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_848_ecustom--CollaborationAgreementsPolicy_z0mhD3BIiuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaboration Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assess whether its collaboration agreements are subject to ASC Topic 808, <i>Collaborative Arrangements</i> (Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company will apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If the Company determines a performance obligation within the arrangement is with a customer, the Company applies the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms of such arrangements typically include payments to the Company for one or more of the following: up-front fees; development and regulatory payments; product supply services; research and development cost reimbursements; profit-sharing arrangements; and royalties on certain products if they are successfully commercialized. As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Up-front License Fees: </i>If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company would recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally would occur at or near the inception of the contract. For licenses that are bundled with other promises, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. The Company will evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development Milestone Payments: </i>At the inception of each arrangement that includes development milestone payments, the Company will evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which the Company will recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development Cost Reimbursements: </i>The Company’s collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer or partner, and they are distinct from the licenses provided to the Company’s collaboration partners, these promises are accounted for as a separate performance obligation which the Company estimates using internal development costs incurred and projections through the term of the arrangements. The Company records revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if the Company concludes that its collaboration partner is not a customer for those collaborative research and development activities, it presents such payments as a reduction of research and development expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development Arrangement: </i>Under the terms of our research and development agreement with the CFF Agreement, the Company did not account for this arrangement in accordance with Topic 606. However, the Company has determined that it is a partner under a collaboration agreement as it shares in the risks and rewards that would be received if the product is successful and commercialized. Therefore the funds received under the terms of this agreement will be recorded as reimbursements of research and development costs and reduce the research and development expenses in the Company’s Statements of Operations and Comprehensive Income/(Loss). The Company records the reimbursements for certain materials and other research and development costs associated with the agreement when it is probable that a significant reversal in the amount of cumulative costs have been recognized. As of December 31, 2021 and 2020, the Company recognized approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--CFFAgreementMember_zubrGtKZt6B7" title="Research and Development, costs incurred">2.2</span> million and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20200101__20201231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--CFFAgreementMember_z7nM7bGTTa25">0.1</span> million, respectively, of reimbursed research and development costs associated with the CFF Agreement. For a complete disclosure of the CFF Agreement, see Note 9 – Collaboration Agreements, License and other Research and Development Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqbgEDStyddj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development expenses</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses primarily consist of costs associated with the preclinical and clinical development of our product candidate portfolio, including the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related expenses, including salaries, benefits and share-based compensation expense.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All research and development expenses are charged to operations as incurred in accordance with FASB ASC Topic 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued Research and Development Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the process of preparing the Company’s financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. Certain of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and adjust if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjust the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_ecustom--PatentExpensesPolicyTextBlock_zc0JhA8kIMla" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent expenses</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--OtherComprehensiveLossPolicyTextBlock_zD1XFVk9PUo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other comprehensive income/(loss)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive income/(loss) consists of net gains/(losses) and unrealized losses on marketable securities available-for-sale and is presented in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlAE8KnPeTH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently adopted accounting pronouncements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB Issued Accounting Standard Update 2019-12, “Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes”. This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted the new standard effective January 1, 2021 with no material impact on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zN1w3mOf1TCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of presentation and principles of consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying audited consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--UnusualRisksAndUncertaintiesPolicyTextBlock_zKrjhA8twawh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the year ended December 31, 2021 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zjquVwlWrjO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant items subject to such estimates and assumptions include, but are not limited to, the Company’s research and development expenses, the assessment of the impairment of goodwill and intangible assets, level 3 fair value measurement of financial instruments, income tax valuations, the determination of stock-based compensation and contingent consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq8FVAOAfsU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment and geographic information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <span id="xdx_900_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20210101__20211231_zwkxOQXwFxHh" title="Number of operating segment">one</span> operating and reporting segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 <p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zsLY94BG6Llb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash, cash equivalents and restricted cash</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. For a complete disclosure of the Company’s cash, cash equivalents and restricted cash, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zvFglrIOSCwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketable Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities, all of which are available-for-sale, consist of U.S. treasury bonds, U.S. government notes, corporate debt securities and state and municipal bonds. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive (loss)/income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in other income, net. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in other income, net. For a complete disclosure of the Company’s marketable securities, see Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z0yycBKwI26a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of credit risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. The Company’s investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. Balances are maintained at U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. The Company has not experienced any credit losses associated with its balances in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWVPSMfcjt92" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leasehold improvements and equipment</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation on equipment is computed using the straight-line method over the estimated useful lives of the assets, which range from <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zMyC5RnAVATh" title="Leasehold improvements and equipment, useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0642">three</span></span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zOdhwkzhiB4d" title="Leasehold improvements and equipment, useful life">ten years</span>. Capitalized costs associated with leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining term of the lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y <p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zfolkKRnnxS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill and other intangible assets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill is recorded when consideration paid for an acquired entity exceeds the fair value of the net assets acquired. Goodwill is not amortized but rather is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances indicate the goodwill may be impaired. U.S. GAAP provides that the Company has the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If the Company determine this is the case, the Company can perform further analysis to identify and measure the amount of goodwill impairment loss to be recognized, if any.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reporting unit is an operating segment, or one level below an operating segment. Historically, the Company has conducted its business in a single operating segment and reporting unit. For the years ended December 31, 2021 and 2020, the Company assessed goodwill impairment by performing a qualitative test for its reporting unit. As part of the qualitative review, the Company considered its cash position and its ability to obtain additional financing in the near term to meet its operational and strategic goals and substantiate the value of its business. Based on the results of the Company’s assessment, it was determined that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amount. There were <span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_pp0p0_do_c20200101__20201231_z4OcyIeVXcvk" title="Goodwill impairments"><span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_pp0p0_do_c20210101__20211231_z3nwUUo2Fxnd">no</span></span> impairments of goodwill during the years ended December 31, 2021 and 2020. If a nonrecurring fair value measurement for a goodwill impairment was required, sufficient information will be provided to permit reconciliation of the fair value of the asset categorized within the fair value hierarchy as level 3 to the amounts presented in the statement of financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indefinite lived intangible assets are composed of in-process research and development (“IPR&amp;D”) and represent projects acquired in a business combination that have not reached technological feasibility or that lack regulatory approval at the time of acquisition. These IPR&amp;D assets are reviewed for impairment annually, or sooner if events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and upon establishment of technological feasibility or regulatory approval. An impairment loss, if any, is calculated by comparing the fair value of the asset to its carrying value. If the asset’s carrying value exceeds its fair value, an impairment loss is recorded for the difference and its carrying value is reduced accordingly. Similar to the impairment test for goodwill, the Company may perform a qualitative approach for testing indefinite-lived intangible assets for impairment. The Company used the qualitative approach and concluded that it was more-likely-than-not that its indefinite-lived assets were not impaired during the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zgmKq20FTWkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 842, “Leases”, establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--PreferredStockDividendsPolicyTextBlock_zbSAqaVS7Csf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred stock dividends</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">S<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ubject </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to provisions detailed more fully in Note 12, Stockholders’ Equity, shares of Series B Preferred Stock earned dividends at rates of <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_c20180618__20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--FirstAnniversaryMember_pdd">10%</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_c20180618__20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecondAnniversaryMember_pdd">15% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_c20180618__20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ThirdAnniversaryMember_pdd">20% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">once per year on the first, second and third anniversary, respectively, of June 19, 2018. The dividends were paid when earned to the holders of the Series B Preferred Stock in the form of shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.15 0.20 <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_z974AjQUTlAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted the provisions of Accounting Standard Codification 740-10 and has analyzed its filing positions in 2021 and 2020 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had <span id="xdx_900_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_pp0p0_do_c20210101__20211231_zuilpgBvQOBh" title="Accrual for interest or penalties">no</span> accrual for interest or penalties as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the Company incurred net operating losses in every tax year since inception, the 2014 through 2020 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0 <p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXe8MjQZ3SM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in ASC 820 “Fair Value Measurement”, fair value measurements should be disclosed separately by three levels of the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs (quoted prices in active markets) and minimized the use of unobservable inputs (the Company’s assumptions) when developing fair value measurements, in accordance with the established fair value hierarchy. For a complete disclosure of the Company’s fair value measurements, see Note 5 – Fair Value Measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zjjftByG8iOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation to employees consist of stock option grants and restricted shares that are recognized in the consolidated statement of operations based on their fair values at the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, <i>Equity-Based Payments to Non-Employees </i>based upon the fair-value of the underlying instrument. The equity instruments, consisting of stock options granted to consultants, are valued using the Black-Scholes valuation model. The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zA4Qtd5Iwphl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and diluted net loss per common share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities that participate in dividends (a “participating security”). The Company considered its Preferred Stock to be participating securities because they included rights to participate in dividends with the common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Preferred Stock. Net losses are not allocated to preferred stockholders as they do not have an obligation to share in the Company’s net losses. In periods with net income attributable to common stockholders, the Company would allocate net income first to preferred stockholders based on dividend rights under the Company’s certificate of incorporation and then to preferred and common stockholders based on ownership interests. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2021 and 2020, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The reconciliation of the diluted shares as of December 31, 2021 and 2020 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z6krGQqR3Vf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zfYXsqblA8f2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Anti-dilutive Securities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zYj87byNmtzi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z7USym8SjpUa" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">22,551</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock and accrued dividend upon conversion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredStockAndAccruedDividendUponConversionMember_zym9SN6ktefi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredStockAndAccruedDividendUponConversionMember_zfK9kWV8PtLb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">8,722</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgtkbD5b8se3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8bZ6AKUT1X7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231_zbiUoVBTn0Rc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">29,172</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231_zHWfJ2JCmIfb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,601</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_znAbd7YzqhEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z6krGQqR3Vf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BC_zfYXsqblA8f2" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Anti-dilutive Securities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zYj87byNmtzi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_z7USym8SjpUa" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">22,551</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock and accrued dividend upon conversion</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredStockAndAccruedDividendUponConversionMember_zym9SN6ktefi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredStockAndAccruedDividendUponConversionMember_zfK9kWV8PtLb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">8,722</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zgtkbD5b8se3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8bZ6AKUT1X7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20210101__20211231_zbiUoVBTn0Rc" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive earnings per share, amount"><span style="font-family: Times New Roman, Times, Serif">29,172</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20200101__20201231_zHWfJ2JCmIfb" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,601</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 28184000 22551000 8722000 988000 1328000 29172000 32601000 <p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_zz6LXs9TLcQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue recognition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 outlines a five-step process for recognizing revenue from customer contracts that includes i) identification of the contract with a customer, ii) identification of the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the separate performance obligations in the contract, and v) recognizing revenue associated with performance obligations as they are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At contract inception, the Company assesses the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2020, the Company’s revenues primarily consist of a research grant to provide research and development services to the Cystic Fibrosis Foundation (“CFF”). The grant contract has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this grant. The Company had approximately $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CFFResearchGrantRevenueMember_zbFniMpfME89" title="Revenue">125</span> thousand of CFF research grant revenue for the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, Genentech paid the Company a total of $<span id="xdx_90D_eus-gaap--ProceedsFromSaleOfProductiveAssets_pn3n3_c20191211__20191212__us-gaap--AwardTypeAxis__custom--ThreeMoleculesMember__us-gaap--TypeOfArrangementAxis__custom--FeasibilityStudyAgreementMember__dei--LegalEntityAxis__custom--GenentechMember_ziqK41Y3RYqi" title="Proceeds from sale of productive assets">100</span> thousand for three molecules, or approximately $<span id="xdx_901_eus-gaap--ProceedsFromSaleOfProductiveAssets_pn3n3_c20191211__20191212__us-gaap--AwardTypeAxis__custom--PerMoleculesMember__us-gaap--TypeOfArrangementAxis__custom--FeasibilityStudyAgreementMember__dei--LegalEntityAxis__custom--GenentechMember_zh9ATdBbVq55" title="Proceeds from sale of productive assets">33</span> thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. The Agreement has a single performance obligation that is recognized over time as the services are performed. There are no contract assets or liabilities associated with this Agreement. As certain Agreement performance obligations in this agreement were completed, disaggregation of revenue is not required. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--GenentechMember__us-gaap--AwardTypeAxis__custom--PerMoleculesMember_zFExQ2RqxFB6" title="Revenue"><span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__dei--LegalEntityAxis__custom--GenentechMember__us-gaap--AwardTypeAxis__custom--PerMoleculesMember_zLNEdgpjtzAi">33</span></span> thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 125000 100000 33000 33000 33000 <p id="xdx_848_ecustom--CollaborationAgreementsPolicy_z0mhD3BIiuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaboration Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assess whether its collaboration agreements are subject to ASC Topic 808, <i>Collaborative Arrangements</i> (Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company will apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If the Company determines a performance obligation within the arrangement is with a customer, the Company applies the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms of such arrangements typically include payments to the Company for one or more of the following: up-front fees; development and regulatory payments; product supply services; research and development cost reimbursements; profit-sharing arrangements; and royalties on certain products if they are successfully commercialized. As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Up-front License Fees: </i>If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company would recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally would occur at or near the inception of the contract. For licenses that are bundled with other promises, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. The Company will evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development Milestone Payments: </i>At the inception of each arrangement that includes development milestone payments, the Company will evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which the Company will recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development Cost Reimbursements: </i>The Company’s collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer or partner, and they are distinct from the licenses provided to the Company’s collaboration partners, these promises are accounted for as a separate performance obligation which the Company estimates using internal development costs incurred and projections through the term of the arrangements. The Company records revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if the Company concludes that its collaboration partner is not a customer for those collaborative research and development activities, it presents such payments as a reduction of research and development expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development Arrangement: </i>Under the terms of our research and development agreement with the CFF Agreement, the Company did not account for this arrangement in accordance with Topic 606. However, the Company has determined that it is a partner under a collaboration agreement as it shares in the risks and rewards that would be received if the product is successful and commercialized. Therefore the funds received under the terms of this agreement will be recorded as reimbursements of research and development costs and reduce the research and development expenses in the Company’s Statements of Operations and Comprehensive Income/(Loss). The Company records the reimbursements for certain materials and other research and development costs associated with the agreement when it is probable that a significant reversal in the amount of cumulative costs have been recognized. As of December 31, 2021 and 2020, the Company recognized approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20210101__20211231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--CFFAgreementMember_zubrGtKZt6B7" title="Research and Development, costs incurred">2.2</span> million and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20200101__20201231__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--CFFAgreementMember_z7nM7bGTTa25">0.1</span> million, respectively, of reimbursed research and development costs associated with the CFF Agreement. For a complete disclosure of the CFF Agreement, see Note 9 – Collaboration Agreements, License and other Research and Development Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2200000 100000 <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqbgEDStyddj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development expenses</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses primarily consist of costs associated with the preclinical and clinical development of our product candidate portfolio, including the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”) and other vendors and contract manufacturing organizations (“CMOs”) for the production of drug substance and drug product; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related expenses, including salaries, benefits and share-based compensation expense.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use, costs of prototypes used in research and development, consultant fees and amounts paid to certain of our collaborative partners.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All research and development expenses are charged to operations as incurred in accordance with FASB ASC Topic 730, Research and Development. The Company accounts for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued Research and Development Expenses</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the process of preparing the Company’s financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. Certain of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and adjust if necessary. The significant estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjust the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_ecustom--PatentExpensesPolicyTextBlock_zc0JhA8kIMla" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent expenses</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_ecustom--OtherComprehensiveLossPolicyTextBlock_zD1XFVk9PUo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other comprehensive income/(loss)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive income/(loss) consists of net gains/(losses) and unrealized losses on marketable securities available-for-sale and is presented in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlAE8KnPeTH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently adopted accounting pronouncements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB Issued Accounting Standard Update 2019-12, “Income Taxes, (Topic 740): Simplifying the Accounting for Income Taxes”. This standard removes certain exceptions to the general principles and improves consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted the new standard effective January 1, 2021 with no material impact on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_806_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_zFua5WwOT0Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_82F_zFYWtirtGs8a">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash, Cash Equivalents and Restricted Cash</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company presents restricted cash with cash and cash equivalents in the Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_z8d468fBjjlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Balance Sheets to the total of the amounts in the Consolidated Statements of Cash Flows as of December 31, 2021, December 31, 2020 and December 31, 2019 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z1uREqn2TU9j" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20211231_zzFfbgwiXB1k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,<br/> 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20201231_zOUCxUXTzTjk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,<br/> 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20191231_z8erRtmWigil" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, <br/> 2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzCRC_zxZ45KPndmW8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,030</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,432</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,170</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RestrictedCashAndCashEquivalents_iI_pn3n3_maCCERCzCRC_zHvjYtv05cWk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted cash included in current/long term assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">336</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">586</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzCRC_zXuEszxwwHz7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents and restricted cash in the statements of cash flows</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,280</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,768</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,756</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zv09OQRZG02h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketable Securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has classified its investments in marketable securities as available-for-sale and as a current asset. The Company’s investments in marketable securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized gains and losses are classified as other comprehensive (loss)/income and costs are determined on a specific identification basis. Realized gains and losses from our marketable securities are recorded in other income, net. For the years ended December 31, 2021 and 2020, the Company recorded unrealized (losses)/gains of approximately ($<span id="xdx_901_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20210101__20211231_zLxQuAG0B7na" title="Marketable securities, unrealized gain loss">374)</span> thousand and $<span id="xdx_904_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pn3n3_c20200101__20201231_zkbAJJGKTGaa" title="Marketable securities, unrealized gain loss">238</span> thousand, respectively, and reclassed approximately $<span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiRealizedLoss_pn3n3_c20210101__20211231_zcQubB0jAc68">0</span> and $<span id="xdx_904_eus-gaap--EquitySecuritiesFvNiRealizedLoss_pn3n3_c20200101__20201231_zJb3JzfWaz7i" title="Net realized loss">9</span> thousand to net realized loss from operations from the sale of certain securities during 2021 and 2020, respectively. As of December 31, 2021 and 2020, the Company had net accumulated unrealized losses of approximately $<span id="xdx_90A_ecustom--MarketableSecuritiesAccumulatedUnrealizedGain_iI_pn3n3_c20211231_zPoD6wL2Yiy7" title="Net accumulated unrealized gain">145</span> thousand and net accumulated unrealized gains of approximately $<span id="xdx_901_ecustom--MarketableSecuritiesAccumulatedUnrealizedGain_iI_pn3n3_c20201231_z7iGS2BcSHO7" title="Net accumulated unrealized gain">228</span> thousand, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--MarketableSecuritiesTextBlock_gL3MSTB-NVYKG_zNJcX20Mewck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zeXA0EgIxAA6" style="display: none">Summary of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_487_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_zXDKrAooomJ8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_910_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_zx2KSFQ2cEFa">Amortized Cost</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_zfBPDngsDTUa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_zoVhlyZglga5">Unrealized Gain</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_zk0jZZ6Mxo8e" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_zLMUBvc7Akq4">Unrealized (Loss)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_zLqj6sZShe54" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><b style="font: normal bold 10pt Times New Roman, Times, Serif"><span id="xdx_916_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_zVhCd9jNWD8l">Fair Value</span></b></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized Cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Unrealized</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Gain</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unrealized (Loss)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/><b>Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_417_20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zL7W6gTXCGXc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,395</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(120</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,277</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zWgUwHd2e4qf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,092</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0749">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,065</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zf2DpXSvWxF7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0753">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0754">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_413_20211231_zSiuJy0BNYMg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total marketable securities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,737</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(147</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zeg5cRrTsx1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_gL3DSAFSTTB-XUDT_zYlNvAusIUKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z9ZvoGiFO8h3" style="display: none">Schedule of Maturities of Debt Securities Available-for-sale</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Carrying Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pn3n3_c20211231_zgkw9TXaWPzj" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, fair value"><span style="font-family: Times New Roman, Times, Serif">8,257</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear_iI_pn3n3_c20211231_zbSErWHzYhPk" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">8,310</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due after one year through five years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pn3n3_c20211231_zSasKBS6LuGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, fair value"><span style="font-family: Times New Roman, Times, Serif">20,335</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYears_iI_pn3n3_c20211231_z14SDke4rEij" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">20,402</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pn3n3_c20211231_znlzVySrBJp1" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, fair value"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateNet_iI_pn3n3_c20211231_zO6YJlYbJGX1" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">28,712</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zTAJuUt4qn01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_C01_gL3MSTB-NVYKG_zjCCH9EVIvCf"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <div id="xdx_C04_gL3MSTB-NVYKG_zZQKQG4uTXd2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_zziwlhcrkHm6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Marketable Securities (Details)"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_zwakFs0gn5K1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span id="xdx_915_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_zU8S1UeXekCk">Amortized Cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_zLJ1FTNFUN6e" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_911_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_zhADaKN9Dan2">Unrealized Gain</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_487_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_zkO1MLRLizgl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_91E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_zWY86qc5UDrf">Unrealized (Loss)</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_482_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_zlWn3Yy3628i" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_918_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_zC0KcTMuKIph">Fair Value</span></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized Cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unrealized Gain</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unrealized (Loss)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/><b>Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_418_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zBMfvU0eOMz9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Treasury Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,293</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0783">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_415_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zSKBNFSfNVbg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,148</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,230</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_416_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zqRLo0Xlydi7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,303</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_419_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_z4c5OSxRuwmd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,275</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0795">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,282</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_418_20201231_zWMWKBPRxMfb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total marketable securities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">228</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0799">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,247</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_C0A_gL3DSAFSTTB-XUDT_zXMlRDWpHuD7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C01_gL3MSTB-NVYKG_zJRClco0pQYb"> </span></span></span></p> <div id="xdx_C0D_gL3DSAFSTTB-XUDT_zkB18rcKV0qg"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_301_134_zc2yPE86GId6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Maturities of Debt Securities Available-for-sale (Details)"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Carrying Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pn3n3_c20201231_z6QSfCM9WaI9" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, fair value"><span style="font-family: Times New Roman, Times, Serif">31,438</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear_iI_pn3n3_c20201231_zygD5QE9TcPd" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">31,602</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due after one year through five years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pn3n3_c20201231_zaMmRnCGJd7a" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, fair value"><span style="font-family: Times New Roman, Times, Serif">14,809</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYears_iI_pn3n3_c20201231_z5FIh2hdpC4c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">14,845</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pn3n3_c20201231_zVPaSF0wsZri" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, fair value"><span style="font-family: Times New Roman, Times, Serif">46,247</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateNet_iI_pn3n3_c20201231_zKNcTVKv9JWg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">46,447</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0D_gL3DSAFSTTB-XUDT_zwJOTvbyT6A6"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the unrealized (losses) and gains are deemed to be temporary as of December 31, 2021 and 2020. Unrealized (losses) and gains generally are the result of increases in the risk premiums required by market participants rather than an adverse change in cash flows for a fundamental weakness in the credit quality of the issuer or underlying assets. The Company has the ability and intent to hold these investments until maturity. The Company does not consider the investment in marketable securities to be other-than-temporarily impaired at December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_z8d468fBjjlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Balance Sheets to the total of the amounts in the Consolidated Statements of Cash Flows as of December 31, 2021, December 31, 2020 and December 31, 2019 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z1uREqn2TU9j" style="display: none">Schedule of Cash, Cash Equivalents and Restricted Cash</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20211231_zzFfbgwiXB1k" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,<br/> 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20201231_zOUCxUXTzTjk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,<br/> 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20191231_z8erRtmWigil" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, <br/> 2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzCRC_zxZ45KPndmW8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,030</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,432</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,170</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RestrictedCashAndCashEquivalents_iI_pn3n3_maCCERCzCRC_zHvjYtv05cWk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted cash included in current/long term assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">336</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">586</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzCRC_zXuEszxwwHz7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, cash equivalents and restricted cash in the statements of cash flows</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,280</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,768</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,756</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 21030000 12432000 22170000 250000 336000 586000 21280000 12768000 22756000 374000 238000 0 9000 145000 228000 <p id="xdx_894_eus-gaap--MarketableSecuritiesTextBlock_gL3MSTB-NVYKG_zNJcX20Mewck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zeXA0EgIxAA6" style="display: none">Summary of Marketable Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_487_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_zXDKrAooomJ8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_910_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_zx2KSFQ2cEFa">Amortized Cost</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_zfBPDngsDTUa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span id="xdx_919_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_zoVhlyZglga5">Unrealized Gain</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_zk0jZZ6Mxo8e" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span id="xdx_917_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_zLMUBvc7Akq4">Unrealized (Loss)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_zLqj6sZShe54" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><b style="font: normal bold 10pt Times New Roman, Times, Serif"><span id="xdx_916_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_zVhCd9jNWD8l">Fair Value</span></b></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized Cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Unrealized</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Gain</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unrealized (Loss)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/><b>Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_417_20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zL7W6gTXCGXc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,395</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(120</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,277</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_41B_20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zWgUwHd2e4qf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,092</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0749">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,065</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_416_20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zf2DpXSvWxF7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0753">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0754">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_413_20211231_zSiuJy0BNYMg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total marketable securities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,737</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(147</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarizes the Company’s marketable securities for the year ended December 31, 2020 consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_30E_134_zziwlhcrkHm6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Marketable Securities (Details)"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48E_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_zwakFs0gn5K1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span id="xdx_915_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_zU8S1UeXekCk">Amortized Cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48F_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_iI_pn3n3_zLJ1FTNFUN6e" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_911_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_zhADaKN9Dan2">Unrealized Gain</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_487_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pn3n3_di_zkO1MLRLizgl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_91E_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_zWY86qc5UDrf">Unrealized (Loss)</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_482_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_zlWn3Yy3628i" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_918_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_zC0KcTMuKIph">Fair Value</span></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortized Cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unrealized Gain</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Unrealized (Loss)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/><b>Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_418_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zBMfvU0eOMz9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Treasury Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,293</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">136</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0783">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_415_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zSKBNFSfNVbg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,148</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,230</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_416_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zqRLo0Xlydi7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,303</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_419_20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_z4c5OSxRuwmd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,275</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0795">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,282</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_418_20201231_zWMWKBPRxMfb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total marketable securities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">228</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0799">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,247</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table>   19395000 2000 120000 19277000 9092000 27000 9065000 250000 250000 28737000 2000 147000 28592000 <p id="xdx_89A_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_gL3DSAFSTTB-XUDT_zYlNvAusIUKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_z9ZvoGiFO8h3" style="display: none">Schedule of Maturities of Debt Securities Available-for-sale</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Carrying Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pn3n3_c20211231_zgkw9TXaWPzj" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, fair value"><span style="font-family: Times New Roman, Times, Serif">8,257</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear_iI_pn3n3_c20211231_zbSErWHzYhPk" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">8,310</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due after one year through five years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pn3n3_c20211231_zSasKBS6LuGg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, fair value"><span style="font-family: Times New Roman, Times, Serif">20,335</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYears_iI_pn3n3_c20211231_z14SDke4rEij" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">20,402</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pn3n3_c20211231_znlzVySrBJp1" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, fair value"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateNet_iI_pn3n3_c20211231_zO6YJlYbJGX1" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">28,712</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C01_gL3MSTB-NVYKG_zJRClco0pQYb"> </span></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of debt securities classified as available-for-sale were as follows at December 31, 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_301_134_zc2yPE86GId6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Maturities of Debt Securities Available-for-sale (Details)"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Carrying Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due within one year</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_iI_pn3n3_c20201231_z6QSfCM9WaI9" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, fair value"><span style="font-family: Times New Roman, Times, Serif">31,438</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear_iI_pn3n3_c20201231_zygD5QE9TcPd" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Due within one year, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">31,602</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due after one year through five years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_iI_pn3n3_c20201231_zaMmRnCGJd7a" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, fair value"><span style="font-family: Times New Roman, Times, Serif">14,809</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYears_iI_pn3n3_c20201231_z5FIh2hdpC4c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Due after one year through five years, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">14,845</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pn3n3_c20201231_zVPaSF0wsZri" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, fair value"><span style="font-family: Times New Roman, Times, Serif">46,247</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_ecustom--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateNet_iI_pn3n3_c20201231_zKNcTVKv9JWg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Debt Securities Available-for-sale, net carrying amount"><span style="font-family: Times New Roman, Times, Serif">46,447</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table>   8257000 8310000 20335000 20402000 28592000 28712000 18293000 136000 18429000 22148000 82000 22230000 4303000 3000 4306000 1275000 7000 1282000 46019000 228000 46247000 31438000 31602000 14809000 14845000 46247000 46447000 <p id="xdx_804_eus-gaap--FairValueDisclosuresTextBlock_zfB81slXGOWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 - <span id="xdx_829_zGj7vbeJro53">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Quoted prices for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of certain cash and cash equivalents, current portion of restricted cash, marketable securities, prepaid expenses and other current assets, accounts payable, current portion of lease liability and accrued expenses approximate fair value due to the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zFNH9K7ahxs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zexydIS5bWP3" style="display: none">Schedule of Fair Value Measurement of Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Hierarchy</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zdcapctlciWg" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">19,277</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_pdn3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zz481h3fVFdi" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0820">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zLtidWsQUPo1" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">19,277</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zWMjFL9fyGMl" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0824">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zn17upkZPLa7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">9,065</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zLsopeExtHV4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0828">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_ziQVpPK5cVBa" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">9,065</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--StateAndMunicipalBondsMember_z7PrdS2Je1th" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0832">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zgT9UzVatSaa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zzKgoQw8TCK1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0835">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_z8c7yYgTPiM3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zXf8FyZ9YQRa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0839">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231_zMks3XNC3h17" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5O3mAWZayhk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0843">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziieZSv9SyJ3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pdn3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoxL8INNAUSj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0847">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Hierarchy</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">U.S. Treasury Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWo6dOA10Def" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zeGvvnpEiH44" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYmfHRXWXNRd" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zmAnIeipKbZa" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_z4W1aRncRX0d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">22,230</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_z6QHDtRsnIyd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zLzjs2AzkuWh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">22,230</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zLTtBHnk6uNh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0863">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbsOvQwNe7Xl" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">4,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zIXHXEIjck5d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0867">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zWUIEKyQ7Ljg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">4,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z2DKvsrzSDXa" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zSzqb1svfoYh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">1,282</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zy0PC1kQsxHg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zvUvxvIZAOLg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">1,282</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_ziJXmnVVydrd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0879">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">46,247</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">27,818</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0887">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AB_zp4SoC2t2uC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable securities consisting of U.S. government notes, corporate debt securities and state and municipal bonds are classified as Level 2 and are valued using quoted market prices in markets that are not active.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zFNH9K7ahxs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zexydIS5bWP3" style="display: none">Schedule of Fair Value Measurement of Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Hierarchy</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zdcapctlciWg" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">19,277</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_pdn3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zz481h3fVFdi" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0820">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zLtidWsQUPo1" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">19,277</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zWMjFL9fyGMl" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0824">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zn17upkZPLa7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">9,065</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zLsopeExtHV4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0828">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_ziQVpPK5cVBa" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">9,065</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__custom--StateAndMunicipalBondsMember_z7PrdS2Je1th" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0832">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zgT9UzVatSaa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zzKgoQw8TCK1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0835">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_z8c7yYgTPiM3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zXf8FyZ9YQRa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0839">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231_zMks3XNC3h17" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z5O3mAWZayhk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0843">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziieZSv9SyJ3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">28,592</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pdn3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoxL8INNAUSj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0847">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Hierarchy</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable Securities:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">U.S. Treasury Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zWo6dOA10Def" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zeGvvnpEiH44" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYmfHRXWXNRd" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zmAnIeipKbZa" style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">U.S. Government Notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_z4W1aRncRX0d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">22,230</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_z6QHDtRsnIyd" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zLzjs2AzkuWh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">22,230</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USGovernmentAgenciesDebtSecuritiesMember_zLTtBHnk6uNh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0863">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Corporate Debt Securities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbsOvQwNe7Xl" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">4,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zIXHXEIjck5d" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0867">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zWUIEKyQ7Ljg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">4,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z2DKvsrzSDXa" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State and Municipal Bonds</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zSzqb1svfoYh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">1,282</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zy0PC1kQsxHg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_zvUvxvIZAOLg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">1,282</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--MarketableSecurities_iI_pdn3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FinancialInstrumentAxis__us-gaap--USStatesAndPoliticalSubdivisionsMember_ziJXmnVVydrd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0879">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--MarketableSecurities_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">46,247</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">18,429</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif">27,818</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--MarketableSecurities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdn3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Marketable Securities"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0887">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 19277000 19277000 9065000 9065000 250000 250000 28592000 28592000 18429000 18429000 22230000 22230000 4306000 4306000 1282000 1282000 46247000 18429000 27818000 <p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRDA7UXggLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_82E_z78N7ppC46Zd">Leasehold Improvements and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_za2htabCKQMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements and equipment, summarized by major category, consist of the following for the years ended December 31, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zK1wx1cmKQTi" style="display: none">Schedule of Leasehold Improvements and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20211231_zo7rpdfgnHXg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 30,<br/> 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20201231_zFvHe5yAx16d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,<br/> 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zikXY5sJQLi3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,640</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,443</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zlzNjN0wHVbb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">935</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">878</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzIKH_zZ23jvE2yXec" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,321</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_msPPAENzIKH_zxJX0EGaRw6g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation and amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,037</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">797</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzIKH_z5m80lztWQ6g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements and equipment, net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,538</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,524</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_zlUq3gv47Msd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_pn3n3_c20210101__20211231_zbDXKOmJwjJ8" title="Depreciation and amortization expenses">244</span> thousand and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_pn3n3_c20200101__20201231_zUnMgBYSeGf9" title="Depreciation and amortization expenses">231</span> thousand, respectively. During the years ended December 31, 2021 and 2020, the Company purchased equipment and leasehold improvements of approximately $<span id="xdx_90C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20210101__20211231_zmGNwcBftKWi" title="Purchase of equipment and leasehold improvements">260</span> thousand and $<span id="xdx_90B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_pn3n3_c20200101__20201231_zZ5ITXqb5RNb" title="Purchase of equipment and leasehold improvements">6</span> thousand, respectively. During the year ended December 31, 2021, the Company recorded an asset write-off of approximately $<span id="xdx_906_eus-gaap--AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1_pn3n3_c20210101__20211231_zu2zgS3avD4" title="Asset write-off">6</span> thousand, including $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20210101__20211231_zVeceQldizgb" title="Accumulated depreciation expense">4</span> thousand of related accumulated depreciation. The Company had <span id="xdx_906_eus-gaap--AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1_pn3n3_do_c20200101__20201231_zXU5Wj1cziDg">no</span> asset write-offs during the year ended December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_za2htabCKQMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements and equipment, summarized by major category, consist of the following for the years ended December 31, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zK1wx1cmKQTi" style="display: none">Schedule of Leasehold Improvements and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20211231_zo7rpdfgnHXg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 30,<br/> 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20201231_zFvHe5yAx16d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,<br/> 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zikXY5sJQLi3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Equipment</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,640</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,443</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zlzNjN0wHVbb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">935</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">878</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzIKH_zZ23jvE2yXec" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,321</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_pn3n3_msPPAENzIKH_zxJX0EGaRw6g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation and amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,037</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">797</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzIKH_z5m80lztWQ6g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold improvements and equipment, net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,538</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,524</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1640000 1443000 935000 878000 2575000 2321000 1037000 797000 1538000 1524000 244000 231000 260000 6000 6000 4000 0 <p id="xdx_800_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFpS9tfC1iKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_823_zz3NheTG47Wk">Accrued Expenses and Other Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAEiLCovOkZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zc7afUK4Jssl" style="display: none">Schedule of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20211231_zVv267HImxy5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20201231_zFlG5Yukt6Y3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_zxgtjxdPiw4c" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Payroll and incentives</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,343</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,094</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--AccruedGeneralAndAdministrativeExpensesCurrent_iI_pn3n3_zd07tDEu4Wxc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--AccruedResearchAndDevelopmentExpensesCurrent_iI_pn3n3_zcbMbJ86UOwa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">381</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">778</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zXYLmeiy7xT3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span id="xdx_F4A_z5s68V2onadk" style="font-family: Times New Roman, Times, Serif">Deferred revenue and other deferred liabilities *</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">932</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">643</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zqzCkxZrchPe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,851</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,795</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F02_zXUw86yZkYa7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z5zdLSEy8WN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021, the balance included approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DeferredTaxLiabilities_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--CFFAgreementMember_zmZaHUQpcw9f" title="Deferred liability">899</span> thousand related to the CFF Agreement’s deferred liability and approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--GenentechFeasibilityStudyAgreementMember_z7cmfWjv8rQk" title="Deferred revenue">33</span> thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DeferredTaxLiabilities_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CFFAgreementMember_zLj3LsHMbhI9" title="Deferred liability">577</span> thousand related to the CFF Agreement’s deferred liability and approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--GenentechFeasibilityStudyAgreementMember_zwMv8MnvQ5dg" title="Deferred revenue">67</span> thousand of deferred revenue related to the Genentech feasibility study agreement. </span></td></tr> </table> <p id="xdx_8A6_zyCGTafutAeh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zAEiLCovOkZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zc7afUK4Jssl" style="display: none">Schedule of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20211231_zVv267HImxy5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2021</td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20201231_zFlG5Yukt6Y3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">2020</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_zxgtjxdPiw4c" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Payroll and incentives</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,343</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,094</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--AccruedGeneralAndAdministrativeExpensesCurrent_iI_pn3n3_zd07tDEu4Wxc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">280</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--AccruedResearchAndDevelopmentExpensesCurrent_iI_pn3n3_zcbMbJ86UOwa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">381</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">778</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_zXYLmeiy7xT3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span id="xdx_F4A_z5s68V2onadk" style="font-family: Times New Roman, Times, Serif">Deferred revenue and other deferred liabilities *</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">932</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">643</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zqzCkxZrchPe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,851</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,795</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F02_zXUw86yZkYa7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_z5zdLSEy8WN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021, the balance included approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DeferredTaxLiabilities_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--CFFAgreementMember_zmZaHUQpcw9f" title="Deferred liability">899</span> thousand related to the CFF Agreement’s deferred liability and approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--GenentechFeasibilityStudyAgreementMember_z7cmfWjv8rQk" title="Deferred revenue">33</span> thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DeferredTaxLiabilities_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--CFFAgreementMember_zLj3LsHMbhI9" title="Deferred liability">577</span> thousand related to the CFF Agreement’s deferred liability and approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFjY3J1ZWQgRXhwZW5zZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_c20201231__us-gaap--TypeOfArrangementAxis__custom--GenentechFeasibilityStudyAgreementMember_zwMv8MnvQ5dg" title="Deferred revenue">67</span> thousand of deferred revenue related to the Genentech feasibility study agreement. </span></td></tr> </table> 1343000 1094000 195000 280000 381000 778000 932000 643000 2851000 2795000 899000 33000 577000 67000 <p id="xdx_808_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zT5JqI6v64S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_824_zCfSIa8Ux8S5">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has various lease agreements with terms up to <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20211231_zVA47GjBLYt7" title="Lease agreement, Terms">10 years</span>, including leases of office space, a laboratory and manufacturing facility, and various equipment. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20210101__20211231_zCyEhQnWQPSj" title="Operating lease, description">Some leases include purchase, termination or extension options for one or more years.</span> These options are included in the lease term when it is reasonably certain that the option will be exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating lease obligations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2013, the Company entered into a <span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20131101_zrHuQ7pC0PS2" title="Operating lease, Terms">7</span>-year lease for office space in Bedminster, New Jersey which commenced in June 2014 at a monthly rent of approximately $<span id="xdx_904_eus-gaap--PaymentsForRent_pp0p0_c20131101__20131101_zlCVnghxCk8l" title="Lease monthly rent expense">13,000</span>, increasing to approximately $<span id="xdx_90A_ecustom--IncreaseOfRentExpenses_pp0p0_c20131101__20131101_zTzliOo3A20k" title="Increase of rent expenses">14,000</span> per month toward the end of the term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 23, 2020, the Company entered into an amendment to the Bedminster lease. Pursuant to the amendment, the Company leased an additional <span id="xdx_90D_eus-gaap--AreaOfLand_iI_pid_uSqft_c20200923_zlrcL4sZOova" title="Area of land">3,034</span> rentable square feet (“Expansion Premises”). The amendment became effective upon delivery to the Company of the Expansion Premises, which occurred on August 1, 2021, and extends the term of the lease for <span id="xdx_90E_ecustom--OperatingLeasesExtendedTerm_dt_c20200922__20200923_zFWpAEsMrsci" title="Operating lease extended term">seven years</span> from such date. There is no renewal option, no security deposit, no residual value or significant restrictions or covenants other than those customary in such arrangements. Except as expressly provided, all other terms, covenants, conditions and agreements as set forth in the lease will remain unchanged and in full force and effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 15, 2016, the Company entered into a <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtYxL_c20161215_zjHLtoibh1Ab" title="::XDX::P10Y3M"><span style="-sec-ix-hidden: xdx2ixbrl0964">10-year, 3-month</span></span> lease to consolidate our locations while expanding our laboratory and manufacturing facilities. The lease began August 2017. The monthly rent will start at approximately $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20161214__20161215_z1Aa5uSz4Mrb">43,000</span> increasing to approximately $<span id="xdx_905_ecustom--IncreaseOfRentExpenses_pp0p0_c20161214__20161215_ztyFAuXTg952">64,000</span> in the final year. To obtain the laboratory and facility site, the Company was obligated to provide an initial security deposit of $<span id="xdx_905_eus-gaap--SecurityDeposit_iI_c20161215_zeALJjRLy3Y8" title="Security deposit">586,000</span>. This deposit was subsequently reduced and is currently $<span id="xdx_909_ecustom--ReducedInSecurityDeposit_iI_c20211231_zU5Z1ZWBuRNi" title="Security deposit at present">200,000</span> at December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s finance leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred lease expense for its operating leases of approximately $<span id="xdx_906_eus-gaap--OperatingLeaseCost_pn3n3_c20210101__20211231_zuda02RXQ9Ag" title="Lease expense">852</span> thousand and $<span id="xdx_901_eus-gaap--OperatingLeaseCost_pn3n3_c20200101__20201231_zG7KVgBFZRu2" title="Lease expense">814</span> thousand for the years ended December 31, 2021 and 2020. The Company incurred amortization expense on its operating lease right-of-use assets of approximately $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn3n3_c20210101__20211231_zC9BLvunWYPa" title="Operating lease right-of-use assets amortization expenses">501</span> thousand and $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pn3n3_c20200101__20201231_zpMGbca5FRc8" title="Operating lease right-of-use assets amortization expenses">485</span> thousand for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Finance Leases</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred interest expense on its finance leases of approximately $<span id="xdx_905_eus-gaap--FinanceLeaseInterestExpense_pn3n3_c20210101__20211231_zPzVGk0RJxm" title="Finance lease, interest expense">3</span> thousand and $<span id="xdx_906_eus-gaap--FinanceLeaseInterestExpense_pn3n3_c20200101__20201231_zQemBtnX31Y7" title="Finance lease, interest expense">7</span> thousand for the years ended December 31, 2021 and 2020, respectively. The Company incurred amortization expense on its finance lease right-of-use assets of approximately $<span id="xdx_900_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_c20210101__20211231_zhncOl24O7Vk" title="Finance lease right-of-use assets amortization expenses">36</span> thousand and $<span id="xdx_901_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_c20200101__20201231_zpP1cUKeLZN1" title="Finance lease right-of-use assets amortization expenses">59</span> thousand for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_zepsjc6E5uUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zaS7fqCSkGA" style="display: none">Schedule of Maturity of Operating and Finance Leases Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Maturity of Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_zsleADhzebLj" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">883</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_zlu8o3oECicd" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Finance Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231_z1Aspbf4q5B5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231_zbVOjpdoE6o1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231_z3InhUImF8zj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif">962</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231_zecU9iudq4E4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231_zUc5XUiYtK9j" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif">1,004</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231_zuZa2dA0ckc4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20211231_zNkM14v5nJ57" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating lease Liabilities, 2026"><span style="font-family: Times New Roman, Times, Serif">1,046</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20211231_zWQvc2zVdtoj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_zZXh7SAGBCmi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif">1,112</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_z1wtFGkMYLIe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted operating lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zXm47PINjlLf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted operating lease payments"><span style="font-family: Times New Roman, Times, Serif">5,929</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zNw02ly8kKba" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted finance lease payments"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231_zdWkTJwjLeLg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif">1,250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231_zuXWaMr0poY8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231_zP2BnUCA3Y6j" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">4,679</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20211231_zhfym25rWER3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of finance lease liabilities"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zRoeg1NPBSVi" title="Operating Lease Liabilities, weighted average remaining lease term in years">6.1</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zTxIT1gNaQR4" style="font-family: Times New Roman, Times, Serif">0.9</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zcNNtUxD4i8e" style="font: 10pt Times New Roman, Times, Serif" title="Operating Lease Liabilities, weighted average discount rate">7.8</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zjB5wh92tryd" title="Finance Lease Liabilities, weighted average discount rate">7.8</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Maturity of Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zZWZzMZkmEP6" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">685</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z0KEn7hxXYtb" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Finance Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zilrlahYrTN7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">645</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zRQVBN0xWxE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zplWr0oyPrse" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif">677</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zUMuKdDEJCig" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zgKKnFlHpM5e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif">710</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_z4mtqKK6rTQi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zwKsZT2FLGrk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2026"><span style="font-family: Times New Roman, Times, Serif">745</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zqhcvMVQfAj6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2026"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20201231_zGTOLvOWcpac" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif">1,458</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20201231_zM5RYbKCqIhl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted operating lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_z812oChrCDh6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted operating lease payments"><span style="font-family: Times New Roman, Times, Serif">4,920</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zmTV6njmQCC4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted finance lease payments"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20201231_zozADcseTMAb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif">1,224</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20201231_z6YoUAVoiOa8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zGhVuISFWM6e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">3,696</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zbWBKAyQuQZj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of finance lease liabilities"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zo520W576Lnl" title="Operating Lease Liabilities, weighted average remaining lease term in years">6.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zliIYUDTFgme" title="Finance Lease Liabilities, weighted average remaining lease term in years">1.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20201231_zgcPGhY0k1P7" title="Operating Lease Liabilities, weighted average discount rate">8.4</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20201231_zZFDcViaJAJd" title="Finance Lease Liabilities, weighted average discount rate">8.1</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8A1_zfr65auP8iH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y Some leases include purchase, termination or extension options for one or more years. P7Y 13000 14000 3034 seven years 43000 64000 586000 200000 852000 814000 501000 485000 3000 7000 36000 59000 <p id="xdx_898_ecustom--ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock_zepsjc6E5uUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zaS7fqCSkGA" style="display: none">Schedule of Maturity of Operating and Finance Leases Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Maturity of Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_zsleADhzebLj" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">883</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20211231_zlu8o3oECicd" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Finance Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231_z1Aspbf4q5B5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20211231_zbVOjpdoE6o1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231_z3InhUImF8zj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif">962</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20211231_zecU9iudq4E4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231_zUc5XUiYtK9j" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif">1,004</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20211231_zuZa2dA0ckc4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_c20211231_zNkM14v5nJ57" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating lease Liabilities, 2026"><span style="font-family: Times New Roman, Times, Serif">1,046</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20211231_zWQvc2zVdtoj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1008">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_zZXh7SAGBCmi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif">1,112</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20211231_z1wtFGkMYLIe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted operating lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zXm47PINjlLf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted operating lease payments"><span style="font-family: Times New Roman, Times, Serif">5,929</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20211231_zNw02ly8kKba" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted finance lease payments"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231_zdWkTJwjLeLg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif">1,250</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20211231_zuXWaMr0poY8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231_zP2BnUCA3Y6j" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">4,679</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20211231_zhfym25rWER3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of finance lease liabilities"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zRoeg1NPBSVi" title="Operating Lease Liabilities, weighted average remaining lease term in years">6.1</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zTxIT1gNaQR4" style="font-family: Times New Roman, Times, Serif">0.9</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zcNNtUxD4i8e" style="font: 10pt Times New Roman, Times, Serif" title="Operating Lease Liabilities, weighted average discount rate">7.8</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zjB5wh92tryd" title="Finance Lease Liabilities, weighted average discount rate">7.8</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Maturity of Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance Lease Liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_zZWZzMZkmEP6" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">685</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20201231_z0KEn7hxXYtb" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Finance Lease Liabilities, 2022"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zilrlahYrTN7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">645</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20201231_zRQVBN0xWxE" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2023"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zplWr0oyPrse" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif">677</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20201231_zUMuKdDEJCig" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2024"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_zgKKnFlHpM5e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif">710</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20201231_z4mtqKK6rTQi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2025"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zwKsZT2FLGrk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, 2026"><span style="font-family: Times New Roman, Times, Serif">745</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20201231_zqhcvMVQfAj6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, 2026"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1051">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20201231_zGTOLvOWcpac" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif">1,458</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20201231_zM5RYbKCqIhl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, Thereafter"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted operating lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_z812oChrCDh6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted operating lease payments"><span style="font-family: Times New Roman, Times, Serif">4,920</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20201231_zmTV6njmQCC4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Total undiscounted finance lease payments"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20201231_zozADcseTMAb" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Operating Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif">1,224</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_c20201231_z6YoUAVoiOa8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Finance Lease Liabilities, less: Imputed interest"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20201231_zGhVuISFWM6e" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">3,696</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20201231_zbWBKAyQuQZj" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Present value of finance lease liabilities"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term in years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zo520W576Lnl" title="Operating Lease Liabilities, weighted average remaining lease term in years">6.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zliIYUDTFgme" title="Finance Lease Liabilities, weighted average remaining lease term in years">1.7</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted average discount rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20201231_zgcPGhY0k1P7" title="Operating Lease Liabilities, weighted average discount rate">8.4</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20201231_zZFDcViaJAJd" title="Finance Lease Liabilities, weighted average discount rate">8.1</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 883000 22000 922000 2000 962000 1004000 1046 1112000 5929000 24000 1250000 4679000 24000 P6Y1M6D P0Y10M24D 0.078 0.078 685000 34000 645000 19000 677000 2000 710000 745000 1458000 4920000 55000 1224000 3696000 55000 P6Y8M12D P1Y8M12D 0.084 0.081 <p id="xdx_802_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zgTNETNBsakg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 - <span id="xdx_826_zZVG5phT7er6">Collaboration Agreements, License and Other Research and Development Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cystic Fibrosis Foundation Therapeutics Development Award</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2020, the Company entered into an award agreement (the “Agreement”) with CFF, pursuant to which it received a Therapeutics Development Award of up to $<span id="xdx_902_ecustom--TherapeuticsDevelopmentAward_iI_pn5n6_c20201119__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_zjsjxDDfC1i7" title="Therapeutics development award">4.2</span> million (the “Award”) (of which $<span id="xdx_905_ecustom--ProceedsFromAward_pp0p0_c20201118__20201119__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_z4DwMvcyu6qh" title="Proceeds from award">484,249</span> had been previously received) to support the preclinical development (the “Development Program”) of the Company’s MAT2501 product candidate (the “Product”), a LNC oral formulation of the broad-spectrum aminoglycoside amikacin, for the treatment of pulmonary non-tubercular mycobacteria infections and other pulmonary diseases (the “Field”). On November 19, 2021, the Company and CFF entered into an Amendment to the Agreement which added an additional milestone payment in the amount of $<span id="xdx_90B_ecustom--AdditionalMilestonePayment_pn3n3_c20211118__20211119__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember_ziHavIAbFBCj" title="Additional milestone payment">321</span> thousand. The milestone payment was invoiced and the payment was received in the fourth quarter of 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first payment under the Agreement, in the amount of $<span id="xdx_906_eus-gaap--GrantsReceivable_iI_pn3n3_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--PrepaidExpensesAndOtherCurrentAssetsMember__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_zfCuWriR3ez7" title="Grants Receivable">650</span> thousand, became due upon execution of the Agreement. The Company invoiced the CFF in November 2020 and payment was subsequently received in February 2021. During 2021, the Company invoiced and received $<span id="xdx_90E_eus-gaap--ProceedsFromCollaborators_pn5n6_c20210101__20211231__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_z3wVDfFKpAnk" title="Amount received from agreement">2.5</span> million related to Agreement and the related deferred liability balance of $<span id="xdx_90E_eus-gaap--OtherLiabilities_iI_pn3n3_c20201231__us-gaap--BalanceSheetLocationAxis__custom--AccruedExpenseAndOtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_ziVMilNYJDHh" title="Other Liabilities">899</span> thousand is included in accrued expense and other current liabilities. The remainder of the Award will be paid to the Company upon the achievement of certain milestones related to the development program and progress of the Development Program, as set forth in the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company ceases to use commercially reasonable efforts directed to the development of MAT2501 in the Field, (an “Interruption”) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the Award actually received by the Company, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Agreement that covers the Product for use in treating infections in CF patients (the “CF Field”), and (2) a non-exclusive, worldwide license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Agreement, the Company is obligated to make royalty payments to CFF contingent upon commercialization of the Product in the Field up to a maximum of five (5) times the Award or approximately $<span id="xdx_902_ecustom--RoyaltyPayable_iI_pn5n6_c20201119__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_zXxf9ZhSrAn5" title="Royalty payable">21.2</span> million (the “Royalty Cap”), payable in three equal annual installments following the first commercial sale of the Product, the first of which is due within 90 days following the first commercial sale of the Product. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction which will be applied against the Royalty Cap. In addition, the Company is also obligated to make up the two royalty payments of CFF of the approximately $<span id="xdx_90F_ecustom--RoyaltyPayable_iI_pn5n6_c20201119__srt--StatementScenarioAxis__custom--UponAchievementOfSalesMilestonesMember__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_zaVQ8CUlgdF6" title="Royalty payable">4.2</span> million each, due in the calendar years in which specific net sales milestones are achieved.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of the Agreement commenced on November 19, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Agreement. Either CFF or the Company may terminate the agreement for cause, which includes the Company’s material failure to achieve certain development milestones. The Company’s payment obligations survive the termination of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company concluded that the CFF award is in the scope of ASC 808. Accordingly, as discussed in Note 3, the award amounts received from CFF upon achievement of certain milestones are recognized as credits to research and development expenses in the period the Development Program’s expenses are incurred. During the years ended December 31, 2021 and 2020, the Company recognized $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_z8YCCryYx3il" title="Research and development expenses">2.2</span> million and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--AwardAgreementMember__dei--LegalEntityAxis__custom--CysticFibrosisFoundationMember_zIkqJy6Gmtj1" title="Research and development expenses">0.1</span> million, respectively, as credits to research and development expenses related to the CFF award. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Genentech Feasibility Study Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 12, 2019, the Company entered into a feasibility study agreement (the “Agreement”) with Genentech, Inc. (“Genentech”). This feasibility study agreement will involve the development of oral formulations using the Company’s LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Under the terms of the Agreement, <span id="xdx_906_ecustom--AgreementDescription_c20191201__20191212__us-gaap--TypeOfArrangementAxis__custom--GenentechFeasibilityStudyAgreementMember__dei--LegalEntityAxis__custom--GenentechMember_zCh5yyijbls2" title="Agreement description">Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement.</span> On December 13, 2019, per Genentech’s request, the Company billed Genentech for the total $<span id="xdx_90C_eus-gaap--DeferredRevenue_iI_pn3n3_c20191213__us-gaap--TypeOfArrangementAxis__custom--GenentechFeasibilityStudyAgreementMember__dei--LegalEntityAxis__custom--GenentechMember_zvTCAr6VMs59" title="Deferred revenue">100</span> thousand and recorded the upfront consideration as deferred revenue, which is recorded in accrued expenses on the consolidated balance sheets, and will recognize it over the term of the contract performance obligation period. As of December 31, 2021, the Company completed the first and second of the three molecules and the Company recognized approximately $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__dei--LegalEntityAxis__custom--GenentechMember_zYjmrR3vC2Wi" title="Revenue"><span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__dei--LegalEntityAxis__custom--GenentechMember_zcKWQGTFlY32" title="Revenue">33</span></span> thousand of Genentech revenue for the years ended December 31, 2021 and 2020, respectively. The Company is scheduled to complete the remaining molecule during 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Research and development agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has financial obligations resulting from Cooperative Research and Development Agreements (“CRADAs”) entered into with the with the National Institute of Allergy and Infectious Diseases (“NIH”) as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 19, 2016, the Company agreed to provide funds in the amount of $<span id="xdx_907_ecustom--RemainingBalanceLeaseTermAmount_pp0p0_c20160216__20160219__us-gaap--OtherCommitmentsAxis__custom--CooperativeResearchAndDevelopmentAgreementsMember_zvgYWMLv4XW" title="Remaining balance lease term amount">200,000</span> per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of LNC platform drug products in patients with fungal, bacterial, or viral infections. The initial term of the CRADA was three years. On April 16, 2019, the Company renewed the CRADA for an additional <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dc_c20190415__20190416__us-gaap--OtherCommitmentsAxis__custom--CooperativeResearchAndDevelopmentAgreementsMember_zKlk0dkCMXI3" title="Initial term">three years</span> with an annual funding commitment of $<span id="xdx_909_eus-gaap--OtherCommitment_iI_pp0p0_c20190416__us-gaap--OtherCommitmentsAxis__custom--CooperativeResearchAndDevelopmentAgreementsMember_z3mea1x65hDe" title="Other commitment">200,000</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 2, 2019, the Company agreed to provide funds in the amount of $<span id="xdx_90E_ecustom--FundsProvideForSupport_iI_pp0p0_c20190402__us-gaap--OtherCommitmentsAxis__custom--CooperativeResearchAndDevelopmentAgreementsMember_zDV7zA11j8g" title="Funds provide for support">157,405</span> per year under a CRADA to support NIH investigators in the conduct of clinical research to investigate the safety, efficacy, and pharmacokinetics of LNC platform drug products in patients with fungal, bacterial, or viral infections. The term of the CRADA is three years.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through the acquisition of Aquarius, the Company acquired a license from Rutgers University, The State University of New Jersey (successor in interest to the University of Medicine and Dentistry of New Jersey) for the LNC platform delivery technology. The Second Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $<span id="xdx_90E_ecustom--RevenueMilestoneMethodMilestoneFee_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zuP3SDKpkOza" title="Milestone fee">100,000</span> when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of $<span id="xdx_90F_eus-gaap--TaxesAndLicenses_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z3qPuSNMXspj" title="Annual license fee">50,000</span> over the term of the license agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4200000 484249 321000 650000 2500000 899000 21200000 4200000 2200000 100000 Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement. 100000 33000 33000 200000 P3Y 200000 157405 100000 50000 <p id="xdx_80F_eus-gaap--CommitmentsDisclosureTextBlock_zIwf2ZhlSNt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_820_zOYXOHakE2v5">Commitments</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Royalty payment rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 12, 2016 the Company conducted a final closing of a private placement offering to accredited investors of shares of the Company’s Series A Preferred Stock. As part of this offer, the investors received royalty payment rights if and when the Company generates sales of its MAT2203 or MAT2501 product candidates. Pursuant to the terms of the Series A Certificate of Designation, the Company may be required to pay royalties of up to $<span id="xdx_902_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_pn6n6_c20160912__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zaSUQaQ3MId2" title="Accrued royalties">35</span> million per year. If and when the Company obtains FDA or the European Medicines Agency (“EMA”) approval of MAT2203 and/or MAT2501, which the Company does not expect to occur before 2023, if ever, and/or if the Company generates sales of such products, or the Company receives any proceeds from the licensing or other disposition of MAT2203 or MAT2501, <span id="xdx_90B_ecustom--RoyaltyPaymentRightsDescription_c20160901__20160912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zF9XuYQDsVtl" title="Royalty payment rights, description">the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the “Royalty Payment Rights”) equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $<span id="xdx_901_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_pn6n6_c20160912__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__custom--FourPointFivePercentOfNetSalesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOUGFvrfGOW4" title="Accrued royalties">25</span> million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $<span id="xdx_90E_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_pn6n6_c20160912__srt--RangeAxis__srt--MaximumMember__srt--StatementScenarioAxis__custom--SevenPointFivePercentOfNetSalesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCXdoSC7LC6g" title="Accrued royalties">10</span> million per calendar year.</span> <span id="xdx_904_ecustom--RoyaltyPaymentRightsExpireDescription_c20160901__20160912__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKgsywdlIULg" title="Royalty payment rights expire description">The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other normal business operating agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in the course of normal business operations, the Company enters into agreements with contract service providers to assist in the performance of research &amp; development and manufacturing activities. Expenditures to these third parties represent significant costs in clinical development and may require upfront payments and long-term commitments of cash. Subject to required notice periods and obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 35000000 the Company is required to pay to the holders of the Series A Preferred Stock, subject to certain vesting requirements, in the aggregate, a royalty (the “Royalty Payment Rights”) equal to (i) 4.5% of Net Sales (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $25 million per calendar year, and (ii) 7.5% of Licensing Proceeds (as defined in the Series A Certificate of Designation), subject in all cases to a cap of $10 million per calendar year. 25000000 10000000 The Royalty Payment Rights will expire when the patents covering the applicable product expire, which is currently expected to be in 2033 <p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zbmQw4P3ad0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_828_z9Av0a9nQWok">Income Taxes</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2021 and 2020, the Company does not believe any material uncertain tax positions were present. Accordingly, interest and penalties have not been accrued due to an uncertain tax position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4M0k8odzTW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the income tax provision are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zktZr2hiuaT3" style="display: none">Schedule of Income Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"> </td><td id="xdx_49C_20210101__20211231_zvJjQPRLIL7g" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td id="xdx_49D_20200101__20201231_zCTn7BdRvLOi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended December 31,</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total income tax expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zA0qtnp36NX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbxr5JjBqM5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z8rW1tlEZ7xk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_z9P0pgjMKgzd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20200101__20201231_zKcUybpxD4yj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zVf8XsXe0nfa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income at US Statutory Rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zLx8fvGJieD9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State Taxes, net of Federal benefit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.95</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_zjgNts5HgPt4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent Differences</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.28</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_zz7z6aRx932e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax Credits</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.16</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.75</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zlyvfJlcCxf3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation Allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25.21</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24.53</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_zrfzj4CwEjbf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Discrete items</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.91</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_zATRjsXXIdCf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> <span style="display: none; font-size: 10pt">Effective income tax rate</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8A8_zVvp4NmYk3wk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no current income taxes payable other than certain state minimum taxes which are included in general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQ1XKh7EaG1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of the Company’s deferred tax assets (liabilities) for 2021 and 2020 consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zNwm5nS2gnGg" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211231_z6NX2qmT3LH2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zJwEg3Z8Xvg8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1eZ_z66GjpQpJjia" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based Compensation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,575</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,220</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGz1eZ_z1frK3s8vAPg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and Amortization</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">166</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(119</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGz1eZ_zuIBWYFPv769" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">307</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1eZ_zRTM1haKgcS3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Operating Loss Carry-forwards</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,076</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,927</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1eZ_zDhtEGU9P80g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D Credit Carryforwards</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,207</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,264</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1eZ_zjLrGtzct7v8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTAGz1eZ_zUOCPuBU7LYk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(848</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(848</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsRIghtOfUseAsset_iNI_pn3n3_di_maDTAGz1eZ_z1CKoMELnD2h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ROU Asset</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,186</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(921</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_ecustom--DeferredTaxLiabilitiesRightOfUseLiability_iI_pn3n3_maDTAGz1eZ_zADqUcJCixka" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">ROU Liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,315</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,045</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz1eZ_maDTALNzAmW_z4RQMZSpkfph" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total Deferred tax assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,681</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,865</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzAmW_zuKM3lA6CWD3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(31,023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,206</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_pn3n3_di_mtDTALNzAmW_z4g3tqxcM9id" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset (liability)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(341</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(341</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8A6_zBnk0N3FAM4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law making several changes to the Internal Revenue Code. The changes include but are not limited to: allowing companies to carryback certain net operating losses, and increasing the amount of net operating loss carryforwards that corporations can use to offset taxable income. The tax law changes in the Act did not have a material impact on the Company’s income tax provision.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible, and is impacted by the Company’s ability to carryforward losses to years in which the Company has taxable income. Due to the Company’s history of losses and lack of other positive evidence to support taxable income, the Company has recorded a valuation allowance against those deferred tax assets that are not expected to be realized. The valuation allowances were approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20211231_zmknHdSriTef">31.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> $<span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20201231_zypqMbL4n7sd">25.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20191231_zujjw7LW7Lfg">19.7</span> million as of December 31, 2021, 2020 and 2019, respectively, representing increases of approximately $<span id="xdx_90F_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20210101__20211231_zssPHdB8Ip6h">5.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20200101__20201231_zcHGxKdfyss3">5.5</span> million for the years ending December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had Federal net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zh5zDES9QwQf">38.1</span> million which will begin to expire in <span id="xdx_906_ecustom--OperatingLossCarryforwardsExpirationYear_c20210101__20211231_zt86WjeIsBuc" title="Operating loss carryforwards, expiration year">2032</span>. In addition, the Company has federal net operating loss carryforwards of approximately $<span id="xdx_90A_ecustom--OperatingLossCarryforwardsWithNoExpiration_iI_pn5n6_c20211231_ziNNXElY1dQa" title="Operating loss carryforwards with no expiration">63.3</span> million which have an indefinite carryforward period. The Company also had federal and state research and development tax credit carryforwards of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--TaxCreditCarryforwardAxis__custom--FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsMember_z36HTUUSwboe" title="Operating loss carryforwards">3.2</span> million. The federal net operating loss and tax credit carryforwards will expire at various dates beginning in 2033, if not utilized. The difference between the statutory tax rate and the effective tax rate is primarily attributable to the valuation allowance offsetting deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 due to changes in ownership of the Company that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. The Company has not completed a study to determine whether it had undergone an ownership change since the Company’s inception</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale of net operating losses (NOLs)</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized approximately $<span id="xdx_90D_ecustom--SaleOfNetOperatingLosses_pn5n6_c20210101__20211231_zIZUZ9Opz5Ec">1.3</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_908_ecustom--SaleOfNetOperatingLosses_pn5n6_c20200101__20201231_zSiIwF3EDbae">1.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the years ended December 31, 2021 and 2020, respectively, in connection with the sale of certain State of New Jersey Net Operating Losses (“NOL”) and Research and Development (“R&amp;D”) tax credits to a third party under the New Jersey Technology Business Tax Certificate Transfer Program. <span id="xdx_908_ecustom--LimitationsOnNetOperatingLossDeductibilityDescription_pid_c20210101__20211231_zsVzP88FJNB3">In addition, the Tax Cuts and Jobs Act, signed into law on December 22, 2017 imposes significant additional limitations on the deductibility of interest and limits NOL deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This NOL limitation was suspended for years 2018 through 2020 as a result of the CARES Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z4M0k8odzTW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the income tax provision are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zktZr2hiuaT3" style="display: none">Schedule of Income Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"> </td><td id="xdx_49C_20210101__20211231_zvJjQPRLIL7g" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td id="xdx_49D_20200101__20201231_zCTn7BdRvLOi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended December 31,</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CurrentForeignTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1144">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1148">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_i_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total income tax expense (benefit):</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbxr5JjBqM5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_z8rW1tlEZ7xk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_z9P0pgjMKgzd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20200101__20201231_zKcUybpxD4yj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zVf8XsXe0nfa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income at US Statutory Rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zLx8fvGJieD9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">State Taxes, net of Federal benefit</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.97</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.95</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_zjgNts5HgPt4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Permanent Differences</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.82</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.28</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_zz7z6aRx932e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax Credits</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.16</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.75</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zlyvfJlcCxf3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation Allowance</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25.21</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(24.53</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_zrfzj4CwEjbf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Discrete items</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.91</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_zATRjsXXIdCf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> <span style="display: none; font-size: 10pt">Effective income tax rate</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 0.2100 0.2100 0.0197 0.0295 -0.0082 -0.0128 0.0216 0.0075 -0.2521 -0.2453 0.0091 0.0111 0.0000 0.0000 <p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQ1XKh7EaG1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of the Company’s deferred tax assets (liabilities) for 2021 and 2020 consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zNwm5nS2gnGg" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211231_z6NX2qmT3LH2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20201231_zJwEg3Z8Xvg8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz1eZ_z66GjpQpJjia" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based Compensation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,575</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,220</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGz1eZ_z1frK3s8vAPg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and Amortization</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">166</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(119</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGz1eZ_zuIBWYFPv769" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued Liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">307</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz1eZ_zRTM1haKgcS3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net Operating Loss Carry-forwards</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,076</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,927</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz1eZ_zDhtEGU9P80g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D Credit Carryforwards</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,207</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,264</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz1eZ_zjLrGtzct7v8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTAGz1eZ_zUOCPuBU7LYk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">IPR&amp;D</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(848</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(848</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsRIghtOfUseAsset_iNI_pn3n3_di_maDTAGz1eZ_z1CKoMELnD2h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ROU Asset</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,186</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(921</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_ecustom--DeferredTaxLiabilitiesRightOfUseLiability_iI_pn3n3_maDTAGz1eZ_zADqUcJCixka" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">ROU Liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,315</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,045</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz1eZ_maDTALNzAmW_z4RQMZSpkfph" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total Deferred tax assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,681</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,865</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzAmW_zuKM3lA6CWD3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(31,023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(25,206</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_pn3n3_di_mtDTALNzAmW_z4g3tqxcM9id" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax asset (liability)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(341</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(341</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> 3575000 3220000 166000 -119000 377000 307000 24076000 19927000 3207000 2264000 -1000 -10000 848000 848000 1186000 921000 1315000 1045000 30681000 24865000 31023000 25206000 341000 341000 31000000.0 25200000 19700000 5800000 5500000 38100000 2032 63300000 3200000 1300000 1100000 In addition, the Tax Cuts and Jobs Act, signed into law on December 22, 2017 imposes significant additional limitations on the deductibility of interest and limits NOL deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmw0BL348y7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_82C_zes1DvMenRt2">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>At-The-Market Equity Offering</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 2, 2020, the Company entered into an At-The-Market (“ATM”) Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pip0_c20200629__20200702__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zFK2aJPble65" title="Aggregate offering price for sale of stock">50,000,000</span>, subject to certain limitations on the amount of common stock that may be offered and sold by the Company set forth in the Sales Agreement. BTIG will be paid a <span id="xdx_906_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pip0_dp_uPure_c20200629__20200702__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zvRHU9l7P781" title="Sale of stock percentage">3</span>% commission on the gross proceeds from each sale. The Company may terminate the Sales Agreement at any time; BTIG may terminate the Sales Agreement in certain limited circumstances. During 2021, BTIG sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210102__20210131__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zK7zCdq9npsh" title="Sale of stock shares">3,023,147</span> shares of the Company’s common stock generating gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210102__20210131__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zmK1OcOsLwoj" title="Proceeds from issuance of common stock">5.8</span> million and net proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20210102__20210131__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z0NEO28dbvs9" title="Net proceeds from public offering of common stock">5.6</span> million, after deducting BTIG’s commission on gross proceeds. During 2020, the Company did not sell any shares of its common stock under the ATM Sales Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 3, 2021, the Company issued <span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20210901__20210903__us-gaap--TypeOfArrangementAxis__custom--AquariusMergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--HoldersOfAquariusBiotechnologiesIncMember__us-gaap--StatementClassOfStockAxis__custom--UnregisteredSharesMember_z7PXFNb2dlg1" title="Business acquisition, equity iterest issued or issuable, shares">1,500,000</span> unregistered shares of its common stock pursuant to the Agreement and Plan of Merger by and among the Company, Saffron Merger Sub, Inc., Aquarius Biotechnologies Inc. (“Aquarius”), and J Carl Craft, as holder representative, dated January 19, 2015, as subsequently amended on September 3, 2021 (the “Aquarius Merger Agreement”), to the holders of Aquarius Biotechnologies Inc., as defined in the Aquarius Merger Agreement. The shares were issued in place of certain milestone payments previously included under the Aquarius Merger Agreement upon the achievement of specified development milestones. The Company recorded a $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210901__20210903__us-gaap--TypeOfArrangementAxis__custom--AquariusMergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--HoldersOfAquariusBiotechnologiesIncMember__us-gaap--StatementClassOfStockAxis__custom--UnregisteredSharesMember_zFeKr6wWlSn5" title="Research and Development Expense">1.2</span> million research and development expense related to the issuance of the <span id="xdx_905_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20210901__20210903__us-gaap--TypeOfArrangementAxis__custom--AquariusMergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--HoldersOfAquariusBiotechnologiesIncMember__us-gaap--StatementClassOfStockAxis__custom--UnregisteredSharesMember_zAKK8ZxBeujf" title="Business acquisition, equity iterest issued or issuable, shares">1,500,000</span> shares based on the closing price of the Company’s common stock of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20210903__us-gaap--TypeOfArrangementAxis__custom--AquariusMergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--HoldersOfAquariusBiotechnologiesIncMember__us-gaap--StatementClassOfStockAxis__custom--UnregisteredSharesMember_zxxbAd8AdgGa" title="Share price">0.80</span> on the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 14, 2020, the Company closed on an underwritten public offering of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200112__20200114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znX6O9c7as0j" title="Issuance of common stock in public offering, shares">32,260,000 </span>shares of its common stock at a purchase price of $</span><span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20200114__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMsemyJlTO5e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.55 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Company generated gross proceeds of approximately $</span><span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20200112__20200114_zhUMpKLsr6w5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.0 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and net proceeds of approximately $</span><span id="xdx_90E_ecustom--NetProceedsFromPublicOfferingOfCommonStock_pn5n6_c20200112__20200114_z25YvV1APyFa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Net proceeds from public offering of common stock">46.7 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to approximately 4.8 million additional shares of its common stock on the same terms and conditions. No additional shares of the Company’s common stock were sold pursuant to this option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the Certificate of Incorporation, the Company is authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zP5zfyHuS3fj" title="Preferred stock shares authorized">10,000,000</span> preferred shares at a par value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z94fRg8q25Rg" title="Preferred stock par value">0.001</span>. In connection with a private placement of Series A Preferred Stock, on July 26, 2016, the Company filed the Series A Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series A Preferred Stock. Pursuant to the Series A Certificate of Designation, the Company designated <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__custom--DesignatedMember_zVT353TYe917" title="Preferred stock shares authorized">1,600,000</span> shares of the Company’s previously undesignated preferred shares as Series A Preferred Stock. In connection with a public offering of Series B Preferred Stock, on June 19, 2018, the Company filed the Series B Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Stock. Pursuant to the Series B Certificate of Designation, the Company designated <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20180619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwHZpAIGriV4" title="Preferred stock shares authorized">8,000</span> shares of the Company’s previously undesignated preferred shares as Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series B Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021 and prior to June 19, 2021, <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zL1NQrbhGkL3" title="Shares converted"><span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210616__20210618__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9i5YYGOpYa3">143</span></span> shares of Series B Preferred Stock were converted by shareholders resulting in the issuance of <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zHWhGHpQh3bb"><span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210616__20210618__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjTkPQMUqwZa" title="Shares issued upon conversion">286,000</span></span> shares of common stock. On June 19, 2021, all <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210619__20210619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGFkwpCH8dLa" title="Sale of Stock, Number of Shares Issued in Transaction">4,218</span> remaining shares of Series B Preferred Stock were automatically converted into <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210719__20210719__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdcY2YOdCvZe" title="Shares converted">2,000</span> shares of the Company’s common stock resulting in the issuance of <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210719__20210719__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUDsMmsD9qpe" title="Shares issued upon conversion">8,436,000</span> shares of common stock. As of December 31, 2021 and December 31, 2020, there were <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeaCpL9FEeOe" title="Preferred stock, shares outstanding">0</span> and <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkRYSeFkhpH2" title="Preferred stock, shares outstanding">4,361</span> shares of Series B Preferred stock outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the automatic conversion of Series B Preferred Stock on June 19, 2021, and subject to certain ownership limitations, each share of Series B Preferred Stock was convertible into shares of the Company’s common stock at any time at the option of the holder at an initial conversion price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210619__us-gaap--TypeOfArrangementAxis__custom--AquariusMergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--HoldersOfAquariusBiotechnologiesIncMember__us-gaap--StatementClassOfStockAxis__custom--UnregisteredSharesMember_z2edY9a0gyuj" title="Conversion price per share">0.50</span> per share subject to adjustment for reverse splits, stock combinations and similar changes as provided in the Certificate of Designation. Based on the conversion price and number of shares outstanding on June 19, 2021, the Series B Preferred Stock were converted into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210617__20210619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__custom--HoldersMember_z3mN0xG0g422" title="Number of preferred stock shares converted">8,436,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to certain ownership limitations, holders of the Series B Preferred Stock received dividends paid in the Company’s common stock as follows: <span id="xdx_909_ecustom--LiquidityValueAndDividendsDescription_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWDZKYgv7VBk">(i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20210619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zntCRC0K6358" title="Common stock, shares outstanding">1,687,200</span> and <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20200619__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRwcCOn0Rnb3" title="Common stock, shares outstanding">1,365,600</span> shares of common stock, respectively</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All warrants issued by the Company are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company’s capital stock or other similar changes to the equity structure of the Company. The warrants do not have a redemption feature. They may be exercised on a cashless basis at the holder’s option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants are classified as equity instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had outstanding warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231_z5CeTcSU3Fw8" title="Number of warrant to purchase of common stock">988,000</span> shares of common stock at exercise prices ranging from $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zieGkOirsJah" title="Class of warrant or right, exercise price of warrants or rights">0.50</span> to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_zvm6HGmnXxDi" title="Class of warrant or right, exercise price of warrants or rights">0.75</span> per share, and with expiration dates between December 31, 2022 and June 21, 2023. A summary of warrants outstanding as of December 31, 2021 and 2020 is presented below, all of which are fully vested (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zoQ3umtjhTKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zQE4SKTk5Q2e" style="display: none">Summary of Shareholders Equity Warrants Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pin3_c20200101__20201231_zR0gnnv0pzHb" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Shares Outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif">5,397</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pin3_c20200101__20201231_zFKFrRDA6rK8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pin3_di_c20200101__20201231_zn6Bz6Cbe9F7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Exercised"><span style="font-family: Times New Roman, Times, Serif">(2,549</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Tendered</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered_iN_pin3_di_c20200101__20201231_zPfF9xIQaPgk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Tendered"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pin3_di_c20200101__20201231_zo6YjCabISna" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Expired"><span style="font-family: Times New Roman, Times, Serif">(1,493</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pin3_c20200101__20201231_fKg_____zZXPflqS5IZ1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td></tr> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span id="xdx_F47_zndtCrmTSj4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 01, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pin3_c20210101__20211231_zfxzaoMpDc0k" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pin3_di_c20210101__20211231_fKio___zbQc3iWgdDJ5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Exercised"><span style="font-family: Times New Roman, Times, Serif">(320</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)**</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Tendered</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered_iN_pin3_di_c20210101__20211231_zY9BgKy6OI2g" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Tendered"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pin3_di_c20210101__20211231_zpA5p8j1eIFk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Expired"><span style="font-family: Times New Roman, Times, Serif">(20</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span id="xdx_F46_zIJr02Vt72C8" style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pin3_c20210101__20211231_fKioq_zwPdx746FdL3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">***</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span id="xdx_F0F_zs9SpFMTS165" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zAsibqoEc6Ll" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise price for outstanding warrants is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgU2hhcmVob2xkZXJzIEVxdWl0eSBXYXJyYW50cyBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iI_c20201231_zb0VG4XLzvdh" title="Weighted average of exercise price for outstanding warrants">0.55</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F06_zDrFJbdmHSVj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zmxaz6vT7BE3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into approximately <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgU2hhcmVob2xkZXJzIEVxdWl0eSBXYXJyYW50cyBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pin3_c20211231_zErvtQ66UC01" title="Number of warrant common stock converted">115</span> thousand shares of common stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zKwmzuIx08sg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F1C_z9VbZijiP2Yl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise price for outstanding warrants is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgU2hhcmVob2xkZXJzIEVxdWl0eSBXYXJyYW50cyBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iI_c20211231_zYfqlQlOT3Ue" title="Weighted average of exercise price for outstanding warrants">0.56</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 50000000 0.03 3023147 5800000 5600000 1500000 1200000 1500000 0.80 32260000 1.55 50000000.0 46700000 10000000 0.001 1600000 8000 143 143 286000 286000 4218 2000 8436000 0 4361 0.50 8436000 (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. Based on an accounting of the holders of record of Series B Preferred Stock on June 19, 2021 and 2020, the Company made dividend payments totaling 1,687,200 and 1,365,600 shares of common stock, respectively 1687200 1365600 988000 0.50 0.75 <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zoQ3umtjhTKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zQE4SKTk5Q2e" style="display: none">Summary of Shareholders Equity Warrants Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 78%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pin3_c20200101__20201231_zR0gnnv0pzHb" style="font-family: Times New Roman, Times, Serif; width: 18%; text-align: right" title="Shares Outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif">5,397</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pin3_c20200101__20201231_zFKFrRDA6rK8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1307">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pin3_di_c20200101__20201231_zn6Bz6Cbe9F7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Exercised"><span style="font-family: Times New Roman, Times, Serif">(2,549</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Tendered</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered_iN_pin3_di_c20200101__20201231_zPfF9xIQaPgk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Tendered"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pin3_di_c20200101__20201231_zo6YjCabISna" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Expired"><span style="font-family: Times New Roman, Times, Serif">(1,493</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pin3_c20200101__20201231_fKg_____zZXPflqS5IZ1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td></tr> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span id="xdx_F47_zndtCrmTSj4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 01, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pin3_c20210101__20211231_zfxzaoMpDc0k" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Issued"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pin3_di_c20210101__20211231_fKio___zbQc3iWgdDJ5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Exercised"><span style="font-family: Times New Roman, Times, Serif">(320</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)**</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Tendered</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered_iN_pin3_di_c20210101__20211231_zY9BgKy6OI2g" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Tendered"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pin3_di_c20210101__20211231_zpA5p8j1eIFk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Expired"><span style="font-family: Times New Roman, Times, Serif">(20</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span id="xdx_F46_zIJr02Vt72C8" style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pin3_c20210101__20211231_fKioq_zwPdx746FdL3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares Outstanding, ending"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">***</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span id="xdx_F0F_zs9SpFMTS165" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zAsibqoEc6Ll" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise price for outstanding warrants is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgU2hhcmVob2xkZXJzIEVxdWl0eSBXYXJyYW50cyBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iI_c20201231_zb0VG4XLzvdh" title="Weighted average of exercise price for outstanding warrants">0.55</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F06_zDrFJbdmHSVj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F16_zmxaz6vT7BE3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into approximately <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgU2hhcmVob2xkZXJzIEVxdWl0eSBXYXJyYW50cyBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pin3_c20211231_zErvtQ66UC01" title="Number of warrant common stock converted">115</span> thousand shares of common stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zKwmzuIx08sg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F1C_z9VbZijiP2Yl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise price for outstanding warrants is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgU2hhcmVob2xkZXJzIEVxdWl0eSBXYXJyYW50cyBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iI_c20211231_zYfqlQlOT3Ue" title="Weighted average of exercise price for outstanding warrants">0.56</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5397000 2549000 1493000 1328000 320000 20000 988000 0.55 115000 0.56 <p id="xdx_802_eus-gaap--OtherComprehensiveIncomeNoncontrollingInterestTextBlock_zyS2CdNvxhEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_828_zy2OY4ZKtafa">Accumulated Other Comprehensive (Loss)/Income</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zmJ0C1LnFN07" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the years ended December 31, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zfMaBvKXW94e">Schedule of Components of Accumulated Other Comprehensive (Loss)/Income</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Unrealized (Losses)/Gains on Available-for-Sale Securities</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated Other Comprehensive (Loss)/Gain</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecurities_iS_pn3n3_c20200101__20201231_zEB5NuMso4F8" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20200101__20201231_zyVudOMTijv1" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net unrealized gain on securities available-for-sale</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20200101__20201231_zzHr3E6wCjO9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized loss on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">237</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20200101__20201231_zDkSEiNFooJe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Net unrealized loss on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">237</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification of realized gain on securities available-for-sale to net loss</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesReclassificationNetLoss_pn3n3_c20200101__20201231_zcdeGYoQkTN" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Reclassification of realized gain on securities available-for-sale to net loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--AccumulatedOtherComprehensiveLossgainReclassificationsNetLoss_pn3n3_c20200101__20201231_zO3QwfTfTtY8" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Reclassification of realized gain on securities available-for-sale to net loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net current period other comprehensive gain</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_pn3n3_c20200101__20201231_zDh4UKQkH0Cc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Other comprehensive income (loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax_pn3n3_c20200101__20201231_zFgjjWpPp2Vc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Other comprehensive gain"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2020</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecurities_iS_pn3n3_c20210101__20211231_zbvMN4XhizQh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">228</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20210101__20211231_zt9EAYWxjjCf" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">228</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net unrealized loss on securities available-for-sale</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20210101__20211231_zv8sMPiNGrOh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized gain (loss) on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(373</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20210101__20211231_zWoNIdNYWYfb" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Net unrealized gain (loss) on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(373</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net current period other comprehensive loss</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_pn3n3_c20210101__20211231_zLrJqFL4CLuj" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net current period other comprehensive loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(374</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax_pn3n3_c20210101__20211231_zgfA8OQ2a5Ol" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Net current period other comprehensive loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(374</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecurities_iE_pn3n3_c20210101__20211231_zzHAhBh8Kcj1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_ecustom--AccumulatedOtherComprehensiveIncomeLossNetOfTaxes_iE_pn3n3_c20210101__20211231_zmhZdWHcGX0a" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td></tr> </table> <p id="xdx_8A9_zIVTrqB6Ghcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All components of accumulated other comprehensive (loss)/income are net of tax.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_zmJ0C1LnFN07" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the years ended December 31, 2021 and 2020 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zfMaBvKXW94e">Schedule of Components of Accumulated Other Comprehensive (Loss)/Income</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Unrealized (Losses)/Gains on Available-for-Sale Securities</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated Other Comprehensive (Loss)/Gain</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2019</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecurities_iS_pn3n3_c20200101__20201231_zEB5NuMso4F8" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20200101__20201231_zyVudOMTijv1" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net unrealized gain on securities available-for-sale</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20200101__20201231_zzHr3E6wCjO9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized loss on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">237</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20200101__20201231_zDkSEiNFooJe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Net unrealized loss on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">237</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification of realized gain on securities available-for-sale to net loss</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesReclassificationNetLoss_pn3n3_c20200101__20201231_zcdeGYoQkTN" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Reclassification of realized gain on securities available-for-sale to net loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--AccumulatedOtherComprehensiveLossgainReclassificationsNetLoss_pn3n3_c20200101__20201231_zO3QwfTfTtY8" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Reclassification of realized gain on securities available-for-sale to net loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net current period other comprehensive gain</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_982_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_pn3n3_c20200101__20201231_zDh4UKQkH0Cc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Other comprehensive income (loss)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax_pn3n3_c20200101__20201231_zFgjjWpPp2Vc" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Other comprehensive gain"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2020</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecurities_iS_pn3n3_c20210101__20211231_zbvMN4XhizQh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">228</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iS_pn3n3_c20210101__20211231_zt9EAYWxjjCf" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">228</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net unrealized loss on securities available-for-sale</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20210101__20211231_zv8sMPiNGrOh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized gain (loss) on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(373</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_ecustom--AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale_pn3n3_c20210101__20211231_zWoNIdNYWYfb" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Net unrealized gain (loss) on securities available-for-sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(373</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net current period other comprehensive loss</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_pn3n3_c20210101__20211231_zLrJqFL4CLuj" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net current period other comprehensive loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(374</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98F_ecustom--AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax_pn3n3_c20210101__20211231_zgfA8OQ2a5Ol" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Net current period other comprehensive loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(374</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2021</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_ecustom--NetUnrealizedGainsLossesOnAvailableforsaleSecurities_iE_pn3n3_c20210101__20211231_zzHAhBh8Kcj1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_ecustom--AccumulatedOtherComprehensiveIncomeLossNetOfTaxes_iE_pn3n3_c20210101__20211231_zmhZdWHcGX0a" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Other Comprehensive (Loss)/Gain, Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(146</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td></tr> </table> -1000 -1000 237000 237000 -8000 -8000 229000 229000 228000 228000 -373000 -373000 -374000 -374000 -146000 -146000 <p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z30wfoy7g1M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_823_zpQuwE3KpkB6">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”) provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. Options under the Plan may be <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_z7Ts6vMkspA" title="Option granted description">granted at prices not less than 100% of the fair value of the shares</span> on the date of grant as determined by the Compensation Committee of the Board of Directors. The Compensation Committee determines the period over which the options become exercisable subject to certain restrictions as defined in the Plan, with the current outstanding options generally vesting over <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtYxL_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember__srt--RangeAxis__srt--MinimumMember_zrPFPvDrN6se" title="Option vested period::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1376">three</span></span> or <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dt_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_ziPaQAndaG51" title="Option vested period">four years</span>. <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_zJFJtF720Gek" title="Option term">The term of the options is no longer than ten years</span>. As of December 31, 2021, the Company had <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_z1fYk4G6i5o5" title="Number of common stock issued under plan">36,952,460</span> shares of common stock authorized for issuance under the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the approval of the Board of Directors and a majority of shareholders, effective May 8, 2014, the Plan was amended and restated. The amendment provides for an automatic increase in the number of shares of common stock available for issuance under the Plan each January (with Board approval), commencing <span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate_c20140507__20140508_zLjHwOnFTzO4" title="Share-based payment award increase of shares offering date">January 1, 2015</span> in an amount up to four percent (<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20140507__20140508_zfYckDrYZew4" title="Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum">4%</span>) of the total number of shares of common stock outstanding on the preceding December 31st.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zIx2m0NZ0o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense (options and restricted share grants) in its consolidated statements of operations as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zIyrkOhxhXSj">Schedule of Recognized Stock-Based Compensation</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and Development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6HNKSFFmgNg" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">1,870</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzZ9yhMxfGD7" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">1,897</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and Administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztGDf5VLK2O4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">2,422</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zedyjGCH6Pya" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">2,668</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231_zp5ZabKIDcZg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">4,292</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231_zEpylW2nUsk3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">4,565</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_z3lrOxQJ99d1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zTkVIPDOrwn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table contains information about the Company’s stock plan at December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZSR3KffnyK">Schedule of Equity Compensation Plan by Arrangements</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Reserved for Issuance</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Issued &amp; Exercised</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Available for Grant</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013 Equity Compensation Plan (in thousands)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_fKg_____z4d7EPQ4E1S9" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Awards Reserved for Issuance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,952</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span id="xdx_F20_zgsguwr9yy6g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn3n3_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_fKio___z3LCe6K8uUrc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Awards Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,669</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pn3n3_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_zvd8hNSRSvi1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Awards Available for Grant"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,283</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F08_zzP7cB0ov7ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zS1yi9d1rl0l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased by <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVxdWl0eSBDb21wZW5zYXRpb24gUGxhbiBieSBBcnJhbmdlbWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--IncreasedSharesOfCommonStockOutstanding_iI_pn3n3_c20210102_zQgR252Djcdd" title="Increased shares of common stock outstanding">8,005</span> thousand on January 1, 2021, representing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVxdWl0eSBDb21wZW5zYXRpb24gUGxhbiBieSBBcnJhbmdlbWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20200101__20201231_zKm6kktzigI1" title="Percentage for common stock outstanding">4%</span> of the total number of shares of common stock outstanding on December 31, 2020.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_z4SfqqIkS6I" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zrGsBcLBWCxc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes both stock grants and option grants</span></td></tr> </table> <p id="xdx_8AF_z0F0DbRvu1Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbwHVWk6cin2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’ stock option activity and related information for the period from January 1, 2020 to December 31, 2021 (options in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zgwmB5d1EXsi">Schedule of Stock Option Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of Options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Contractual Term in Years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_c20200101__20201231_z96pJIoWmMA9" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Options, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">17,529</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zfVgmHnGH1gj" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average Exercise Price, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zFxanFPH2UOj" title="Weighted Average Contractual Term in Years, Beginning">6.2</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_c20200101__20201231_zx2qNePPKzz7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted"><span style="font-family: Times New Roman, Times, Serif">6,501</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zqJkjdzmvws8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.59</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_c20200101__20201231_zlr7I222MRwk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Exercised"><span style="font-family: Times New Roman, Times, Serif">(826</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z8tiiuiQLM94" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.74</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_c20200101__20201231_zlNClahjHfl1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zZypEFHVE8Ia" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pin3_c20200101__20201231_z6c2REyaS7hc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1436">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zOOOIf4ZwKS7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1438">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pin3_di_c20200101__20201231_ztMoMAEWITc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Expired"><span style="font-family: Times New Roman, Times, Serif">(581</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zunoq4PkL6e2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">1.25</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_c20210101__20211231_zn0aQePRcKob" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">22,551</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zS46LpDua62j" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">1.26</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zmuVK6B1Td53" title="Weighted Average Contractual Term in Years, Beginning">6.9</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_c20210101__20211231_zC65Nz82Tx47" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted"><span style="font-family: Times New Roman, Times, Serif">10,976</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zbsJn2HbHLHb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_c20210101__20211231_zBzVWixM5yC7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Exercised"><span style="font-family: Times New Roman, Times, Serif">(1,077</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zdaK7lBcsDki" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.60</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_c20210101__20211231_zq9HQ6b48M1l" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(2,824</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zXzyhvTC5ke4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif">1.08</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pin3_c20210101__20211231_ztyKTGaWy4O4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1462">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zAbUAQbANqh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pin3_di_c20210101__20211231_zNQ4FLNaqsDh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Expired"><span style="font-family: Times New Roman, Times, Serif">(1,441</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_ze1w8JOnMC14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">1.98</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_c20210101__20211231_znPQsxlqdfF9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Outstanding at Ending"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zmaJCzOQ2lx3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Outstanding at Ending"><span style="font-family: Times New Roman, Times, Serif">1.21</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z6aPpS6jgNR4" title="Weighted Average Contractual Term in Years, Ending">7.2</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zZSb3e52NMp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zgvVva68OjZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes outstanding options at December 31, 2021, by their exercise price (options in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zkHYPUAD5Sw3" style="display: none">Summary of Outstanding Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Range of Exercise Prices</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise Price Per Share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z16oPFbhB0O" title="Exercise price, minimum">0.41</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zDJCwf3cVDql" title="Exercise price, maximum">0.69</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRth0ND55cQi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">1,935</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuPXS0ph1Dh3" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">0.49</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmM3Nugtb5Cl" title="Exercise price, minimum">0.74</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNMCXDtO4J6b" title="Exercise price, maximum">1.12</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmn4VFbu7dVj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">15,940</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zShHVW6AuOni" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">0.93</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zvMYpntIMdt7" title="Exercise price, minimum">1.24</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRVRcl0UCqrf" title="Exercise price, maximum">1.61</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zgPOQAU9VG9h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">6,525</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zszqHtWp3qJg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">1.35</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zckcz13CFph1" title="Exercise price, minimum">2.27</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zfhFVMgXSgI" title="Exercise price, maximum">3.32</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zRifDTr8vx36" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">3,784</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zviWhBjDlln4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">2.50</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231_zuUMMhAEGsV" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231_z8i0CIXar6P" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">1.21</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AF_zwDJUvuuh03" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the number of vested shares underlying outstanding options was <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20211231_ztL6Hp86TVHb" title="Number of option vested">14,625,397</span> at a weighted average exercise price of $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20210101__20211231_znE0985T7euf" title="Option vested price per share">1.20</span>. The aggregate intrinsic value of in-the-money options outstanding as of December 31, 2021 was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pin3_c20211231_z11ThyYk2gbh" title="Option intrinsic value">2.5</span> million. The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pid_c20210101__20211231_zki0XU4lr6Cj" title="Aggregate intrinsic price">1.01</span> on December 31, 2021, and the exercise price of options, multiplied by the number of options. As of December 31, 2021, there was approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231_zA0wuyKZxNkj" title="Unrecognized share-based compensation">11.7</span> million of total unrecognized share-based compensation. Such costs are expected to be recognized over a weighted average period of approximately <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231_zdoEmQbAeIo5" title="Share-based compensation weighted average period">2.9</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20210101__20211231_zpHvWYIowHwl" title="Vesting description">All outstanding options expire <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210101__20211231_zMY5Fy03EQi1" title="Stock options expire term">ten years</span> from date of grant. Options granted to employees prior to 2018 vest in equal monthly installments over three years. Beginning in 2018, options granted to employees vest over four years, with <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zl3cl9TiggKl" title="Stock option shares vesting percentage">25%</span> of the shares vesting on the first annual anniversary of grant and the remaining shares vesting in 36 equal monthly installments over the following 3 years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2021 and 2020, the Company granted restricted stock awards for <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20211231_zi3egMYrndje" title="Number of restricted stock awards granted">31,769</span> and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20200101__20201231_zU3px0mlQVLd" title="Number of restricted stock awards granted">379,385</span> shares of common stock, respectively. These awards are typically granted to members of the Board of Directors as payment in lieu of cash fees or as payment to a vendor pursuant to a consulting agreement. The Company values restricted stock awards at the fair market value on the date of grant. The Company recorded the value of these restricted awards as general and administrative expense of approximately $<span id="xdx_902_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_c20210101__20211231_zNHTQvDIKMRh" title="General and administrative expense">100</span> thousand and $<span id="xdx_907_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_c20200101__20201231_zm0WxDIKbwI1" title="General and administrative expense">292</span> thousand in the consolidated statement of operations for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation expense for stock option awards and restricted stock awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of awards granted subject to a vendor’s consulting agreement, whereby the award vesting period and the service period defined pursuant to the terms of the consulting agreement may be different. Beginning January 1, 2020, stock options issued to consultants are recorded at fair value on the date of grant and the award is recognized as an expense on a straight-line basis over the requisite service period. The following weighted-average assumptions were used to calculate share-based compensation for the comparative periods presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8VcHV1vaEEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zJQ7NHkmaEvc">Schedule of Stock Option Awards and Restricted Stock Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_zU5wvxRmR0H8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.4</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% -<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zYfnDzE2O06e">101.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20200101__20201231_z1HIofZVLkpk" title="Volatility, minimum">100.5</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20200101__20201231_zh7ZyrkmTyzc" title="Volatility, maximum">107.4</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJpa2hNkRlog" title="Risk-free interest rate, minimum">0.47</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z5qxJPY7uwOl" title="Risk-free interest rate, maximum">1.28</span> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20200101__20201231_zBojE9Rtyjx8" title="Risk-free interest rate, minimum">0.34</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20200101__20201231_zoguPUClfyX8" title="Risk-free interest rate, maximum">1.74</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zOiop1MuWxyk" title="Dividend yield">0.0</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zB9NxIifxy8j" title="Dividend yield">0.0</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_uPure_c20210101__20211231_zQxDZfXusEZi" title="Expected life">6.0</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_uPure_c20200101__20201231_znh25WLqW37k" title="Expected life">6.0</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_z1TwiLFlHg64" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Hence, the Company uses the “simplified method” described in Staff Accounting Bulletin (SAB) 107 to estimated the expected term of share option grants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected stock price volatility assumption is based the Company’s historical stock price volatility.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> granted at prices not less than 100% of the fair value of the shares P4Y The term of the options is no longer than ten years 36952460 January 1, 2015 0.04 <p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zIx2m0NZ0o87" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense (options and restricted share grants) in its consolidated statements of operations as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zIyrkOhxhXSj">Schedule of Recognized Stock-Based Compensation</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Research and Development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6HNKSFFmgNg" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">1,870</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zzZ9yhMxfGD7" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">1,897</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and Administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_ztGDf5VLK2O4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">2,422</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zedyjGCH6Pya" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">2,668</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231_zp5ZabKIDcZg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">4,292</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231_zEpylW2nUsk3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Share-based compensation expense"><span style="font-family: Times New Roman, Times, Serif">4,565</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1870000 1897000 2422000 2668000 4292000 4565000 <p id="xdx_895_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zTkVIPDOrwn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table contains information about the Company’s stock plan at December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zZSR3KffnyK">Schedule of Equity Compensation Plan by Arrangements</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Reserved for Issuance</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Issued &amp; Exercised</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards Available for Grant</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013 Equity Compensation Plan (in thousands)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_985_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_fKg_____z4d7EPQ4E1S9" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Awards Reserved for Issuance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,952</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span id="xdx_F20_zgsguwr9yy6g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pn3n3_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_fKio___z3LCe6K8uUrc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Awards Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,669</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pn3n3_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandThirteenEquityCompensationPlanMember_zvd8hNSRSvi1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Awards Available for Grant"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,283</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F08_zzP7cB0ov7ud" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zS1yi9d1rl0l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased by <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVxdWl0eSBDb21wZW5zYXRpb24gUGxhbiBieSBBcnJhbmdlbWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--IncreasedSharesOfCommonStockOutstanding_iI_pn3n3_c20210102_zQgR252Djcdd" title="Increased shares of common stock outstanding">8,005</span> thousand on January 1, 2021, representing <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVxdWl0eSBDb21wZW5zYXRpb24gUGxhbiBieSBBcnJhbmdlbWVudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20200101__20201231_zKm6kktzigI1" title="Percentage for common stock outstanding">4%</span> of the total number of shares of common stock outstanding on December 31, 2020.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_z4SfqqIkS6I" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zrGsBcLBWCxc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes both stock grants and option grants</span></td></tr> </table> 36952000 32669000 4283000 8005000 0.04 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbwHVWk6cin2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’ stock option activity and related information for the period from January 1, 2020 to December 31, 2021 (options in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zgwmB5d1EXsi">Schedule of Stock Option Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of Options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Contractual Term in Years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_c20200101__20201231_z96pJIoWmMA9" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Options, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">17,529</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zfVgmHnGH1gj" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average Exercise Price, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zFxanFPH2UOj" title="Weighted Average Contractual Term in Years, Beginning">6.2</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_c20200101__20201231_zx2qNePPKzz7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted"><span style="font-family: Times New Roman, Times, Serif">6,501</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zqJkjdzmvws8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.59</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_c20200101__20201231_zlr7I222MRwk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Exercised"><span style="font-family: Times New Roman, Times, Serif">(826</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_z8tiiuiQLM94" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.74</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_c20200101__20201231_zlNClahjHfl1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(72</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zZypEFHVE8Ia" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pin3_c20200101__20201231_z6c2REyaS7hc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1436">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zOOOIf4ZwKS7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1438">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pin3_di_c20200101__20201231_ztMoMAEWITc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Expired"><span style="font-family: Times New Roman, Times, Serif">(581</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zunoq4PkL6e2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">1.25</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_c20210101__20211231_zn0aQePRcKob" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">22,551</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zS46LpDua62j" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Outstanding at Beginning"><span style="font-family: Times New Roman, Times, Serif">1.26</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zmuVK6B1Td53" title="Weighted Average Contractual Term in Years, Beginning">6.9</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_c20210101__20211231_zC65Nz82Tx47" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Granted"><span style="font-family: Times New Roman, Times, Serif">10,976</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zbsJn2HbHLHb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Granted"><span style="font-family: Times New Roman, Times, Serif">1.11</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_c20210101__20211231_zBzVWixM5yC7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Exercised"><span style="font-family: Times New Roman, Times, Serif">(1,077</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zdaK7lBcsDki" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Exercised"><span style="font-family: Times New Roman, Times, Serif">0.60</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_c20210101__20211231_zq9HQ6b48M1l" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif">(2,824</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zXzyhvTC5ke4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Forfeited"><span style="font-family: Times New Roman, Times, Serif">1.08</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cancelled</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_pin3_c20210101__20211231_ztyKTGaWy4O4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1462">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zAbUAQbANqh" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pin3_di_c20210101__20211231_zNQ4FLNaqsDh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Expired"><span style="font-family: Times New Roman, Times, Serif">(1,441</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_ze1w8JOnMC14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Expired"><span style="font-family: Times New Roman, Times, Serif">1.98</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_c20210101__20211231_znPQsxlqdfF9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of Options, Outstanding at Ending"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zmaJCzOQ2lx3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average Exercise Price, Outstanding at Ending"><span style="font-family: Times New Roman, Times, Serif">1.21</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z6aPpS6jgNR4" title="Weighted Average Contractual Term in Years, Ending">7.2</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 17529000 1.11 P6Y2M12D 6501000 1.59 826000 0.74 72000 1.11 581000 1.25 22551000 1.26 P6Y10M24D 10976000 1.11 1077000 0.60 2824000 1.08 1441000 1.98 28184000 1.21 P7Y2M12D <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zgvVva68OjZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes outstanding options at December 31, 2021, by their exercise price (options in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zkHYPUAD5Sw3" style="display: none">Summary of Outstanding Options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Range of Exercise Prices</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise Price Per Share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z16oPFbhB0O" title="Exercise price, minimum">0.41</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zDJCwf3cVDql" title="Exercise price, maximum">0.69</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRth0ND55cQi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">1,935</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zuPXS0ph1Dh3" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">0.49</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmM3Nugtb5Cl" title="Exercise price, minimum">0.74</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zNMCXDtO4J6b" title="Exercise price, maximum">1.12</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmn4VFbu7dVj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">15,940</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zShHVW6AuOni" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">0.93</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zvMYpntIMdt7" title="Exercise price, minimum">1.24</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRVRcl0UCqrf" title="Exercise price, maximum">1.61</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zgPOQAU9VG9h" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">6,525</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zszqHtWp3qJg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">1.35</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zckcz13CFph1" title="Exercise price, minimum">2.27</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zfhFVMgXSgI" title="Exercise price, maximum">3.32</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zRifDTr8vx36" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">3,784</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zviWhBjDlln4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">2.50</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pin3_c20211231_zuUMMhAEGsV" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">28,184</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231_z8i0CIXar6P" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif">1.21</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 0.41 0.69 1935000 0.49 0.74 1.12 15940000 0.93 1.24 1.61 6525000 1.35 2.27 3.32 3784000 2.50 28184000 1.21 14625397 1.20 2500 1.01 11700000 P2Y10M24D All outstanding options expire ten years from date of grant. Options granted to employees prior to 2018 vest in equal monthly installments over three years. Beginning in 2018, options granted to employees vest over four years, with 25% of the shares vesting on the first annual anniversary of grant and the remaining shares vesting in 36 equal monthly installments over the following 3 years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives P10Y 0.25 31769 379385 100000 292000 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8VcHV1vaEEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zJQ7NHkmaEvc">Schedule of Stock Option Awards and Restricted Stock Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended December 31,</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_zU5wvxRmR0H8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.4</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% -<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_zYfnDzE2O06e">101.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20200101__20201231_z1HIofZVLkpk" title="Volatility, minimum">100.5</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20200101__20201231_zh7ZyrkmTyzc" title="Volatility, maximum">107.4</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zJpa2hNkRlog" title="Risk-free interest rate, minimum">0.47</span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231_z5qxJPY7uwOl" title="Risk-free interest rate, maximum">1.28</span> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20200101__20201231_zBojE9Rtyjx8" title="Risk-free interest rate, minimum">0.34</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20200101__20201231_zoguPUClfyX8" title="Risk-free interest rate, maximum">1.74</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231_zOiop1MuWxyk" title="Dividend yield">0.0</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231_zB9NxIifxy8j" title="Dividend yield">0.0</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_uPure_c20210101__20211231_zQxDZfXusEZi" title="Expected life">6.0</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_uPure_c20200101__20201231_znh25WLqW37k" title="Expected life">6.0</span> years</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.984 1.016 1.005 1.074 0.0047 0.0128 0.0034 0.0174 0.000 0.000 P6Y P6Y <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zSPVwgCpFAld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15 – <span id="xdx_827_z5UKmC63smcl">Subsequent Events</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p> At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement. Weighted average exercise price for outstanding warrants is $0.55. Converted into approximately 115 thousand shares of common stock. Weighted average exercise price for outstanding warrants is $0.56. Increased by 8,005 thousand on January 1, 2021, representing 4% of the total number of shares of common stock outstanding on December 31, 2020. Includes both stock grants and option grants EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ⅅ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ǎ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�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end

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˦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end XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 170 474 1 true 61 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://matinasbiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://matinasbiopharma.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://matinasbiopharma.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders Equity Sheet http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Stockholders Equity (Parenthetical) Sheet http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical Consolidated Statements of Changes in Stockholders Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://matinasbiopharma.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Description of Business Sheet http://matinasbiopharma.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - Liquidity and Plan of Operations Sheet http://matinasbiopharma.com/role/LiquidityAndPlanOfOperations Liquidity and Plan of Operations Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities Sheet http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecurities Cash, Cash Equivalents, Restricted Cash and Marketable Securities Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://matinasbiopharma.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Leasehold Improvements and Equipment Sheet http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipment Leasehold Improvements and Equipment Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses and Other Liabilities Sheet http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilities Accrued Expenses and Other Liabilities Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://matinasbiopharma.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Collaboration Agreements, License and Other Research and Development Agreements Sheet http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreements Collaboration Agreements, License and Other Research and Development Agreements Notes 16 false false R17.htm 00000017 - Disclosure - Commitments Sheet http://matinasbiopharma.com/role/Commitments Commitments Notes 17 false false R18.htm 00000018 - Disclosure - Income Taxes Sheet http://matinasbiopharma.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 00000019 - Disclosure - Stockholders??? Equity Sheet http://matinasbiopharma.com/role/StockholdersEquity Stockholders??? Equity Notes 19 false false R20.htm 00000020 - Disclosure - Accumulated Other Comprehensive (Loss)/Income Sheet http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincome Accumulated Other Comprehensive (Loss)/Income Notes 20 false false R21.htm 00000021 - Disclosure - Stock-based Compensation Sheet http://matinasbiopharma.com/role/Stock-basedCompensation Stock-based Compensation Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Events Sheet http://matinasbiopharma.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables) Sheet http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables) Tables http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecurities 25 false false R26.htm 00000026 - Disclosure - Fair Value Measurements (Tables) Sheet http://matinasbiopharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://matinasbiopharma.com/role/FairValueMeasurements 26 false false R27.htm 00000027 - Disclosure - Leasehold Improvements and Equipment (Tables) Sheet http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentTables Leasehold Improvements and Equipment (Tables) Tables http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipment 27 false false R28.htm 00000028 - Disclosure - Accrued Expenses and Other Liabilities (Tables) Sheet http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilitiesTables Accrued Expenses and Other Liabilities (Tables) Tables http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilities 28 false false R29.htm 00000029 - Disclosure - Leases (Tables) Sheet http://matinasbiopharma.com/role/LeasesTables Leases (Tables) Tables http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipment 29 false false R30.htm 00000030 - Disclosure - Income Taxes (Tables) Sheet http://matinasbiopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://matinasbiopharma.com/role/IncomeTaxes 30 false false R31.htm 00000031 - Disclosure - Stockholders??? Equity (Tables) Sheet http://matinasbiopharma.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://matinasbiopharma.com/role/StockholdersEquity 31 false false R32.htm 00000032 - Disclosure - Accumulated Other Comprehensive (Loss)/Income (Tables) Sheet http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincomeTables Accumulated Other Comprehensive (Loss)/Income (Tables) Tables http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincome 32 false false R33.htm 00000033 - Disclosure - Stock-based Compensation (Tables) Sheet http://matinasbiopharma.com/role/Stock-basedCompensationTables Stock-based Compensation (Tables) Tables http://matinasbiopharma.com/role/Stock-basedCompensation 33 false false R34.htm 00000034 - Disclosure - Liquidity and Plan of Operations (Details Narrative) Sheet http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative Liquidity and Plan of Operations (Details Narrative) Details http://matinasbiopharma.com/role/LiquidityAndPlanOfOperations 34 false false R35.htm 00000035 - Disclosure - Schedule of Anti-dilutive Securities (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails Schedule of Anti-dilutive Securities (Details) Details 35 false false R36.htm 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails Schedule of Cash, Cash Equivalents and Restricted Cash (Details) Details 37 false false R38.htm 00000038 - Disclosure - Summary of Marketable Securities (Details) Sheet http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails Summary of Marketable Securities (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Maturities of Debt Securities Available-for-sale (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails Schedule of Maturities of Debt Securities Available-for-sale (Details) Details 39 false false R40.htm 00000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) Sheet http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetailsNarrative Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) Details http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables 40 false false R41.htm 00000041 - Disclosure - Schedule of Fair Value Measurement of Assets and Liabilities (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails Schedule of Fair Value Measurement of Assets and Liabilities (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Leasehold Improvements and Equipment (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails Schedule of Leasehold Improvements and Equipment (Details) Details 42 false false R43.htm 00000043 - Disclosure - Leasehold Improvements and Equipment (Details Narrative) Sheet http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentDetailsNarrative Leasehold Improvements and Equipment (Details Narrative) Details http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentTables 43 false false R44.htm 00000044 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Accrued Expenses (Details) (Parenthetical) Sheet http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical Schedule of Accrued Expenses (Details) (Parenthetical) Details 45 false false R46.htm 00000046 - Disclosure - Schedule of Maturity of Operating and Finance Leases Liabilities (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails Schedule of Maturity of Operating and Finance Leases Liabilities (Details) Details 46 false false R47.htm 00000047 - Disclosure - Leases (Details Narrative) Sheet http://matinasbiopharma.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentTables 47 false false R48.htm 00000048 - Disclosure - Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative) Sheet http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative) Details http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreements 48 false false R49.htm 00000049 - Disclosure - Commitments (Details Narrative) Sheet http://matinasbiopharma.com/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://matinasbiopharma.com/role/Commitments 49 false false R50.htm 00000050 - Disclosure - Schedule of Income Tax Provision (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails Schedule of Income Tax Provision (Details) Details 50 false false R51.htm 00000051 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 52 false false R53.htm 00000053 - Disclosure - Income Taxes (Details Narrative) Sheet http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://matinasbiopharma.com/role/IncomeTaxesTables 53 false false R54.htm 00000054 - Disclosure - Summary of Shareholders Equity Warrants Outstanding (Details) Sheet http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails Summary of Shareholders Equity Warrants Outstanding (Details) Details 54 false false R55.htm 00000055 - Disclosure - Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical) Sheet http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetailsParenthetical Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical) Details 55 false false R56.htm 00000056 - Disclosure - Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details) Details 56 false false R57.htm 00000057 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://matinasbiopharma.com/role/StockholdersEquityTables 57 false false R58.htm 00000058 - Disclosure - Schedule of Recognized Stock-Based Compensation (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails Schedule of Recognized Stock-Based Compensation (Details) Details 58 false false R59.htm 00000059 - Disclosure - Schedule of Equity Compensation Plan by Arrangements (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails Schedule of Equity Compensation Plan by Arrangements (Details) Details 59 false false R60.htm 00000060 - Disclosure - Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical) Sheet http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetailsParenthetical Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical) Details 60 false false R61.htm 00000061 - Disclosure - Schedule of Stock Option Activity (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails Schedule of Stock Option Activity (Details) Details 61 false false R62.htm 00000062 - Disclosure - Summary of Outstanding Options (Details) Sheet http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails Summary of Outstanding Options (Details) Details 62 false false R63.htm 00000063 - Disclosure - Schedule of Stock Option Awards and Restricted Stock Awards (Details) Sheet http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails Schedule of Stock Option Awards and Restricted Stock Awards (Details) Details 63 false false R64.htm 00000064 - Disclosure - Stock-based Compensation (Details Narrative) Sheet http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative Stock-based Compensation (Details Narrative) Details http://matinasbiopharma.com/role/Stock-basedCompensationTables 64 false false All Reports Book All Reports form10k.htm ex10-15.htm ex10-16.htm ex21-1.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex4-6.htm mtnb-20211231.xsd mtnb-20211231_cal.xml mtnb-20211231_def.xml mtnb-20211231_lab.xml mtnb-20211231_pre.xml form10k_002.jpg form10k_003.jpg form10k_005.jpg form10k_006.jpg form10k_008.jpg form10k_009.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10k.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 170, "dts": { "calculationLink": { "local": [ "mtnb-20211231_cal.xml" ] }, "definitionLink": { "local": [ "mtnb-20211231_def.xml" ] }, "inline": { "local": [ "form10k.htm" ] }, "labelLink": { "local": [ "mtnb-20211231_lab.xml" ] }, "presentationLink": { "local": [ "mtnb-20211231_pre.xml" ] }, "schema": { "local": [ "mtnb-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 576, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 114, "http://matinasbiopharma.com/20211231": 34, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 151 }, "keyCustom": 62, "keyStandard": 412, "memberCustom": 36, "memberStandard": 23, "nsprefix": "MTNB", "nsuri": "http://matinasbiopharma.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://matinasbiopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities", "role": "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecurities", "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Fair Value Measurements", "role": "http://matinasbiopharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Leasehold Improvements and Equipment", "role": "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipment", "shortName": "Leasehold Improvements and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Accrued Expenses and Other Liabilities", "role": "http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilities", "shortName": "Accrued Expenses and Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Leases", "role": "http://matinasbiopharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Collaboration Agreements, License and Other Research and Development Agreements", "role": "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreements", "shortName": "Collaboration Agreements, License and Other Research and Development Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Commitments", "role": "http://matinasbiopharma.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Income Taxes", "role": "http://matinasbiopharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Stockholders\u2019 Equity", "role": "http://matinasbiopharma.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://matinasbiopharma.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Accumulated Other Comprehensive (Loss)/Income", "role": "http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincome", "shortName": "Accumulated Other Comprehensive (Loss)/Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Stock-based Compensation", "role": "http://matinasbiopharma.com/role/Stock-basedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Subsequent Events", "role": "http://matinasbiopharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)", "role": "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables", "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Fair Value Measurements (Tables)", "role": "http://matinasbiopharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Leasehold Improvements and Equipment (Tables)", "role": "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentTables", "shortName": "Leasehold Improvements and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Accrued Expenses and Other Liabilities (Tables)", "role": "http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilitiesTables", "shortName": "Accrued Expenses and Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Leases (Tables)", "role": "http://matinasbiopharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://matinasbiopharma.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Income Taxes (Tables)", "role": "http://matinasbiopharma.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://matinasbiopharma.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Accumulated Other Comprehensive (Loss)/Income (Tables)", "role": "http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincomeTables", "shortName": "Accumulated Other Comprehensive (Loss)/Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Stock-based Compensation (Tables)", "role": "http://matinasbiopharma.com/role/Stock-basedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Liquidity and Plan of Operations (Details Narrative)", "role": "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "shortName": "Liquidity and Plan of Operations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Anti-dilutive Securities (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails", "shortName": "Schedule of Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Schedule of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "MTNB:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Summary of Marketable Securities (Details)", "role": "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails", "shortName": "Summary of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Maturities of Debt Securities Available-for-sale (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails", "shortName": "Schedule of Maturities of Debt Securities Available-for-sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative)", "role": "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetailsNarrative", "shortName": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Fair Value Measurement of Assets and Liabilities (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "shortName": "Schedule of Fair Value Measurement of Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Leasehold Improvements and Equipment (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails", "shortName": "Schedule of Leasehold Improvements and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Leasehold Improvements and Equipment (Details Narrative)", "role": "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentDetailsNarrative", "shortName": "Leasehold Improvements and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Accrued Expenses (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails", "shortName": "Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31_custom_CFFAgreementMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Accrued Expenses (Details) (Parenthetical)", "role": "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical", "shortName": "Schedule of Accrued Expenses (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31_custom_CFFAgreementMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "MTNB:ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock", "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Schedule of Maturity of Operating and Finance Leases Liabilities (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails", "shortName": "Schedule of Maturity of Operating and Finance Leases Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "MTNB:ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock", "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "p", "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2013-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Leases (Details Narrative)", "role": "http://matinasbiopharma.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "MTNB:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2013-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative)", "role": "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "shortName": "Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2016-02-162016-02-19_custom_CooperativeResearchAndDevelopmentAgreementsMember", "decimals": "0", "lang": null, "name": "MTNB:RemainingBalanceLeaseTermAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2016-09-012016-09-12_us-gaap_SeriesAPreferredStockMember", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:RoyaltyPaymentRightsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Commitments (Details Narrative)", "role": "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "shortName": "Commitments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2016-09-012016-09-12_us-gaap_SeriesAPreferredStockMember", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:RoyaltyPaymentRightsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2019-12-31_custom_RedeemableConvertiblePreferredStockBMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders Equity", "role": "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2019-12-31_custom_RedeemableConvertiblePreferredStockBMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Schedule of Income Tax Provision (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails", "shortName": "Schedule of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Income Taxes (Details Narrative)", "role": "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Summary of Shareholders Equity Warrants Outstanding (Details)", "role": "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails", "shortName": "Summary of Shareholders Equity Warrants Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "MTNB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical)", "role": "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetailsParenthetical", "shortName": "Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "MTNB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "MTNB:NetUnrealizedGainsLossesOnAvailableforsaleSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails", "shortName": "Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "lang": null, "name": "MTNB:NetUnrealizedGainsLossesOnAvailableforsaleSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2020-01-122020-01-14", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Schedule of Recognized Stock-Based Compensation (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails", "shortName": "Schedule of Recognized Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2020-12-31_custom_TwoThousandThirteenEquityCompensationPlanMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Schedule of Equity Compensation Plan by Arrangements (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails", "shortName": "Schedule of Equity Compensation Plan by Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2020-12-31_custom_TwoThousandThirteenEquityCompensationPlanMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders Equity (Parenthetical)", "role": "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "shortName": "Consolidated Statements of Changes in Stockholders Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-01-02", "decimals": "-3", "first": true, "lang": null, "name": "MTNB:IncreasedSharesOfCommonStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical)", "role": "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetailsParenthetical", "shortName": "Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-01-02", "decimals": "-3", "first": true, "lang": null, "name": "MTNB:IncreasedSharesOfCommonStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Schedule of Stock Option Activity (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Summary of Outstanding Options (Details)", "role": "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails", "shortName": "Summary of Outstanding Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Schedule of Stock Option Awards and Restricted Stock Awards (Details)", "role": "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails", "shortName": "Schedule of Stock Option Awards and Restricted Stock Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2014-05-072014-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Stock-based Compensation (Details Narrative)", "role": "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2014-05-072014-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "MTNB:SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "role": "http://matinasbiopharma.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Description of Business", "role": "http://matinasbiopharma.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Liquidity and Plan of Operations", "role": "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperations", "shortName": "Liquidity and Plan of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 61, "tag": { "MTNB_AccruedExpenseAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Expense and Other Current Liabilities [Member]", "label": "Accrued Expense And Other Current Liabilities [Member]" } } }, "localname": "AccruedExpenseAndOtherCurrentLiabilitiesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_AccruedGeneralAndAdministrativeExpensesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued general and administrative expenses current.", "label": "General and administrative expenses" } } }, "localname": "AccruedGeneralAndAdministrativeExpensesCurrent", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AccruedResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses current.", "label": "AccruedResearchAndDevelopmentExpensesCurrent", "verboseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income loss adjustment net of tax.", "label": "Accumulated Other Comprehensive (Loss)/Gain, Net current period other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAdjustmentNetOfTax", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AccumulatedOtherComprehensiveIncomeLossNetOfTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxes", "periodEndLabel": "Accumulated Other Comprehensive (Loss)/Gain, Ending Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxes", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive loss gain net unrealized loss on securities available for sale", "label": "Accumulated Other Comprehensive (Loss)/Gain, Net unrealized gain (loss) on securities available-for-sale" } } }, "localname": "AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AccumulatedOtherComprehensiveLossgainReclassificationsNetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive loss gain re-classifications net loss.", "label": "Accumulated Other Comprehensive (Loss)/Gain, Reclassification of realized gain on securities available-for-sale to net loss" } } }, "localname": "AccumulatedOtherComprehensiveLossgainReclassificationsNetLoss", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AdditionalMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional milestone payment.", "label": "Additional milestone payment" } } }, "localname": "AdditionalMilestonePayment", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_AgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement description.", "label": "Agreement description" } } }, "localname": "AgreementDescription", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_AquariusMergerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aquarius Merger Agreement.", "label": "Aquarius Merger Agreement [Member]" } } }, "localname": "AquariusMergerAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_AtTheMarketSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At The Market Sales Agreement [Member]", "label": "At The Market Sales Agreement [Member]" } } }, "localname": "AtTheMarketSalesAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYears": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net carrying value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Due after one year through five years, net carrying amount" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYears", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net carrying value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities Available-for-sale, net carrying amount" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateNet", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net carrying value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Due within one year, net carrying amount" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_AwardAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award Agreement [Member]", "label": "Award Agreement [Member]" } } }, "localname": "AwardAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_CFFAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CFF Agreement [Member]", "label": "CFF Agreement [Member]" } } }, "localname": "CFFAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_CFFResearchGrantRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CFF Research Grant Revenue [Member]", "label": "CFF Research Grant Revenue [Member]" } } }, "localname": "CFFResearchGrantRevenueMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_CashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of warrants.", "label": "Cashless exercise of warrants" } } }, "localname": "CashlessExerciseOfWarrants", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MTNB_CollaborationAgreementsPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Agreements Policy [Text Block]", "label": "Collaboration Agreements" } } }, "localname": "CollaborationAgreementsPolicy", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MTNB_CooperativeResearchAndDevelopmentAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cooperative Research and Development Agreements [Member]", "label": "Cooperative Research And Development Agreements [Member]" } } }, "localname": "CooperativeResearchAndDevelopmentAgreementsMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_CysticFibrosisFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cystic Fibrosis Foundation [Member]", "label": "Cystic Fibrosis Foundation [Member]" } } }, "localname": "CysticFibrosisFoundationMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_DeferredTaxAssetsDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets depreciation and amortization.", "label": "Depreciation and Amortization" } } }, "localname": "DeferredTaxAssetsDepreciationAndAmortization", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_DeferredTaxAssetsRIghtOfUseAsset": { "auth_ref": [], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets Right-Of-Use asset.", "label": "DeferredTaxAssetsRIghtOfUseAsset", "negatedLabel": "ROU Asset" } } }, "localname": "DeferredTaxAssetsRIghtOfUseAsset", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_DeferredTaxLiabilitiesRightOfUseLiability": { "auth_ref": [], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "ROU Liability.", "label": "ROU Liability" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseLiability", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_DesignatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated [Member].", "label": "Designated [Member]" } } }, "localname": "DesignatedMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Maturity Of Operating And Finance Leases Liabilities" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://matinasbiopharma.com/20211231", "xbrltype": "stringItemType" }, "MTNB_ExercisePriceFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price four [Member].", "label": "Exercise Price Four [Member]" } } }, "localname": "ExercisePriceFourMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "domainItemType" }, "MTNB_ExercisePriceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price One [Member].", "label": "Exercise Price One [Member]" } } }, "localname": "ExercisePriceOneMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "domainItemType" }, "MTNB_ExercisePriceThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Three [Member].", "label": "Exercise Price Three [Member]" } } }, "localname": "ExercisePriceThreeMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "domainItemType" }, "MTNB_ExercisePriceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Two [Member].", "label": "Exercise Price Two [Member]" } } }, "localname": "ExercisePriceTwoMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "domainItemType" }, "MTNB_FeasibilityStudyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Feasibility Study Agreement [Member]", "label": "Feasibility Study Agreement [Member]" } } }, "localname": "FeasibilityStudyAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal and State research and development tax credit carry forwards [Member].", "label": "Federal and State research and development tax credit carry forwards [Member]" } } }, "localname": "FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_FirstAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Anniversary [Member]", "label": "First Anniversary [Member]" } } }, "localname": "FirstAnniversaryMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_FourPointFivePercentOfNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales [Member]", "label": "Net Sales [Member]" } } }, "localname": "FourPointFivePercentOfNetSalesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_FundsProvideForSupport": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Funds provide for support.", "label": "Funds provide for support" } } }, "localname": "FundsProvideForSupport", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_GenentechFeasibilityStudyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech Feasibility Study Agreement [Member]", "label": "Genentech Feasibility Study Agreement [Member]" } } }, "localname": "GenentechFeasibilityStudyAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical" ], "xbrltype": "domainItemType" }, "MTNB_GenentechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech [Member]", "label": "Genentech [Member]" } } }, "localname": "GenentechMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_HoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holders [Member]", "label": "Holders [Member]" } } }, "localname": "HoldersMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_HoldersOfAquariusBiotechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holders Of Aquarius Biotechnologies Inc.", "label": "Holders Of Aquarius Biotechnologies Inc [Member]" } } }, "localname": "HoldersOfAquariusBiotechnologiesIncMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_IncreaseOfRentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase of rent expenses.", "label": "Increase of rent expenses" } } }, "localname": "IncreaseOfRentExpenses", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_IncreasedSharesOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increased shares of common stock outstanding.", "label": "Increased shares of common stock outstanding" } } }, "localname": "IncreasedSharesOfCommonStockOutstanding", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "MTNB_IssuanceOfCommonStockInExchangeForPreferredSharesB": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in exchange for preferred shares B.", "label": "Issuance of common stock in exchange for preferred shares B" } } }, "localname": "IssuanceOfCommonStockInExchangeForPreferredSharesB", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "MTNB_IssuanceOfCommonStockInExchangeForPreferredSharesBShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in exchange for preferred shares B, shares.", "label": "Issuance of common stock in exchange for preferred shares B, shares" } } }, "localname": "IssuanceOfCommonStockInExchangeForPreferredSharesBShares", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "MTNB_LesseeOperatingAndFinancingLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating and financing leases [Text Block].", "label": "LesseeOperatingAndFinancingLeasesTextBlock", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinancingLeasesTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "MTNB_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement [Member]", "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_LimitationsOnNetOperatingLossDeductibilityDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Limitations on Net operating loss deductibility, description.", "label": "[custom:LimitationsOnNetOperatingLossDeductibilityDescription]" } } }, "localname": "LimitationsOnNetOperatingLossDeductibilityDescription", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_LiquidityValueAndDividendsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity value and dividends description.", "label": "Liquidity value and dividends description" } } }, "localname": "LiquidityValueAndDividendsDescription", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_MarketableSecuritiesAccumulatedUnrealizedGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain.", "label": "Net accumulated unrealized gain" } } }, "localname": "MarketableSecuritiesAccumulatedUnrealizedGain", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_NetProceedsFromPublicOfferingOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds from public offering of common stock.", "label": "NetProceedsFromPublicOfferingOfCommonStock", "verboseLabel": "Net proceeds from public offering of common stock" } } }, "localname": "NetProceedsFromPublicOfferingOfCommonStock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_NetUnrealizedGainsLossesOnAvailableforsaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net unrealized gains losses on available-for-sale securities.", "label": "NetUnrealizedGainsLossesOnAvailableforsaleSecurities", "periodEndLabel": "Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance", "periodStartLabel": "Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance" } } }, "localname": "NetUnrealizedGainsLossesOnAvailableforsaleSecurities", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net unrealized gains losses on available-for-sale-securities net unrealized loss on securities available-for-sale.", "label": "Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized gain (loss) on securities available-for-sale" } } }, "localname": "NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesReclassificationNetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net unrealized gains losses on available for sale securities reclassification net loss.", "label": "Net Unrealized Gains (Losses) on Available-for-Sale Securities, Reclassification of realized gain on securities available-for-sale to net loss" } } }, "localname": "NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesReclassificationNetLoss", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "MTNB_NoncashPrepaidFromExerciseOfOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-Cash prepaid from exercise of options.", "label": "Non-cash prepaid from exercise of options" } } }, "localname": "NoncashPrepaidFromExerciseOfOptions", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MTNB_OperatingLeasesExtendedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases extended term.", "label": "Operating lease extended term" } } }, "localname": "OperatingLeasesExtendedTerm", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration year.", "label": "Operating loss carryforwards, expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "gYearItemType" }, "MTNB_OperatingLossCarryforwardsWithNoExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards with no expiration.", "label": "Operating loss carryforwards with no expiration" } } }, "localname": "OperatingLossCarryforwardsWithNoExpiration", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_OtherComprehensiveLossPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Loss [PolicyTextBlock]", "label": "Other comprehensive income/(loss)" } } }, "localname": "OtherComprehensiveLossPolicyTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MTNB_PatentExpensesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent Expenses Policy [TextBlock]", "label": "Patent expenses" } } }, "localname": "PatentExpensesPolicyTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MTNB_PerMoleculesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Molecules [Member]", "label": "Per Molecules [Member]" } } }, "localname": "PerMoleculesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_PreferredStockAndAccruedDividendUponConversionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock and Accrued Dividend Upon Conversion [Member]", "label": "Preferred Stock and Accrued Dividend Upon Conversion [Member]" } } }, "localname": "PreferredStockAndAccruedDividendUponConversionMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "MTNB_PreferredStockConversionIntoCommonStockSeriesB": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock conversion into common stock - Series B.", "label": "Preferred stock conversion into common stock - series B" } } }, "localname": "PreferredStockConversionIntoCommonStockSeriesB", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MTNB_PreferredStockDividendsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Dividends [PolicyTextBlock]", "label": "Preferred stock dividends" } } }, "localname": "PreferredStockDividendsPolicyTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MTNB_ProceedsFromAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from award.", "label": "Proceeds from award" } } }, "localname": "ProceedsFromAward", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_ProceedsFromIssuanceInitialPublicOfferingGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Initial Public Offering Gross.", "label": "Proceeds from public offering, gross" } } }, "localname": "ProceedsFromIssuanceInitialPublicOfferingGross", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_RedeemableConvertiblePreferredStockBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Convertible Preferred Stock B [Member]", "label": "Redeemable Convertible Preferred Stock B [Member]" } } }, "localname": "RedeemableConvertiblePreferredStockBMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "MTNB_ReducedInSecurityDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduced in security deposit.", "label": "Security deposit at present" } } }, "localname": "ReducedInSecurityDeposit", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_RemainingBalanceLeaseTermAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remaining balance lease term amount.", "label": "Remaining balance lease term amount" } } }, "localname": "RemainingBalanceLeaseTermAmount", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_RevenueMilestoneMethodMilestoneFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone fee.", "label": "Milestone fee" } } }, "localname": "RevenueMilestoneMethodMilestoneFee", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_RoyaltyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty payable.", "label": "Royalty payable" } } }, "localname": "RoyaltyPayable", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_RoyaltyPaymentRightsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payment rights, description.", "label": "Royalty payment rights, description" } } }, "localname": "RoyaltyPaymentRightsDescription", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_RoyaltyPaymentRightsExpireDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payment rights expire description.", "label": "Royalty payment rights expire description" } } }, "localname": "RoyaltyPaymentRightsExpireDescription", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_SaleOfNetOperatingLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of net operating losses.", "label": "Sale of net operating losses" } } }, "localname": "SaleOfNetOperatingLosses", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Agreement [Member].", "label": "Sales Agreement [Member]" } } }, "localname": "SalesAgreementMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalents and restricted cash [Table Text Block].", "label": "Schedule of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "MTNB_ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of maturity of operating and finance leases liabilities [Table Text Block].", "label": "Schedule of Maturity of Operating and Finance Leases Liabilities" } } }, "localname": "ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesTableTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "MTNB_SecondAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Anniversary [Member]", "label": "Second Anniversary [Member]" } } }, "localname": "SecondAnniversaryMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_SevenPointFivePercentOfNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales [Member]", "label": "Net Sales [Member] [Default Label]", "verboseLabel": "Net Sales [Member]" } } }, "localname": "SevenPointFivePercentOfNetSalesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share based payment award non-option equity instruments tendered.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered", "negatedLabel": "Shares Tendered" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsTendered", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "MTNB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non-options equity instruments weighted average exercise price.", "label": "Weighted average of exercise price for outstanding warrants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "MTNB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share based payment award options cancelled in period.", "label": "Number of Options, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "MTNB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangements by share based payment award options cancelled in period weighted average exercise price.", "label": "Weighted average Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "MTNB_SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share based payment award increase of shares offering date.", "label": "Share-based payment award increase of shares offering date" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "MTNB_StateAndMunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State and Municipal Bonds [Member]", "label": "State and Municipal Bonds [Member]" } } }, "localname": "StateAndMunicipalBondsMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "MTNB_StockIssuedDuringPeriodSharesCommonStockInExchangeForOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in exchange for options, shares.", "label": "Issuance of common stock in exchange for Options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockInExchangeForOptionsShares", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "MTNB_StockIssuedDuringPeriodSharesExchangeForWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock from the exercise of Warrants, shares.", "label": "Issuance of common stock in exchange for Warrants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesExchangeForWarrantsShares", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "MTNB_StockIssuedDuringPeriodStockDividend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock dividend.", "label": "Stock dividends" } } }, "localname": "StockIssuedDuringPeriodStockDividend", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "MTNB_StockIssuedDuringPeriodValueCommonStockInExchangeForOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in exchange for options.", "label": "Issuance of common stock in exchange for Options" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockInExchangeForOptions", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "MTNB_StockIssuedDuringPeriodValueExchangeForWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in exchange for warrants.", "label": "Issuance of common stock in exchange for Warrants" } } }, "localname": "StockIssuedDuringPeriodValueExchangeForWarrants", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "MTNB_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "MTNB_TherapeuticsDevelopmentAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Therapeutics development award.", "label": "Therapeutics development award" } } }, "localname": "TherapeuticsDevelopmentAward", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "MTNB_ThirdAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Anniversary [Member]", "label": "Third Anniversary [Member]" } } }, "localname": "ThirdAnniversaryMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_ThreeMoleculesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Molecules [Member]", "label": "Three Molecules [Member]" } } }, "localname": "ThreeMoleculesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_TwoThousandThirteenEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2013 Equity Compensation Plan [Member].", "label": "2013 Equity Compensation Plan [Member]" } } }, "localname": "TwoThousandThirteenEquityCompensationPlanMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten Public Offering [Member].", "label": "Underwritten Public Offering [Member]" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_UnearnedRestrictedStockGrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unearned restricted stock grants.", "label": "Unearned restricted stock grants" } } }, "localname": "UnearnedRestrictedStockGrants", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MTNB_UnrealizedLossOnMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrealized (loss)/gains on securities for sale.", "label": "Unrealized (loss)/gain on marketable securities" } } }, "localname": "UnrealizedLossOnMarketableSecurities", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "MTNB_UnregisteredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unregistered Shares [Member]", "label": "Unregistered Shares [Member]" } } }, "localname": "UnregisteredSharesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "MTNB_UnusualRisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unusual Risks And Uncertainties [PolicyTextBlock]", "label": "COVID-19" } } }, "localname": "UnusualRisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "MTNB_UponAchievementOfSalesMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upon Achievement of Sales Milestones [Member]", "label": "Upon Achievement Of Sales Milestones [Member]" } } }, "localname": "UponAchievementOfSalesMilestonesMember", "nsuri": "http://matinasbiopharma.com/20211231", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r528", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r528", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r528", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r528", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r247", "r257", "r291", "r294", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r499", "r501", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r247", "r257", "r291", "r294", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r499", "r501", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r171", "r278", "r280", "r463", "r498", "r500" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r171", "r278", "r280", "r463", "r498", "r500" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r247", "r257", "r281", "r291", "r294", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r499", "r501", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r247", "r257", "r281", "r291", "r294", "r437", "r438", "r439", "r440", "r441", "r442", "r461", "r499", "r501", "r513", "r514" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r117", "r121", "r292" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r117", "r121", "r227", "r292", "r429" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r174", "r424" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accrued Expenses and Other Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other liabilities", "verboseLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r473", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r220" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r55", "r57", "r58", "r489", "r506", "r507" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive (loss)/income", "periodStartLabel": "Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r54", "r58", "r66", "r67", "r68", "r109", "r110", "r111", "r381", "r502", "r503", "r544" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r328", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r109", "r110", "r111", "r325", "r326", "r327", "r393" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r79", "r90", "r249", "r409" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of bond discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r154", "r163", "r169", "r194", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r377", "r382", "r400", "r425", "r427", "r470", "r487" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r51", "r103", "r194", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r377", "r382", "r400", "r425", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1": { "auth_ref": [ "r216", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the disposal of an asset through means other than sale, for example, but not limited to, abandonment, spin-off, and expropriation.", "label": "Asset write-off" } } }, "localname": "AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r15", "r16", "r17", "r18", "r19", "r20", "r21", "r22", "r103", "r194", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r377", "r382", "r400", "r425" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized (Loss)", "negatedLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r179", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r183", "r185", "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Due after one year through five years, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "auth_ref": [ "r183", "r186", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities Available-for-sale, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r183", "r184", "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Due within one year, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturitiesOfDebtSecuritiesAvailable-for-saleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r176", "r180", "r201", "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r297", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation and principles of consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r290", "r293" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r290", "r293", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business acquisition, equity iterest issued or issuable, shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r464", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by project.", "label": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r37", "r92" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r14", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r92", "r97" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "totalLabel": "Cash, cash equivalents and restricted cash in the statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r85", "r92", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r401" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase/(decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r101", "r103", "r124", "r125", "r126", "r129", "r131", "r136", "r137", "r138", "r194", "r235", "r239", "r240", "r241", "r244", "r245", "r255", "r256", "r259", "r263", "r400", "r533" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of warrant or right, exercise price of warrants or rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Number of warrant common stock converted" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Number of warrant to purchase of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Awards Reserved for Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Stock dividend, shares" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r109", "r110", "r393" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r27", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock par value $0.0001 per share, 500,000,000 shares authorized at December 31, 2021 and 2020, respectively; 216,269,450 and 200,113,431 issued and outstanding as of December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r72", "r478", "r496" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to shareholders" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r142", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r275", "r276", "r279" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r94", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued upon conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r282", "r289", "r508" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r76" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r104", "r354", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r104", "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r354", "r361", "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Total current expense (benefit):" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r104", "r354", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r94", "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Number of preferred stock shares converted" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r246", "r251" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Initial term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Schedule of Maturities of Debt Securities Available-for-sale" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r355", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r355", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r90", "r104", "r355", "r361", "r362", "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Total deferred expense (benefit):" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r337", "r338" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r355", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r345" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "R&D Credit Carryforwards" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r347" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "negatedTotalLabel": "Net deferred tax asset (liability)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net Operating Loss Carry-forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Share-based Compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accrued Liability" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r346" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r338", "r347" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "IPR&D" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r90", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Accumulated depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r90", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization expenses" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r152" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r297", "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Schedule of Equity Compensation Plan by Arrangements" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss attributable to common shareholders per share \u2013 basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and diluted net loss per common share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r105", "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Income at US Statutory Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation Allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Permanent Differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Discrete items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State Taxes, net of Federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r340", "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Tax Credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Payroll and incentives" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based compensation weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r109", "r110", "r111", "r113", "r118", "r120", "r135", "r195", "r270", "r272", "r325", "r326", "r327", "r357", "r358", "r393", "r402", "r403", "r404", "r405", "r406", "r408", "r502", "r503", "r504", "r544" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedLoss": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Net realized loss" } } }, "localname": "EquitySecuritiesFvNiRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r248", "r252", "r253", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r396", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r248", "r282", "r283", "r288", "r289", "r396", "r434" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r248", "r252", "r253", "r282", "r283", "r288", "r289", "r396", "r435" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r248", "r252", "r253", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r396", "r436" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Schedule of Fair Value Measurement of Assets and Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r248", "r252", "r253", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]" } } }, "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r412", "r416", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance lease, interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r411", "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Present value of finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r411" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Financing lease liabilities - current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r411" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Financing lease liabilities - net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Total undiscounted finance lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liabilities, Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liabilities, 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liabilities, 2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liabilities, 2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liabilities, 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liabilities, 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease Liabilities, less: Imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r413", "r418" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments of capital lease liability \u2013 principal" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r410" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance lease right-of-use assets - net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r412", "r416", "r423" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of finance lease right-of-use assets", "verboseLabel": "Finance lease right-of-use assets amortization expenses" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r421", "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease Liabilities, weighted average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r420", "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease Liabilities, weighted average remaining lease term in years" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r187", "r188", "r190", "r191", "r192", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r250", "r268", "r391", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r533", "r534", "r535", "r536", "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r78", "r90", "r178" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Sale of New Jersey net operating loss" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r90" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r206", "r208", "r427", "r469" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r210", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and other intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r90", "r207", "r209", "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill impairments" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantsReceivable": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.", "label": "Grants Receivable" } } }, "localname": "GrantsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r105", "r341", "r343", "r349", "r359", "r365", "r369", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r119", "r120", "r153", "r339", "r360", "r367", "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Total income tax expense (benefit):" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r335", "r336", "r343", "r344", "r348", "r356" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "verboseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r212", "r215" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "In-process research and development" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total undiscounted operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Lease Liabilities, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Lease Liabilities, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Lease Liabilities, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Lease Liabilities, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Lease Liabilities, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Operating Lease Liabilities, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Operating Lease Liabilities, less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Operating lease, description" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease, Terms" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r103", "r164", "r194", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r378", "r382", "r383", "r400", "r425", "r426" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r103", "r194", "r400", "r427", "r471", "r491" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r103", "r194", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r378", "r382", "r383", "r400", "r425", "r426", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r11", "r12", "r13", "r23", "r24", "r103", "r194", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r378", "r382", "r383", "r400", "r425", "r426" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities [Default Label]", "verboseLabel": "Marketable Securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r4", "r44" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss)", "negatedLabel": "Realized gain on sale of marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Summary of Marketable Securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable securities, unrealized gain loss" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CashCashEquivalentsRestrictedCashAndMarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r139", "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by/(used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r88", "r91" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r59", "r62", "r68", "r70", "r91", "r103", "r112", "r114", "r115", "r116", "r117", "r119", "r120", "r127", "r154", "r162", "r165", "r168", "r170", "r194", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r394", "r400", "r476", "r494" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r114", "r115", "r116", "r117", "r122", "r123", "r128", "r131", "r154", "r162", "r165", "r168", "r170" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently adopted accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of operating segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r154", "r162", "r165", "r168", "r170" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r417", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r411" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r411" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities - net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r410" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets - net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r90" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets amortization expenses" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r421", "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Liabilities, weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r420", "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Liabilities, weighted average remaining lease term in years" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfMaturityOfOperatingAndFinanceLeasesLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r254", "r389", "r390", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation." } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r52", "r53", "r55" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Net unrealized (loss)/gain on securities available-for-sale" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r52", "r53", "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net current period other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfComponentsOfAccumulatedOtherComprehensiveLossincomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r63", "r66", "r67", "r69", "r71", "r270", "r402", "r407", "r408", "r477", "r495" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive (loss)/income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive (loss)/income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r56", "r66", "r71", "r339", "r366", "r368", "r402", "r405", "r408", "r477", "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other comprehensive income loss" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for tabular information relating to Other Comprehensive Income (OCI) as is applicable to noncontrolling interests. This text block may also include OCI relative to the filing entity, the aforementioned noncontrolling interest OCI, as well as OCI on a consolidated basis.", "label": "Accumulated Other Comprehensive (Loss)/Income" } } }, "localname": "OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "General and administrative expense" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r75" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other income, net" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Lease monthly rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Stock issuance cost" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r177" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Purchase of equipment and leasehold improvements", "negatedLabel": "Purchases of leasehold improvements and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r297", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r123", "r132" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Preferred stock series B accumulated dividends" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r26", "r255" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Series B Convertible preferred stock, par value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Series B Convertible preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r26", "r255" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Series B Convertible preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Series B Convertible preferred stock, shares outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheetsParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r26", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series B Convertible preferred stock, stated value $1,000 per share, 8,000 shares authorized as of December 31, 2021 and 2020, respectively; 0 and 4,361 shares issued and outstanding as of December 31, 2021 and 2020, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r35", "r36" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Amount received from agreement" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r82" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Net proceeds from public offering of common stock", "verboseLabel": "Gross proceeds from public offering of common stock" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfCashFlows", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from sales of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from sale of productive assets" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r82", "r324" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r82" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r59", "r62", "r68", "r84", "r103", "r112", "r119", "r120", "r154", "r162", "r165", "r168", "r170", "r194", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r376", "r379", "r380", "r384", "r385", "r394", "r400", "r479" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Planned program of work." } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r40", "r221" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r223", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Leasehold Improvements and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r39", "r219" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r221", "r427", "r485", "r492" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Leasehold improvements and equipment - net", "totalLabel": "Leasehold improvements and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r38", "r221", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Leasehold improvements and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r18", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Leasehold Improvements and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeaseholdImprovementsAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r219" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Leasehold improvements and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r58", "r66", "r67", "r69", "r402", "r406", "r408" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Reclassification of realized gain on securities available-for-sale to net loss" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": { "auth_ref": [ "r333", "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development, costs incurred" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r213" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Stock issued pursuant to the Aquarius Merger Agreement charged to Research and Development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r332", "r462", "r515" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "terseLabel": "Research and Development Expense", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Collaboration Agreements, License and Other Research and Development Agreements" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r97", "r468", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r14", "r92", "r97", "r468", "r488" ], "calculation": { "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted cash included in current/long term assets" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r3", "r14", "r97" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r7", "r22", "r97", "r509" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash - security deposits" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r272", "r328", "r427", "r490", "r505", "r507" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r109", "r110", "r111", "r113", "r118", "r120", "r195", "r325", "r326", "r327", "r357", "r358", "r393", "r502", "r504" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r150", "r151", "r161", "r166", "r167", "r171", "r172", "r173", "r277", "r278", "r463" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Contract research revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r419", "r423" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use asset in exchange from liabilities from operating lease" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Aggregate offering price for sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Sale of stock percentage" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/AccruedExpensesAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r58", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Components of Accumulated Other Comprehensive (Loss)/Income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/AccumulatedOtherComprehensiveLossincomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Anti-dilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r296", "r321", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r296", "r321", "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Recognized Stock-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "auth_ref": [ "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.", "label": "Schedule of Fair Value, Off-balance Sheet Risks [Table]" } } }, "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r40", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfLeaseholdImprovementsAndEquipmentDetails", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r297", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Summary of Outstanding Options" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r304", "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Stock Option Awards and Restricted Stock Awards" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r273", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Summary of Shareholders Equity Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r155", "r156", "r157", "r158", "r159", "r160", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment and geographic information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://matinasbiopharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfRecognizedStock-basedCompensationDetails", "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Option vested period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r295", "r298" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Option granted description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Shares Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Shares Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Shares Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r305", "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Shares Outstanding, ending", "periodStartLabel": "Shares Outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfShareholdersEquityWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of common stock issued under plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Awards Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Aggregate intrinsic price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Option intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r306", "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options, Outstanding at Ending", "periodStartLabel": "Number of Options, Outstanding at Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average Exercise Price, Outstanding at Ending", "periodStartLabel": "Weighted average Exercise Price, Outstanding at Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Number of option vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Percentage for common stock outstanding", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetailsParenthetical", "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Awards Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfEquityCompensationPlanByArrangementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Option term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r295", "r302" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r297", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise price, minimum" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Number of options outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise price, maximum" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Stock option shares vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock options expire term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r318", "r329" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionAwardsAndRestrictedStockAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Contractual Term in Years, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Option vested price per share" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Weighted Average Exercise Price Per Share" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfOutstandingOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r98", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r25", "r26", "r27", "r101", "r103", "r124", "r125", "r126", "r129", "r131", "r136", "r137", "r138", "r194", "r235", "r239", "r240", "r241", "r244", "r245", "r255", "r256", "r259", "r263", "r270", "r400", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CommitmentsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r48", "r66", "r67", "r68", "r109", "r110", "r111", "r113", "r118", "r120", "r135", "r195", "r270", "r272", "r325", "r326", "r327", "r357", "r358", "r393", "r402", "r403", "r404", "r405", "r406", "r408", "r502", "r503", "r504", "r544" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r109", "r110", "r111", "r135", "r463" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r94", "r95", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock dividends issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r26", "r27", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Issuance of common stock pursuant to the Aquarius Merger, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock as compensation for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r26", "r27", "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock in public offering, net of stock issuance costs, shares", "terseLabel": "Issuance of common stock in public offering, shares", "verboseLabel": "Number of underwritten public offering of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Number of restricted stock awards granted" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r26", "r27", "r270", "r272", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r48", "r270", "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Issuance of common stock pursuant to the Aquarius Merger" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock as compensation for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r26", "r27", "r270", "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock in public offering, net of stock issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r31", "r32", "r103", "r175", "r194", "r400", "r427" ], "calculation": { "http://matinasbiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets", "http://matinasbiopharma.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r102", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r269", "r272", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r428", "r430" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Liquidity and Plan of Operations" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental non-cash financing and investing activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesAndLicenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.", "label": "Annual license fee" } } }, "localname": "TaxesAndLicenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r187", "r188", "r190", "r191", "r192", "r250", "r268", "r391", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r533", "r534", "r535", "r536", "r537", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/CollaborationAgreementsLicenseAndOtherResearchAndDevelopmentAgreementsDetailsNarrative", "http://matinasbiopharma.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://matinasbiopharma.com/role/ScheduleOfAccruedExpensesDetailsParenthetical", "http://matinasbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r107", "r282", "r480" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r282", "r508" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r107", "r282", "r289", "r480" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesDetails", "http://matinasbiopharma.com/role/SummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Accrual for interest or penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r140", "r141", "r143", "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://matinasbiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123374638&loc=d3e2212-110226" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r516": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r519": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r520": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r523": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r524": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r525": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r526": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r527": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r528": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r529": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r530": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r531": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r532": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r533": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r534": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r535": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r536": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r537": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r538": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r539": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r540": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r541": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r542": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r543": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 93 0001493152-22-006231-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-006231-xbrl.zip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�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